{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "data/analysis/df_retracted_retraction_0_100.tsv\n",
      "68\n",
      "data/analysis/df_retracted_retraction_100_200.tsv\n",
      "93\n",
      "data/analysis/df_retracted_retraction_200_300.tsv\n",
      "84\n",
      "data/analysis/df_retracted_retraction_300_400.tsv\n",
      "127\n",
      "data/analysis/df_retracted_retraction_400_450.tsv\n",
      "3\n"
     ]
    }
   ],
   "source": [
    "%run get_df_retractionwatch.ipynb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1186/s40478-016-0393-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1016/j.freeradbiomed.2011.11.027</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;comment&gt;\\n   S0891-\\n  &lt;/c...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                             DOI_cited  \\\n",
       "0               10.1136/ip.2006.015115   \n",
       "1               10.1136/ip.2006.015115   \n",
       "2            10.1186/s40478-016-0393-5   \n",
       "3  10.1016/j.freeradbiomed.2011.11.027   \n",
       "\n",
       "                                      article_citing  \n",
       "0  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...  \n",
       "1  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...  \n",
       "2  <html>\\n <body>\\n  <article article-type=\"rese...  \n",
       "3  <html>\\n <body>\\n  <comment>\\n   S0891-\\n  </c...  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_articles_citing_retracted_paper.head(4)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# FIND PAPERS BEFORE AND AFTER RETRACTION, THE RETRACTION NOTE AND THE RETRACTION ITSELF. \n",
    "# YOU MAY CONSIDER TO  INTRODUCE A GAP BERORE AND AFTER RETRACTION"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "1\n",
      "2\n",
      "PMID not found\n",
      "3\n",
      "DOI not found\n",
      "Date not found\n",
      "4\n",
      "PMID not found\n",
      "5\n",
      "DOI not found\n",
      "Date not found\n",
      "6\n",
      "7\n",
      "8\n",
      "DOI not found\n",
      "9\n",
      "PMID not found\n",
      "10\n",
      "PMID not found\n",
      "11\n",
      "12\n",
      "PMID not found\n",
      "13\n",
      "Day or month out of range!!!\n",
      "day:  \n",
      "         31\n",
      "         month:  \n",
      "         11\n",
      "         year:  \n",
      "      2010\n",
      "     \n",
      "Date set to: \n",
      "day:  29 month:  \n",
      "         11\n",
      "         year:  \n",
      "      2010\n",
      "     \n",
      "14\n",
      "PMID not found\n",
      "15\n",
      "DOI not found\n",
      "Date not found\n",
      "16\n",
      "17\n",
      "DOI not found\n",
      "Date not found\n",
      "18\n",
      "PMID not found\n",
      "19\n",
      "DOI not found\n",
      "Date not found\n",
      "20\n",
      "21\n",
      "PMID not found\n",
      "22\n",
      "23\n",
      "DOI not found\n",
      "Date not found\n",
      "24\n",
      "PMID not found\n",
      "25\n",
      "DOI not found\n",
      "Date not found\n",
      "26\n",
      "27\n",
      "28\n",
      "29\n",
      "DOI not found\n",
      "Date not found\n",
      "30\n",
      "DOI not found\n",
      "Date not found\n",
      "31\n",
      "32\n",
      "PMID not found\n",
      "33\n",
      "DOI not found\n",
      "Date not found\n",
      "34\n",
      "DOI not found\n",
      "Date not found\n",
      "35\n",
      "DOI not found\n",
      "Date not found\n",
      "36\n",
      "DOI not found\n",
      "Date not found\n",
      "37\n",
      "DOI not found\n",
      "Date not found\n",
      "38\n",
      "DOI not found\n",
      "Date not found\n",
      "39\n",
      "DOI not found\n",
      "Date not found\n",
      "40\n",
      "DOI not found\n",
      "Date not found\n",
      "41\n",
      "DOI not found\n",
      "Date not found\n",
      "42\n",
      "DOI not found\n",
      "Date not found\n",
      "43\n",
      "DOI not found\n",
      "Date not found\n",
      "44\n",
      "DOI not found\n",
      "Date not found\n",
      "45\n",
      "DOI not found\n",
      "Date not found\n",
      "46\n",
      "DOI not found\n",
      "47\n",
      "DOI not found\n",
      "Date not found\n",
      "48\n",
      "DOI not found\n",
      "Date not found\n",
      "49\n",
      "DOI not found\n",
      "50\n",
      "DOI not found\n",
      "Date not found\n",
      "51\n",
      "52\n",
      "DOI not found\n",
      "53\n",
      "DOI not found\n",
      "Date not found\n",
      "54\n",
      "55\n",
      "Day or month out of range!!!\n",
      "day:  \n",
      "        30\n",
      "        month:  \n",
      "        2\n",
      "        year:  \n",
      "        2018\n",
      "       \n",
      "56\n",
      "57\n",
      "PMID not found\n",
      "58\n",
      "PMID not found\n",
      "59\n",
      "DOI not found\n",
      "Date not found\n",
      "60\n",
      "DOI not found\n",
      "Date not found\n",
      "61\n",
      "PMID not found\n",
      "62\n",
      "PMID not found\n",
      "63\n",
      "DOI not found\n",
      "Date not found\n",
      "64\n",
      "DOI not found\n",
      "Date not found\n",
      "65\n",
      "PMID not found\n",
      "66\n",
      "DOI not found\n",
      "Date not found\n",
      "67\n",
      "DOI not found\n",
      "Date not found\n",
      "68\n",
      "0\n",
      "DOI not found\n",
      "Date not found\n",
      "1\n",
      "DOI not found\n",
      "Date not found\n",
      "2\n",
      "3\n",
      "DOI not found\n",
      "Date not found\n",
      "4\n",
      "DOI not found\n",
      "Date not found\n",
      "5\n",
      "DOI not found\n",
      "Date not found\n",
      "6\n",
      "DOI not found\n",
      "Date not found\n",
      "7\n",
      "DOI not found\n",
      "Date not found\n",
      "8\n",
      "9\n",
      "10\n",
      "11\n",
      "DOI not found\n",
      "Date not found\n",
      "12\n",
      "DOI not found\n",
      "Date not found\n",
      "13\n",
      "14\n",
      "DOI not found\n",
      "Date not found\n",
      "15\n",
      "DOI not found\n",
      "16\n",
      "17\n",
      "DOI not found\n",
      "Date not found\n",
      "18\n",
      "19\n",
      "PMID not found\n",
      "20\n",
      "DOI not found\n",
      "Date not found\n",
      "21\n",
      "PMID not found\n",
      "22\n",
      "PMID not found\n",
      "Date not found\n",
      "23\n",
      "24\n",
      "DOI not found\n",
      "Date not found\n",
      "25\n",
      "DOI not found\n",
      "Date not found\n",
      "26\n",
      "DOI not found\n",
      "Date not found\n",
      "27\n",
      "PMID not found\n",
      "28\n",
      "PMID not found\n",
      "Date not found\n",
      "29\n",
      "DOI not found\n",
      "Date not found\n",
      "30\n",
      "DOI not found\n",
      "Date not found\n",
      "31\n",
      "32\n",
      "DOI not found\n",
      "Date not found\n",
      "33\n",
      "34\n",
      "35\n",
      "DOI not found\n",
      "Date not found\n",
      "36\n",
      "DOI not found\n",
      "Date not found\n",
      "37\n",
      "DOI not found\n",
      "Date not found\n",
      "38\n",
      "DOI not found\n",
      "Date not found\n",
      "39\n",
      "DOI not found\n",
      "Date not found\n",
      "40\n",
      "41\n",
      "DOI not found\n",
      "Date not found\n",
      "42\n",
      "DOI not found\n",
      "Date not found\n",
      "43\n",
      "DOI not found\n",
      "Date not found\n",
      "44\n",
      "DOI not found\n",
      "Date not found\n",
      "45\n",
      "PMID not found\n",
      "46\n",
      "DOI not found\n",
      "Date not found\n",
      "47\n",
      "48\n",
      "49\n",
      "DOI not found\n",
      "Date not found\n",
      "50\n",
      "DOI not found\n",
      "Date not found\n",
      "51\n",
      "52\n",
      "DOI not found\n",
      "Date not found\n",
      "53\n",
      "DOI not found\n",
      "Date not found\n",
      "54\n",
      "DOI not found\n",
      "55\n",
      "56\n",
      "57\n",
      "58\n",
      "59\n",
      "60\n",
      "61\n",
      "62\n",
      "63\n",
      "64\n",
      "DOI not found\n",
      "Date not found\n",
      "65\n",
      "DOI not found\n",
      "Date not found\n",
      "66\n",
      "67\n",
      "DOI not found\n",
      "Date not found\n",
      "68\n",
      "DOI not found\n",
      "Date not found\n",
      "69\n",
      "DOI not found\n",
      "Date not found\n",
      "70\n",
      "71\n",
      "72\n",
      "DOI not found\n",
      "73\n",
      "DOI not found\n",
      "Date not found\n",
      "74\n",
      "75\n",
      "DOI not found\n",
      "Date not found\n",
      "76\n",
      "77\n",
      "DOI not found\n",
      "Date not found\n",
      "78\n",
      "DOI not found\n",
      "Date not found\n",
      "79\n",
      "DOI not found\n",
      "Date not found\n",
      "80\n",
      "DOI not found\n",
      "Date not found\n",
      "81\n",
      "82\n",
      "DOI not found\n",
      "Date not found\n",
      "83\n",
      "84\n",
      "85\n",
      "86\n",
      "87\n",
      "88\n",
      "DOI not found\n",
      "89\n",
      "90\n",
      "PMID not found\n",
      "91\n",
      "92\n",
      "PMID not found\n",
      "93\n",
      "DOI not found\n",
      "Date not found\n",
      "0\n",
      "1\n",
      "DOI not found\n",
      "Date not found\n",
      "2\n",
      "DOI not found\n",
      "Date not found\n",
      "3\n",
      "4\n",
      "5\n",
      "DOI not found\n",
      "Date not found\n",
      "6\n",
      "DOI not found\n",
      "Date not found\n",
      "7\n",
      "DOI not found\n",
      "Date not found\n",
      "8\n",
      "DOI not found\n",
      "PMID not found\n",
      "Date not found\n",
      "9\n",
      "DOI not found\n",
      "10\n",
      "11\n",
      "DOI not found\n",
      "Date not found\n",
      "12\n",
      "DOI not found\n",
      "Date not found\n",
      "13\n",
      "14\n",
      "15\n",
      "DOI not found\n",
      "Date not found\n",
      "16\n",
      "DOI not found\n",
      "Date not found\n",
      "17\n",
      "DOI not found\n",
      "Date not found\n",
      "18\n",
      "PMID not found\n",
      "19\n",
      "20\n",
      "PMID not found\n",
      "21\n",
      "DOI not found\n",
      "Date not found\n",
      "22\n",
      "DOI not found\n",
      "Date not found\n",
      "23\n",
      "DOI not found\n",
      "Date not found\n",
      "24\n",
      "DOI not found\n",
      "Date not found\n",
      "25\n",
      "PMID not found\n",
      "26\n",
      "27\n",
      "DOI not found\n",
      "Date not found\n",
      "28\n",
      "DOI not found\n",
      "Date not found\n",
      "29\n",
      "DOI not found\n",
      "Date not found\n",
      "30\n",
      "31\n",
      "32\n",
      "DOI not found\n",
      "Date not found\n",
      "33\n",
      "DOI not found\n",
      "Date not found\n",
      "34\n",
      "35\n",
      "36\n",
      "37\n",
      "DOI not found\n",
      "Date not found\n",
      "38\n",
      "DOI not found\n",
      "Date not found\n",
      "39\n",
      "40\n",
      "41\n",
      "42\n",
      "PMID not found\n",
      "43\n",
      "DOI not found\n",
      "Date not found\n",
      "44\n",
      "PMID not found\n",
      "45\n",
      "DOI not found\n",
      "Date not found\n",
      "46\n",
      "47\n",
      "48\n",
      "49\n",
      "50\n",
      "51\n",
      "DOI not found\n",
      "Date not found\n",
      "52\n",
      "53\n",
      "PMID not found\n",
      "54\n",
      "55\n",
      "56\n",
      "DOI not found\n",
      "Date not found\n",
      "57\n",
      "DOI not found\n",
      "Date not found\n",
      "58\n",
      "59\n",
      "PMID not found\n",
      "60\n",
      "DOI not found\n",
      "Date not found\n",
      "61\n",
      "DOI not found\n",
      "Date not found\n",
      "62\n",
      "DOI not found\n",
      "Date not found\n",
      "63\n",
      "64\n",
      "65\n",
      "66\n",
      "DOI not found\n",
      "Date not found\n",
      "67\n",
      "DOI not found\n",
      "Date not found\n",
      "68\n",
      "DOI not found\n",
      "Date not found\n",
      "69\n",
      "70\n",
      "DOI not found\n",
      "Date not found\n",
      "71\n",
      "DOI not found\n",
      "Date not found\n",
      "72\n",
      "DOI not found\n",
      "Date not found\n",
      "73\n",
      "74\n",
      "75\n",
      "76\n",
      "77\n",
      "PMID not found\n",
      "78\n",
      "DOI not found\n",
      "Date not found\n",
      "79\n",
      "80\n",
      "81\n",
      "PMID not found\n",
      "82\n",
      "PMID not found\n",
      "83\n",
      "84\n",
      "DOI not found\n",
      "Date not found\n",
      "0\n",
      "DOI not found\n",
      "Date not found\n",
      "1\n",
      "2\n",
      "3\n",
      "DOI not found\n",
      "Date not found\n",
      "4\n",
      "PMID not found\n",
      "5\n",
      "DOI not found\n",
      "Date not found\n",
      "6\n",
      "PMID not found\n",
      "7\n",
      "8\n",
      "9\n",
      "10\n",
      "11\n",
      "12\n",
      "13\n",
      "14\n",
      "15\n",
      "16\n",
      "17\n",
      "18\n",
      "19\n",
      "20\n",
      "21\n",
      "DOI not found\n",
      "Date not found\n",
      "22\n",
      "DOI not found\n",
      "Date not found\n",
      "23\n",
      "DOI not found\n",
      "Date not found\n",
      "24\n",
      "DOI not found\n",
      "Date not found\n",
      "25\n",
      "26\n",
      "27\n",
      "28\n",
      "29\n",
      "30\n",
      "31\n",
      "32\n",
      "33\n",
      "34\n",
      "35\n",
      "36\n",
      "37\n",
      "38\n",
      "39\n",
      "40\n",
      "41\n",
      "DOI not found\n",
      "Date not found\n",
      "42\n",
      "Date not found\n",
      "43\n",
      "44\n",
      "45\n",
      "46\n",
      "47\n",
      "48\n",
      "49\n",
      "DOI not found\n",
      "Date not found\n",
      "50\n",
      "51\n",
      "52\n",
      "53\n",
      "DOI not found\n",
      "Date not found\n",
      "54\n",
      "55\n",
      "DOI not found\n",
      "Date not found\n",
      "56\n",
      "DOI not found\n",
      "Date not found\n",
      "57\n",
      "DOI not found\n",
      "Date not found\n",
      "58\n",
      "59\n",
      "DOI not found\n",
      "Date not found\n",
      "60\n",
      "61\n",
      "DOI not found\n",
      "Date not found\n",
      "62\n",
      "DOI not found\n",
      "Date not found\n",
      "63\n",
      "DOI not found\n",
      "Date not found\n",
      "64\n",
      "DOI not found\n",
      "Date not found\n",
      "65\n",
      "DOI not found\n",
      "Date not found\n",
      "66\n",
      "67\n",
      "68\n",
      "DOI not found\n",
      "Date not found\n",
      "69\n",
      "DOI not found\n",
      "Date not found\n",
      "70\n",
      "71\n",
      "72\n",
      "DOI not found\n",
      "Date not found\n",
      "73\n",
      "74\n",
      "75\n",
      "DOI not found\n",
      "76\n",
      "DOI not found\n",
      "Date not found\n",
      "77\n",
      "DOI not found\n",
      "Date not found\n",
      "78\n",
      "DOI not found\n",
      "Date not found\n",
      "79\n",
      "DOI not found\n",
      "Date not found\n",
      "80\n",
      "DOI not found\n",
      "Date not found\n",
      "81\n",
      "82\n",
      "DOI not found\n",
      "Date not found\n",
      "83\n",
      "84\n",
      "DOI not found\n",
      "Date not found\n",
      "85\n",
      "DOI not found\n",
      "Date not found\n",
      "86\n",
      "87\n",
      "DOI not found\n",
      "Date not found\n",
      "88\n",
      "DOI not found\n",
      "Date not found\n",
      "89\n",
      "90\n",
      "DOI not found\n",
      "Date not found\n",
      "91\n",
      "DOI not found\n",
      "Date not found\n",
      "92\n",
      "DOI not found\n",
      "Date not found\n",
      "93\n",
      "94\n",
      "DOI not found\n",
      "Date not found\n",
      "95\n",
      "DOI not found\n",
      "Date not found\n",
      "96\n",
      "DOI not found\n",
      "Date not found\n",
      "97\n",
      "98\n",
      "99\n",
      "100\n",
      "101\n",
      "DOI not found\n",
      "Date not found\n",
      "102\n",
      "103\n",
      "DOI not found\n",
      "Date not found\n",
      "104\n",
      "DOI not found\n",
      "Date not found\n",
      "105\n",
      "DOI not found\n",
      "Date not found\n",
      "106\n",
      "DOI not found\n",
      "Date not found\n",
      "107\n",
      "108\n",
      "109\n",
      "DOI not found\n",
      "Date not found\n",
      "110\n",
      "DOI not found\n",
      "Date not found\n",
      "111\n",
      "DOI not found\n",
      "Date not found\n",
      "112\n",
      "DOI not found\n",
      "Date not found\n",
      "113\n",
      "114\n",
      "DOI not found\n",
      "Date not found\n",
      "115\n",
      "DOI not found\n",
      "Date not found\n",
      "116\n",
      "117\n",
      "118\n",
      "DOI not found\n",
      "Date not found\n",
      "119\n",
      "DOI not found\n",
      "Date not found\n",
      "120\n",
      "DOI not found\n",
      "121\n",
      "DOI not found\n",
      "Date not found\n",
      "122\n",
      "DOI not found\n",
      "Date not found\n",
      "123\n",
      "124\n",
      "PMID not found\n",
      "125\n",
      "PMID not found\n",
      "126\n",
      "PMID not found\n",
      "127\n",
      "DOI not found\n",
      "Date not found\n",
      "0\n",
      "1\n",
      "DOI not found\n",
      "Date not found\n",
      "2\n",
      "3\n"
     ]
    }
   ],
   "source": [
    "from modules import Article_object\n",
    "\n",
    "list_Articles_citing = []\n",
    "list_Article_citing_dois = []\n",
    "list_Article_citing_pmids = []\n",
    "list_Article_citing_dates = []\n",
    "list_Article_citing_references = []\n",
    "\n",
    "\n",
    "for index, row in df_articles_citing_retracted_paper.iterrows():\n",
    "    print(index)\n",
    "    \n",
    "    #for text in row['article_citing']:\n",
    "    \n",
    "    Article_citing = Article_object.Article_object()\n",
    "    Article_citing.text = row['article_citing']\n",
    "\n",
    "    Article_citing.get_doi_from_text()\n",
    "    list_Article_citing_dois.append(Article_citing.doi)\n",
    "\n",
    "    Article_citing.get_pmid_from_text()\n",
    "    list_Article_citing_pmids.append(Article_citing.pmid)\n",
    "    \n",
    "    Article_citing.get_date_from_text()\n",
    "    list_Article_citing_dates.append(Article_citing.date)\n",
    "\n",
    "    Article_citing.get_list_references_dois_and_pmids_from_text()\n",
    "    list_Article_citing_references.append(Article_citing.references_dois)\n",
    "    \n",
    "    \n",
    "\n",
    "    list_Articles_citing.append(Article_citing)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "df_Articles_citing_retracted_paper = pd.concat([df_articles_citing_retracted_paper.reset_index(drop=True), \n",
    "                                    pd.DataFrame({\"Article\": list_Articles_citing,\n",
    "                                            \"date_article_citing\": list_Article_citing_dates,\n",
    "                                            \"doi_article_citing\": list_Article_citing_dois,\n",
    "                                            \"pmid_article_citing\": list_Article_citing_pmids,\n",
    "                                            \"pmid_article_citing\": list_Article_citing_pmids,\n",
    "                                            \"references_in_article_citing\": list_Article_citing_references                     \n",
    "                                            })\n",
    "                                    ], axis=1)\n",
    "df_Articles_citing_retracted_paper\n",
    "\n",
    "# Let's add the date of the retraction\n",
    "list_date_retracion = []\n",
    "for  doi in df_Articles_citing_retracted_paper[\"DOI_cited\"]:\n",
    "    mask = df_retracted_retraction[\"doi\"] == doi\n",
    "    list_date_retracion.append(datetime.date(df_retracted_retraction[mask][\"date_retraction\"].iloc[0]))\n",
    "\n",
    "df_Articles_citing =  pd.concat([df_Articles_citing_retracted_paper,\n",
    "                                 pd.DataFrame({\"date_doi_cited_retraction\": list_date_retracion\n",
    "                                               })\n",
    "                                ], axis = 1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(380, 8)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_citing.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>1993-08-30</td>\n",
       "      <td>10.1136/ip.2006.015115eoc1</td>\n",
       "      <td>25662882</td>\n",
       "      <td></td>\n",
       "      <td>2017-12-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>1993-08-30</td>\n",
       "      <td>10.1136/ip.2006.015115eoc1</td>\n",
       "      <td>25662882</td>\n",
       "      <td></td>\n",
       "      <td>2017-12-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1186/s40478-016-0393-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2016-11-18</td>\n",
       "      <td>10.1186/s40478-016-0393-5</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2017-12-13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1016/j.freeradbiomed.2011.11.027</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;comment&gt;\\n   S0891-\\n  &lt;/c...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>22198263</td>\n",
       "      <td></td>\n",
       "      <td>2017-11-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>10.1128/genomeA.00731-17</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"brie...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-08-10</td>\n",
       "      <td>10.1128/genomeA.00731-17</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2017-11-16</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                             DOI_cited  \\\n",
       "0               10.1136/ip.2006.015115   \n",
       "1               10.1136/ip.2006.015115   \n",
       "2            10.1186/s40478-016-0393-5   \n",
       "3  10.1016/j.freeradbiomed.2011.11.027   \n",
       "4             10.1128/genomeA.00731-17   \n",
       "\n",
       "                                      article_citing  \\\n",
       "0  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...   \n",
       "1  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...   \n",
       "2  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "3  <html>\\n <body>\\n  <comment>\\n   S0891-\\n  </c...   \n",
       "4  <html>\\n <body>\\n  <article article-type=\"brie...   \n",
       "\n",
       "                                             Article date_article_citing  \\\n",
       "0  <modules.Article_object.Article_object object ...          1993-08-30   \n",
       "1  <modules.Article_object.Article_object object ...          1993-08-30   \n",
       "2  <modules.Article_object.Article_object object ...          2016-11-18   \n",
       "3  <modules.Article_object.Article_object object ...                       \n",
       "4  <modules.Article_object.Article_object object ...          2017-08-10   \n",
       "\n",
       "           doi_article_citing pmid_article_citing  \\\n",
       "0  10.1136/ip.2006.015115eoc1            25662882   \n",
       "1  10.1136/ip.2006.015115eoc1            25662882   \n",
       "2   10.1186/s40478-016-0393-5                       \n",
       "3                                        22198263   \n",
       "4    10.1128/genomeA.00731-17                       \n",
       "\n",
       "  references_in_article_citing date_doi_cited_retraction  \n",
       "0                                             2017-12-20  \n",
       "1                                             2017-12-20  \n",
       "2                                             2017-12-13  \n",
       "3                                             2017-11-20  \n",
       "4                                             2017-11-16  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_citing.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>1993-08-30</td>\n",
       "      <td>10.1136/ip.2006.015115eoc1</td>\n",
       "      <td>25662882</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-12-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1136/ip.2006.015115</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;pub-id pub-id-type=\"pmid\"&gt;...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>1993-08-30</td>\n",
       "      <td>10.1136/ip.2006.015115eoc1</td>\n",
       "      <td>25662882</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-12-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1186/s40478-016-0393-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2016-11-18</td>\n",
       "      <td>10.1186/s40478-016-0393-5</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-12-13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1128/genomeA.00731-17</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"brie...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-08-10</td>\n",
       "      <td>10.1128/genomeA.00731-17</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-11-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>10.3892/mmr.2017.7084</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-10-25</td>\n",
       "      <td>10.3892/mmr.2017.7084</td>\n",
       "      <td>24663092</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-09-28</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   DOI_cited  \\\n",
       "0     10.1136/ip.2006.015115   \n",
       "1     10.1136/ip.2006.015115   \n",
       "2  10.1186/s40478-016-0393-5   \n",
       "3   10.1128/genomeA.00731-17   \n",
       "4      10.3892/mmr.2017.7084   \n",
       "\n",
       "                                      article_citing  \\\n",
       "0  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...   \n",
       "1  <html>\\n <body>\\n  <pub-id pub-id-type=\"pmid\">...   \n",
       "2  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "3  <html>\\n <body>\\n  <article article-type=\"brie...   \n",
       "4  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "\n",
       "                                             Article date_article_citing  \\\n",
       "0  <modules.Article_object.Article_object object ...          1993-08-30   \n",
       "1  <modules.Article_object.Article_object object ...          1993-08-30   \n",
       "2  <modules.Article_object.Article_object object ...          2016-11-18   \n",
       "3  <modules.Article_object.Article_object object ...          2017-08-10   \n",
       "4  <modules.Article_object.Article_object object ...          2017-10-25   \n",
       "\n",
       "           doi_article_citing pmid_article_citing  \\\n",
       "0  10.1136/ip.2006.015115eoc1            25662882   \n",
       "1  10.1136/ip.2006.015115eoc1            25662882   \n",
       "2   10.1186/s40478-016-0393-5                 NaN   \n",
       "3    10.1128/genomeA.00731-17                 NaN   \n",
       "4       10.3892/mmr.2017.7084            24663092   \n",
       "\n",
       "   references_in_article_citing date_doi_cited_retraction  \n",
       "0                           NaN                2017-12-20  \n",
       "1                           NaN                2017-12-20  \n",
       "2                           NaN                2017-12-13  \n",
       "3                           NaN                2017-11-16  \n",
       "4                           NaN                2017-09-28  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import numpy as np\n",
    "df_Articles_citing.replace('', np.nan, inplace=True)\n",
    "df_Articles_citing2 = df_Articles_citing.dropna(subset = [\"date_article_citing\"])\n",
    "df_Articles_citing_clean = df_Articles_citing2.reset_index(drop = True)\n",
    "df_Articles_citing_clean.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(206, 8)"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_citing_clean.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "list_index_is_the_retracted_paper =[]\n",
    "list_index_is_the_retraction_note = []\n",
    "for index, row in df_Articles_citing_clean.iterrows():   \n",
    "    if row.doi_article_citing in list(df_retracted_retraction[\"doi\"]):\n",
    "        list_index_is_the_retracted_paper.append(index)\n",
    "        \n",
    "    if row.doi_article_citing in list(df_retracted_retraction[\"doi_retraction\"]):\n",
    "        list_index_is_the_retraction_note.append(index)\n",
    "        #print(row.DOI_cited)\n",
    "        #print(row.doi_article_citing)\n",
    "        #print(index)\n",
    "\n",
    "df_Articles_citing_no_retractions =  df_Articles_citing_clean.drop(list_index_is_the_retracted_paper + \n",
    "                                                                   list_index_is_the_retraction_note)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(142, 8)"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_citing_no_retractions.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>before_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;p&gt;\\n   Int_J_Ment_Health_S...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-11-30</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28503193</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2016-08-16</td>\n",
       "      <td>10.1042/BSR20160174</td>\n",
       "      <td>21980456</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-24</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1371/journal.pone.0164571</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-06-05</td>\n",
       "      <td>10.3390/ijerph14060602</td>\n",
       "      <td>24800926</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-05-26</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>\\n              &lt;floats-group&gt;\\n              ...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2016-11-16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23823472</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>\\n                     Lipids_Health_Dis/PMC47...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2013-03-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23623304</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      DOI_cited  \\\n",
       "0     10.1186/s13033-017-0143-5   \n",
       "1            10.1002/cbin.10291   \n",
       "2  10.1371/journal.pone.0164571   \n",
       "3    10.1016/j.cell.2013.04.008   \n",
       "4    10.1016/j.cell.2013.04.008   \n",
       "\n",
       "                                      article_citing  \\\n",
       "0  <html>\\n <body>\\n  <p>\\n   Int_J_Ment_Health_S...   \n",
       "1  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "2  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "3  \\n              <floats-group>\\n              ...   \n",
       "4  \\n                     Lipids_Health_Dis/PMC47...   \n",
       "\n",
       "                                             Article date_article_citing  \\\n",
       "0  <modules.Article_object.Article_object object ...          2017-11-30   \n",
       "1  <modules.Article_object.Article_object object ...          2016-08-16   \n",
       "2  <modules.Article_object.Article_object object ...          2017-06-05   \n",
       "3  <modules.Article_object.Article_object object ...          2016-11-16   \n",
       "4  <modules.Article_object.Article_object object ...          2013-03-03   \n",
       "\n",
       "       doi_article_citing pmid_article_citing  references_in_article_citing  \\\n",
       "0                     NaN            28503193                           NaN   \n",
       "1     10.1042/BSR20160174            21980456                           NaN   \n",
       "2  10.3390/ijerph14060602            24800926                           NaN   \n",
       "3                     NaN            23823472                           NaN   \n",
       "4                     NaN            23623304                           NaN   \n",
       "\n",
       "  date_doi_cited_retraction  after_retraction  before_retraction  \n",
       "0                2017-09-15                 1                  0  \n",
       "1                2017-07-24                 0                  1  \n",
       "2                2017-05-26                 1                  0  \n",
       "3                2017-01-01                 0                  1  \n",
       "4                2017-01-01                 0                  1  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list_before_retraction = []\n",
    "list_after_retraction = []\n",
    "\n",
    "for index, row in df_Articles_citing_no_retractions.iterrows():\n",
    "    if row['date_article_citing'] < row['date_doi_cited_retraction']:\n",
    "        list_before_retraction.append(1)\n",
    "        list_after_retraction.append(0)\n",
    "    else:\n",
    "        list_before_retraction.append(0)\n",
    "        list_after_retraction.append(1)\n",
    "\n",
    "\n",
    "df_Articles_before_after_retraction = pd.concat([df_Articles_citing_no_retractions.reset_index(drop = True),\n",
    "                                                pd.DataFrame({\"before_retraction\": list_before_retraction,\n",
    "                                                              \"after_retraction\": list_after_retraction\n",
    "                                                             })\n",
    "                                                ], axis = 1)\n",
    "        \n",
    "\n",
    "df_Articles_before_after_retraction.head(5)        \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "53"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_Articles_before_after_retraction[\"DOI_cited\"].unique())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Summary\n",
    "\n",
    "61 different DOIs of retracted papers cited by\n",
    "218 articles.\n",
    "\n",
    "42 retracted papers, 25 retraction notes, and 152 new manuscripts.\n",
    "\n",
    "152 new manuscripts:\n",
    "     45 were published after the retraction\n",
    "    107 before the retraction."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's analyse the text and find the sentence were the paper was cited"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>before_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>10.1073/pnas.0501997102</td>\n",
       "      <td>\\n     &lt;floats-group&gt;\\n      &lt;fig id=\"ijms-18-...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2012-05-04</td>\n",
       "      <td>10.1186/1465-9921-13-36</td>\n",
       "      <td>11401896</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2009-07-09</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   DOI_cited  \\\n",
       "141  10.1073/pnas.0501997102   \n",
       "\n",
       "                                        article_citing  \\\n",
       "141  \\n     <floats-group>\\n      <fig id=\"ijms-18-...   \n",
       "\n",
       "                                               Article date_article_citing  \\\n",
       "141  <modules.Article_object.Article_object object ...          2012-05-04   \n",
       "\n",
       "          doi_article_citing pmid_article_citing  \\\n",
       "141  10.1186/1465-9921-13-36            11401896   \n",
       "\n",
       "     references_in_article_citing date_doi_cited_retraction  after_retraction  \\\n",
       "141                           NaN                2009-07-09                 1   \n",
       "\n",
       "     before_retraction  \n",
       "141                  0  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_before_after_retraction.tail(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>before_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;p&gt;\\n   Int_J_Ment_Health_S...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-11-30</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28503193</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2016-08-16</td>\n",
       "      <td>10.1042/BSR20160174</td>\n",
       "      <td>21980456</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-24</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1371/journal.pone.0164571</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;article article-type=\"rese...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-06-05</td>\n",
       "      <td>10.3390/ijerph14060602</td>\n",
       "      <td>24800926</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-05-26</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      DOI_cited  \\\n",
       "0     10.1186/s13033-017-0143-5   \n",
       "1            10.1002/cbin.10291   \n",
       "2  10.1371/journal.pone.0164571   \n",
       "\n",
       "                                      article_citing  \\\n",
       "0  <html>\\n <body>\\n  <p>\\n   Int_J_Ment_Health_S...   \n",
       "1  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "2  <html>\\n <body>\\n  <article article-type=\"rese...   \n",
       "\n",
       "                                             Article date_article_citing  \\\n",
       "0  <modules.Article_object.Article_object object ...          2017-11-30   \n",
       "1  <modules.Article_object.Article_object object ...          2016-08-16   \n",
       "2  <modules.Article_object.Article_object object ...          2017-06-05   \n",
       "\n",
       "       doi_article_citing pmid_article_citing  references_in_article_citing  \\\n",
       "0                     NaN            28503193                           NaN   \n",
       "1     10.1042/BSR20160174            21980456                           NaN   \n",
       "2  10.3390/ijerph14060602            24800926                           NaN   \n",
       "\n",
       "  date_doi_cited_retraction  after_retraction  before_retraction  \n",
       "0                2017-09-15                 1                  0  \n",
       "1                2017-07-24                 0                  1  \n",
       "2                2017-05-26                 1                  0  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_before_after_retraction.head(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cited_DOI</th>\n",
       "      <th>cited_in_conclusions</th>\n",
       "      <th>cited_in_discussion</th>\n",
       "      <th>cited_in_introduction</th>\n",
       "      <th>cited_in_maintext</th>\n",
       "      <th>citing_DOI</th>\n",
       "      <th>conclusions_found</th>\n",
       "      <th>discussion_found</th>\n",
       "      <th>introduction_found</th>\n",
       "      <th>maintext_found</th>\n",
       "      <th>reference_number</th>\n",
       "      <th>sentence_citing_conclusions</th>\n",
       "      <th>sentence_citing_discussion</th>\n",
       "      <th>sentence_citing_intro</th>\n",
       "      <th>sentence_citing_maintext</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b1-cpn-15-361</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Han and Renshaw\\n     &lt;xref ref-type=\"bibr\" r...</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\"&gt; 1 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1042/BSR20160174\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B49</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[* indicates &lt;italic&gt; P &lt;/italic&gt; &amp;lt;0.05 for...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1371/journal.pone.0164571</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3390/ijerph14060602\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B34-ijerph-14-00602</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Other factors included the absence of hand wa...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Other factors included the absence of hand wa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B5</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Overexpression of betatrophin in mice livers ...</td>\n",
       "      <td>[However these inspiring discoveries were late...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>CR30</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n                           10.3892/ijmm.2017...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b21-ijmm-39-04-0936</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In the present study, the impact of human ADM...</td>\n",
       "      <td>[The biological characteristics and differenti...</td>\n",
       "      <td>[Its transient overexpression in the liver ind...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>R1</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"R9\"&gt;&lt;sup&gt; 9 &lt;/sup&gt;...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.14740/jocmr3114w\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>R04</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Because SGLT2 inhibitors decrease insulin lev...</td>\n",
       "      <td>[&lt;/p&gt;\\n&lt;p&gt;\\n     On the other hand, recent cli...</td>\n",
       "      <td>[However, some recent studies show positive as...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n         10.1007/s13238-014-0123-3\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>CR71</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Betatrophin is mainly expressed in the liver ...</td>\n",
       "      <td>[Betatrophin is mainly expressed in the liver ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10.1074/jbc.M306295200</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n        10.3892/ol.2016.5392\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b32-ol-0-0-5392</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The latter is able to boost prostate cancer g...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10.1074/jbc.M100194200</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n        10.1186/1476-4598-9-236\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B64</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10.1074/jbc.M100194200</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n       10.1371/journal.pone.0081133\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B50</td>\n",
       "      <td>[]</td>\n",
       "      <td>[These results might imply that compensatory i...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>10.1016/j.cell.2010.09.011</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n      10.1186/bcr2829\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>B8</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>10.1186/1742-2094-9-223</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b34-cpn-14-338</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"b38-cpn-14-338\"&gt;\\n...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>10.1038/srep19222</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3390/cancers9050042\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B26-cancers-09-00042</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[A study in pancreatic cancer patient tumors, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>10.1038/srep19222</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3390/ijms18061201\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B115-ijms-18-01201</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Also, it has recently been shown that patient...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>10.1128/AEM.02433-12</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1754-6834-6-117\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B31</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Finally, a fourth challenge may be the appare...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Although degradation of lignocellulose has be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>10.1128/AEM.02433-12</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1754-6834-6-126\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B25</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[It is therefore critical to find approaches t...</td>\n",
       "      <td>[It is therefore critical to find approaches t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>10.1126/science.1237242</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3762/bjnano.7.29\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>R1</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Spiros Skourtis introduced the audience to th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>10.1098/rspb.2009.1774</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2164-14-546\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B43</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;/bold&gt;\\n         The alignment was 1,000 tim...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Nonetheless, using RaXML [ &lt;xref ref-type=\"bi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>10.1016/j.cell.2012.02.055</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n             10.3892/mmr.2016.5979\\n        ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b20-mmr-15-01-0210</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>10.1152/ajplung.00134.2011</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>R64</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/ar4282\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B10</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[These results argue that RhoA is a target of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2407-12-111\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B9</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;/p&gt;\\n&lt;p&gt;\\n      The ability of miR-135a to p...</td>\n",
       "      <td>[The abnormal expression profiles of miRNAs ha...</td>\n",
       "      <td>[The abnormal expression profiles of miRNAs ha...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2407-10-318\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B15</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[For example, miR-155 may play an important ro...</td>\n",
       "      <td>[MiR-21 has been shown to stimulate cell invas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2407-10-616\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B17</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Taken together, it seems that not only the ex...</td>\n",
       "      <td>[In the present study, we applied anti-miR mi...</td>\n",
       "      <td>[Taken together, it seems that not only the ex...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2164-12-54\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B46</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Tiling array t-statistics represent the signi...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Tiling array t-statistics represent the signi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2164-12-62\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B37</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In\\n       &lt;italic&gt;\\n        B. mori\\n       ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In &lt;italic&gt; Drosophila &lt;/italic&gt; it is expres...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2164-13-43\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B27</td>\n",
       "      <td>[]</td>\n",
       "      <td>[MiR-31, downregulated in BC datasets, was rep...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The tumor suppressor miRNA of miR-31 were dow...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>10.1016/j.cell.2009.03.047</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/1471-2164-14-371\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B66</td>\n",
       "      <td>[]</td>\n",
       "      <td>[An interesting recently published study indic...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[miR-31 also inhibits breast cancer metastasis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>10.1073/pnas.0806674105</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1752-0509-7-S5-S5\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B6</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In this study, the focus is on using gene exp...</td>\n",
       "      <td>[In this study, the focus is on using gene exp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>10.1073/pnas.0806674105</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n       10.18632/oncotarget.18692\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>R8</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>10.1126/science.1190532</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3389/fnagi.2011.00003\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>B7</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[There is therefore a move among geneticists a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>10.1126/science.1190532</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n         10.1371/journal.pone.0022075\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>pone.0022075-Sebastiani1</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[They used these posterior probabilities to ra...</td>\n",
       "      <td>[They used these posterior probabilities to ra...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>10.1101/gad.489409</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2180-13-101\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B6</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In this reaction, the ethanolamine moiety is ...</td>\n",
       "      <td>[Catalysis of arginine methylation is carried ...</td>\n",
       "      <td>[Catalysis of arginine methylation is carried ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>10.1101/gad.489409</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n             10.1186/1476-4598-10-21\\n      ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B51</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In this study we have identified PIAS1 as a n...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;/given-names&gt;&lt;/name&gt;&lt;etal&gt;&lt;/etal&gt;&lt;/person-gr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>10.1073/pnas.0812470106</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2164-14-374\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B34</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Importantly, computational assessment of GAF5...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Importantly, computational assessment of GAF5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>10.1016/j.cell.2008.12.021</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1478-811X-9-7\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B46</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;/p&gt;\\n&lt;p&gt;\\n      An additional level of regul...</td>\n",
       "      <td>[As an example, phosphorylation of nuclear cas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>10.1016/j.cell.2008.12.021</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>R31</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"R37\"&gt;\\n&lt;sup&gt;\\n    ...</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"R36\"&gt;&lt;sup&gt; 36 &lt;/su...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>10.1158/0008-5472.CAN-08-0482</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n      10.3892/ol.2017.6088\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b18-ol-0-0-6088</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2407-9-145\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B13</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Similarly, other groups have previously repor...</td>\n",
       "      <td>[Furthermore, additional studies to validate t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>123</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n      10.1186/1755-8794-3-26\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B10</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>124</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1752-0509-5-146\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>B73</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[More recently, new powerful transcriptomics t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1756-9966-29-120\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B3</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[After the \"training\" of a predictor it must b...</td>\n",
       "      <td>[After the \"training\" of a predictor it must b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/bcr1662\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B34</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The predictive capacity of these signatures w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/bcr2159\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B25</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The authors conclude that selecting patients ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/bcr2909\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>B2</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[breast cancer intrinsic subtype analysis, pat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>10.1038/nm1491</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n       10.1186/bcr2890\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B96</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Subsequently, after a series of investigation...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>10.1200/JCO.2007.11.0593</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2407-9-359\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B20</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;/p&gt;\\n&lt;p&gt;\\n     To determine the sensitivity ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[For both cytotoxicity assays a correlation wi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>10.1073/pnas.0809516106</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/bcr2927\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B12</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The 4T1 cells were derived from the mammary t...</td>\n",
       "      <td>[&lt;/p&gt;&lt;p&gt; In this study we demonstrated that th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>10.1158/0008-5472.CAN-07-5937</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1423-0127-18-44\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B33</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[After scraping, centrifuging and rinsing twic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>10.1126/science.1124755</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1471-2202-8-S3-S1\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>B25</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Apparently, black raspberries and Provenal ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>10.1126/science.1124755</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n           10.3389/neuro.10.009.2008\\n      ...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B74</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In vertebrates, odor mixture interactions wer...</td>\n",
       "      <td>[Recent behavioral studies could show that a p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135</th>\n",
       "      <td>10.1126/science.1124755</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n      10.3389/fncir.2010.00120\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B44</td>\n",
       "      <td>[]</td>\n",
       "      <td>[As a result of this, a vast reorganization of...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>10.1158/0008-5472.CAN-04-4194</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B42</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Nevertheless, testing the genetic stability o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>10.1073/pnas.0503877102</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/gb-2007-8-s1-s12\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B122</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Although retroviruses do not exhibit a strong...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>10.1083/jcb.200705182</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>\\n       10.1083/jcb.20070518220090127c\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>Not found</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>10.1104/pp.011019</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1186/1472-6882-13-155\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B69</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The higher concentration is found in leaf., S...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The higher concentration is found in leaf., S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>10.1073/pnas.0501997102</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n        10.3390/ijms18122636\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B9-ijms-18-02636</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[In vitro and in vivo preclinical studies reve...</td>\n",
       "      <td>[&lt;/p&gt;&lt;p&gt; Cenerimod (ACT-334441) is a potent S1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>10.1073/pnas.0501997102</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n               10.1186/1465-9921-13-36\\n    ...</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B26</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[The primary objective of this study was to de...</td>\n",
       "      <td>[&lt;/p&gt;&lt;/sec&gt;&lt;sec sec-type=\"methods\"&gt;&lt;title&gt; Met...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>142 rows  15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                         cited_DOI  cited_in_conclusions  cited_in_discussion  \\\n",
       "0        10.1186/s13033-017-0143-5                 False                False   \n",
       "1               10.1002/cbin.10291                 False                False   \n",
       "2     10.1371/journal.pone.0164571                 False                 True   \n",
       "3       10.1016/j.cell.2013.04.008                 False                False   \n",
       "4       10.1016/j.cell.2013.04.008                 False                False   \n",
       "5       10.1016/j.cell.2013.04.008                 False                 True   \n",
       "6       10.1016/j.cell.2013.04.008                 False                False   \n",
       "7       10.1016/j.cell.2013.04.008                 False                 True   \n",
       "8       10.1016/j.cell.2013.04.008                 False                False   \n",
       "9           10.1074/jbc.M306295200                 False                 True   \n",
       "10          10.1074/jbc.M100194200                 False                False   \n",
       "11          10.1074/jbc.M100194200                 False                 True   \n",
       "12      10.1016/j.cell.2010.09.011                 False                False   \n",
       "13         10.1186/1742-2094-9-223                 False                 True   \n",
       "14               10.1038/srep19222                 False                False   \n",
       "15               10.1038/srep19222                 False                False   \n",
       "16            10.1128/AEM.02433-12                 False                 True   \n",
       "17            10.1128/AEM.02433-12                 False                False   \n",
       "18         10.1126/science.1237242                 False                False   \n",
       "19          10.1098/rspb.2009.1774                 False                 True   \n",
       "20      10.1016/j.cell.2012.02.055                 False                False   \n",
       "21      10.1152/ajplung.00134.2011                 False                False   \n",
       "22      10.1016/j.cell.2009.03.047                 False                False   \n",
       "23      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "24      10.1016/j.cell.2009.03.047                 False                False   \n",
       "25      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "26      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "27      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "28      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "29      10.1016/j.cell.2009.03.047                 False                 True   \n",
       "..                             ...                   ...                  ...   \n",
       "112        10.1073/pnas.0806674105                 False                False   \n",
       "113        10.1073/pnas.0806674105                 False                False   \n",
       "114        10.1126/science.1190532                 False                False   \n",
       "115        10.1126/science.1190532                 False                False   \n",
       "116             10.1101/gad.489409                 False                 True   \n",
       "117             10.1101/gad.489409                 False                 True   \n",
       "118        10.1073/pnas.0812470106                 False                 True   \n",
       "119     10.1016/j.cell.2008.12.021                 False                False   \n",
       "120     10.1016/j.cell.2008.12.021                 False                False   \n",
       "121  10.1158/0008-5472.CAN-08-0482                 False                False   \n",
       "122                 10.1038/nm1491                 False                False   \n",
       "123                 10.1038/nm1491                 False                False   \n",
       "124                 10.1038/nm1491                 False                False   \n",
       "125                 10.1038/nm1491                 False                False   \n",
       "126                 10.1038/nm1491                 False                False   \n",
       "127                 10.1038/nm1491                 False                False   \n",
       "128                 10.1038/nm1491                 False                False   \n",
       "129                 10.1038/nm1491                 False                False   \n",
       "130       10.1200/JCO.2007.11.0593                 False                 True   \n",
       "131        10.1073/pnas.0809516106                 False                False   \n",
       "132  10.1158/0008-5472.CAN-07-5937                 False                False   \n",
       "133        10.1126/science.1124755                 False                False   \n",
       "134        10.1126/science.1124755                 False                False   \n",
       "135        10.1126/science.1124755                 False                 True   \n",
       "136  10.1158/0008-5472.CAN-04-4194                 False                False   \n",
       "137        10.1073/pnas.0503877102                 False                False   \n",
       "138          10.1083/jcb.200705182                  True                 True   \n",
       "139              10.1104/pp.011019                 False                 True   \n",
       "140        10.1073/pnas.0501997102                 False                False   \n",
       "141        10.1073/pnas.0501997102                 False                False   \n",
       "\n",
       "     cited_in_introduction  cited_in_maintext  \\\n",
       "0                     True               True   \n",
       "1                    False               True   \n",
       "2                    False               True   \n",
       "3                     True               True   \n",
       "4                    False              False   \n",
       "5                     True               True   \n",
       "6                    False               True   \n",
       "7                     True               True   \n",
       "8                     True               True   \n",
       "9                    False              False   \n",
       "10                   False              False   \n",
       "11                   False              False   \n",
       "12                   False              False   \n",
       "13                   False              False   \n",
       "14                   False               True   \n",
       "15                   False               True   \n",
       "16                   False               True   \n",
       "17                    True               True   \n",
       "18                   False               True   \n",
       "19                   False               True   \n",
       "20                   False              False   \n",
       "21                   False              False   \n",
       "22                   False               True   \n",
       "23                    True               True   \n",
       "24                    True               True   \n",
       "25                    True               True   \n",
       "26                   False               True   \n",
       "27                   False               True   \n",
       "28                   False               True   \n",
       "29                   False               True   \n",
       "..                     ...                ...   \n",
       "112                   True               True   \n",
       "113                  False              False   \n",
       "114                  False               True   \n",
       "115                   True               True   \n",
       "116                   True               True   \n",
       "117                  False               True   \n",
       "118                  False               True   \n",
       "119                   True               True   \n",
       "120                   True               True   \n",
       "121                  False              False   \n",
       "122                   True               True   \n",
       "123                  False              False   \n",
       "124                  False               True   \n",
       "125                   True               True   \n",
       "126                  False               True   \n",
       "127                  False               True   \n",
       "128                  False               True   \n",
       "129                  False               True   \n",
       "130                  False               True   \n",
       "131                   True               True   \n",
       "132                  False               True   \n",
       "133                  False               True   \n",
       "134                   True               True   \n",
       "135                  False              False   \n",
       "136                  False               True   \n",
       "137                  False               True   \n",
       "138                   True              False   \n",
       "139                  False               True   \n",
       "140                   True               True   \n",
       "141                   True               True   \n",
       "\n",
       "                                            citing_DOI  conclusions_found  \\\n",
       "0                                        DOI not found              False   \n",
       "1                   \\n      10.1042/BSR20160174\\n                   False   \n",
       "2                \\n      10.3390/ijerph14060602\\n                    True   \n",
       "3                                        DOI not found               True   \n",
       "4                                        DOI not found               True   \n",
       "5    \\n                           10.3892/ijmm.2017...              False   \n",
       "6                                        DOI not found              False   \n",
       "7                   \\n      10.14740/jocmr3114w\\n                   False   \n",
       "8       \\n         10.1007/s13238-014-0123-3\\n                      False   \n",
       "9              \\n        10.3892/ol.2016.5392\\n                     False   \n",
       "10          \\n        10.1186/1476-4598-9-236\\n                      True   \n",
       "11       \\n       10.1371/journal.pone.0081133\\n                    False   \n",
       "12                      \\n      10.1186/bcr2829\\n                   False   \n",
       "13                                       DOI not found              False   \n",
       "14               \\n      10.3390/cancers9050042\\n                    True   \n",
       "15                 \\n      10.3390/ijms18061201\\n                    True   \n",
       "16              \\n      10.1186/1754-6834-6-117\\n                    True   \n",
       "17            \\n       10.1186/1754-6834-6-126\\n                     True   \n",
       "18                  \\n      10.3762/bjnano.7.29\\n                   False   \n",
       "19             \\n      10.1186/1471-2164-14-546\\n                    True   \n",
       "20   \\n             10.3892/mmr.2016.5979\\n        ...               True   \n",
       "21                                       DOI not found              False   \n",
       "22                       \\n      10.1186/ar4282\\n                    True   \n",
       "23           \\n       10.1186/1471-2407-12-111\\n                     True   \n",
       "24           \\n       10.1186/1471-2407-10-318\\n                     True   \n",
       "25           \\n       10.1186/1471-2407-10-616\\n                     True   \n",
       "26            \\n       10.1186/1471-2164-12-54\\n                     True   \n",
       "27            \\n       10.1186/1471-2164-12-62\\n                     True   \n",
       "28            \\n       10.1186/1471-2164-13-43\\n                     True   \n",
       "29           \\n       10.1186/1471-2164-14-371\\n                     True   \n",
       "..                                                 ...                ...   \n",
       "112           \\n      10.1186/1752-0509-7-S5-S5\\n                    True   \n",
       "113         \\n       10.18632/oncotarget.18692\\n                    False   \n",
       "114            \\n      10.3389/fnagi.2011.00003\\n                   False   \n",
       "115  \\n         10.1371/journal.pone.0022075\\n                      False   \n",
       "116            \\n      10.1186/1471-2180-13-101\\n                    True   \n",
       "117  \\n             10.1186/1476-4598-10-21\\n      ...               True   \n",
       "118            \\n      10.1186/1471-2164-14-374\\n                    True   \n",
       "119               \\n      10.1186/1478-811X-9-7\\n                    True   \n",
       "120                                      DOI not found              False   \n",
       "121                \\n      10.3892/ol.2017.6088\\n                   False   \n",
       "122             \\n      10.1186/1471-2407-9-145\\n                    True   \n",
       "123              \\n      10.1186/1755-8794-3-26\\n                    True   \n",
       "124             \\n      10.1186/1752-0509-5-146\\n                    True   \n",
       "125            \\n      10.1186/1756-9966-29-120\\n                    True   \n",
       "126                   \\n       10.1186/bcr1662\\n                    False   \n",
       "127                     \\n      10.1186/bcr2159\\n                    True   \n",
       "128                     \\n      10.1186/bcr2909\\n                   False   \n",
       "129                   \\n       10.1186/bcr2890\\n                     True   \n",
       "130             \\n      10.1186/1471-2407-9-359\\n                    True   \n",
       "131                     \\n      10.1186/bcr2927\\n                    True   \n",
       "132             \\n      10.1186/1423-0127-18-44\\n                    True   \n",
       "133           \\n      10.1186/1471-2202-8-S3-S1\\n                   False   \n",
       "134  \\n           10.3389/neuro.10.009.2008\\n      ...              False   \n",
       "135            \\n      10.3389/fncir.2010.00120\\n                   False   \n",
       "136                                      DOI not found               True   \n",
       "137            \\n      10.1186/gb-2007-8-s1-s12\\n                    True   \n",
       "138    \\n       10.1083/jcb.20070518220090127c\\n                    False   \n",
       "139            \\n      10.1186/1472-6882-13-155\\n                    True   \n",
       "140            \\n        10.3390/ijms18122636\\n                     False   \n",
       "141  \\n               10.1186/1465-9921-13-36\\n    ...               True   \n",
       "\n",
       "     discussion_found  introduction_found  maintext_found  \\\n",
       "0                True                True            True   \n",
       "1                True                True            True   \n",
       "2                True                True            True   \n",
       "3                True                True            True   \n",
       "4               False                True            True   \n",
       "5                True                True            True   \n",
       "6               False               False            True   \n",
       "7                True                True            True   \n",
       "8               False                True            True   \n",
       "9                True                True            True   \n",
       "10              False                True            True   \n",
       "11               True                True            True   \n",
       "12              False               False            True   \n",
       "13               True                True            True   \n",
       "14              False                True            True   \n",
       "15              False                True            True   \n",
       "16               True                True            True   \n",
       "17               True                True            True   \n",
       "18              False               False            True   \n",
       "19               True                True            True   \n",
       "20               True                True            True   \n",
       "21               True                True            True   \n",
       "22               True                True            True   \n",
       "23               True                True            True   \n",
       "24               True                True            True   \n",
       "25               True                True            True   \n",
       "26               True                True            True   \n",
       "27               True                True            True   \n",
       "28               True                True            True   \n",
       "29               True                True            True   \n",
       "..                ...                 ...             ...   \n",
       "112             False                True            True   \n",
       "113              True                True            True   \n",
       "114             False               False            True   \n",
       "115              True                True            True   \n",
       "116              True                True            True   \n",
       "117              True                True            True   \n",
       "118              True                True            True   \n",
       "119             False                True            True   \n",
       "120              True                True            True   \n",
       "121              True                True            True   \n",
       "122              True                True            True   \n",
       "123              True                True            True   \n",
       "124             False               False            True   \n",
       "125              True                True            True   \n",
       "126             False                True            True   \n",
       "127             False                True            True   \n",
       "128             False               False            True   \n",
       "129             False                True            True   \n",
       "130              True                True            True   \n",
       "131              True                True            True   \n",
       "132              True                True            True   \n",
       "133             False               False            True   \n",
       "134              True                True            True   \n",
       "135              True                True            True   \n",
       "136             False                True            True   \n",
       "137             False                True            True   \n",
       "138             False               False            True   \n",
       "139              True                True            True   \n",
       "140              True                True            True   \n",
       "141             False                True            True   \n",
       "\n",
       "             reference_number sentence_citing_conclusions  \\\n",
       "0               b1-cpn-15-361                          []   \n",
       "1                         B49                          []   \n",
       "2         B34-ijerph-14-00602                          []   \n",
       "3                          B5                          []   \n",
       "4                        CR30                          []   \n",
       "5         b21-ijmm-39-04-0936                          []   \n",
       "6                          R1                          []   \n",
       "7                         R04                          []   \n",
       "8                        CR71                          []   \n",
       "9             b32-ol-0-0-5392                          []   \n",
       "10                        B64                          []   \n",
       "11                        B50                          []   \n",
       "12                         B8                          []   \n",
       "13             b34-cpn-14-338                          []   \n",
       "14       B26-cancers-09-00042                          []   \n",
       "15         B115-ijms-18-01201                          []   \n",
       "16                        B31                          []   \n",
       "17                        B25                          []   \n",
       "18                         R1                          []   \n",
       "19                        B43                          []   \n",
       "20         b20-mmr-15-01-0210                          []   \n",
       "21                        R64                          []   \n",
       "22                        B10                          []   \n",
       "23                         B9                          []   \n",
       "24                        B15                          []   \n",
       "25                        B17                          []   \n",
       "26                        B46                          []   \n",
       "27                        B37                          []   \n",
       "28                        B27                          []   \n",
       "29                        B66                          []   \n",
       "..                        ...                         ...   \n",
       "112                        B6                          []   \n",
       "113                        R8                          []   \n",
       "114                        B7                          []   \n",
       "115  pone.0022075-Sebastiani1                          []   \n",
       "116                        B6                          []   \n",
       "117                       B51                          []   \n",
       "118                       B34                          []   \n",
       "119                       B46                          []   \n",
       "120                       R31                          []   \n",
       "121           b18-ol-0-0-6088                          []   \n",
       "122                       B13                          []   \n",
       "123                       B10                          []   \n",
       "124                       B73                          []   \n",
       "125                        B3                          []   \n",
       "126                       B34                          []   \n",
       "127                       B25                          []   \n",
       "128                        B2                          []   \n",
       "129                       B96                          []   \n",
       "130                       B20                          []   \n",
       "131                       B12                          []   \n",
       "132                       B33                          []   \n",
       "133                       B25                          []   \n",
       "134                       B74                          []   \n",
       "135                       B44                          []   \n",
       "136                       B42                          []   \n",
       "137                      B122                          []   \n",
       "138                 Not found                          []   \n",
       "139                       B69                          []   \n",
       "140          B9-ijms-18-02636                          []   \n",
       "141                       B26                          []   \n",
       "\n",
       "                            sentence_citing_discussion  \\\n",
       "0                                                   []   \n",
       "1                                                   []   \n",
       "2    [Other factors included the absence of hand wa...   \n",
       "3                                                   []   \n",
       "4                                                   []   \n",
       "5    [In the present study, the impact of human ADM...   \n",
       "6                                                   []   \n",
       "7    [Because SGLT2 inhibitors decrease insulin lev...   \n",
       "8                                                   []   \n",
       "9    [The latter is able to boost prostate cancer g...   \n",
       "10                                                  []   \n",
       "11   [These results might imply that compensatory i...   \n",
       "12                                                  []   \n",
       "13   [<xref ref-type=\"bibr\" rid=\"b38-cpn-14-338\">\\n...   \n",
       "14                                                  []   \n",
       "15                                                  []   \n",
       "16   [Finally, a fourth challenge may be the appare...   \n",
       "17                                                  []   \n",
       "18                                                  []   \n",
       "19   [</bold>\\n         The alignment was 1,000 tim...   \n",
       "20                                                  []   \n",
       "21                                                  []   \n",
       "22                                                  []   \n",
       "23   [</p>\\n<p>\\n      The ability of miR-135a to p...   \n",
       "24                                                  []   \n",
       "25   [Taken together, it seems that not only the ex...   \n",
       "26   [Tiling array t-statistics represent the signi...   \n",
       "27   [In\\n       <italic>\\n        B. mori\\n       ...   \n",
       "28   [MiR-31, downregulated in BC datasets, was rep...   \n",
       "29   [An interesting recently published study indic...   \n",
       "..                                                 ...   \n",
       "112                                                 []   \n",
       "113                                                 []   \n",
       "114                                                 []   \n",
       "115                                                 []   \n",
       "116  [In this reaction, the ethanolamine moiety is ...   \n",
       "117  [In this study we have identified PIAS1 as a n...   \n",
       "118  [Importantly, computational assessment of GAF5...   \n",
       "119                                                 []   \n",
       "120                                                 []   \n",
       "121                                                 []   \n",
       "122                                                 []   \n",
       "123                                                 []   \n",
       "124                                                 []   \n",
       "125                                                 []   \n",
       "126                                                 []   \n",
       "127                                                 []   \n",
       "128                                                 []   \n",
       "129                                                 []   \n",
       "130  [</p>\\n<p>\\n     To determine the sensitivity ...   \n",
       "131                                                 []   \n",
       "132                                                 []   \n",
       "133                                                 []   \n",
       "134                                                 []   \n",
       "135  [As a result of this, a vast reorganization of...   \n",
       "136                                                 []   \n",
       "137                                                 []   \n",
       "138                                                 []   \n",
       "139  [The higher concentration is found in leaf., S...   \n",
       "140                                                 []   \n",
       "141                                                 []   \n",
       "\n",
       "                                 sentence_citing_intro  \\\n",
       "0    [Han and Renshaw\\n     <xref ref-type=\"bibr\" r...   \n",
       "1                                                   []   \n",
       "2                                                   []   \n",
       "3    [Overexpression of betatrophin in mice livers ...   \n",
       "4                                                   []   \n",
       "5    [The biological characteristics and differenti...   \n",
       "6                                                   []   \n",
       "7    [</p>\\n<p>\\n     On the other hand, recent cli...   \n",
       "8    [Betatrophin is mainly expressed in the liver ...   \n",
       "9                                                   []   \n",
       "10                                                  []   \n",
       "11                                                  []   \n",
       "12                                                  []   \n",
       "13                                                  []   \n",
       "14                                                  []   \n",
       "15                                                  []   \n",
       "16                                                  []   \n",
       "17   [It is therefore critical to find approaches t...   \n",
       "18                                                  []   \n",
       "19                                                  []   \n",
       "20                                                  []   \n",
       "21                                                  []   \n",
       "22                                                  []   \n",
       "23   [The abnormal expression profiles of miRNAs ha...   \n",
       "24   [For example, miR-155 may play an important ro...   \n",
       "25   [In the present study, we applied anti-miR mi...   \n",
       "26                                                  []   \n",
       "27                                                  []   \n",
       "28                                                  []   \n",
       "29                                                  []   \n",
       "..                                                 ...   \n",
       "112  [In this study, the focus is on using gene exp...   \n",
       "113                                                 []   \n",
       "114                                                 []   \n",
       "115  [They used these posterior probabilities to ra...   \n",
       "116  [Catalysis of arginine methylation is carried ...   \n",
       "117                                                 []   \n",
       "118                                                 []   \n",
       "119  [</p>\\n<p>\\n      An additional level of regul...   \n",
       "120  [<xref ref-type=\"bibr\" rid=\"R37\">\\n<sup>\\n    ...   \n",
       "121                                                 []   \n",
       "122  [Similarly, other groups have previously repor...   \n",
       "123                                                 []   \n",
       "124                                                 []   \n",
       "125  [After the \"training\" of a predictor it must b...   \n",
       "126                                                 []   \n",
       "127                                                 []   \n",
       "128                                                 []   \n",
       "129                                                 []   \n",
       "130                                                 []   \n",
       "131  [The 4T1 cells were derived from the mammary t...   \n",
       "132                                                 []   \n",
       "133                                                 []   \n",
       "134  [In vertebrates, odor mixture interactions wer...   \n",
       "135                                                 []   \n",
       "136                                                 []   \n",
       "137                                                 []   \n",
       "138                                                 []   \n",
       "139                                                 []   \n",
       "140  [In vitro and in vivo preclinical studies reve...   \n",
       "141  [The primary objective of this study was to de...   \n",
       "\n",
       "                              sentence_citing_maintext  \n",
       "0    [<xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\"> 1 ...  \n",
       "1    [* indicates <italic> P </italic> &lt;0.05 for...  \n",
       "2    [Other factors included the absence of hand wa...  \n",
       "3    [However these inspiring discoveries were late...  \n",
       "4                                                   []  \n",
       "5    [Its transient overexpression in the liver ind...  \n",
       "6    [<xref ref-type=\"bibr\" rid=\"R9\"><sup> 9 </sup>...  \n",
       "7    [However, some recent studies show positive as...  \n",
       "8    [Betatrophin is mainly expressed in the liver ...  \n",
       "9                                                   []  \n",
       "10                                                  []  \n",
       "11                                                  []  \n",
       "12                                                  []  \n",
       "13                                                  []  \n",
       "14   [A study in pancreatic cancer patient tumors, ...  \n",
       "15   [Also, it has recently been shown that patient...  \n",
       "16   [Although degradation of lignocellulose has be...  \n",
       "17   [It is therefore critical to find approaches t...  \n",
       "18   [Spiros Skourtis introduced the audience to th...  \n",
       "19   [Nonetheless, using RaXML [ <xref ref-type=\"bi...  \n",
       "20                                                  []  \n",
       "21                                                  []  \n",
       "22   [These results argue that RhoA is a target of ...  \n",
       "23   [The abnormal expression profiles of miRNAs ha...  \n",
       "24   [MiR-21 has been shown to stimulate cell invas...  \n",
       "25   [Taken together, it seems that not only the ex...  \n",
       "26   [Tiling array t-statistics represent the signi...  \n",
       "27   [In <italic> Drosophila </italic> it is expres...  \n",
       "28   [The tumor suppressor miRNA of miR-31 were dow...  \n",
       "29   [miR-31 also inhibits breast cancer metastasis...  \n",
       "..                                                 ...  \n",
       "112  [In this study, the focus is on using gene exp...  \n",
       "113                                                 []  \n",
       "114  [There is therefore a move among geneticists a...  \n",
       "115  [They used these posterior probabilities to ra...  \n",
       "116  [Catalysis of arginine methylation is carried ...  \n",
       "117  [</given-names></name><etal></etal></person-gr...  \n",
       "118  [Importantly, computational assessment of GAF5...  \n",
       "119  [As an example, phosphorylation of nuclear cas...  \n",
       "120  [<xref ref-type=\"bibr\" rid=\"R36\"><sup> 36 </su...  \n",
       "121                                                 []  \n",
       "122  [Furthermore, additional studies to validate t...  \n",
       "123                                                 []  \n",
       "124  [More recently, new powerful transcriptomics t...  \n",
       "125  [After the \"training\" of a predictor it must b...  \n",
       "126  [The predictive capacity of these signatures w...  \n",
       "127  [The authors conclude that selecting patients ...  \n",
       "128  [breast cancer intrinsic subtype analysis, pat...  \n",
       "129  [Subsequently, after a series of investigation...  \n",
       "130  [For both cytotoxicity assays a correlation wi...  \n",
       "131  [</p><p> In this study we demonstrated that th...  \n",
       "132  [After scraping, centrifuging and rinsing twic...  \n",
       "133  [Apparently, black raspberries and Provenal ...  \n",
       "134  [Recent behavioral studies could show that a p...  \n",
       "135                                                 []  \n",
       "136  [Nevertheless, testing the genetic stability o...  \n",
       "137  [Although retroviruses do not exhibit a strong...  \n",
       "138                                                 []  \n",
       "139  [The higher concentration is found in leaf., S...  \n",
       "140  [</p><p> Cenerimod (ACT-334441) is a potent S1...  \n",
       "141  [</p></sec><sec sec-type=\"methods\"><title> Met...  \n",
       "\n",
       "[142 rows x 15 columns]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import imp\n",
    "import sys\n",
    "sys.path.insert(0, \"./modules\")\n",
    "from modules import get_df_analise_section\n",
    "#imp.reload()\n",
    "\n",
    "list_DOI_cited = df_Articles_before_after_retraction.DOI_cited.unique()\n",
    "\n",
    "df_1sentence = pd.DataFrame() # To get only the sentence citing\n",
    "df_3sentences = pd.DataFrame() # To get the sentence citing plus the following 3.\n",
    "\n",
    "df_5sentences = pd.DataFrame()\n",
    "\n",
    "for index, row in df_Articles_before_after_retraction.iterrows():\n",
    "    \n",
    "    df_analysis_row = get_df_analise_section.get_df(row.DOI_cited, [row.article_citing])\n",
    "    #df_1sentence = df.append(df_analysis_row)\n",
    "    df_1sentence = df_1sentence.append(df_analysis_row)\n",
    "\n",
    "    \n",
    "    df_3_analysis_row = get_df_analise_section.get_df(row.DOI_cited, [row.article_citing], 3) # We will get 3 additinal sentences\n",
    "    df_3sentences = df_3sentences.append(df_3_analysis_row)\n",
    "    \n",
    "    df_5_analysis_row = get_df_analise_section.get_df(row.DOI_cited, [row.article_citing], 5) # We will get 3 additinal sentences\n",
    "    df_5sentences = df_5sentences.append(df_5_analysis_row)\n",
    "    \n",
    "    \n",
    "df_1sentence.reset_index(drop = True)\n",
    "df_3sentences.reset_index(drop = True)\n",
    "\n",
    "df_5sentences.reset_index(drop = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cited_DOI</th>\n",
       "      <th>cited_in_conclusions</th>\n",
       "      <th>cited_in_discussion</th>\n",
       "      <th>cited_in_introduction</th>\n",
       "      <th>cited_in_maintext</th>\n",
       "      <th>citing_DOI</th>\n",
       "      <th>conclusions_found</th>\n",
       "      <th>discussion_found</th>\n",
       "      <th>introduction_found</th>\n",
       "      <th>maintext_found</th>\n",
       "      <th>reference_number</th>\n",
       "      <th>sentence_citing_conclusions</th>\n",
       "      <th>sentence_citing_discussion</th>\n",
       "      <th>sentence_citing_intro</th>\n",
       "      <th>sentence_citing_maintext</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>b1-cpn-15-361</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\"&gt;\\n ...</td>\n",
       "      <td>[&lt;xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\"&gt; 1)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.1042/BSR20160174\\n</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B49</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[To verify the activation of FOXO1in our mode...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1371/journal.pone.0164571</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>\\n      10.3390/ijerph14060602\\n</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B34-ijerph-14-00602</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Boiling or chlorinating water at the point of...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Boiling or chlorinating water at the point of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>B5</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[in a S961-induced insulin resistance mouse mo...</td>\n",
       "      <td>[in a S961-induced insulin resistance mouse mo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1016/j.cell.2013.04.008</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>DOI not found</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>CR30</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      cited_DOI  cited_in_conclusions  cited_in_discussion  \\\n",
       "0     10.1186/s13033-017-0143-5                 False                False   \n",
       "0            10.1002/cbin.10291                 False                False   \n",
       "0  10.1371/journal.pone.0164571                 False                 True   \n",
       "0    10.1016/j.cell.2013.04.008                 False                False   \n",
       "0    10.1016/j.cell.2013.04.008                 False                False   \n",
       "\n",
       "   cited_in_introduction  cited_in_maintext  \\\n",
       "0                   True               True   \n",
       "0                  False               True   \n",
       "0                  False               True   \n",
       "0                   True               True   \n",
       "0                  False              False   \n",
       "\n",
       "                              citing_DOI  conclusions_found  discussion_found  \\\n",
       "0                          DOI not found              False              True   \n",
       "0     \\n      10.1042/BSR20160174\\n                   False              True   \n",
       "0  \\n      10.3390/ijerph14060602\\n                    True              True   \n",
       "0                          DOI not found               True              True   \n",
       "0                          DOI not found               True             False   \n",
       "\n",
       "   introduction_found  maintext_found     reference_number  \\\n",
       "0                True            True        b1-cpn-15-361   \n",
       "0                True            True                  B49   \n",
       "0                True            True  B34-ijerph-14-00602   \n",
       "0                True            True                   B5   \n",
       "0                True            True                 CR30   \n",
       "\n",
       "  sentence_citing_conclusions  \\\n",
       "0                          []   \n",
       "0                          []   \n",
       "0                          []   \n",
       "0                          []   \n",
       "0                          []   \n",
       "\n",
       "                          sentence_citing_discussion  \\\n",
       "0                                                 []   \n",
       "0                                                 []   \n",
       "0  [Boiling or chlorinating water at the point of...   \n",
       "0                                                 []   \n",
       "0                                                 []   \n",
       "\n",
       "                               sentence_citing_intro  \\\n",
       "0  [<xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\">\\n ...   \n",
       "0                                                 []   \n",
       "0                                                 []   \n",
       "0  [in a S961-induced insulin resistance mouse mo...   \n",
       "0                                                 []   \n",
       "\n",
       "                            sentence_citing_maintext  \n",
       "0  [<xref ref-type=\"bibr\" rid=\"b1-cpn-15-361\"> 1)...  \n",
       "0  [To verify the activation of FOXO1in our mode...  \n",
       "0  [Boiling or chlorinating water at the point of...  \n",
       "0  [in a S961-induced insulin resistance mouse mo...  \n",
       "0                                                 []  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_1sentence.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['cited_DOI', 'cited_in_conclusions', 'cited_in_discussion',\n",
       "       'cited_in_introduction', 'cited_in_maintext', 'citing_DOI',\n",
       "       'conclusions_found', 'discussion_found', 'introduction_found',\n",
       "       'maintext_found', 'reference_number', 'sentence_citing_conclusions',\n",
       "       'sentence_citing_discussion', 'sentence_citing_intro',\n",
       "       'sentence_citing_maintext'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_1sentence.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "53"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_1sentence.cited_DOI.unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "142"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_1sentence)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "df.sentence_citing_discussion.iloc[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Get Dataframe with preprocessed sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "#for index, row in df.iterrows():\n",
    "import re\n",
    "import numpy as np\n",
    "\n",
    "\"\"\"\n",
    "df_1sentence[['sentence_citing_conclusions',\n",
    "       'sentence_citing_discussion', 'sentence_citing_intro',\n",
    "       'sentence_citing_maintext']]\n",
    "\"\"\"\n",
    "\n",
    "def remove_citations(text):\n",
    "    number_citations = text.count(\"[\")\n",
    "    while number_citations > 0:\n",
    "        init = text.find(\"[\") \n",
    "        end = text.find(\"]\") \n",
    "        text = text.replace(text[init : end +1 ], \" \") # replace the string between two delimiters\n",
    "        number_citations -= 1\n",
    "    return text\n",
    "\n",
    "def remove_html_tags(text):\n",
    "    to_clean = re.compile('<.*?>')\n",
    "    clean_text = re.sub(to_clean, '', text)\n",
    "    return clean_text\n",
    "    \n",
    "\n",
    "def get_df_sentences_preprocessed_and_classified(dataframe):\n",
    "    \n",
    "    list_all_citing_citing_sentences = []\n",
    "    \n",
    "    for index, row in dataframe.iterrows():\n",
    "\n",
    "        list_sentences_citing_conclusions = row['sentence_citing_conclusions']\n",
    "        list_sentences_citing_discussion = row['sentence_citing_discussion']\n",
    "        list_sentences_citing_intro = row['sentence_citing_intro']\n",
    "        list_sentences_citing_maintext = row['sentence_citing_maintext']\n",
    "\n",
    "        if list_sentences_citing_conclusions != None:\n",
    "            sentences_conclusions = \" \".join(list_sentences_citing_conclusions)\n",
    "            sentences_conclusions = remove_html_tags(sentences_conclusions)\n",
    "            sentences_conclusions = remove_citations(sentences_conclusions)\n",
    "        else:\n",
    "            sentences_conclusions = \"\"\n",
    "\n",
    "        if list_sentences_citing_discussion != None:\n",
    "            sentences_discussion = \" \".join(list_sentences_citing_discussion)\n",
    "            sentences_discussion = remove_html_tags(sentences_discussion)\n",
    "            sentences_discussion = remove_citations(sentences_discussion)\n",
    "\n",
    "        else:\n",
    "            sentences_discussion = \"\"\n",
    "\n",
    "        if list_sentences_citing_intro != None:\n",
    "            sentences_intro = \" \".join(list_sentences_citing_intro)\n",
    "            sentences_intro = remove_html_tags(sentences_intro)\n",
    "            sentences_intro = remove_citations(sentences_intro)\n",
    "\n",
    "        else:\n",
    "            sentences_intro = \"\"\n",
    "\n",
    "        if list_sentences_citing_maintext != None:\n",
    "            sentences_maintext = \" \".join(list_sentences_citing_maintext)\n",
    "            sentences_maintext = remove_html_tags(sentences_maintext)\n",
    "            sentences_maintext = remove_citations(sentences_maintext)\n",
    "        else:\n",
    "            sentences_maintext = \"\"\n",
    "\n",
    "        all_sentences = (sentences_maintext + \" \" + \n",
    "                         sentences_discussion + \" \" +\n",
    "                         sentences_intro + \" \" +\n",
    "                         sentences_maintext)\n",
    "        if all_sentences != \"   \":\n",
    "            list_all_citing_citing_sentences.append(all_sentences)\n",
    "        else:\n",
    "            list_all_citing_citing_sentences.append(np.nan)\n",
    "\n",
    "    #print(all_sentences)\n",
    "\n",
    "    dataframe_sentences_classification = pd.concat([df_Articles_before_after_retraction[[\"DOI_cited\", \n",
    "                                                                                         \"doi_article_citing\",\n",
    "                                                                                         #\"pmid_article_citing\",\n",
    "                                                                                         \"before_retraction\",\n",
    "                                                                                         \"after_retraction\"]],\n",
    "                                            pd.DataFrame({\"sentences_citing\" : list_all_citing_citing_sentences\n",
    "                                                          })\n",
    "                                            ], axis = 1)\n",
    "    return dataframe_sentences_classification\n",
    "\n",
    "df1sentence_sentences_classification = get_df_sentences_preprocessed_and_classified(df_1sentence)\n",
    "df3sentences_sentences_classification = get_df_sentences_preprocessed_and_classified(df_3sentences)\n",
    "\n",
    "df5sentences_sentences_classification = get_df_sentences_preprocessed_and_classified(df_5sentences)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "##############TEST####################"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "#for index, row in df.iterrows():\n",
    "import re\n",
    "import numpy as np\n",
    "\n",
    "\"\"\"\n",
    "df_1sentence[['sentence_citing_conclusions',\n",
    "       'sentence_citing_discussion', 'sentence_citing_intro',\n",
    "       'sentence_citing_maintext']]\n",
    "\"\"\"\n",
    "\n",
    "def remove_citations(text):\n",
    "    number_citations = text.count(\"[\")\n",
    "    while number_citations > 0:\n",
    "        init = text.find(\"[\") \n",
    "        end = text.find(\"]\") \n",
    "        text = text.replace(text[init : end +1 ], \" \") # replace the string between two delimiters\n",
    "        number_citations -= 1\n",
    "    return text\n",
    "\n",
    "def remove_html_tags(text):\n",
    "    to_clean = re.compile('<.*?>')\n",
    "    clean_text = re.sub(to_clean, '', text)\n",
    "    return clean_text\n",
    "    \n",
    "\n",
    "def get_df_sentences_preprocessed_and_classified(dataframe):\n",
    "    \n",
    "    list_all_citing_citing_sentences = []\n",
    "    \n",
    "    for index, row in dataframe.iterrows():\n",
    "\n",
    "        list_sentences_citing_conclusions = row['sentence_citing_conclusions']\n",
    "        list_sentences_citing_discussion = row['sentence_citing_discussion']\n",
    "        list_sentences_citing_intro = row['sentence_citing_intro']\n",
    "        list_sentences_citing_maintext = row['sentence_citing_maintext']\n",
    "\n",
    "        if list_sentences_citing_conclusions != None:\n",
    "            sentences_conclusions = \" \".join(list_sentences_citing_conclusions)\n",
    "            sentences_conclusions = remove_html_tags(sentences_conclusions)\n",
    "            #sentences_conclusions = remove_citations(sentences_conclusions)\n",
    "        else:\n",
    "            sentences_conclusions = \"\"\n",
    "\n",
    "        if list_sentences_citing_discussion != None:\n",
    "            sentences_discussion = \" \".join(list_sentences_citing_discussion)\n",
    "            sentences_discussion = remove_html_tags(sentences_discussion)\n",
    "            #sentences_discussion = remove_citations(sentences_discussion)\n",
    "\n",
    "        else:\n",
    "            sentences_discussion = \"\"\n",
    "\n",
    "        if list_sentences_citing_intro != None:\n",
    "            sentences_intro = \" \".join(list_sentences_citing_intro)\n",
    "            sentences_intro = remove_html_tags(sentences_intro)\n",
    "            #sentences_intro = remove_citations(sentences_intro)\n",
    "\n",
    "        else:\n",
    "            sentences_intro = \"\"\n",
    "\n",
    "        if list_sentences_citing_maintext != None:\n",
    "            sentences_maintext = \" \".join(list_sentences_citing_maintext)\n",
    "            sentences_maintext = remove_html_tags(sentences_maintext)\n",
    "            #sentences_maintext = remove_citations(sentences_maintext)\n",
    "        else:\n",
    "            sentences_maintext = \"\"\n",
    "\n",
    "        all_sentences = (sentences_maintext + \" \" + \n",
    "                         sentences_discussion + \" \" +\n",
    "                         sentences_intro + \" \" +\n",
    "                         sentences_maintext)\n",
    "        if all_sentences != \"   \":\n",
    "            list_all_citing_citing_sentences.append(all_sentences)\n",
    "        else:\n",
    "            list_all_citing_citing_sentences.append(np.nan)\n",
    "\n",
    "    #print(all_sentences)\n",
    "\n",
    "    dataframe_sentences_classification = pd.concat([df_Articles_before_after_retraction[[\"DOI_cited\", \n",
    "                                                                                         \"doi_article_citing\",\n",
    "                                                                                         #\"pmid_article_citing\",\n",
    "                                                                                         \"before_retraction\",\n",
    "                                                                                         \"after_retraction\"]],\n",
    "                                            pd.DataFrame({\"sentences_citing\" : list_all_citing_citing_sentences\n",
    "                                                          })\n",
    "                                            ], axis = 1)\n",
    "    return dataframe_sentences_classification\n",
    "\n",
    "df1sentence_sentences_classification = get_df_sentences_preprocessed_and_classified(df_1sentence)\n",
    "df3sentences_sentences_classification = get_df_sentences_preprocessed_and_classified(df_3sentences)\n",
    "\n",
    "df5sentences_sentences_classification = get_df_sentences_preprocessed_and_classified(df_5sentences)\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " 1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  \n",
      "      1)\n",
      "     \n",
      "     Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,\n",
      "     \n",
      "      4)\n",
      "     \n",
      "     research has already begun to investigate treatments for the disorder. \n",
      "      1\n",
      "     \n",
      "     \n",
      "     \n",
      "      3)\n",
      "     \n",
      "     In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.\n",
      "To verify the activation of FOXO1in our model, we measured mRNA levels of  PIK3C3  and  Sod2  , gene targets of FOXO1 that also encode for autophagy-associated proteins [  47    49  ].   To verify the activation of FOXO1in our model, we measured mRNA levels of  PIK3C3  and  Sod2  , gene targets of FOXO1 that also encode for autophagy-associated proteins [  47    49  ].\n",
      "Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ]. Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [\n",
      "     \n",
      "      32\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      33\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ].  Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ].\n",
      "in a S961-induced insulin resistance mouse model [  5  ].  in a S961-induced insulin resistance mouse model [\n",
      "                 \n",
      "                  5\n",
      "                 \n",
      "                 ]. in a S961-induced insulin resistance mouse model [  5  ].\n",
      "nan\n",
      " Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ). However, the effects of betatrophin on human islets were not analyzed (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). Betatrophin is a novel -cell mitogen reported by Yi\n",
      "                           \n",
      "                            et al\n",
      "                           \n",
      "                           (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ) that enhances endogenous -cell replication and improves glucose tolerance and insulin secretion following hydrodynamic tail injections of plasmids encoding mouse and human betatrophin into mice with insulin resistance induced by the insulin receptor antagonist, S961. Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). \n",
      "\n",
      "                           Betatrophin, also known as lipasin (\n",
      "                           \n",
      "                            19\n",
      "                           \n",
      "                           ) or angiopoietin-like 8 (\n",
      "                           \n",
      "                            20\n",
      "                           \n",
      "                           ), was recently described as a potent stimulator of mouse -cell proliferation (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ).  Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ).\n",
      " 16  However, although these findings are interesting, the receptor for HGF is the protooncogene C-Met, which may pose a problem from a drugability safety point of view.  1  The official name of the gene encoding mouse betatrophin is Gm6484, but it has been annotated a number of times under different names: EG624219  2  ,  3  , RIFL  4  , Lipasin  5  and ANGPTL8.  14  ,  15  These data suggest the existence of a circulating factor induced in glucagon resistant states which can induce -cell proliferation independent of a vagus nerve signal to the pancreas.  Interestingly, it was recently reported that a liver specific glucagon receptor knockout displays increased -cell proliferation and hyperplasia similar to what has been previously reported for the global glucagon receptor knockout,  14  and that wild-type islets transplanted under the kidney capsule of glucagon receptor deficient mice or the liver specific knockout likewise increase their -cell proliferation.  1  ,  19  They confirm, albeit in a NOD-Scid immunodeficient background, that S961 induced insulin resistance results in a marked increase in hepatic betatrophin expression and an increase in the proliferation of the pancreatic -cells. This observationcombined with studies from the same group demonstrating that a liver specific INSR knockout displays a large increase in the pancreatic -cell mass  10  whereas muscle specific INSR knockout has normal glucose metabolism  11  led the authors to suggest the liver as a possible source of the circulating factor.  13  Together, these data provide compelling evidence for a circulating liver-derived factor in insulin resistant mice that is able to induce proliferation of mouse and human -cells.  1  They developed an elegant pharmacological model of insulin resistance utilizing a peptide insulin receptor antagonist, S961, invented by Lauge Schffer at Novo Nordisk A/S  17  which induces severe insulin resistance when infused in mice.  12  The observation that a liver-specific INSR knockout (the LIRKO mouse) results in increased -cell mass was further studied by the group of Rohit N. Kulkarni: they used a parabiotic model where the circulation of mice is coupled by surgery thus allowing the study of the effect of circulating factors between mice of different genotypes.  18  To investigate the effect of betatrophin in vivo  ,  expression in the liver was achieved by hydrodynamic tail injection of expression plasmids encoding mouse and human betatrophin.  1  did not investigate the effect of betatrophin on triglycerides, the consequence of loss-of-function of betatrophin on -cell mass and glucose homeostasis, or the dependence of the effect on ANGPTL3.  13  Importantly, it was also shown that serum from LIRKO mice was able to induce specific -cell replication in wild-type mice by interperitoneal serum injection and that LIRKO serum could increase mouse and human -cell replication rates in vitro.  13  It was further shown that wild-type islets transplanted into the kidney capsule of LIRKO mice also increased their proliferation rate demonstrating that the effect on proliferation is uncoupled from the vagus innervation of the pancreas in this model.    16  However, although these findings are interesting, the receptor for HGF is the protooncogene C-Met, which may pose a problem from a drugability safety point of view.  1  The official name of the gene encoding mouse betatrophin is Gm6484, but it has been annotated a number of times under different names: EG624219  2  ,  3  , RIFL  4  , Lipasin  5  and ANGPTL8.  14  ,  15  These data suggest the existence of a circulating factor induced in glucagon resistant states which can induce -cell proliferation independent of a vagus nerve signal to the pancreas.  Interestingly, it was recently reported that a liver specific glucagon receptor knockout displays increased -cell proliferation and hyperplasia similar to what has been previously reported for the global glucagon receptor knockout,  14  and that wild-type islets transplanted under the kidney capsule of glucagon receptor deficient mice or the liver specific knockout likewise increase their -cell proliferation.  1  ,  19  They confirm, albeit in a NOD-Scid immunodeficient background, that S961 induced insulin resistance results in a marked increase in hepatic betatrophin expression and an increase in the proliferation of the pancreatic -cells. This observationcombined with studies from the same group demonstrating that a liver specific INSR knockout displays a large increase in the pancreatic -cell mass  10  whereas muscle specific INSR knockout has normal glucose metabolism  11  led the authors to suggest the liver as a possible source of the circulating factor.  13  Together, these data provide compelling evidence for a circulating liver-derived factor in insulin resistant mice that is able to induce proliferation of mouse and human -cells.  1  They developed an elegant pharmacological model of insulin resistance utilizing a peptide insulin receptor antagonist, S961, invented by Lauge Schffer at Novo Nordisk A/S  17  which induces severe insulin resistance when infused in mice.  12  The observation that a liver-specific INSR knockout (the LIRKO mouse) results in increased -cell mass was further studied by the group of Rohit N. Kulkarni: they used a parabiotic model where the circulation of mice is coupled by surgery thus allowing the study of the effect of circulating factors between mice of different genotypes.  18  To investigate the effect of betatrophin in vivo  ,  expression in the liver was achieved by hydrodynamic tail injection of expression plasmids encoding mouse and human betatrophin.  1  did not investigate the effect of betatrophin on triglycerides, the consequence of loss-of-function of betatrophin on -cell mass and glucose homeostasis, or the dependence of the effect on ANGPTL3.  13  Importantly, it was also shown that serum from LIRKO mice was able to induce specific -cell replication in wild-type mice by interperitoneal serum injection and that LIRKO serum could increase mouse and human -cell replication rates in vitro.  13  It was further shown that wild-type islets transplanted into the kidney capsule of LIRKO mice also increased their proliferation rate demonstrating that the effect on proliferation is uncoupled from the vagus innervation of the pancreas in this model.\n",
      "The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ]. Because SGLT2 inhibitors decrease insulin levels [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], and because circulating betatrophin levels were remarkably elevated by administration of an insulin receptor blocker resulting in liver insulin resistance [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], we hypothesized that administration of SGLT2 inhibitors, such as canagliflozin, may increase circulating betatrophin levels and therefore may influence serum lipid concentrations. The reason for the potentially positive association between betatrophin and glycemic control as evaluated by HbA1c or FPG remains unclear since the effect of betatrophin on regeneration of pancreatic  cells which was previously reported [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ] is currently considered to be negative [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ].\n",
      " OTHER FACTORS  Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,  2013  ).  \n",
      "\n",
      "\n",
      "\n",
      "         OTHER FACTORS\n",
      "        \n",
      "\n",
      "         Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,\n",
      "         \n",
      "          2013\n",
      "         \n",
      "         ).  OTHER FACTORS  Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,  2013  ).\n",
      " Another example is the Akt signaling cascade (\n",
      "        \n",
      "         32\n",
      "        \n",
      "        ) or the overexpression of human epidermal growth factor receptor-2/neu tyrosine kinase.  \n",
      "nan\n",
      " Although the exact mechanism, by which PTEN4A could block TGF-induced -catenin translocation from the cell membrane into the cytoplasm, remains elusive, a previous study has suggested that phosphorylation of -catenin might induce its translocation via dissociation from E-cadherin complexes [\n",
      "      \n",
      "       50\n",
      "      \n",
      "      ].  \n",
      "nan\n",
      " \n",
      "     34)\n",
      "    \n",
      "    Results from our previous study\n",
      "    \n",
      "     19)\n",
      "    \n",
      "    showed that marked increases in astrocyte number and level of GFAP expression in the PND 21 frontal cortex after postnatal VPA treatment.  \n",
      "One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].   One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].\n",
      "Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].   Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].\n",
      "Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [  31  ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [  31  ] created a strain of  B. subtilis  able to grow on untreated natural feedstocks through expression of  C. cellulolyticum  Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin. Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ] created a strain of\n",
      "      \n",
      "       B. subtilis\n",
      "      \n",
      "      able to grow on untreated natural feedstocks through expression of\n",
      "      \n",
      "       C. cellulolyticum\n",
      "      \n",
      "      Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin.  Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [  31  ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [  31  ] created a strain of  B. subtilis  able to grow on untreated natural feedstocks through expression of  C. cellulolyticum  Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin.\n",
      "Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [  16  ,  18  -  21  ,  25  ,  26  ].  Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       18\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       26\n",
      "      \n",
      "      ]. Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [  16  ,  18  -  21  ,  25  ,  26  ].\n",
      "One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].   One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].\n",
      "Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [  43  ]. Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [\n",
      "       \n",
      "        43\n",
      "       \n",
      "       ].  Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [  43  ].\n",
      "nan\n",
      "nan\n",
      "RhoA has been reported to be one of the targets of miR-31 in breast cancer [  10  ], and plays an important role as a molecular switch in transducing extracellular signals to actin and microtubule cytoskeleton [  11  ].   RhoA has been reported to be one of the targets of miR-31 in breast cancer [  10  ], and plays an important role as a molecular switch in transducing extracellular signals to actin and microtubule cytoskeleton [  11  ].\n",
      "The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [  3  ,  4  ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [  5  -  9  ]. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [  32  ] and pro-metastatic [  5  ,  6  ] or anti-metastatic functions [  9  ] have been identified. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [\n",
      "      \n",
      "       32\n",
      "      \n",
      "      ] and pro-metastatic [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ] or anti-metastatic functions [\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ] have been identified. The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      -\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ]. The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [  3  ,  4  ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [  5  -  9  ]. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [  32  ] and pro-metastatic [  5  ,  6  ] or anti-metastatic functions [  9  ] have been identified.\n",
      " Recently, miRNAs have been shown to play a role in invasion and metastasis [  11  -  15  ].  \n",
      "\n",
      "      Recently, miRNAs have been shown to play a role in invasion and metastasis [\n",
      "      \n",
      "       11\n",
      "      \n",
      "      -\n",
      "      \n",
      "       15\n",
      "      \n",
      "      ].  Recently, miRNAs have been shown to play a role in invasion and metastasis [  11  -  15  ].\n",
      "Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [  17  ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [  18  ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [  6  -  10  ], head and neck squamous cell carcinoma (HNSCC) [  11  ], hepatocellular carcinoma [  12  ], squamous cell carcinoma of tongue [  13  ], and lung cancer [  14  ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [  2  ], prostate cancer [  15  ], gastric cancer [  16  ], breast cancer [  17  ], and serous ovarian cancer [  18  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation  in vitro  [  17  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [\n",
      "      \n",
      "       18\n",
      "      \n",
      "      ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ], head and neck squamous cell carcinoma (HNSCC) [\n",
      "      \n",
      "       11\n",
      "      \n",
      "      ], hepatocellular carcinoma [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ], squamous cell carcinoma of tongue [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ], and lung cancer [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ], prostate cancer [\n",
      "      \n",
      "       15\n",
      "      \n",
      "      ], gastric cancer [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ], breast cancer [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ], and serous ovarian cancer [\n",
      "      \n",
      "       18\n",
      "      \n",
      "      ]. Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [  17  ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [  18  ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [  6  -  10  ], head and neck squamous cell carcinoma (HNSCC) [  11  ], hepatocellular carcinoma [  12  ], squamous cell carcinoma of tongue [  13  ], and lung cancer [  14  ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [  2  ], prostate cancer [  15  ], gastric cancer [  16  ], breast cancer [  17  ], and serous ovarian cancer [  18  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation  in vitro  [  17  ].\n",
      " H3K9Ac ChIP  L v P  p  L v 5Aza  p  P v 5Aza  p  Epi./Cancer  MIRLET7c  21  +  34.26  -0.14  3.07  54.948  *  0.986  1.505  -/[  33  ]  MIR141  12  +  7.2  -0.46  4.31  2.928  *  2.235  *  1.110  [  34  ]  MIR15b  3  +  11.41  -4.65  -4.02  2.071  *  0.616  0.986  -/[  35  ]  MIR16-2  3  +  10.52  -3.6  -2.54  2.713  *  1.424  *  0.742  -/[  36  ]  MIR423  17  +  8.91  -0.81  2.39  4.857  *  0.774  2.445  *  -/[  37  ]  MIR491  9  +  9.03  -2.08  0.83  5.352  *  1.117  1.301  -/[  38  ]  MIR615  12  +  4.03  -3.45  5.5  1.9E+03  *  1.231  32.672  *  -/-  MIR618  12  -  4.18  2.44  5.73  4.1E+02  *  1.945  *  1.385  -/[  39  ]  MIR99a  21  +  26.52  -2.9  3.72  2.329  *  1.035  0.908  -/[  40  ]  MIR130a  11  +  -7.19  -1.92  -3.85  0.004  *  2.532  *  1.102  -/[  41  ]  MIR135b  1  -  -3.93  2.8  -7.82  0.003  *  0.337  1.828  -/[  42  ]  MIR137  1  -  -3.81  1.19  -3.41  0.016  *  2.173  5.897  [  43  ]  MIR196b  7  -  -11.26  2.07  -5.05  0.356  *  1.591  *  0.829  [  21  ]/[  44  ]  MIR205  1  +  -26.47  2.37  -12.09  1.2E-05  *  1.1E+02  *  1.659  [  13  ]/[  15  ]  MIR21  17  +  -21.68  13.78  -12.98  0.637  *  2.362  *  3.272  *  [  19  ]/[  18  ]  MIR24-1  9  +  -5.64  3.73  -0.27  0.057  *  1.569  *  1.231  -/[  45  ]  MIR31  9  -  -2.79  -9.75  -3.04  1.7E-06  *  1.357  0.959  -/[  46  ]  MIR376a-2  14  +  -5.98  2.96  2.59  0.020  *  4.857  2.888  -/[  47  ]  MIR424  X  -  -3.94  1.95  -2.56  0.259  *  0.883  4.287  *  -/[  39  ]  MIR654  14  +  -5.42  2.57  4.14  0.136  *  1.357  0.295  *  -/-  Table listing significantly changed miRNA genes identified in this study. \n",
      "\n",
      "\n",
      "           H3K9Ac ChIP\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           L v P\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           L v 5Aza\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           P v 5Aza\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           Epi./Cancer\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIRLET7c\n",
      "          \n",
      "\n",
      "\n",
      "          21\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          34.26\n",
      "         \n",
      "\n",
      "          -0.14\n",
      "         \n",
      "\n",
      "          3.07\n",
      "         \n",
      "\n",
      "          54.948\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.986\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.505\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           33\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR141\n",
      "          \n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          7.2\n",
      "         \n",
      "\n",
      "          -0.46\n",
      "         \n",
      "\n",
      "          4.31\n",
      "         \n",
      "\n",
      "          2.928\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.235\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.110\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           34\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR15b\n",
      "          \n",
      "\n",
      "\n",
      "          3\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          11.41\n",
      "         \n",
      "\n",
      "          -4.65\n",
      "         \n",
      "\n",
      "          -4.02\n",
      "         \n",
      "\n",
      "          2.071\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.616\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.986\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           35\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR16-2\n",
      "          \n",
      "\n",
      "\n",
      "          3\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          10.52\n",
      "         \n",
      "\n",
      "          -3.6\n",
      "         \n",
      "\n",
      "          -2.54\n",
      "         \n",
      "\n",
      "          2.713\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.424\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.742\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR423\n",
      "          \n",
      "\n",
      "\n",
      "          17\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          8.91\n",
      "         \n",
      "\n",
      "          -0.81\n",
      "         \n",
      "\n",
      "          2.39\n",
      "         \n",
      "\n",
      "          4.857\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.774\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          2.445\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/[\n",
      "          \n",
      "           37\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR491\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          9.03\n",
      "         \n",
      "\n",
      "          -2.08\n",
      "         \n",
      "\n",
      "          0.83\n",
      "         \n",
      "\n",
      "          5.352\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.117\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.301\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           38\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR615\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          4.03\n",
      "         \n",
      "\n",
      "          -3.45\n",
      "         \n",
      "\n",
      "          5.5\n",
      "         \n",
      "\n",
      "          1.9E+03\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.231\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          32.672\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/-\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR618\n",
      "          \n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          4.18\n",
      "         \n",
      "\n",
      "          2.44\n",
      "         \n",
      "\n",
      "          5.73\n",
      "         \n",
      "\n",
      "          4.1E+02\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.945\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.385\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           39\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR99a\n",
      "          \n",
      "\n",
      "\n",
      "          21\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          26.52\n",
      "         \n",
      "\n",
      "          -2.9\n",
      "         \n",
      "\n",
      "          3.72\n",
      "         \n",
      "\n",
      "          2.329\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.035\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.908\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           40\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR130a\n",
      "          \n",
      "\n",
      "\n",
      "          11\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -7.19\n",
      "         \n",
      "\n",
      "          -1.92\n",
      "         \n",
      "\n",
      "          -3.85\n",
      "         \n",
      "\n",
      "          0.004\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.532\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.102\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           41\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR135b\n",
      "          \n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.93\n",
      "         \n",
      "\n",
      "          2.8\n",
      "         \n",
      "\n",
      "          -7.82\n",
      "         \n",
      "\n",
      "          0.003\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.337\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.828\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           42\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR137\n",
      "          \n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.81\n",
      "         \n",
      "\n",
      "          1.19\n",
      "         \n",
      "\n",
      "          -3.41\n",
      "         \n",
      "\n",
      "          0.016\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.173\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          5.897\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           43\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR196b\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          7\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -11.26\n",
      "         \n",
      "\n",
      "          2.07\n",
      "         \n",
      "\n",
      "          -5.05\n",
      "         \n",
      "\n",
      "          0.356\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.591\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.829\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           21\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           44\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR205\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -26.47\n",
      "         \n",
      "\n",
      "          2.37\n",
      "         \n",
      "\n",
      "          -12.09\n",
      "         \n",
      "\n",
      "          1.2E-05\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.1E+02\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.659\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           13\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           15\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR21\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          17\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -21.68\n",
      "         \n",
      "\n",
      "          13.78\n",
      "         \n",
      "\n",
      "          -12.98\n",
      "         \n",
      "\n",
      "          0.637\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.362\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          3.272\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          [\n",
      "          \n",
      "           19\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           18\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR24-1\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.64\n",
      "         \n",
      "\n",
      "          3.73\n",
      "         \n",
      "\n",
      "          -0.27\n",
      "         \n",
      "\n",
      "          0.057\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.569\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.231\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           45\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR31\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -2.79\n",
      "         \n",
      "\n",
      "          -9.75\n",
      "         \n",
      "\n",
      "          -3.04\n",
      "         \n",
      "\n",
      "          1.7E-06\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.357\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.959\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           46\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR376a-2\n",
      "          \n",
      "\n",
      "\n",
      "          14\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.98\n",
      "         \n",
      "\n",
      "          2.96\n",
      "         \n",
      "\n",
      "          2.59\n",
      "         \n",
      "\n",
      "          0.020\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          4.857\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          2.888\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           47\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR424\n",
      "          \n",
      "\n",
      "\n",
      "          X\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.94\n",
      "         \n",
      "\n",
      "          1.95\n",
      "         \n",
      "\n",
      "          -2.56\n",
      "         \n",
      "\n",
      "          0.259\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.883\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          4.287\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/[\n",
      "          \n",
      "           39\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR654\n",
      "          \n",
      "\n",
      "\n",
      "          14\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.42\n",
      "         \n",
      "\n",
      "          2.57\n",
      "         \n",
      "\n",
      "          4.14\n",
      "         \n",
      "\n",
      "          0.136\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.357\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.295\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/-\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "        Table listing significantly changed miRNA genes identified in this study.   H3K9Ac ChIP  L v P  p  L v 5Aza  p  P v 5Aza  p  Epi./Cancer  MIRLET7c  21  +  34.26  -0.14  3.07  54.948  *  0.986  1.505  -/[  33  ]  MIR141  12  +  7.2  -0.46  4.31  2.928  *  2.235  *  1.110  [  34  ]  MIR15b  3  +  11.41  -4.65  -4.02  2.071  *  0.616  0.986  -/[  35  ]  MIR16-2  3  +  10.52  -3.6  -2.54  2.713  *  1.424  *  0.742  -/[  36  ]  MIR423  17  +  8.91  -0.81  2.39  4.857  *  0.774  2.445  *  -/[  37  ]  MIR491  9  +  9.03  -2.08  0.83  5.352  *  1.117  1.301  -/[  38  ]  MIR615  12  +  4.03  -3.45  5.5  1.9E+03  *  1.231  32.672  *  -/-  MIR618  12  -  4.18  2.44  5.73  4.1E+02  *  1.945  *  1.385  -/[  39  ]  MIR99a  21  +  26.52  -2.9  3.72  2.329  *  1.035  0.908  -/[  40  ]  MIR130a  11  +  -7.19  -1.92  -3.85  0.004  *  2.532  *  1.102  -/[  41  ]  MIR135b  1  -  -3.93  2.8  -7.82  0.003  *  0.337  1.828  -/[  42  ]  MIR137  1  -  -3.81  1.19  -3.41  0.016  *  2.173  5.897  [  43  ]  MIR196b  7  -  -11.26  2.07  -5.05  0.356  *  1.591  *  0.829  [  21  ]/[  44  ]  MIR205  1  +  -26.47  2.37  -12.09  1.2E-05  *  1.1E+02  *  1.659  [  13  ]/[  15  ]  MIR21  17  +  -21.68  13.78  -12.98  0.637  *  2.362  *  3.272  *  [  19  ]/[  18  ]  MIR24-1  9  +  -5.64  3.73  -0.27  0.057  *  1.569  *  1.231  -/[  45  ]  MIR31  9  -  -2.79  -9.75  -3.04  1.7E-06  *  1.357  0.959  -/[  46  ]  MIR376a-2  14  +  -5.98  2.96  2.59  0.020  *  4.857  2.888  -/[  47  ]  MIR424  X  -  -3.94  1.95  -2.56  0.259  *  0.883  4.287  *  -/[  39  ]  MIR654  14  +  -5.42  2.57  4.14  0.136  *  1.357  0.295  *  -/-  Table listing significantly changed miRNA genes identified in this study.\n",
      "This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [  37  -  40  ]. This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [\n",
      "       \n",
      "        37\n",
      "       \n",
      "       -\n",
      "       \n",
      "        40\n",
      "       \n",
      "       ].  This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [  37  -  40  ].\n",
      "The tumor suppressor miRNA of miR-31 were downregulated in BC datasets comparing to the BO datasets [  27  ].  Analysis of known breast cancer related miRNAs  We also analyzed miRNAs previously reported to be differentially expressed in BC, including oncogenic miRNAs, miR-155[  17  ], miR-21[  18  ,  19  ], miR-25[  30  ], and miR-27a[  24  ], and tumor suppressor miRNAs, miR-125a/b[  17  ], miR-17[  26  ], miR-205[  25  ], miR-27b[  24  ], miR-31[  27  ], and miR-34a[  28  ,  29  ]. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  27  ], was observed to be downregulated in BC datasets. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [\n",
      "      \n",
      "       27\n",
      "      \n",
      "      ], was observed to be downregulated in BC datasets.  The tumor suppressor miRNA of miR-31 were downregulated in BC datasets comparing to the BO datasets [  27  ].  Analysis of known breast cancer related miRNAs  We also analyzed miRNAs previously reported to be differentially expressed in BC, including oncogenic miRNAs, miR-155[  17  ], miR-21[  18  ,  19  ], miR-25[  30  ], and miR-27a[  24  ], and tumor suppressor miRNAs, miR-125a/b[  17  ], miR-17[  26  ], miR-205[  25  ], miR-27b[  24  ], miR-31[  27  ], and miR-34a[  28  ,  29  ]. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  27  ], was observed to be downregulated in BC datasets.\n",
      "miR-31 also inhibits breast cancer metastasis [  66  ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [  67  ]. miR-31 also inhibits breast cancer metastasis [\n",
      "       \n",
      "        66\n",
      "       \n",
      "       ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [\n",
      "       \n",
      "        67\n",
      "       \n",
      "       ].  miR-31 also inhibits breast cancer metastasis [  66  ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [  67  ].\n",
      "In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].  In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ]), tumor progression [\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ], and clinical outcomes, such as patient survival [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ]. In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].\n",
      " Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells  Cell Biology International  2012  36  3  311  319  10.1042/cbi20110069  2-s2.0-84859243460  22070397  36  Miyaki  S.  Sato  T.  Inoue  A. Tumor invasiveness was assessed by determining the extent of infiltration of cancer cells to the surrounding tissue (stroma, fat pad, skin and muscle tissue), as previously described [  36  ].    Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells  Cell Biology International  2012  36  3  311  319  10.1042/cbi20110069  2-s2.0-84859243460  22070397  36  Miyaki  S.  Sato  T.  Inoue  A. Tumor invasiveness was assessed by determining the extent of infiltration of cancer cells to the surrounding tissue (stroma, fat pad, skin and muscle tissue), as previously described [  36  ].\n",
      "Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [  7  -  10  ].  Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ]. Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [  7  -  10  ].\n",
      "This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [  50  -  52  ]. This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [\n",
      "       \n",
      "        50\n",
      "       \n",
      "       -\n",
      "       \n",
      "        52\n",
      "       \n",
      "       ].  This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [  50  -  52  ].\n",
      " MiR-31 expression was elevated in endometrial cancer [\n",
      "         \n",
      "          15\n",
      "         \n",
      "         ] but paradoxically down-regulated in breast [\n",
      "         \n",
      "          16\n",
      "         \n",
      "         ] and prostate cancer [\n",
      "         \n",
      "          18\n",
      "         \n",
      "         ].  \n",
      "miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [  24  ,  36  ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([  36  ] and Sossey-Alaoui, unpublished data). Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [  24  ,  36  ]. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [  24  ,  36  ]. Expression levels of miR-31diminish as the tumors progress to more invasive stages [  24  ] and become undetectable in metastatic BC tumors [  36  ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [  24  ], RhoA, Radexin [  36  ] and several integrin subunits [  47  ] that regulate key steps in the invasion-metastasis cascade. In fact, several miRs, miR-15a, miR-16-1, and let-7 [  23  ,  26  -  30  ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [  23  ,  31  ,  32  ], possess oncogenic properties  Several recent reports have identified a major role of miR31 in cancer metastasis [  33  -  36  ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] and Sossey-Alaoui, unpublished data). Expression levels of miR-31diminish as the tumors progress to more invasive stages [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ] and become undetectable in metastatic BC tumors [\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ], RhoA, Radexin [\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] and several integrin subunits [\n",
      "          \n",
      "           47\n",
      "          \n",
      "          ] that regulate key steps in the invasion-metastasis cascade. miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. In fact, several miRs, miR-15a, miR-16-1, and let-7 [\n",
      "          \n",
      "           23\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           26\n",
      "          \n",
      "          -\n",
      "          \n",
      "           30\n",
      "          \n",
      "          ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [\n",
      "          \n",
      "           23\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           31\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           32\n",
      "          \n",
      "          ], possess oncogenic properties\n",
      "         \n",
      "\n",
      "          Several recent reports have identified a major role of miR31 in cancer metastasis [\n",
      "          \n",
      "           33\n",
      "          \n",
      "          -\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts. miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [  24  ,  36  ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([  36  ] and Sossey-Alaoui, unpublished data). Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [  24  ,  36  ]. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [  24  ,  36  ]. Expression levels of miR-31diminish as the tumors progress to more invasive stages [  24  ] and become undetectable in metastatic BC tumors [  36  ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [  24  ], RhoA, Radexin [  36  ] and several integrin subunits [  47  ] that regulate key steps in the invasion-metastasis cascade. In fact, several miRs, miR-15a, miR-16-1, and let-7 [  23  ,  26  -  30  ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [  23  ,  31  ,  32  ], possess oncogenic properties  Several recent reports have identified a major role of miR31 in cancer metastasis [  33  -  36  ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts.\n",
      "Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [  22  ], esophageal [  23  ], lung [  24  ], oral [  25  ] and head and neck [  26  ] cancer, and a tumor suppressor gene in breast [  27  ] and gastric [  28  ] cancers and malignant mesothelioma [  29  ].  Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ], esophageal [\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ], lung [\n",
      "     \n",
      "      24\n",
      "     \n",
      "     ], oral [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ] and head and neck [\n",
      "     \n",
      "      26\n",
      "     \n",
      "     ] cancer, and a tumor suppressor gene in breast [\n",
      "     \n",
      "      27\n",
      "     \n",
      "     ] and gastric [\n",
      "     \n",
      "      28\n",
      "     \n",
      "     ] cancers and malignant mesothelioma [\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ]. Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [  22  ], esophageal [  23  ], lung [  24  ], oral [  25  ] and head and neck [  26  ] cancer, and a tumor suppressor gene in breast [  27  ] and gastric [  28  ] cancers and malignant mesothelioma [  29  ].\n",
      " miR-31  miR-31 was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  61  ].  Table 1  miRNAs and their targets in breast cancer cells  miRNA  Target  Functional pathway  Reference  Tumor suppressor miRNAs  miR-206  ESR1  ER signaling  [  28  ,  33  ]  miR-17-5p  AIB1  ,  CCND1  ,  E2F1  Proliferation  [  37  ,  38  ]  miR-125a, b  HER2  ,  HER3  Anchorage-dependent growth  [  40  ,  41  ]  miR-200  BMI1  ,  ZEB1  ,  ZEB2  TGF- signaling  [  47  ,  52  ,  54  ]  let-7  H-RAS  ,  HMGA2  ,  LIN28  ,  PEBP1  Proliferation, differentiation  [  73  -  75  ]  miR-34a  CCND1  ,  CDK6  ,  E2F3  ,  MYC  DNA damage, proliferation  [  76  -  78  ]  miR-31  FZD3  ,  ITGA5  ,  M-RIP  ,  MMP16  ,  RDX  ,  RHOA  Metastasis  [  61  ]  Oncogenic miRNAs  miR-21  BCL-2  ,  TPM1  ,  PDCD4  ,  PTEN  ,  MASPIN  Apoptosis  [  64  -  67  ]  miR-155  RHOA  TGF- signaling  [  68  ]  miR-10b  HOXD10  Metastasis  [  69  ]  miR-373/520c  CD44  Metastasis  [  79  ]  miRNAs and their targets in breast cancer.    miR-31  miR-31 was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  61  ].  Table 1  miRNAs and their targets in breast cancer cells  miRNA  Target  Functional pathway  Reference  Tumor suppressor miRNAs  miR-206  ESR1  ER signaling  [  28  ,  33  ]  miR-17-5p  AIB1  ,  CCND1  ,  E2F1  Proliferation  [  37  ,  38  ]  miR-125a, b  HER2  ,  HER3  Anchorage-dependent growth  [  40  ,  41  ]  miR-200  BMI1  ,  ZEB1  ,  ZEB2  TGF- signaling  [  47  ,  52  ,  54  ]  let-7  H-RAS  ,  HMGA2  ,  LIN28  ,  PEBP1  Proliferation, differentiation  [  73  -  75  ]  miR-34a  CCND1  ,  CDK6  ,  E2F3  ,  MYC  DNA damage, proliferation  [  76  -  78  ]  miR-31  FZD3  ,  ITGA5  ,  M-RIP  ,  MMP16  ,  RDX  ,  RHOA  Metastasis  [  61  ]  Oncogenic miRNAs  miR-21  BCL-2  ,  TPM1  ,  PDCD4  ,  PTEN  ,  MASPIN  Apoptosis  [  64  -  67  ]  miR-155  RHOA  TGF- signaling  [  68  ]  miR-10b  HOXD10  Metastasis  [  69  ]  miR-373/520c  CD44  Metastasis  [  79  ]  miRNAs and their targets in breast cancer.\n",
      "nan\n",
      "nan\n",
      "While the suppressive effects of miR-31, miR-126, miR-206, and miR-335 on metastasis have been directly documented  in vivo  [  8  ,  9  ], the roles of miR-130 and miR-200 in metastasis are implied by  in vitro  studies [  3  ,  7  ], but have yet to be analyzed directly  in vivo  . However, the authors [  4  ] did not address the relevance of these miR-200-dependent signaling events for  in vivo  metastatic abilities, nor did they determine the contributions of other known anti-metastatic miRNAs - such as miR-31, miR-126, miR-206 and miR-335 [  8  ,  9  ] - for mediating the observed anti-malignant responses.   While the suppressive effects of miR-31, miR-126, miR-206, and miR-335 on metastasis have been directly documented  in vivo  [  8  ,  9  ], the roles of miR-130 and miR-200 in metastasis are implied by  in vitro  studies [  3  ,  7  ], but have yet to be analyzed directly  in vivo  . However, the authors [  4  ] did not address the relevance of these miR-200-dependent signaling events for  in vivo  metastatic abilities, nor did they determine the contributions of other known anti-metastatic miRNAs - such as miR-31, miR-126, miR-206 and miR-335 [  8  ,  9  ] - for mediating the observed anti-malignant responses.\n",
      "nan\n",
      " Previous studies have attempted to delineate their role in the regulation of metastasis and disease progression (\n",
      "         \n",
      "          34\n",
      "         \n",
      "         \n",
      "         \n",
      "          36\n",
      "         \n",
      "         ).  \n",
      "nan\n",
      "Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[  11    19  ].  Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[\n",
      "     \n",
      "      11\n",
      "     \n",
      "     \n",
      "     \n",
      "      19\n",
      "     \n",
      "     ]. Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[  11    19  ].\n",
      "A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ]. A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ].\n",
      "As BAFF is capable of inducing T  H  17 cell differentiation in addition to regulating B cell activation [  41  ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis. As BAFF is capable of inducing T\n",
      "      \n",
      "       H\n",
      "      \n",
      "      17 cell differentiation in addition to regulating B cell activation [\n",
      "      \n",
      "       41\n",
      "      \n",
      "      ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis.  As BAFF is capable of inducing T  H  17 cell differentiation in addition to regulating B cell activation [  41  ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis.\n",
      "Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].  Besides patients with lupus having abnormally high levels of IL-17A along with IFN-\n",
      "       \n",
      "        \n",
      "       \n",
      "       are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [\n",
      "       \n",
      "        12\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ]. Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].\n",
      "Among these genes, it is interesting to note that TRAF3IP2 (alias ACT1) is a negative regulator of B cell function, its absence leading to lymphoproliferation and autoantibody production  [20]  , but ACT1 is also essential in IL-17 dependent signaling during autoimmune diseases  [21]  , IL-17 being implicated during lupus physiopathology  [22]  . On the other hand, the down expression of ACT1 (TRAF3IP2), could be linked to SLE because of the importance of this negative regulator on the B cell function\n",
      "              \n",
      "               [20]\n",
      "              \n",
      "              \n",
      "              \n",
      "               [22]\n",
      "              \n",
      "              .  Among these genes, it is interesting to note that TRAF3IP2 (alias ACT1) is a negative regulator of B cell function, its absence leading to lymphoproliferation and autoantibody production  [20]  , but ACT1 is also essential in IL-17 dependent signaling during autoimmune diseases  [21]  , IL-17 being implicated during lupus physiopathology  [22]  .\n",
      "The sample was then diluted 40 times in dilution buffer and immunoprecipitations, washes and elution were performed as before ([  18  ]).   The sample was then diluted 40 times in dilution buffer and immunoprecipitations, washes and elution were performed as before ([  18  ]).\n",
      " Chromatin Immunoprecipitation (ChIP) assays  BT474 cells treated or not with RAD001 (20 nM) were washed and cross-linked with formaldehyde at room temperature for 8 min essentially as previously described [  22  ].    Chromatin Immunoprecipitation (ChIP) assays  BT474 cells treated or not with RAD001 (20 nM) were washed and cross-linked with formaldehyde at room temperature for 8 min essentially as previously described [  22  ].\n",
      "For direction, reprogramming motility and toxin degradation in bacteria [  102  ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption.  For direction, reprogramming motility and toxin degradation in bacteria [\n",
      "      \n",
      "       102\n",
      "      \n",
      "      ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption. For direction, reprogramming motility and toxin degradation in bacteria [  102  ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption.\n",
      "nan\n",
      "Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].   Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].\n",
      " \n",
      "\n",
      "      USP4 is overexpressed in various types of cancer and the increased levels of USP4 appear to play a functional role in malignant cells (\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       20\n",
      "      \n",
      "      \n",
      "      \n",
      "       22\n",
      "      \n",
      "      ).  \n",
      "We also added a  baseline  condition in which participants read the abstract of an article from the same issue of  JPSP  by Mahajan and colleagues  [49]  .   We also added a  baseline  condition in which participants read the abstract of an article from the same issue of  JPSP  by Mahajan and colleagues  [49]  .\n",
      "These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).   These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).\n",
      "Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [  5  ,  6  ]. Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ].  Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [  5  ,  6  ].\n",
      "Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (  Lee et al., 2009  ;  Lee et al., 2013  ;  Han et al., 2011  ;  Han et al., 2013  ). We previously showed that Ax21 was found in the supernatant of  Xoo  cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (  Lee et al., 2009  ;  Han et al., 2011  ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (  Han et al., 2011  ), and probed with an anti-Ax21 antibody (  Fig.  Subsequent research from our lab, focused on the biological function of Ax21 in  Xanthomonas  , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (  Han et al., 2011  ). The generation of this antibody was first described in  Han et al. Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (\n",
      "        \n",
      "         Lee et al., 2009\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Lee et al., 2013\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2013\n",
      "        \n",
      "        ). We previously showed that Ax21 was found in the supernatant of\n",
      "        \n",
      "         Xoo\n",
      "        \n",
      "        cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (\n",
      "        \n",
      "         Lee et al., 2009\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ), and probed with an anti-Ax21 antibody (\n",
      "        \n",
      "         Fig. \n",
      "\n",
      "       Subsequent research from our lab, focused on the biological function of Ax21 in\n",
      "       \n",
      "        Xanthomonas\n",
      "       \n",
      "       , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (\n",
      "       \n",
      "        Han et al., 2011\n",
      "       \n",
      "       ). Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (  Lee et al., 2009  ;  Lee et al., 2013  ;  Han et al., 2011  ;  Han et al., 2013  ). We previously showed that Ax21 was found in the supernatant of  Xoo  cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (  Lee et al., 2009  ;  Han et al., 2011  ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (  Han et al., 2011  ), and probed with an anti-Ax21 antibody (  Fig.  Subsequent research from our lab, focused on the biological function of Ax21 in  Xanthomonas  , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (  Han et al., 2011  ). The generation of this antibody was first described in  Han et al.\n",
      "There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis. Although functional proof of this mechanism is necessary, several reports support our model [\n",
      "      \n",
      "       52\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       58\n",
      "      \n",
      "      -\n",
      "      \n",
      "       60\n",
      "      \n",
      "      ]. There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ] underlines this hypothesis.  There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis.\n",
      "GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [  74  ].  GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [\n",
      "       \n",
      "        74\n",
      "       \n",
      "       ]. GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [  74  ].\n",
      "Together with  let-7c  , both  miR-125  and  miR-99  are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [  51  ]. Together with\n",
      "      \n",
      "       let-7c\n",
      "      \n",
      "      , both\n",
      "      \n",
      "       miR-125\n",
      "      \n",
      "      and\n",
      "      \n",
      "       miR-99\n",
      "      \n",
      "      are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [\n",
      "      \n",
      "       51\n",
      "      \n",
      "      ].  Together with  let-7c  , both  miR-125  and  miR-99  are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [  51  ].\n",
      "nan\n",
      "nan\n",
      "These findings were further confirmed by immunohistochemical studies with a CPOX-specific antibody, as well [  33  ]. By quantitative real-time PCR (qRT-PCR), we measured the mRNA levels of key genes in a total of 20 tumor samples that had been surgically resected from brain tumor patients [  33  ].   These findings were further confirmed by immunohistochemical studies with a CPOX-specific antibody, as well [  33  ]. By quantitative real-time PCR (qRT-PCR), we measured the mRNA levels of key genes in a total of 20 tumor samples that had been surgically resected from brain tumor patients [  33  ].\n",
      "Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. The possibility that an unusual branched TCA cycle may operate in the asexual stages of\n",
      "     \n",
      "      P. falciparum\n",
      "     \n",
      "     , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ], but subsequently retracted [\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ].\n",
      "Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [  13  ].  Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ]. Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [  13  ].\n",
      "These results are in agreement with those previously reported by Olszewski  et al  [  42  ]. At this stage the parasites are early rings and after 32 hours (within 1 cycle) the metabolites from the medium and red blood cells were extracted with 80% methanol on dry ice, as described by Olszewski  et al  [  42  ]. Metabolites were extracted and incorporation of heavy isotopes was analysed by liquid chromatography followed by mass spectrometry as previously described [  42  ,  47  ]. The metabolites were analysed by LC-MS using a Synergy Hydro-RP column (Phenomenex, UK) and an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific, UK) and RAW files were converted and loaded into MAVEN, as detailed by Olszewski  et al  [  42  ]. \n",
      "\n",
      "      The second reaction product of the oxidative deamination of glutamate by GDHa is -ketoglutarate, an intermediate of the\n",
      "      \n",
      "       P. falciparum\n",
      "      \n",
      "      TCA pathway [\n",
      "      \n",
      "       42\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       46\n",
      "      \n",
      "      ].  These results are in agreement with those previously reported by Olszewski  et al  [  42  ]. At this stage the parasites are early rings and after 32 hours (within 1 cycle) the metabolites from the medium and red blood cells were extracted with 80% methanol on dry ice, as described by Olszewski  et al  [  42  ]. Metabolites were extracted and incorporation of heavy isotopes was analysed by liquid chromatography followed by mass spectrometry as previously described [  42  ,  47  ]. The metabolites were analysed by LC-MS using a Synergy Hydro-RP column (Phenomenex, UK) and an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific, UK) and RAW files were converted and loaded into MAVEN, as detailed by Olszewski  et al  [  42  ].\n",
      " Plasmodium falciparum  [  33  ,  34  ]. \n",
      "       Plasmodium falciparum\n",
      "      \n",
      "      [\n",
      "      \n",
      "       33\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       34\n",
      "      \n",
      "      ].   Plasmodium falciparum  [  33  ,  34  ].\n",
      "nan\n",
      "demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[  25  ]. demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ].  demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[  25  ].\n",
      "Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [  2  ].  Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [\n",
      "             \n",
      "              2\n",
      "             \n",
      "             ]. Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [  2  ].\n",
      "There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance. There is no evidence to suggest a significant displacement of government funding by international support [\n",
      "     \n",
      "      45\n",
      "     \n",
      "     ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.  There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.\n",
      " In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ]. \n",
      "\n",
      "       In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       -\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ].   In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ].\n",
      "nan\n",
      " It is shown that ketamine can function on opioid receptors [\n",
      "       \n",
      "        38\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        39\n",
      "       \n",
      "       ] and TLRs [\n",
      "       \n",
      "        40\n",
      "       \n",
      "       -\n",
      "       \n",
      "        42\n",
      "       \n",
      "       ] and thus inhibiting astrocytic activation.  \n",
      "Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      TLR2-4 have been implicated in pathological pain [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       37\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       40\n",
      "      \n",
      "      ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ].\n",
      "It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ].\n",
      " In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ]. \n",
      "\n",
      "       In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       -\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ].   In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ].\n",
      "nan\n",
      " It is shown that ketamine can function on opioid receptors [\n",
      "       \n",
      "        38\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        39\n",
      "       \n",
      "       ] and TLRs [\n",
      "       \n",
      "        40\n",
      "       \n",
      "       -\n",
      "       \n",
      "        42\n",
      "       \n",
      "       ] and thus inhibiting astrocytic activation.  \n",
      "Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      TLR2-4 have been implicated in pathological pain [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       37\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       40\n",
      "      \n",
      "      ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ].\n",
      "It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ].\n",
      "Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [  13  ].  Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ]. Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [  13  ].\n",
      "The  Drosophila  homologs,  Ten-m  and  Ten-a  , are the only pair-rule genes that do not encode traditional transcription factors [  3  -  5  ].  The\n",
      "      \n",
      "       Drosophila\n",
      "      \n",
      "      homologs,\n",
      "      \n",
      "       Ten-m\n",
      "      \n",
      "      and\n",
      "      \n",
      "       Ten-a\n",
      "      \n",
      "      , are the only pair-rule genes that do not encode traditional transcription factors [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      -\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. The  Drosophila  homologs,  Ten-m  and  Ten-a  , are the only pair-rule genes that do not encode traditional transcription factors [  3  -  5  ].\n",
      "nan\n",
      "APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [  19  ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [  20  ]. APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [\n",
      "      \n",
      "       20\n",
      "      \n",
      "      ].  APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [  19  ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [  20  ].\n",
      "Most recently, to add to the confusion, a new paper [  6  ] reports an association between CFS and a different retrovirus - a report erroneously described in some of the press coverage as confirmation of the original report of Lombardi  et al  . In that paper, human T-lymphotropic virus type II (HTLV-II) was detected in a study remarkably similar to those reported in the new papers [  1  ,  6  ] (which do not cite it). [  6  ]. The recently reported [  6  ] murine retrovirus distinct from XMRV, more closely related to polytropic MLV (should it be called PMRV? There is also a polytropic MLV that can infect the cells of both species, and it is this virus that most closely resembles the retrovirus identified in the latest claim for a retroviral association with CFS [  6  ]. were collected over several years from persons with no contact with each other and widely dispersed across states in New England [  6  ], it does not make epidemiological sense that the two types of CFS-associated MLV segregate according to the laboratory performing the tests.   Most recently, to add to the confusion, a new paper [  6  ] reports an association between CFS and a different retrovirus - a report erroneously described in some of the press coverage as confirmation of the original report of Lombardi  et al  . In that paper, human T-lymphotropic virus type II (HTLV-II) was detected in a study remarkably similar to those reported in the new papers [  1  ,  6  ] (which do not cite it). [  6  ]. The recently reported [  6  ] murine retrovirus distinct from XMRV, more closely related to polytropic MLV (should it be called PMRV? There is also a polytropic MLV that can infect the cells of both species, and it is this virus that most closely resembles the retrovirus identified in the latest claim for a retroviral association with CFS [  6  ]. were collected over several years from persons with no contact with each other and widely dispersed across states in New England [  6  ], it does not make epidemiological sense that the two types of CFS-associated MLV segregate according to the laboratory performing the tests.\n",
      "A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [  10  ].  A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ]. A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [  10  ].\n",
      "Novel retroviruses may also be involved [  31  ,  32  ] but that possibility has been challenged [  33  ].  Novel retroviruses may also be involved [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       32\n",
      "      \n",
      "      ] but that possibility has been challenged [\n",
      "      \n",
      "       33\n",
      "      \n",
      "      ]. Novel retroviruses may also be involved [  31  ,  32  ] but that possibility has been challenged [  33  ].\n",
      " This report by Lombardi, et al was followed by 4 subsequent reports of failure to detect any murine leukemia virus (MLV)-related virus gene sequences in blood from CFS patients [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       66\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       67\n",
      "      \n",
      "      ] and one report of MLV-like virus gag gene sequences, but not XMRV, in 86.5% CFS cases compared with only 6.8% of healthy volunteer blood donors [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ].  \n",
      "detected MLV-related viruses which are distinct from XMRV but resemble polytropic endogenous MLVs in CFS patients and healthy blood donors [  13  ]. [  13  ] were derived from contaminating MLV RNA and/or DNA. mentioned in the report that Platinum Taq from Invitrogen gave them the best results among  Taq  polymerases from several suppliers and was used to test the patient samples [  13  ]. [  13  ], assurance that control samples were assayed simultaneously with the positively identified ones in a blinded, randomized way was missing in their study, unfortunately.  In studies investigating XMRV infection, a PCR approach to detect proviral DNA and/or a RT-PCR approach to detect viral RNA have been commonly employed [  1  ,  3  -  6  ,  8  ,  13  -  15  ]. They also used Invitrogen's Superscript II RT and Platinum Taq for RT-PCR, albeit in a two-step cDNA synthesis and PCR amplification procedure [  13  ]. The nucleotide sequences of the representative clone [GenBank:  AB597300  ] were aligned with sequences deposited in GenBank as follows: MLV-like virus from CFS patients types 1, 2 and 3 [GenBank:  HM630562  ,  HM630558  , and  HM630559  ] [  13  ], XMRV strain VP62 [GenBank:  NC_007815  ] [  2  ] and one representative PmERV on chr 7 [GenBank:  AC167978  ; nt 65,391-64,647] (Figure  3  ).   detected MLV-related viruses which are distinct from XMRV but resemble polytropic endogenous MLVs in CFS patients and healthy blood donors [  13  ]. [  13  ] were derived from contaminating MLV RNA and/or DNA. mentioned in the report that Platinum Taq from Invitrogen gave them the best results among  Taq  polymerases from several suppliers and was used to test the patient samples [  13  ]. [  13  ], assurance that control samples were assayed simultaneously with the positively identified ones in a blinded, randomized way was missing in their study, unfortunately.  In studies investigating XMRV infection, a PCR approach to detect proviral DNA and/or a RT-PCR approach to detect viral RNA have been commonly employed [  1  ,  3  -  6  ,  8  ,  13  -  15  ]. They also used Invitrogen's Superscript II RT and Platinum Taq for RT-PCR, albeit in a two-step cDNA synthesis and PCR amplification procedure [  13  ]. The nucleotide sequences of the representative clone [GenBank:  AB597300  ] were aligned with sequences deposited in GenBank as follows: MLV-like virus from CFS patients types 1, 2 and 3 [GenBank:  HM630562  ,  HM630558  , and  HM630559  ] [  13  ], XMRV strain VP62 [GenBank:  NC_007815  ] [  2  ] and one representative PmERV on chr 7 [GenBank:  AC167978  ; nt 65,391-64,647] (Figure  3  ).\n",
      "that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [  6  ]. in their analysis of CFS patient samples [  6  ].  that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ]. that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [  6  ]. in their analysis of CFS patient samples [  6  ].\n",
      "Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [  1  ,  30  ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [  30  ] and healthy donors. Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [\n",
      "       \n",
      "        1\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        30\n",
      "       \n",
      "       ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [\n",
      "       \n",
      "        30\n",
      "       \n",
      "       ] and healthy donors.  Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [  1  ,  30  ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [  30  ] and healthy donors.\n",
      "It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [  2  ,  7  ], because all studies employed highly sensitive PCR methods. [  7  ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors. It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ], because all studies employed highly sensitive PCR methods. [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors. It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [  2  ,  7  ], because all studies employed highly sensitive PCR methods. [  7  ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors.\n",
      "Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [  5  ]. It is striking that there have been no independent reports of patient-derived XMRV integration sites nor have there been any descriptions of polytropic or modified polytropic MLV integration sites in human samples despite the apparent detection of these viruses in CFS patients [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [  5  ].\n",
      " Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [  16  ]. In contrast to the published VP [  1  ] and WPI [  3  ] XMRV sequences, which are tightly clustered, the  gag  sequences found in this study were dispersed, similar to the sequences reported in [  16  ];  i.e  ., the 15 unique XMRV-related partial  gag  sequences found among from the 37 single PCR products were distributed over a minimum of 3 clusters, each of which contains endogenous MLV sequences of a different subtype (XMV, PMV, and MPMV (xenotropic, polytropic, modified polytropic MLV)). Several reports have appeared in the literature since then contesting these findings [  4  -  6  ,  8  ,  9  ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [  16  ]. Several reports have appeared in the literature since then contesting these findings [\n",
      "      \n",
      "       4\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       8\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ].  Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [  16  ]. In contrast to the published VP [  1  ] and WPI [  3  ] XMRV sequences, which are tightly clustered, the  gag  sequences found in this study were dispersed, similar to the sequences reported in [  16  ];  i.e  ., the 15 unique XMRV-related partial  gag  sequences found among from the 37 single PCR products were distributed over a minimum of 3 clusters, each of which contains endogenous MLV sequences of a different subtype (XMV, PMV, and MPMV (xenotropic, polytropic, modified polytropic MLV)). Several reports have appeared in the literature since then contesting these findings [  4  -  6  ,  8  ,  9  ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [  16  ].\n",
      " Table 7  Comparison of MLV sequences amplified from patient samples [  16  ] with mouse genomic sequences  Sequence  Length (nt)  Closest relative  GenBank no  . Sequences from [  16  ] are colored blue.  Similarity  Nucleotide difference  51_PCR_LF2_GagR (  JF288878  )  608  Mus musculus BAC clone RP23-457E5  AC121813  100%  0/608  51_PCR_LF3_GagR (  JF288879  )  250  Mus musculus chrom 7, clone RP24-220N8  AC167466  99%  1/250  15_PCR_LF2_GagR (  JF288880  )  608  Mus musculus BAC clone RP23-152O2  AC163634  100%  0/608  15_PCR_LF3_GagR (  JF288881  )  271  Mus musculus BAC clone RP23-152O2  AC163634  &gt;99%  1/271  52_PCR_GagF_GagR (  JF288882  )  525  Mouse DNA sequence, clone CH29-187G15  CU407131  100%  0/525  52_PCR_LF2_GagR (  JF288883  )  540  Mus musculus chrom 5, clone RP23-280N22  AC123679  &gt;99%  1/540  112_PCR_LF2_GagR (  JF288884  )  691  Mouse DNA sequence, CH29-187G15  CU407131  &gt;99%  6/691  NB: Gaps are treated as mismatches  Because the sequences we amplified were similar to the MLV sequences detected in CFS patients [  16  ], we also analyzed the sequences reported in that study. Furthermore, a recent study reported a high frequency of MLV that was distinct from XMRV by PCR in patients with chronic fatigue syndrome [  16  ]. [  16  ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure  1  ). Positive samples yielded PCR products at 153 bp [  16  ]. [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure\n",
      "      \n",
      "       1\n",
      "      \n",
      "      ).   Table 7  Comparison of MLV sequences amplified from patient samples [  16  ] with mouse genomic sequences  Sequence  Length (nt)  Closest relative  GenBank no  . Sequences from [  16  ] are colored blue.  Similarity  Nucleotide difference  51_PCR_LF2_GagR (  JF288878  )  608  Mus musculus BAC clone RP23-457E5  AC121813  100%  0/608  51_PCR_LF3_GagR (  JF288879  )  250  Mus musculus chrom 7, clone RP24-220N8  AC167466  99%  1/250  15_PCR_LF2_GagR (  JF288880  )  608  Mus musculus BAC clone RP23-152O2  AC163634  100%  0/608  15_PCR_LF3_GagR (  JF288881  )  271  Mus musculus BAC clone RP23-152O2  AC163634  &gt;99%  1/271  52_PCR_GagF_GagR (  JF288882  )  525  Mouse DNA sequence, clone CH29-187G15  CU407131  100%  0/525  52_PCR_LF2_GagR (  JF288883  )  540  Mus musculus chrom 5, clone RP23-280N22  AC123679  &gt;99%  1/540  112_PCR_LF2_GagR (  JF288884  )  691  Mouse DNA sequence, CH29-187G15  CU407131  &gt;99%  6/691  NB: Gaps are treated as mismatches  Because the sequences we amplified were similar to the MLV sequences detected in CFS patients [  16  ], we also analyzed the sequences reported in that study. Furthermore, a recent study reported a high frequency of MLV that was distinct from XMRV by PCR in patients with chronic fatigue syndrome [  16  ]. [  16  ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure  1  ). Positive samples yielded PCR products at 153 bp [  16  ].\n",
      "It is therefore not surprising that MLV-related ERVs are found in the genomes of amphibians, reptiles, birds and mammals [  113  ], and that X/P-MLV-related viruses and viral sequences have now been reported in humans [  114  -  119  ]. This, coupled with the recent finding of  M/Pmv  related  env  and  glycogag  sequences in human blood donors and chronic fatigue patients [  119  ] points out the need for further work to clarify the evolutionary path linking the human and mouse viruses and to describe the epidemiology of this virus family in wild mice [  121  ].   It is therefore not surprising that MLV-related ERVs are found in the genomes of amphibians, reptiles, birds and mammals [  113  ], and that X/P-MLV-related viruses and viral sequences have now been reported in humans [  114  -  119  ]. This, coupled with the recent finding of  M/Pmv  related  env  and  glycogag  sequences in human blood donors and chronic fatigue patients [  119  ] points out the need for further work to clarify the evolutionary path linking the human and mouse viruses and to describe the epidemiology of this virus family in wild mice [  121  ].\n",
      "More recently, matters were further complicated by the publication of a study finding  gag  sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [  17  ]. Sequences were aligned against VP62 [Genbank:  EF185282  ], MLV-releated virus CFS isolate CSF-type1 ([Genbank:  HM630562  ], as described in Lo [  17  ]) and mouse strain 129X1/SvJ [Genbank  AAHY01591888.1  ].  More recently, matters were further complicated by the publication of a study finding\n",
      "      \n",
      "       gag\n",
      "      \n",
      "      sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. More recently, matters were further complicated by the publication of a study finding  gag  sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [  17  ]. Sequences were aligned against VP62 [Genbank:  EF185282  ], MLV-releated virus CFS isolate CSF-type1 ([Genbank:  HM630562  ], as described in Lo [  17  ]) and mouse strain 129X1/SvJ [Genbank  AAHY01591888.1  ].\n",
      "Lo  , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [  31  ].  Lo\n",
      "       \n",
      "       , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [\n",
      "       \n",
      "        31\n",
      "       \n",
      "       ]. Lo  , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [  31  ].\n",
      " in people with CFS using tests with less sensitive PCR tests [  5  ,  12  ]. study since like previous studies, this study also failed to identify XMRV in any of the CFS samples or controls [  6  -  12  ].  can at best detect 1 copy of XMRV/MuLV in a background of 30 to 50 ng and 100 to 250 ng of DNA respectively [  5  ,  12  ]. Unlike other reports [  5  ,  12  ], we also found no evidence of active XMRV/MuLV viremia using highly sensitive RT-PCR tests excluding possibilities of peripheral infection seeding the blood compartment from other body locations. A more recent study failed to detect XMRV, but found a polytropic MuLV most similar to mouse endogenous retroviruses in 87% of CFS cases [  12  ].    in people with CFS using tests with less sensitive PCR tests [  5  ,  12  ]. study since like previous studies, this study also failed to identify XMRV in any of the CFS samples or controls [  6  -  12  ].  can at best detect 1 copy of XMRV/MuLV in a background of 30 to 50 ng and 100 to 250 ng of DNA respectively [  5  ,  12  ]. Unlike other reports [  5  ,  12  ], we also found no evidence of active XMRV/MuLV viremia using highly sensitive RT-PCR tests excluding possibilities of peripheral infection seeding the blood compartment from other body locations. A more recent study failed to detect XMRV, but found a polytropic MuLV most similar to mouse endogenous retroviruses in 87% of CFS cases [  12  ].\n",
      " PBMCs from patients with CFS are not more likely to have a signal for MLV-related viruses than controls  Recently MLV-related virus DNA was detected in patients with CFS using nested PCR [  2  ]. [  2  ], but the no template controls also amplified a DNA product. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  22  ], or due to very low levels of MLV related sequences in human DNA. [  25  ], Satterfield et al. [  2  ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls. [  24  ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [  8  -  11  ], two states [  7  ], or other countries [  3  -  6  ,  23  ,  25  ]. A positive control, in which an XMRV gp70-reactive rat monoclonal antibody 83A25 [  21  ] was used to immunoprecipitate gp70, readily detected gp70 from XMRV-infected ferret cells (Figure  1A, B  last lanes). [  24  ] did not detect MLV in CFS patients from 17 states in the United States. [  1  ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [  3  ,  4  ], the Netherlands [  5  ], China [  6  ], Japan [  12  ,  23  ], and the United States [  7  -  10  ,  19  ,  24  ] that did not detect XMRV DNA in patients with CFS. [  2  ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [  22  ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. Most of these PCR products were also highly related to MLV-related sequences that were previously identified in samples from patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  24  ], Knox et al. [\n",
      "      \n",
      "       22\n",
      "      \n",
      "      ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. [\n",
      "      \n",
      "       1\n",
      "      \n",
      "      ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ], the Netherlands [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ], China [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ], Japan [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       23\n",
      "      \n",
      "      ], and the United States [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] that did not detect XMRV DNA in patients with CFS. [\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ], Satterfield et al. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       20\n",
      "      \n",
      "      ]. [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [\n",
      "      \n",
      "       22\n",
      "      \n",
      "      ], or due to very low levels of MLV related sequences in human DNA. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ], Knox et al. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] did not detect MLV in CFS patients from 17 states in the United States. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [\n",
      "      \n",
      "       8\n",
      "      \n",
      "      -\n",
      "      \n",
      "       11\n",
      "      \n",
      "      ], two states [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ], or other countries [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       23\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ]. [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls.  PBMCs from patients with CFS are not more likely to have a signal for MLV-related viruses than controls  Recently MLV-related virus DNA was detected in patients with CFS using nested PCR [  2  ]. [  2  ], but the no template controls also amplified a DNA product. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  22  ], or due to very low levels of MLV related sequences in human DNA. [  25  ], Satterfield et al. [  2  ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls. [  24  ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [  8  -  11  ], two states [  7  ], or other countries [  3  -  6  ,  23  ,  25  ]. A positive control, in which an XMRV gp70-reactive rat monoclonal antibody 83A25 [  21  ] was used to immunoprecipitate gp70, readily detected gp70 from XMRV-infected ferret cells (Figure  1A, B  last lanes). [  24  ] did not detect MLV in CFS patients from 17 states in the United States. [  1  ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [  3  ,  4  ], the Netherlands [  5  ], China [  6  ], Japan [  12  ,  23  ], and the United States [  7  -  10  ,  19  ,  24  ] that did not detect XMRV DNA in patients with CFS. [  2  ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [  22  ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. Most of these PCR products were also highly related to MLV-related sequences that were previously identified in samples from patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  24  ], Knox et al.\n",
      " 2010  ).    2010  ).\n",
      " \n",
      "\n",
      "      A very recent publication reports finding MLV-like\n",
      "      \n",
      "       gag\n",
      "      \n",
      "      sequences in 32 out of 37 (86.5%) CFS patients and in 3 out of 44 (6.8%) healthy blood donors\n",
      "      \n",
      "       [29]\n",
      "      \n",
      "      . Nevertheless, we can presently not formally exclude that a proportion of the non-XMRV proviruses that have been amplified in the report by Lo and co-workers\n",
      "      \n",
      "       [29]\n",
      "      \n",
      "      could have been missed using our primer set.  \n",
      "Nested PCR was performed under the same conditions for 45 amplification cycles with 5 l of the first round PCR product and two different primer pairs, Gag-I-F (  5-TCTCGAGATCATGGGACAGA-3  ) and Gag-I-R (  5-AGAGGGTAAGGGCAGGGTAA-3  ) or NP116 (  5-CATGGGACAGACCGTAACTACC-3  ) and NP117 (  5-GCAGATCGGGACGGAGGTTG-3  ), both of which have been shown to detect both XMRV and MLV sequences  [6]  . While one study reported the presence of other MLV-like sequences in CFS patients  [6]  , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination  [7]  . \n",
      "\n",
      "       [6]\n",
      "      \n",
      "      . While one study reported the presence of other MLV-like sequences in CFS patients\n",
      "      \n",
      "       [6]\n",
      "      \n",
      "      , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination\n",
      "      \n",
      "       [7]\n",
      "      \n",
      "      . Nested PCR was performed under the same conditions for 45 amplification cycles with 5 l of the first round PCR product and two different primer pairs, Gag-I-F (  5-TCTCGAGATCATGGGACAGA-3  ) and Gag-I-R (  5-AGAGGGTAAGGGCAGGGTAA-3  ) or NP116 (  5-CATGGGACAGACCGTAACTACC-3  ) and NP117 (  5-GCAGATCGGGACGGAGGTTG-3  ), both of which have been shown to detect both XMRV and MLV sequences  [6]  . While one study reported the presence of other MLV-like sequences in CFS patients  [6]  , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination  [7]  .\n",
      "As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].  As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].\n",
      "He et al [  10  ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs. He et al [\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs.  He et al [  10  ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs.\n",
      "Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).  Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      (\n",
      "      \n",
      "       He et al., 2010\n",
      "      \n",
      "      ). Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).\n",
      " As FoxP3 is not exclusively expressed in Tregs [\n",
      "     \n",
      "      46\n",
      "     \n",
      "     ], we measured the intracellular expression of IL-10, a cytokine constitutively produced at low levels by Tregs [\n",
      "     \n",
      "      47\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      48\n",
      "     \n",
      "     ].  \n",
      "Indeed, the range of autoimmune/autoinflammatory diseases that have been investigated encompasses SLE [  20  ,  21  ,  48  ,  49  ], juvenile idiopathic arthritis [  16  ,  50  -  53  ], multiple sclerosis [  54  ,  55  ], rheumatoid arthritis [  56  -  59  ], Sjogren's syndrome [  60  ], diabetes [  61  ,  62  ], inflammatory bowel disease [  63  ], psoriasis and psoriatic arthritis [  45  ,  47  ], inflammatory myopathies [  64  ,  65  ], scleroderma [  66  ,  67  ], vasculitis [  68  ] and anti-phospholipid syndrome [  69  ].   Indeed, the range of autoimmune/autoinflammatory diseases that have been investigated encompasses SLE [  20  ,  21  ,  48  ,  49  ], juvenile idiopathic arthritis [  16  ,  50  -  53  ], multiple sclerosis [  54  ,  55  ], rheumatoid arthritis [  56  -  59  ], Sjogren's syndrome [  60  ], diabetes [  61  ,  62  ], inflammatory bowel disease [  63  ], psoriasis and psoriatic arthritis [  45  ,  47  ], inflammatory myopathies [  64  ,  65  ], scleroderma [  66  ,  67  ], vasculitis [  68  ] and anti-phospholipid syndrome [  69  ].\n",
      "[  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].  Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [\n",
      "     \n",
      "      2\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. [  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].\n",
      "[  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].  This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [\n",
      "      \n",
      "       1\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ]. [  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].\n",
      "nan\n",
      "A recent study investigated the genetic profiles of centenarians and claimed evidence for Methuselah genes which enable certain people to live to 100 and beyond (Sebastiani et al.,  2010  ).   A recent study investigated the genetic profiles of centenarians and claimed evidence for Methuselah genes which enable certain people to live to 100 and beyond (Sebastiani et al.,  2010  ).\n",
      " [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  \n",
      "         [25]\n",
      "        \n",
      "        computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.\n",
      "In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [\n",
      "     \n",
      "      61\n",
      "     \n",
      "     -\n",
      "     \n",
      "      63\n",
      "     \n",
      "     ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     cell growth [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. In\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. \n",
      "      In T. brucei\n",
      "     \n",
      "     , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. In addition, a small fraction of PC is generated by sequential methylation of PE [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [\n",
      "     \n",
      "      11\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      21\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      59\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      60\n",
      "     \n",
      "     ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids\n",
      "     \n",
      "      de novo\n",
      "     \n",
      "     [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      65\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      66\n",
      "     \n",
      "     ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      6\n",
      "     \n",
      "     ], RNA transport [\n",
      "     \n",
      "      7\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ] and processing [\n",
      "     \n",
      "      9\n",
      "     \n",
      "     -\n",
      "     \n",
      "      12\n",
      "     \n",
      "     ], protein localization [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     -\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ], and transcription [\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ].\n",
      " The essential role of Cited2, a negative regulator for HIF-1    , in heart development and neurulation  Proceedings of the National Academy of Sciences of the United States of America  2002  99  16  10488  10493  10.1073/pnas.162371799  2-s2.0-0036679122  12149478  75  Kranc  K. R.  Schepers  H.  Rodrigues  N. P.  Cited2 is an essential regulator of adult hematopoietic stem cells  Cell Stem Cell  2009  5  6  659  665  10.1016/j.stem.2009.11.001  2-s2.0-70450253358  19951693  76  Lou  X. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [  50  ,  51  ]. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [\n",
      "            \n",
      "             50\n",
      "            \n",
      "            ,\n",
      "            \n",
      "             51\n",
      "            \n",
      "            ].   The essential role of Cited2, a negative regulator for HIF-1    , in heart development and neurulation  Proceedings of the National Academy of Sciences of the United States of America  2002  99  16  10488  10493  10.1073/pnas.162371799  2-s2.0-0036679122  12149478  75  Kranc  K. R.  Schepers  H.  Rodrigues  N. P.  Cited2 is an essential regulator of adult hematopoietic stem cells  Cell Stem Cell  2009  5  6  659  665  10.1016/j.stem.2009.11.001  2-s2.0-70450253358  19951693  76  Lou  X. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [  50  ,  51  ].\n",
      "SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ]. SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      31\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. As described for previously characterized prion determining regions of yeast proteins [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      28\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     -\n",
      "     \n",
      "      43\n",
      "     \n",
      "     ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure\n",
      "     \n",
      "      5\n",
      "     \n",
      "     A-C and Additional file\n",
      "     \n",
      "      2\n",
      "     \n",
      "     : Figure S2B). However, only a limited number of Q/N rich sequences are\n",
      "     \n",
      "      bone fide\n",
      "     \n",
      "     prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      27\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     ].  SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ].\n",
      "As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].  As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [\n",
      "      \n",
      "       46\n",
      "      \n",
      "      ]. As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].\n",
      " 30  In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,  31  DNA repair,  32  lipid sensing,  33  tumor suppressor,  34  metabolic regulation,  35  and regulation of oxidant levels in cells.  \n",
      "\n",
      "         30\n",
      "        \n",
      "\n",
      "       In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,\n",
      "       \n",
      "\n",
      "         31\n",
      "        \n",
      "\n",
      "       DNA repair,\n",
      "       \n",
      "\n",
      "         32\n",
      "        \n",
      "\n",
      "       lipid sensing,\n",
      "       \n",
      "\n",
      "         33\n",
      "        \n",
      "\n",
      "       tumor suppressor,\n",
      "       \n",
      "\n",
      "         34\n",
      "        \n",
      "\n",
      "       metabolic regulation,\n",
      "       \n",
      "\n",
      "         35\n",
      "        \n",
      "\n",
      "       and regulation of oxidant levels in cells.  30  In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,  31  DNA repair,  32  lipid sensing,  33  tumor suppressor,  34  metabolic regulation,  35  and regulation of oxidant levels in cells.\n",
      "nan\n",
      "Similarly, other groups have previously reported portability of gene expression signatures [  13  ,  14  ].  Similarly, other groups have previously reported portability of gene expression signatures [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ]. Similarly, other groups have previously reported portability of gene expression signatures [  13  ,  14  ].\n",
      "nan\n",
      " Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].    Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].\n",
      "One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [  3  ].  One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [\n",
      "     \n",
      "      3\n",
      "     \n",
      "     ]. One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [  3  ].\n",
      " Taking these concepts further, Potti and colleagues [  34  ] combined microarray data from the NCI-60 cell lines with historical pharmacologic data generated from the NCI-60 panel at the National Cancer Institute to define expression signatures capable of discriminating between cell lines that are sensitive to various drugs and those that are resistant.    Taking these concepts further, Potti and colleagues [  34  ] combined microarray data from the NCI-60 cell lines with historical pharmacologic data generated from the NCI-60 panel at the National Cancer Institute to define expression signatures capable of discriminating between cell lines that are sensitive to various drugs and those that are resistant.\n",
      " In a similar approach, Nevins and colleagues [  25  ] demonstrated that gene expression signatures deriving from the NCI-60 cell line set matched with cytotoxic sensitivity data could be used to predict response to chemotherapy in tumours from patients treated with the same drugs.    In a similar approach, Nevins and colleagues [  25  ] demonstrated that gene expression signatures deriving from the NCI-60 cell line set matched with cytotoxic sensitivity data could be used to predict response to chemotherapy in tumours from patients treated with the same drugs.\n",
      " Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].    Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].\n",
      "The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].   The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].\n",
      " To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [  8  -  12  ,  17  ,  18  ], of predictive marker genes [  19  ], relevant genomics [  19  ,  20  ], or proteomics [  21  ]. \n",
      "\n",
      "     To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [\n",
      "     \n",
      "      8\n",
      "     \n",
      "     -\n",
      "     \n",
      "      12\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      18\n",
      "     \n",
      "     ], of predictive marker genes [\n",
      "     \n",
      "      19\n",
      "     \n",
      "     ], relevant genomics [\n",
      "     \n",
      "      19\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      20\n",
      "     \n",
      "     ], or proteomics [\n",
      "     \n",
      "      21\n",
      "     \n",
      "     ].   To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [  8  -  12  ,  17  ,  18  ], of predictive marker genes [  19  ], relevant genomics [  19  ,  20  ], or proteomics [  21  ].\n",
      "The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].  The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ]. The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].\n",
      " Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].    Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].\n",
      "Nevertheless, empirical research in the field of how we perceive odours is still fairly new, although we know more today about our brain's strategy in computing odour perception [  25  -  28  ] than we did only a few years ago.   Nevertheless, empirical research in the field of how we perceive odours is still fairly new, although we know more today about our brain's strategy in computing odour perception [  25  -  28  ] than we did only a few years ago.\n",
      "In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,  2003  ), in the olfactory bulb (Davison and Katz,  2007  ; Giraudet et al.,  2002  ; Lin et al.,  2006  ; Tabor et al.,  2004  ) and in the olfactory cortex (Lei et al.,  2006  ; Zou and Buck,  2006  ).  In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,\n",
      "           \n",
      "            2003\n",
      "           \n",
      "           ), in the olfactory bulb (Davison and Katz,\n",
      "           \n",
      "            2007\n",
      "           \n",
      "           ; Giraudet et al.,\n",
      "           \n",
      "            2002\n",
      "           \n",
      "           ; Lin et al.,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ; Tabor et al.,\n",
      "           \n",
      "            2004\n",
      "           \n",
      "           ) and in the olfactory cortex (Lei et al.,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ; Zou and Buck,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ). In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,  2003  ), in the olfactory bulb (Davison and Katz,  2007  ; Giraudet et al.,  2002  ; Lin et al.,  2006  ; Tabor et al.,  2004  ) and in the olfactory cortex (Lei et al.,  2006  ; Zou and Buck,  2006  ).\n",
      " Olfactory cortical neurons have been shown to receive multiglomerular inputs (Illig and Haberly,\n",
      "      \n",
      "       2003\n",
      "      \n",
      "      ; Murakami et al.,\n",
      "      \n",
      "       2005\n",
      "      \n",
      "      ; Zou et al.,\n",
      "      \n",
      "       2005\n",
      "      \n",
      "      ; Lei et al.,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Zou and Buck,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Rennaker et al.,\n",
      "      \n",
      "       2007\n",
      "      \n",
      "      ; Poo and Isaacson,\n",
      "      \n",
      "       2009\n",
      "      \n",
      "      ; Stettler and Axel,\n",
      "      \n",
      "       2009\n",
      "      \n",
      "      ), and individual OC neurons may reasonably collect such multiglomerular inputs in a different manner in different OC areas (Kadohisa and Wilson,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Yoshida and Mori,\n",
      "      \n",
      "       2007\n",
      "      \n",
      "      ; Kikuta et al.,\n",
      "      \n",
      "       2008\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       2010\n",
      "      \n",
      "      ; Wesson and Wilson,\n",
      "      \n",
      "       2010\n",
      "      \n",
      "      ).  \n",
      "Indeed, there were two reports presenting spontaneous transformation and/or aneuploidy of ASCs, following long-term in vitro culture [  42  ,  43  ].   Indeed, there were two reports presenting spontaneous transformation and/or aneuploidy of ASCs, following long-term in vitro culture [  42  ,  43  ].\n",
      "Some vector integrases, such as those for phages C31 [  119  -  121  ], BT1 [  122  ], as well as the  Escherichia coli Tn7  transposon [  123  ], recognize specific DNA sequences or degenerate sequences that exist in mammalian genomes.   Some vector integrases, such as those for phages C31 [  119  -  121  ], BT1 [  122  ], as well as the  Escherichia coli Tn7  transposon [  123  ], recognize specific DNA sequences or degenerate sequences that exist in mammalian genomes.\n",
      "nan\n",
      "For example, flavonoids showed antimicrobial activity [  69  ]. For example, flavonoids showed antimicrobial activity [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ].  For example, flavonoids showed antimicrobial activity [  69  ].\n",
      "Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P  3  agonism [  8  ,  9  ,  10  ], these effects were also observed with selective modulation of S1P  1  R [  11  ,  12  ,  13  ,  14  ,  15  ].  Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P\n",
      "       \n",
      "        3\n",
      "       \n",
      "       agonism [\n",
      "       \n",
      "        8\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        9\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        10\n",
      "       \n",
      "       ], these effects were also observed with selective modulation of S1P\n",
      "       \n",
      "        1\n",
      "       \n",
      "       R [\n",
      "       \n",
      "        11\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        12\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        14\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        15\n",
      "       \n",
      "       ]. Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P  3  agonism [  8  ,  9  ,  10  ], these effects were also observed with selective modulation of S1P  1  R [  11  ,  12  ,  13  ,  14  ,  15  ].\n",
      "Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.  Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [\n",
      "              \n",
      "               24\n",
      "              \n",
      "              ,\n",
      "              \n",
      "               26\n",
      "              \n",
      "              -\n",
      "              \n",
      "               28\n",
      "              \n",
      "              ]. Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.\n"
     ]
    }
   ],
   "source": [
    "for sentence in df1sentence_sentences_classification.sentences_citing:\n",
    "    print(sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "###############  FIN TEST  #######################"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "142"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df1sentence_sentences_classification)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>article_citing</th>\n",
       "      <th>Article</th>\n",
       "      <th>date_article_citing</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>pmid_article_citing</th>\n",
       "      <th>references_in_article_citing</th>\n",
       "      <th>date_doi_cited_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>before_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>&lt;html&gt;\\n &lt;body&gt;\\n  &lt;p&gt;\\n   Int_J_Ment_Health_S...</td>\n",
       "      <td>&lt;modules.Article_object.Article_object object ...</td>\n",
       "      <td>2017-11-30</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28503193</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   DOI_cited  \\\n",
       "0  10.1186/s13033-017-0143-5   \n",
       "\n",
       "                                      article_citing  \\\n",
       "0  <html>\\n <body>\\n  <p>\\n   Int_J_Ment_Health_S...   \n",
       "\n",
       "                                             Article date_article_citing  \\\n",
       "0  <modules.Article_object.Article_object object ...          2017-11-30   \n",
       "\n",
       "  doi_article_citing pmid_article_citing  references_in_article_citing  \\\n",
       "0                NaN            28503193                           NaN   \n",
       "\n",
       "  date_doi_cited_retraction  after_retraction  before_retraction  \n",
       "0                2017-09-15                 1                  0  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Articles_before_after_retraction.head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>before_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>sentences_citing</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>10.1104/pp.011019</td>\n",
       "      <td>10.1186/1472-6882-13-155</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>For example, flavonoids showed antimicrobial a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>10.1073/pnas.0501997102</td>\n",
       "      <td>10.3390/ijms18122636</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>Whereas cardiodynamic (heart rate [HR] reducti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>10.1073/pnas.0501997102</td>\n",
       "      <td>10.1186/1465-9921-13-36</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Others have reported that changes in occludin ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   DOI_cited        doi_article_citing  before_retraction  \\\n",
       "139        10.1104/pp.011019  10.1186/1472-6882-13-155                  0   \n",
       "140  10.1073/pnas.0501997102      10.3390/ijms18122636                  1   \n",
       "141  10.1073/pnas.0501997102   10.1186/1465-9921-13-36                  0   \n",
       "\n",
       "     after_retraction                                   sentences_citing  \n",
       "139                 1  For example, flavonoids showed antimicrobial a...  \n",
       "140                 0  Whereas cardiodynamic (heart rate [HR] reducti...  \n",
       "141                 1  Others have reported that changes in occludin ...  "
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1sentence_sentences_classification.tail(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "#df.dropna(subset = \"sentences_citing\")\n",
    "\n",
    "df1sentence_sentences_classification  = df1sentence_sentences_classification.dropna(subset = [\"sentences_citing\"])\n",
    "\n",
    "df3sentences_sentences_classification  = df3sentences_sentences_classification.dropna(subset = [\"sentences_citing\"])\n",
    "\n",
    "\n",
    "df5sentences_sentences_classification  = df5sentences_sentences_classification.dropna(subset = [\"sentences_citing\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "111"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df1sentence_sentences_classification.doi_article_citing.unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>before_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>sentences_citing</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1)  Although there has been meaningful debate...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>10.1042/BSR20160174</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>To verify the activation of FOXO1in our model...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1371/journal.pone.0164571</td>\n",
       "      <td>10.3390/ijerph14060602</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>Boiling or chlorinating water at the point of ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      DOI_cited      doi_article_citing  before_retraction  \\\n",
       "0     10.1186/s13033-017-0143-5                     NaN                  0   \n",
       "1            10.1002/cbin.10291     10.1042/BSR20160174                  1   \n",
       "2  10.1371/journal.pone.0164571  10.3390/ijerph14060602                  0   \n",
       "\n",
       "   after_retraction                                   sentences_citing  \n",
       "0                 1   1)  Although there has been meaningful debate...  \n",
       "1                 0  To verify the activation of FOXO1in our model...  \n",
       "2                 1  Boiling or chlorinating water at the point of ...  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df1sentence_sentences_classification.head(3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "47"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df1sentence_sentences_classification.DOI_cited.unique())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's split the dataframe on sentences before and after retraction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "df_sentences_before:  (90, 5)\n",
      "df_sentences_after:  (32, 5)\n"
     ]
    }
   ],
   "source": [
    "df_sentences_before = df1sentence_sentences_classification[df1sentence_sentences_classification[\"before_retraction\"] == 1]\n",
    "df_sentences_after = df1sentence_sentences_classification[df1sentence_sentences_classification[\"after_retraction\"] == 1]\n",
    "print(\"df_sentences_before: \", df_sentences_before.shape)\n",
    "print(\"df_sentences_after: \", df_sentences_after.shape)\n",
    "\n",
    "df_3sentences_before = df3sentences_sentences_classification[df3sentences_sentences_classification[\"before_retraction\"] == 1]\n",
    "df_3sentences_after = df3sentences_sentences_classification[df3sentences_sentences_classification[\"after_retraction\"] == 1]\n",
    "\n",
    "df_5sentences_before = df5sentences_sentences_classification[df5sentences_sentences_classification[\"before_retraction\"] == 1]\n",
    "df_5sentences_after = df5sentences_sentences_classification[df5sentences_sentences_classification[\"after_retraction\"] == 1]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_sentences_after.DOI_cited.unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " 1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  \n",
      "      1)\n",
      "     \n",
      "     Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,\n",
      "     \n",
      "      4)\n",
      "     \n",
      "     research has already begun to investigate treatments for the disorder. \n",
      "      1\n",
      "     \n",
      "     \n",
      "     \n",
      "      3)\n",
      "     \n",
      "     In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.\n",
      "Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ]. Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [\n",
      "     \n",
      "      32\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      33\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ].  Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ].\n",
      " Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ). However, the effects of betatrophin on human islets were not analyzed (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). Betatrophin is a novel -cell mitogen reported by Yi\n",
      "                           \n",
      "                            et al\n",
      "                           \n",
      "                           (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ) that enhances endogenous -cell replication and improves glucose tolerance and insulin secretion following hydrodynamic tail injections of plasmids encoding mouse and human betatrophin into mice with insulin resistance induced by the insulin receptor antagonist, S961. Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). \n",
      "\n",
      "                           Betatrophin, also known as lipasin (\n",
      "                           \n",
      "                            19\n",
      "                           \n",
      "                           ) or angiopoietin-like 8 (\n",
      "                           \n",
      "                            20\n",
      "                           \n",
      "                           ), was recently described as a potent stimulator of mouse -cell proliferation (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ).  Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ).\n",
      "The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ]. Because SGLT2 inhibitors decrease insulin levels [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], and because circulating betatrophin levels were remarkably elevated by administration of an insulin receptor blocker resulting in liver insulin resistance [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], we hypothesized that administration of SGLT2 inhibitors, such as canagliflozin, may increase circulating betatrophin levels and therefore may influence serum lipid concentrations. The reason for the potentially positive association between betatrophin and glycemic control as evaluated by HbA1c or FPG remains unclear since the effect of betatrophin on regeneration of pancreatic  cells which was previously reported [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ] is currently considered to be negative [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ].\n",
      " \n",
      "     34)\n",
      "    \n",
      "    Results from our previous study\n",
      "    \n",
      "     19)\n",
      "    \n",
      "    showed that marked increases in astrocyte number and level of GFAP expression in the PND 21 frontal cortex after postnatal VPA treatment.  \n",
      "One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].   One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].\n",
      "Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].   Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].\n",
      "One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].   One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].\n",
      "In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].  In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ]), tumor progression [\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ], and clinical outcomes, such as patient survival [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ]. In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].\n",
      " MiR-31 expression was elevated in endometrial cancer [\n",
      "         \n",
      "          15\n",
      "         \n",
      "         ] but paradoxically down-regulated in breast [\n",
      "         \n",
      "          16\n",
      "         \n",
      "         ] and prostate cancer [\n",
      "         \n",
      "          18\n",
      "         \n",
      "         ].  \n",
      "Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].  Besides patients with lupus having abnormally high levels of IL-17A along with IFN-\n",
      "       \n",
      "        \n",
      "       \n",
      "       are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [\n",
      "       \n",
      "        12\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ]. Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].\n",
      "Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].   Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].\n",
      " \n",
      "\n",
      "      USP4 is overexpressed in various types of cancer and the increased levels of USP4 appear to play a functional role in malignant cells (\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       20\n",
      "      \n",
      "      \n",
      "      \n",
      "       22\n",
      "      \n",
      "      ).  \n",
      "These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).   These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).\n",
      "There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis. Although functional proof of this mechanism is necessary, several reports support our model [\n",
      "      \n",
      "       52\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       58\n",
      "      \n",
      "      -\n",
      "      \n",
      "       60\n",
      "      \n",
      "      ]. There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ] underlines this hypothesis.  There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis.\n",
      "Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. The possibility that an unusual branched TCA cycle may operate in the asexual stages of\n",
      "     \n",
      "      P. falciparum\n",
      "     \n",
      "     , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ], but subsequently retracted [\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ].\n",
      "There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance. There is no evidence to suggest a significant displacement of government funding by international support [\n",
      "     \n",
      "      45\n",
      "     \n",
      "     ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.  There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.\n",
      "As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].  As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].\n",
      "Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).  Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      (\n",
      "      \n",
      "       He et al., 2010\n",
      "      \n",
      "      ). Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).\n",
      "[  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].  Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [\n",
      "     \n",
      "      2\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. [  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].\n",
      "[  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].  This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [\n",
      "      \n",
      "       1\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ]. [  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].\n",
      " [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  \n",
      "         [25]\n",
      "        \n",
      "        computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.\n",
      "In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [\n",
      "     \n",
      "      61\n",
      "     \n",
      "     -\n",
      "     \n",
      "      63\n",
      "     \n",
      "     ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     cell growth [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. In\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. \n",
      "      In T. brucei\n",
      "     \n",
      "     , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. In addition, a small fraction of PC is generated by sequential methylation of PE [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [\n",
      "     \n",
      "      11\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      21\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      59\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      60\n",
      "     \n",
      "     ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids\n",
      "     \n",
      "      de novo\n",
      "     \n",
      "     [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      65\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      66\n",
      "     \n",
      "     ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      6\n",
      "     \n",
      "     ], RNA transport [\n",
      "     \n",
      "      7\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ] and processing [\n",
      "     \n",
      "      9\n",
      "     \n",
      "     -\n",
      "     \n",
      "      12\n",
      "     \n",
      "     ], protein localization [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     -\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ], and transcription [\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ].\n",
      "SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ]. SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      31\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. As described for previously characterized prion determining regions of yeast proteins [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      28\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     -\n",
      "     \n",
      "      43\n",
      "     \n",
      "     ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure\n",
      "     \n",
      "      5\n",
      "     \n",
      "     A-C and Additional file\n",
      "     \n",
      "      2\n",
      "     \n",
      "     : Figure S2B). However, only a limited number of Q/N rich sequences are\n",
      "     \n",
      "      bone fide\n",
      "     \n",
      "     prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      27\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     ].  SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ].\n",
      "As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].  As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [\n",
      "      \n",
      "       46\n",
      "      \n",
      "      ]. As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].\n",
      " Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].    Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].\n",
      " Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].    Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].\n",
      "The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].   The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].\n",
      "The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].  The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ]. The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].\n",
      " Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].    Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].\n",
      "For example, flavonoids showed antimicrobial activity [  69  ]. For example, flavonoids showed antimicrobial activity [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ].  For example, flavonoids showed antimicrobial activity [  69  ].\n",
      "Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.  Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [\n",
      "              \n",
      "               24\n",
      "              \n",
      "              ,\n",
      "              \n",
      "               26\n",
      "              \n",
      "              -\n",
      "              \n",
      "               28\n",
      "              \n",
      "              ]. Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.\n"
     ]
    }
   ],
   "source": [
    "for sentence in df_sentences_after.sentences_citing:\n",
    "    print(sentence)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's analyse the documents\n",
    "\n",
    "* How many the documents from df_sentences_before cite DOIs that are not cited after retraction? \n",
    "* How many cite DOIs that are also cited after retraction?\n",
    "\n",
    "* How many the documents from df_sentences_after cite DOIs that are not cited before retraction? \n",
    "* How many cite DOIs that are also cited before retraction?\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " unique dois_cited_before  35\n",
      "\n",
      " unique dois_cited_after  24\n",
      "\n",
      " unique doi_cited_before_and_after  12\n",
      "\n",
      " unqiue doi_cited_only_before  23\n",
      "\n",
      " unique doi_cited_only_after  12\n"
     ]
    }
   ],
   "source": [
    "dois_cited_before = set(df_sentences_before[\"DOI_cited\"])\n",
    "dois_cited_after = set(df_sentences_after[\"DOI_cited\"])\n",
    "\n",
    "doi_cited_before_and_after = dois_cited_before.intersection(dois_cited_after)\n",
    "doi_cited_before_and_after \n",
    "\n",
    "doi_cited_only_before = dois_cited_before.difference(dois_cited_after)\n",
    "doi_cited_only_before\n",
    "\n",
    "doi_cited_only_after = dois_cited_after.difference(dois_cited_before)\n",
    "doi_cited_only_after\n",
    "\n",
    "print(\"\\n unique dois_cited_before \", len(dois_cited_before))\n",
    "print(\"\\n unique dois_cited_after \", len(dois_cited_after))\n",
    "print(\"\\n unique doi_cited_before_and_after \", len(doi_cited_before_and_after))\n",
    "print(\"\\n unqiue doi_cited_only_before \", len(doi_cited_only_before))\n",
    "print(\"\\n unique doi_cited_only_after \", len(doi_cited_only_after))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " number documents citing after - DOIS that are only cited after: \n",
      "15\n",
      "\n",
      " number documents citing after - DOIS that are cited before and after:\n",
      "17\n",
      "\n",
      " number documents citing before - DOIS that are only cited before: \n",
      "53\n",
      "\n",
      " number documents citing before - DOIS that are cited before and after:\n",
      "37\n"
     ]
    }
   ],
   "source": [
    "print(\"\\n number documents citing after - DOIS that are only cited after: \")\n",
    "df_sentences_after_only = df_sentences_after[df_sentences_after.DOI_cited.isin(doi_cited_only_after)]\n",
    "print(df_sentences_after_only.shape[0])\n",
    "\n",
    "print(\"\\n number documents citing after - DOIS that are cited before and after:\")\n",
    "df_sentences_after_not_only = df_sentences_after[df_sentences_after.DOI_cited.isin(doi_cited_before_and_after)]\n",
    "print(df_sentences_after_not_only.shape[0])\n",
    "\n",
    "print(\"\\n number documents citing before - DOIS that are only cited before: \")\n",
    "df_sentences_before_only = df_sentences_before[df_sentences_before.DOI_cited.isin(doi_cited_only_before)]\n",
    "print(df_sentences_before_only.shape[0])\n",
    "\n",
    "print(\"\\n number documents citing before - DOIS that are cited before and after:\")\n",
    "df_sentences_before_not_only = df_sentences_before[df_sentences_before.DOI_cited.isin(doi_cited_before_and_after)]\n",
    "print(df_sentences_before_not_only.shape[0])\n",
    "\n",
    "########################3\n",
    "\n",
    "df_3sentences_after_only = df_3sentences_after[df_3sentences_after.DOI_cited.isin(doi_cited_only_after)]\n",
    "\n",
    "df_3sentences_after_not_only = df_3sentences_after[df_3sentences_after.DOI_cited.isin(doi_cited_before_and_after)]\n",
    "\n",
    "df_3sentences_before_only = df_3sentences_before[df_3sentences_before.DOI_cited.isin(doi_cited_only_before)]\n",
    "\n",
    "df_3sentences_before_not_only = df_3sentences_before[df_3sentences_before.DOI_cited.isin(doi_cited_before_and_after)]\n",
    "\n",
    "\n",
    "#######################\n",
    "\n",
    "df_5sentences_after_only = df_5sentences_after[df_5sentences_after.DOI_cited.isin(doi_cited_only_after)]\n",
    "\n",
    "df_5sentences_after_not_only = df_5sentences_after[df_5sentences_after.DOI_cited.isin(doi_cited_before_and_after)]\n",
    "\n",
    "df_5sentences_before_only = df_5sentences_before[df_5sentences_before.DOI_cited.isin(doi_cited_only_before)]\n",
    "\n",
    "df_5sentences_before_not_only = df_5sentences_before[df_5sentences_before.DOI_cited.isin(doi_cited_before_and_after)]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(90, 5)"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sentences_before.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Summary 3:\n",
    "\n",
    "90 documents before retractions:\n",
    "    \n",
    "    - 53 documents cite DOIs (23 unique DOIs) that are not cited after retraction.\n",
    "    - 37 documents cite DOIs (12 unique DOIs) that are also cited after retraction.\n",
    "\n",
    "    - 83 unique doi_article_citing - len(df_sentences_before.doi_article_citing.unique())\n",
    "        There are 7 documents without the DOIS_citing     \n",
    "    - 35 unique DOI_cited - len(df_sentences_before.DOI_cited.unique())\n",
    "        Of those 23 DOI are only cited before. 12 before and after.\n",
    "\n",
    "\n",
    "32 documents after retraction:\n",
    "    \n",
    "    - 15 documents cite DOIs (12 unique DOIs) that are not cited before retraction.\n",
    "    - 17 documents cite DOIs (12 unique DOIs) that are also cited before retraction.\n",
    "\n",
    "\n",
    "    - 29 unique doi_article_citing - len(df_sentences_after.doi_article_citing.unique())\n",
    "        There are 3 documents without the DOIS_citing        \n",
    "    - 24 unique DOI_cited - len(df_sentences_after.DOI_cited.unique())\n",
    "        Of those 12 DOI are only cited after. 12 before and after.\n",
    "    \n",
    "\n",
    "We will select documents before retraction only if they also have been cited after retraction.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#####################################################################################"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Summary 2 \n",
    "\n",
    "61 different DOIs of retracted papers cited by\n",
    "218 articles.\n",
    "\n",
    "42 retracted papers, 25 retraction notes, and 152 new manuscripts.\n",
    "\n",
    "152 new manuscripts:\n",
    "     45 were published after the retraction\n",
    "    107 before the retraction.\n",
    "    \n",
    "* The algorithm is able to find the text citing in:\n",
    "    \n",
    "127 manuscripts:\n",
    "    36 were published after retraction\n",
    "    91 were published before retraction\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Selection of documents, stemming and counting of words to train a classifier"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "import imp\n",
    "#imp.reload('modules.get_stemmed_sentences_and_list_words')\n",
    "#import importlib\n",
    "\n",
    "#import modules.get_stemmed_sentences_and_list_words\n",
    "#from modules.get_stemmed_sentences_and_list_words import get_tuple_articles_stemmed_classified_and_list_words # get_stemmed_sentences_and_list_words\n",
    "#import imp\n",
    "#from modules.get_stemmed_sentences_and_list_words import get_tuple_articles_stemmed_classified_and_list_words # get_stemmed_sentences_and_list_words\n",
    "\n",
    "#path = \"/project/eLife_retractions/modules\"\n",
    "#os.chdir(path)\n",
    "#importlib.reload(\"get_stemmed_sentences_and_list_words.py\")\n",
    "\n",
    "from modules.get_stemmed_sentences_and_list_words import *\n",
    "#from modules.get_stemmed_sentences_and_list_words import get_tuple_articles_stemmed_classified_and_list_words # get_stemmed_sentences_and_list_words\n",
    "#import imp\n",
    "#imp.reload(modules.get_stemmed_sentences_and_list_words)\n",
    "\n",
    "\n",
    "\n",
    "# 1. With one sentence citing:\n",
    "\n",
    "# 1.1 -  All documents\n",
    "sentences_before = df_sentences_before.sentences_citing\n",
    "sentences_after = df_sentences_after.sentences_citing\n",
    "(documents_all, list_all_words, list_all_bigrams) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n",
    "\n",
    "df_documents_all = df_sentences_before.append(df_sentences_after) # I will used this in unsupervised models\n",
    "\n",
    "\n",
    "\n",
    "# 1.2 -  50 % before - 50% after\n",
    "#documents = document_before[:len(document_after)] + document_after\n",
    "sentences_before = df_sentences_before.sentences_citing\n",
    "sentences_after = df_sentences_after.sentences_citing\n",
    "sentences_before_part = sentences_before[:len(sentences_after)]\n",
    "(documents_50_50, list_all_words_50_50, list_all_bigrams_50_50) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before_part, sentences_after)\n",
    "\n",
    "\n",
    "# 2. With one sentence citing + following 3 sentences:\n",
    "\n",
    "# 2.1 -  All documents\n",
    "#documents_3_all = document_3_before + document_3_after\n",
    "sentences_before = df_3sentences_before.sentences_citing\n",
    "sentences_after = df_3sentences_after.sentences_citing\n",
    "\n",
    "df_documents_all_3sentences = df_3sentences_before.append(df_3sentences_after)\n",
    "# used for unsupervised training\n",
    "\n",
    "(documents_all_3sentences, list_all_words_3sentences, list_all_bigrams_3sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n",
    "\n",
    "\n",
    "# 2.2 -  50 % before - 50% after\n",
    "#documents = document_before[:len(document_after)] + document_after\n",
    "sentences_before = df_3sentences_before.sentences_citing\n",
    "sentences_after = df_3sentences_after.sentences_citing\n",
    "sentences_before_part = sentences_before[:len(sentences_after)]\n",
    "(documents_50_50_3sentences, list_all_words_50_50_3sentences, list_all_bigrams_50_50_3sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before_part, sentences_after)\n",
    "\n",
    "  \n",
    "    \n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Note you could use CountVectorizer from sklearn, but I have done this manually in order to \n",
    "# filter the words we are adding or not.\n",
    "\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "from random import randint\n",
    "\n",
    "count_vectorizer = CountVectorizer(\n",
    "    ngram_range=(2,2))#, max_features=10, max_df=0.6\n",
    "\n",
    "\n",
    "#i = randint(0, len(df_sentences_before) - 1)\n",
    "tokenizer = CountVectorizer().build_tokenizer()\n",
    "tokenizer(df_sentences_before['sentences_citing'].iloc[0])#.iloc[i])\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 3. With one sentence citing + following 5 sentences:\n",
    "\n",
    "# 3.1 -  All documents\n",
    "#documents_3_all = document_3_before + document_3_after\n",
    "sentences_before = df_5sentences_before.sentences_citing\n",
    "sentences_after = df_5sentences_after.sentences_citing\n",
    "(documents_all_5sentences, list_all_words_5sentences, list_all_bigrams_5sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n",
    "\n",
    "\n",
    "# 3.2 -  50 % before - 50% after\n",
    "#documents = document_before[:len(document_after)] + document_after\n",
    "sentences_before = df_5sentences_before.sentences_citing\n",
    "sentences_after = df_5sentences_after.sentences_citing\n",
    "sentences_before_part = sentences_before[:len(sentences_after)]\n",
    "(documents_50_50_5sentences, list_all_words_50_50_5sentences, list_all_bigrams_50_50_5sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before_part, sentences_after)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "10630 6007 32659 16912\n"
     ]
    }
   ],
   "source": [
    "print(len(list_all_words),\n",
    "len(list_all_words_50_50), \n",
    "len(list_all_words_3sentences),\n",
    "len(list_all_words_50_50_3sentences))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "23702"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list_all_words_50_50_5sentences)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Selection: same number of documents_citing before_only than after_only, and same number of documents citing the same DOI before and ater\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 1.3. Same number of documents_citing before_only than after_only, and same number of documents citing the same DOI before and ater\n",
    "\n",
    "# Let's get all the papers from df_sentences_after_only (X), and from df_sentences_after_not_only (Y)\n",
    "# and X papers from df_sentences_before_only, and Y documents from df_sentences_before_and_after. \n",
    "# When selecting the documents for df_sentences_before_and_after we must be sure that we are not selecting \n",
    "# all the papers the same doi (for each cited doi, we want to have the number of douments citing before and \n",
    "# after)\n",
    "\n",
    "df_sentences_before_only_selection = df_sentences_before_only.sample(frac=1) #https://stackoverflow.com/questions/29576430/shuffle-dataframe-rows\n",
    "df_sentences_before_only_selection = df_sentences_before_only_selection.drop_duplicates(subset = \"DOI_cited\")\n",
    "df_sentences_before_only_selection = df_sentences_before_only_selection[:df_sentences_after_only.shape[0]]\n",
    "df_sentences_before_only_selection\n",
    "\n",
    "list_doi_added = []\n",
    "df_sentences_before_not_only_selection = pd.DataFrame()\n",
    "df_sentences_after_not_only_selection = pd.DataFrame()\n",
    "#more_dois_in_\n",
    "\n",
    "for doi in list(df_sentences_after_not_only.DOI_cited.unique()):\n",
    "\n",
    "    #times_doi_in_df_sentences_after_not_only = list(df_sentences_after_not_only.DOI_cited).count(doi)\n",
    "    \n",
    "    df_sentences_after_not_only_doi_selected = df_sentences_after_not_only[df_sentences_after_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_sentences_after_not_only =  df_sentences_after_not_only_doi_selected.shape[0]\n",
    "    \n",
    "    df_sentences_before_not_only_doi_selected = df_sentences_before_not_only[df_sentences_before_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_sentences_before_not_only = df_sentences_before_not_only_doi_selected.shape[0]\n",
    "\n",
    "    \"\"\"    print(doi)\n",
    "    print(\"times_doi in df_sentences_after_not_only: \", times_doi_in_df_sentences_after_not_only)\n",
    "    print(\"times_doi in df_sentences_before_not_only: \", times_doi_in_df_sentences_before_not_only)\n",
    "    \"\"\"    \n",
    "    #threshold_difference_in_number = 0 # if you want to allow X documents more before/after or after/before\n",
    "    if times_doi_in_df_sentences_after_not_only <= times_doi_in_df_sentences_before_not_only:\n",
    "        df_sentences_before_not_only_selection = df_sentences_before_not_only_selection.append(\n",
    "                                  df_sentences_before_not_only[:times_doi_in_df_sentences_after_not_only])\n",
    "        df_sentences_after_not_only_selection = df_sentences_after_not_only_selection.append(\n",
    "                                  df_sentences_after_not_only[:times_doi_in_df_sentences_after_not_only])\n",
    "    else: \n",
    "        df_sentences_before_not_only_selection = df_sentences_before_not_only_selection.append(\n",
    "                                  df_sentences_before_not_only[:times_doi_in_df_sentences_before_not_only])\n",
    "        df_sentences_after_not_only_selection = df_sentences_after_not_only_selection.append(\n",
    "                                  df_sentences_after_not_only[:times_doi_in_df_sentences_before_not_only])\n",
    "\n",
    "# The dataframes with the selected documents are:\n",
    "# df_sentences_before_not_only_selection\n",
    "# df_sentences_after_not_only_selection\n",
    "# df_sentences_before_only_selection\n",
    "# df_sentences_after_only\n",
    "\n",
    "df_sentences_before_selection = df_sentences_before_only_selection.append(df_sentences_before_not_only_selection)\n",
    "df_sentences_after_selection = df_sentences_after_only.append(df_sentences_after_not_only_selection)\n",
    "\n",
    "df_documents_50_50_balanced = df_sentences_before_selection.append(df_sentences_after_selection)\n",
    "# used for unsupervised\n",
    "\n",
    "\n",
    "sentences_before = df_sentences_before_selection.sentences_citing\n",
    "sentences_after = df_sentences_after_selection.sentences_citing\n",
    "(documents_50_50_balanced, list_all_words_50_50_balanced, list_all_bigrams_50_50_balanced) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(16, 5)"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sentences_before_not_only_selection.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(16, 5)"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sentences_after_not_only_selection.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(31, 5)"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sentences_before_selection.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(31, 5)"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sentences_after_selection.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "62"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(documents_50_50_balanced)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 3.3. Same number of documents_citing before_only than after_only, and same number of documents citing the same DOI before and ater\n",
    "\n",
    "df_3sentences_before_only_selection = df_3sentences_before_only.sample(frac=1) #https://stackoverflow.com/questions/29576430/shuffle-dataframe-rows\n",
    "df_3sentences_before_only_selection = df_3sentences_before_only_selection.drop_duplicates(subset = \"DOI_cited\")\n",
    "df_3sentences_before_only_selection = df_3sentences_before_only_selection[:df_3sentences_after_only.shape[0]]\n",
    "df_3sentences_before_only_selection\n",
    "\n",
    "list_doi_added = []\n",
    "df_3sentences_before_not_only_selection = pd.DataFrame()\n",
    "df_3sentences_after_not_only_selection = pd.DataFrame()\n",
    "#more_dois_in_\n",
    "\n",
    "for doi in list(df_3sentences_after_not_only.DOI_cited.unique()):\n",
    "\n",
    "    #times_doi_in_df_sentences_after_not_only = list(df_sentences_after_not_only.DOI_cited).count(doi)\n",
    "    \n",
    "    df_3sentences_after_not_only_doi_selected = df_3sentences_after_not_only[df_3sentences_after_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_3sentences_after_not_only =  df_3sentences_after_not_only_doi_selected.shape[0]\n",
    "    \n",
    "    df_3sentences_before_not_only_doi_selected = df_3sentences_before_not_only[df_3sentences_before_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_3sentences_before_not_only = df_3sentences_before_not_only_doi_selected.shape[0]\n",
    "\n",
    "    \"\"\"    print(doi)\n",
    "    print(\"times_doi in df_sentences_after_not_only: \", times_doi_in_df_sentences_after_not_only)\n",
    "    print(\"times_doi in df_sentences_before_not_only: \", times_doi_in_df_sentences_before_not_only)\n",
    "    \"\"\"    \n",
    "    #threshold_difference_in_number = 0 # if you want to allow X documents more before/after or after/before\n",
    "    if times_doi_in_df_3sentences_after_not_only <= times_doi_in_df_3sentences_before_not_only:\n",
    "        df_3sentences_before_not_only_selection = df_3sentences_before_not_only_selection.append(\n",
    "                                  df_3sentences_before_not_only[:times_doi_in_df_3sentences_after_not_only])\n",
    "        df_3sentences_after_not_only_selection = df_3sentences_after_not_only_selection.append(\n",
    "                                  df_3sentences_after_not_only[:times_doi_in_df_3sentences_after_not_only])\n",
    "    else: \n",
    "        df_3sentences_before_not_only_selection = df_3sentences_before_not_only_selection.append(\n",
    "                                  df_3sentences_before_not_only[:times_doi_in_df_3sentences_before_not_only])\n",
    "        df_3sentences_after_not_only_selection = df_3sentences_after_not_only_selection.append(\n",
    "                                  df_3sentences_after_not_only[:times_doi_in_df_3sentences_before_not_only])\n",
    "\n",
    "# The dataframes with the selected documents are:\n",
    "# df_3sentences_before_not_only_selection\n",
    "# df_3sentences_after_not_only_selection\n",
    "# df_3sentences_before_only_selection\n",
    "# df_3sentences_after_only\n",
    "\n",
    "df_3sentences_before_balanced = df_3sentences_before_only_selection.append(df_3sentences_before_not_only_selection)\n",
    "df_3sentences_after_balanced = df_3sentences_after_only.append(df_3sentences_after_not_only_selection)\n",
    "\n",
    "df_documents_50_50_balanced_3sentences = df_3sentences_before_balanced.append(df_3sentences_after_balanced)\n",
    "# for unsupervised training\n",
    "\n",
    "sentences_before = df_3sentences_before_balanced.sentences_citing\n",
    "sentences_after = df_3sentences_after_balanced.sentences_citing\n",
    "(documents_50_50_balanced_3sentences, list_all_words_50_50_balanced_3sentences, list_all_bigrams_50_50_balanced_3sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(31, 5)"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_3sentences_before_balanced.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(31, 5)"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_3sentences_after_balanced.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 3.3. Same number of documents_citing before_only than after_only, and same number of documents citing the same DOI before and ater\n",
    "\n",
    "df_5sentences_before_only_selection = df_5sentences_before_only.sample(frac=1) #https://stackoverflow.com/questions/29576430/shuffle-dataframe-rows\n",
    "df_5sentences_before_only_selection = df_5sentences_before_only_selection.drop_duplicates(subset = \"DOI_cited\")\n",
    "df_5sentences_before_only_selection = df_5sentences_before_only_selection[:df_5sentences_after_only.shape[0]]\n",
    "df_5sentences_before_only_selection\n",
    "\n",
    "list_doi_added = []\n",
    "df_5sentences_before_not_only_selection = pd.DataFrame()\n",
    "df_5sentences_after_not_only_selection = pd.DataFrame()\n",
    "#more_dois_in_\n",
    "\n",
    "for doi in list(df_5sentences_after_not_only.DOI_cited.unique()):\n",
    "\n",
    "    #times_doi_in_df_sentences_after_not_only = list(df_sentences_after_not_only.DOI_cited).count(doi)\n",
    "    \n",
    "    df_5sentences_after_not_only_doi_selected = df_5sentences_after_not_only[df_5sentences_after_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_5sentences_after_not_only =  df_5sentences_after_not_only_doi_selected.shape[0]\n",
    "    \n",
    "    df_5sentences_before_not_only_doi_selected = df_5sentences_before_not_only[df_5sentences_before_not_only[\"DOI_cited\"] == doi]\n",
    "    times_doi_in_df_5sentences_before_not_only = df_5sentences_before_not_only_doi_selected.shape[0]\n",
    "\n",
    "    \"\"\"    print(doi)\n",
    "    print(\"times_doi in df_sentences_after_not_only: \", times_doi_in_df_sentences_after_not_only)\n",
    "    print(\"times_doi in df_sentences_before_not_only: \", times_doi_in_df_sentences_before_not_only)\n",
    "    \"\"\"    \n",
    "    #threshold_difference_in_number = 0 # if you want to allow X documents more before/after or after/before\n",
    "    if times_doi_in_df_5sentences_after_not_only <= times_doi_in_df_5sentences_before_not_only:\n",
    "        df_5sentences_before_not_only_selection = df_5sentences_before_not_only_selection.append(\n",
    "                                  df_5sentences_before_not_only[:times_doi_in_df_5sentences_after_not_only])\n",
    "        df_5sentences_after_not_only_selection = df_5sentences_after_not_only_selection.append(\n",
    "                                  df_5sentences_after_not_only[:times_doi_in_df_5sentences_after_not_only])\n",
    "    else: \n",
    "        df_5sentences_before_not_only_selection = df_5sentences_before_not_only_selection.append(\n",
    "                                  df_5sentences_before_not_only[:times_doi_in_df_5sentences_before_not_only])\n",
    "        df_5sentences_after_not_only_selection = df_5sentences_after_not_only_selection.append(\n",
    "                                  df_5sentences_after_not_only[:times_doi_in_df_5sentences_before_not_only])\n",
    "\n",
    "# The dataframes with the selected documents are:\n",
    "# df_3sentences_before_not_only_selection\n",
    "# df_3sentences_after_not_only_selection\n",
    "# df_3sentences_before_only_selection\n",
    "# df_3sentences_after_only\n",
    "\n",
    "df_5sentences_before_balanced = df_3sentences_before_only_selection.append(df_5sentences_before_not_only_selection)\n",
    "df_5sentences_after_balanced = df_3sentences_after_only.append(df_5sentences_after_not_only_selection)\n",
    "\n",
    "\n",
    "sentences_before = df_5sentences_before_balanced.sentences_citing\n",
    "sentences_after = df_5sentences_after_balanced.sentences_citing\n",
    "(documents_50_50_balanced_5sentences, list_all_words_50_50_balanced_5sentences, list_all_bigrams_50_50_balanced_5sentences) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10509"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list_all_bigrams)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# SUM UP:\n",
    "\n",
    "\n",
    "### 1. With one sentence citing:\n",
    "\n",
    "#### 1.1 -  All documents\n",
    "* documents_all\n",
    "* list_all_words\n",
    "* list_all_bigrams\n",
    "\n",
    "#### 1.2 -  50 % before - 50% after\n",
    "* documents_50_50\n",
    "* list_all_words_50_50\n",
    "* list_all_bigrams_50_50\n",
    "\n",
    "#### 1.3 - Balanced: 50 % before - 50% after. If doi cited before and after same number of documents before are after.\n",
    "* documents_50_50_balanced\n",
    "* list_all_words_50_50_balanced\n",
    "* list_all_bigrams_50_50_balanced \n",
    "\n",
    "### 2. With one sentence citing + following 3 sentences:\n",
    "\n",
    "#### 2.1 -  All documents\n",
    "* documents_all_3sentences\n",
    "* list_all_words_3sentences\n",
    "* list_all_bigrams_3sentences\n",
    "\n",
    "#### 2.2 -  50 % before - 50% after\n",
    "* documents_50_50_3sentences\n",
    "* list_all_words_50_50_3sentences\n",
    "* list_all_bigrams_50_50_3sentences\n",
    "\n",
    "#### 2.3 - Balanced: 50 % before - 50% after. If doi cited before and after same number of documents before are after.\n",
    "* documents_50_50_balanced_3sentences\n",
    "* list_all_words_50_50_balanced_3sentences\n",
    "* list_all_bigrams_50_50_balanced_3sentences\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Naive Bayes Algorithm"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Some checkings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of words in : \n",
      "\n",
      "list_all_words: \t 10630 \n",
      "list_all_words_50_50: \t 6007 \n",
      "list_all_words_50_50_balanced: \t 5664 \n",
      "\n",
      "list_all_words_3sentences: \t 32659 \n",
      "list_all_words_50_50_3sentences: \t 16912 \n",
      "list_all_words_50_50_balanced_3sentences: \t 18357\n"
     ]
    }
   ],
   "source": [
    "print(\"Number of words in : \\n\\nlist_all_words: \\t\", len(list_all_words),\n",
    "    \"\\nlist_all_words_50_50: \\t\", len(list_all_words_50_50), \n",
    "    \"\\nlist_all_words_50_50_balanced: \\t\", len(list_all_words_50_50_balanced),\n",
    "    \"\\n\\nlist_all_words_3sentences: \\t\", len(list_all_words_3sentences),\n",
    "    \"\\nlist_all_words_50_50_3sentences: \\t\", len(list_all_words_50_50_3sentences),\n",
    "    \"\\nlist_all_words_50_50_balanced_3sentences: \\t\", len(list_all_words_50_50_balanced_3sentences)\n",
    "     )"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Naive Bayes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\nlist_all_words_50_50_freq = nltk.FreqDist(list_all_words_50_50) \\nall_words_50_50_features = list(list_all_words_50_50_freq.keys())\\n\\nlist_all_words_50_50_balanced_freq = nltk.FreqDist(list_all_words_50_50_balanced)\\nall_words_50_50_balanced_features =  nltk.FreqDist(list_all_words_50_50_balanced)\\n\\nlist_all_words_3sentences_freq = nltk.FreqDist(list_all_words_3sentences)\\n\\nlist_all_words_50_50_3sentences_freq = nltk.FreqDist(list_all_words_50_50_3sentences)\\n\\nlist_all_words_50_50_balanced_3sentences_freq = nltk.FreqDist(list_all_words_50_50_balanced_3sentences)\\n'"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import nltk \n",
    "\n",
    "def find_features(document, word_features):\n",
    "    words = set(document)\n",
    "    features = {}\n",
    "    for w in word_features:\n",
    "        features[w] = (w in words)\n",
    "\n",
    "    return features\n",
    "\n",
    "def train_Naive_Bayes(documents, list_all_words, spliting_training_test_ratio = 0.25):\n",
    "    \n",
    "    # Word frequencies\n",
    "    all_words_freq = nltk.FreqDist(list_all_words)\n",
    "    word_features = list(all_words_freq.keys()) # Those are all teh words in the document. Each word is a feature\n",
    "\n",
    "    featuresets = [(find_features(article, word_features), cat) for (article, cat) in documents]\n",
    "\n",
    "    # set that we'll train our classifier with                    \n",
    "    test_size = round(spliting_training_test_ratio * len(featuresets))\n",
    "    print(\"documents in test_set: \\t\", test_size)\n",
    "    print(\"documents in training_set: \\t\", len(featuresets) -test_size)\n",
    "    \n",
    "    training_set = featuresets[test_size:]\n",
    "\n",
    "    # set that we'll test against.\n",
    "    testing_set = featuresets[:test_size]\n",
    "\n",
    "    classifier = nltk.NaiveBayesClassifier.train(training_set)\n",
    "    print(\"\\nClassifier accuracy percent:\",(nltk.classify.accuracy(classifier, testing_set))*100)\n",
    "    \n",
    "    classifier.show_most_informative_features(100)\n",
    "    \n",
    "    return classifier\n",
    "    \n",
    "    \n",
    "\n",
    "                         \n",
    "                         \n",
    "\"\"\"\n",
    "list_all_words_50_50_freq = nltk.FreqDist(list_all_words_50_50) \n",
    "all_words_50_50_features = list(list_all_words_50_50_freq.keys())\n",
    "\n",
    "list_all_words_50_50_balanced_freq = nltk.FreqDist(list_all_words_50_50_balanced)\n",
    "all_words_50_50_balanced_features =  nltk.FreqDist(list_all_words_50_50_balanced)\n",
    "\n",
    "list_all_words_3sentences_freq = nltk.FreqDist(list_all_words_3sentences)\n",
    "\n",
    "list_all_words_50_50_3sentences_freq = nltk.FreqDist(list_all_words_50_50_3sentences)\n",
    "\n",
    "list_all_words_50_50_balanced_3sentences_freq = nltk.FreqDist(list_all_words_50_50_balanced_3sentences)\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 70.83333333333334\n",
      "Most Informative Features\n",
      "                   serum = True            after : before =      8.1 : 1.0\n",
      "                    caus = True            after : before =      6.3 : 1.0\n",
      "                  glucos = True            after : before =      6.3 : 1.0\n",
      "                  branch = True            after : before =      4.5 : 1.0\n",
      "                   novel = True            after : before =      4.5 : 1.0\n",
      "                 upregul = True            after : before =      4.5 : 1.0\n",
      "               pulmonari = True            after : before =      4.5 : 1.0\n",
      "                     due = True            after : before =      4.5 : 1.0\n",
      "                  analyz = True            after : before =      4.5 : 1.0\n",
      "                  surviv = True            after : before =      4.5 : 1.0\n",
      "                  remain = True            after : before =      4.5 : 1.0\n",
      "                  articl = True            after : before =      4.5 : 1.0\n",
      "                   there = True            after : before =      4.5 : 1.0\n",
      "                 consist = True            after : before =      4.5 : 1.0\n",
      "                   chang = True            after : before =      4.5 : 1.0\n",
      "                 mainten = True            after : before =      4.5 : 1.0\n",
      "                  mammal = True            after : before =      4.5 : 1.0\n",
      "                    show = True            after : before =      4.2 : 1.0\n",
      "                 increas = True            after : before =      3.9 : 1.0\n",
      "                   liver = True            after : before =      3.8 : 1.0\n",
      "                  associ = True            after : before =      3.8 : 1.0\n",
      "                  number = True            after : before =      3.8 : 1.0\n",
      "                   figur = True            after : before =      3.8 : 1.0\n",
      "                 previou = True            after : before =      3.5 : 1.0\n",
      "                 protein = True            after : before =      3.5 : 1.0\n",
      "                 sequenc = True           before : after  =      3.1 : 1.0\n",
      "                    gene = True           before : after  =      3.0 : 1.0\n",
      "                     use = True            after : before =      3.0 : 1.0\n",
      "                  glutam = True            after : before =      2.7 : 1.0\n",
      "                    novo = True            after : before =      2.7 : 1.0\n",
      "                 respons = True            after : before =      2.7 : 1.0\n",
      "                  reptil = True            after : before =      2.7 : 1.0\n",
      "                  aggreg = True            after : before =      2.7 : 1.0\n",
      "                  stress = True            after : before =      2.7 : 1.0\n",
      "                progress = True            after : before =      2.7 : 1.0\n",
      "                    cite = True            after : before =      2.7 : 1.0\n",
      "                  replic = True            after : before =      2.7 : 1.0\n",
      "             betatrophin = True            after : before =      2.7 : 1.0\n",
      "                    oxid = True            after : before =      2.7 : 1.0\n",
      "                  inform = True            after : before =      2.7 : 1.0\n",
      "                   potti = True            after : before =      2.7 : 1.0\n",
      "                   lipid = True            after : before =      2.7 : 1.0\n",
      "                 pattern = True            after : before =      2.7 : 1.0\n",
      "                   appli = True            after : before =      2.7 : 1.0\n",
      "                    serv = True            after : before =      2.7 : 1.0\n",
      "              transcript = True            after : before =      2.7 : 1.0\n",
      "                 convert = True            after : before =      2.7 : 1.0\n",
      "                    bird = True            after : before =      2.7 : 1.0\n",
      "                  abnorm = True            after : before =      2.7 : 1.0\n",
      "                   genet = True            after : before =      2.7 : 1.0\n",
      "              nonapoptot = True            after : before =      2.7 : 1.0\n",
      "                   asexu = True            after : before =      2.7 : 1.0\n",
      "                  provid = True            after : before =      2.7 : 1.0\n",
      "                  reduct = True            after : before =      2.7 : 1.0\n",
      "                 essenti = True            after : before =      2.7 : 1.0\n",
      "                   becom = True            after : before =      2.7 : 1.0\n",
      "                 against = True            after : before =      2.7 : 1.0\n",
      "              hydrodynam = True            after : before =      2.7 : 1.0\n",
      "                   enzym = True            after : before =      2.7 : 1.0\n",
      "                  cortex = True            after : before =      2.7 : 1.0\n",
      "                    bone = True            after : before =      2.7 : 1.0\n",
      "                  system = True            after : before =      2.7 : 1.0\n",
      "                   natur = True            after : before =      2.7 : 1.0\n",
      "                   polar = True            after : before =      2.7 : 1.0\n",
      "                    tail = True            after : before =      2.7 : 1.0\n",
      "                  intern = True            after : before =      2.7 : 1.0\n",
      "                     for = True            after : before =      2.7 : 1.0\n",
      "                 subsequ = True            after : before =      2.7 : 1.0\n",
      "                   damag = True            after : before =      2.7 : 1.0\n",
      "                   tight = True            after : before =      2.7 : 1.0\n",
      "                 coverag = True            after : before =      2.7 : 1.0\n",
      "                dysregul = True            after : before =      2.7 : 1.0\n",
      "                  within = True            after : before =      2.7 : 1.0\n",
      "              falciparum = True            after : before =      2.7 : 1.0\n",
      "                     msc = True            after : before =      2.7 : 1.0\n",
      "                interact = True            after : before =      2.7 : 1.0\n",
      "                  cultur = True            after : before =      2.7 : 1.0\n",
      "                   kinas = True            after : before =      2.7 : 1.0\n",
      "                  circul = True            after : before =      2.7 : 1.0\n",
      "                independ = True            after : before =      2.7 : 1.0\n",
      "                  receiv = True            after : before =      2.7 : 1.0\n",
      "                   unusu = True            after : before =      2.7 : 1.0\n",
      "                  repair = True            after : before =      2.7 : 1.0\n",
      "                 conduct = True            after : before =      2.7 : 1.0\n",
      "                properti = True            after : before =      2.7 : 1.0\n",
      "                   mutat = True            after : before =      2.7 : 1.0\n",
      "                  remark = True            after : before =      2.7 : 1.0\n",
      "                    fact = True            after : before =      2.7 : 1.0\n",
      "             importantli = True            after : before =      2.7 : 1.0\n",
      "                  secret = True            after : before =      2.7 : 1.0\n",
      "                strategi = True            after : before =      2.7 : 1.0\n",
      "                  resect = True            after : before =      2.7 : 1.0\n",
      "                astrocyt = True            after : before =      2.7 : 1.0\n",
      "                   refer = True            after : before =      2.7 : 1.0\n",
      "                synthesi = True            after : before =      2.7 : 1.0\n",
      "                  exclus = True            after : before =      2.7 : 1.0\n",
      "                  inject = True            after : before =      2.7 : 1.0\n",
      "               autoimmun = True            after : before =      2.7 : 1.0\n",
      "               downregul = True            after : before =      2.7 : 1.0\n",
      "                  global = True            after : before =      2.7 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e9248978>"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "### 1. With one sentence citing:\n",
    "\n",
    "#### 1.1 -  All documents\n",
    "\n",
    "train_Naive_Bayes(documents_all, list_all_words, 0.20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 75.0\n",
      "Most Informative Features\n",
      "      ('bond', 'member') = False           after : before =      1.0 : 1.0\n",
      "     ('contest', 'find') = False           after : before =      1.0 : 1.0\n",
      "       ('infect', 'pcr') = False           after : before =      1.0 : 1.0\n",
      "  ('intrigu', 'problem') = False           after : before =      1.0 : 1.0\n",
      "    ('insulin', 'level') = False           after : before =      1.0 : 1.0\n",
      "    ('manner', 'differ') = False           after : before =      1.0 : 1.0\n",
      "    ('recent', 'effort') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "     ('env', 'glycogag') = False           after : before =      1.0 : 1.0\n",
      "       ('vitro', 'hand') = False           after : before =      1.0 : 1.0\n",
      "  ('protein', 'consist') = False           after : before =      1.0 : 1.0\n",
      "('antibacteri', 'antifung') = False           after : before =      1.0 : 1.0\n",
      "     ('exchang', 'acyl') = False           after : before =      1.0 : 1.0\n",
      "    ('cavin', 'patient') = False           after : before =      1.0 : 1.0\n",
      "     ('apoptosi', 'mir') = False           after : before =      1.0 : 1.0\n",
      "         ('base', 'dna') = False           after : before =      1.0 : 1.0\n",
      "       ('cox', 'cancer') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'lost') = False           after : before =      1.0 : 1.0\n",
      "    ('encompass', 'sle') = False           after : before =      1.0 : 1.0\n",
      "        ('sex', 'match') = False           after : before =      1.0 : 1.0\n",
      "('adipos', 'tissuederiv') = False           after : before =      1.0 : 1.0\n",
      "     ('variou', 'human') = False           after : before =      1.0 : 1.0\n",
      "('antitubercular', 'local') = False           after : before =      1.0 : 1.0\n",
      "     ('describ', 'mous') = False           after : before =      1.0 : 1.0\n",
      "('suppli', 'glucosephosph') = False           after : before =      1.0 : 1.0\n",
      "  ('cancer', 'institut') = False           after : before =      1.0 : 1.0\n",
      "      ('patient', 'one') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      "      ('appear', 'play') = False           after : before =      1.0 : 1.0\n",
      "    ('identifi', 'mous') = False           after : before =      1.0 : 1.0\n",
      "       ('cell', 'figur') = False           after : before =      1.0 : 1.0\n",
      "('circul', 'liverderiv') = False           after : before =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False           after : before =      1.0 : 1.0\n",
      "('xanthomona', 'suggest') = False           after : before =      1.0 : 1.0\n",
      "     ('mediat', 'motil') = False           after : before =      1.0 : 1.0\n",
      "  ('review', 'previous') = False           after : before =      1.0 : 1.0\n",
      "         ('cite', 'neg') = False           after : before =      1.0 : 1.0\n",
      "('descript', 'polytrop') = False           after : before =      1.0 : 1.0\n",
      "        ('malat', 'via') = False           after : before =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False           after : before =      1.0 : 1.0\n",
      "         ('xmrv', 'mlv') = False           after : before =      1.0 : 1.0\n",
      "  ('metastasi', 'mirna') = False           after : before =      1.0 : 1.0\n",
      "    ('geograph', 'area') = False           after : before =      1.0 : 1.0\n",
      "    ('region', 'pertin') = False           after : before =      1.0 : 1.0\n",
      "       ('bifurc', 'tca') = False           after : before =      1.0 : 1.0\n",
      " ('counterpart', 'hand') = False           after : before =      1.0 : 1.0\n",
      "    ('katz', 'giraudet') = False           after : before =      1.0 : 1.0\n",
      "       ('remain', 'rel') = False           after : before =      1.0 : 1.0\n",
      "       ('event', 'vivo') = False           after : before =      1.0 : 1.0\n",
      "  ('resist', 'hypothes') = False           after : before =      1.0 : 1.0\n",
      "    ('catabol', 'pyruv') = False           after : before =      1.0 : 1.0\n",
      "       ('color', 'blue') = False           after : before =      1.0 : 1.0\n",
      "   ('found', 'directli') = False           after : before =      1.0 : 1.0\n",
      "    ('accumul', 'studi') = False           after : before =      1.0 : 1.0\n",
      "         ('use', 'test') = False           after : before =      1.0 : 1.0\n",
      "         ('via', 'oxid') = False           after : before =      1.0 : 1.0\n",
      "      ('buck', 'rennak') = False           after : before =      1.0 : 1.0\n",
      "  ('mass', 'spectromet') = False           after : before =      1.0 : 1.0\n",
      "   ('public', 'retract') = False           after : before =      1.0 : 1.0\n",
      "('inhibitor', 'decreas') = False           after : before =      1.0 : 1.0\n",
      "     ('also', 'amplifi') = False           after : before =      1.0 : 1.0\n",
      "     ('pdac', 'patient') = False           after : before =      1.0 : 1.0\n",
      "   ('enhanc', 'segment') = False           after : before =      1.0 : 1.0\n",
      "('geneticsutahedu', 'acharya') = False           after : before =      1.0 : 1.0\n",
      "    ('normal', 'glucos') = False           after : before =      1.0 : 1.0\n",
      "('metabolit', 'extract') = False           after : before =      1.0 : 1.0\n",
      "  ('stimul', 'adipocyt') = False           after : before =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      " ('studi', 'furthermor') = False           after : before =      1.0 : 1.0\n",
      "('hippocampu', 'individu') = False           after : before =      1.0 : 1.0\n",
      "     ('posit', 'associ') = False           after : before =      1.0 : 1.0\n",
      "        ('taq', 'rtpcr') = False           after : before =      1.0 : 1.0\n",
      "       ('the', 'combin') = False           after : before =      1.0 : 1.0\n",
      "('pharmacolog', 'toxicolog') = False           after : before =      1.0 : 1.0\n",
      "     ('human', 'cancer') = False           after : before =      1.0 : 1.0\n",
      "   ('carolina', 'mason') = False           after : before =      1.0 : 1.0\n",
      "  ('amplifi', 'similar') = False           after : before =      1.0 : 1.0\n",
      "     ('report', 'liver') = False           after : before =      1.0 : 1.0\n",
      "      ('way', 'increas') = False           after : before =      1.0 : 1.0\n",
      "    ('assur', 'control') = False           after : before =      1.0 : 1.0\n",
      "('monocyt', 'chemoattract') = False           after : before =      1.0 : 1.0\n",
      "('metastasi', 'suppressor') = False           after : before =      1.0 : 1.0\n",
      " ('provirus', 'amplifi') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      "    ('clarifi', 'major') = False           after : before =      1.0 : 1.0\n",
      "   ('strain', 'genbank') = False           after : before =      1.0 : 1.0\n",
      "  ('strike', 'independ') = False           after : before =      1.0 : 1.0\n",
      "  ('synthesi', 'suppli') = False           after : before =      1.0 : 1.0\n",
      "         ('claim', 'cf') = False           after : before =      1.0 : 1.0\n",
      "      ('state', 'studi') = False           after : before =      1.0 : 1.0\n",
      "     ('cancer', 'serou') = False           after : before =      1.0 : 1.0\n",
      "       ('scienc', 'amp') = False           after : before =      1.0 : 1.0\n",
      "  ('similar', 'sequenc') = False           after : before =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False           after : before =      1.0 : 1.0\n",
      "     ('function', 'may') = False           after : before =      1.0 : 1.0\n",
      "      ('cultur', 'inde') = False           after : before =      1.0 : 1.0\n",
      "      ('test', 'exclud') = False           after : before =      1.0 : 1.0\n",
      "('signatur', 'similarli') = False           after : before =      1.0 : 1.0\n",
      "       ('factor', 'the') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e6f47cf8>"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_all, list_all_bigrams, 0.20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 100.0\n",
      "Most Informative Features\n",
      "                   mirna = True           before : after  =      6.0 : 1.0\n",
      "                     use = True            after : before =      5.2 : 1.0\n",
      "                     mir = True           before : after  =      4.4 : 1.0\n",
      "                prolifer = True           before : after  =      4.4 : 1.0\n",
      "                   human = True           before : after  =      3.6 : 1.0\n",
      "                    gene = True           before : after  =      3.1 : 1.0\n",
      "                    mous = True           before : after  =      2.8 : 1.0\n",
      "                     act = True           before : after  =      2.8 : 1.0\n",
      "                    role = True           before : after  =      2.8 : 1.0\n",
      "                     thi = True           before : after  =      2.8 : 1.0\n",
      "                   shown = True           before : after  =      2.6 : 1.0\n",
      "                   activ = True            after : before =      2.5 : 1.0\n",
      "                     the = True            after : before =      2.5 : 1.0\n",
      "                  associ = True            after : before =      2.5 : 1.0\n",
      "                  signal = True           before : after  =      2.2 : 1.0\n",
      "             overexpress = True           before : after  =      2.2 : 1.0\n",
      "                 increas = True            after : before =      2.2 : 1.0\n",
      "                progress = True           before : after  =      2.0 : 1.0\n",
      "                 essenti = True           before : after  =      2.0 : 1.0\n",
      "                   howev = True           before : after  =      2.0 : 1.0\n",
      "                   cell = True           before : after  =      2.0 : 1.0\n",
      "                    grow = True           before : after  =      2.0 : 1.0\n",
      "                    lupu = True           before : after  =      2.0 : 1.0\n",
      "                    head = True           before : after  =      2.0 : 1.0\n",
      "           significantli = True           before : after  =      2.0 : 1.0\n",
      "               downregul = True           before : after  =      2.0 : 1.0\n",
      "                  target = True           before : after  =      2.0 : 1.0\n",
      "                  promot = True           before : after  =      2.0 : 1.0\n",
      "                  normal = True           before : after  =      2.0 : 1.0\n",
      "                  number = True           before : after  =      2.0 : 1.0\n",
      "              differenti = True           before : after  =      2.0 : 1.0\n",
      "                   sever = True           before : after  =      2.0 : 1.0\n",
      "                  specif = True           before : after  =      2.0 : 1.0\n",
      "                 multipl = True           before : after  =      2.0 : 1.0\n",
      "                  depend = True           before : after  =      2.0 : 1.0\n",
      "                    play = True           before : after  =      2.0 : 1.0\n",
      "                 previou = True            after : before =      1.9 : 1.0\n",
      "                 protein = True            after : before =      1.9 : 1.0\n",
      "                    mice = True            after : before =      1.9 : 1.0\n",
      "                  glucos = True            after : before =      1.9 : 1.0\n",
      "                     one = True            after : before =      1.9 : 1.0\n",
      "                receptor = True            after : before =      1.9 : 1.0\n",
      "                   serum = True            after : before =      1.9 : 1.0\n",
      "                  breast = True           before : after  =      1.9 : 1.0\n",
      "                    also = True           before : after  =      1.9 : 1.0\n",
      "                  resist = True           before : after  =      1.7 : 1.0\n",
      "                 insulin = True           before : after  =      1.7 : 1.0\n",
      "                   other = True           before : after  =      1.7 : 1.0\n",
      "                   model = True           before : after  =      1.7 : 1.0\n",
      "                previous = True           before : after  =      1.6 : 1.0\n",
      "                function = True            after : before =      1.5 : 1.0\n",
      "                 express = True           before : after  =      1.5 : 1.0\n",
      "               metastasi = False           after : before =      1.4 : 1.0\n",
      "                  recent = True           before : after  =      1.4 : 1.0\n",
      "                   studi = True           before : after  =      1.4 : 1.0\n",
      "                  cancer = True           before : after  =      1.4 : 1.0\n",
      "                     use = False          before : after  =      1.4 : 1.0\n",
      "                   organ = True            after : before =      1.4 : 1.0\n",
      "                    show = True            after : before =      1.4 : 1.0\n",
      "                   found = True            after : before =      1.4 : 1.0\n",
      "                 pathway = True            after : before =      1.4 : 1.0\n",
      "                 develop = True            after : before =      1.4 : 1.0\n",
      "                   mirna = False           after : before =      1.4 : 1.0\n",
      "                  analyz = True            after : before =      1.4 : 1.0\n",
      "                   chang = True            after : before =      1.4 : 1.0\n",
      "                  involv = True            after : before =      1.4 : 1.0\n",
      "                 analysi = True            after : before =      1.4 : 1.0\n",
      "                  includ = True            after : before =      1.4 : 1.0\n",
      "                  enhanc = True            after : before =      1.4 : 1.0\n",
      "                  effect = True            after : before =      1.3 : 1.0\n",
      "                   shown = False           after : before =      1.3 : 1.0\n",
      "                    gene = False           after : before =      1.3 : 1.0\n",
      "                prolifer = False           after : before =      1.2 : 1.0\n",
      "                     mir = False           after : before =      1.2 : 1.0\n",
      "                  factor = False           after : before =      1.2 : 1.0\n",
      "                 inhibit = False           after : before =      1.2 : 1.0\n",
      "                   invas = False           after : before =      1.2 : 1.0\n",
      "                    cell = True           before : after  =      1.2 : 1.0\n",
      "                  examin = True           before : after  =      1.2 : 1.0\n",
      "                   point = True           before : after  =      1.2 : 1.0\n",
      "                   local = True           before : after  =      1.2 : 1.0\n",
      "                    novo = True           before : after  =      1.2 : 1.0\n",
      "                 process = True           before : after  =      1.2 : 1.0\n",
      "                 upregul = True           before : after  =      1.2 : 1.0\n",
      "                  replic = True           before : after  =      1.2 : 1.0\n",
      "             betatrophin = True           before : after  =      1.2 : 1.0\n",
      "                    larg = True           before : after  =      1.2 : 1.0\n",
      "                although = True           before : after  =      1.2 : 1.0\n",
      "                  growth = True           before : after  =      1.2 : 1.0\n",
      "                 prostat = True           before : after  =      1.2 : 1.0\n",
      "                   tumor = True           before : after  =      1.2 : 1.0\n",
      "                 metabol = True           before : after  =      1.2 : 1.0\n",
      "                   these = True           before : after  =      1.2 : 1.0\n",
      "                  provid = True           before : after  =      1.2 : 1.0\n",
      "                  either = True           before : after  =      1.2 : 1.0\n",
      "                    time = True           before : after  =      1.2 : 1.0\n",
      "                   deriv = True           before : after  =      1.2 : 1.0\n",
      "              hydrodynam = True           before : after  =      1.2 : 1.0\n",
      "                 patient = False          before : after  =      1.2 : 1.0\n",
      "                   enzym = True           before : after  =      1.2 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e7f5e2e8>"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 1.2 -  50 % before - 50% after\n",
    "\n",
    "train_Naive_Bayes(documents_50_50, list_all_words_50_50, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 30.76923076923077\n",
      "Most Informative Features\n",
      "  ('intrigu', 'problem') = False          before : after  =      1.0 : 1.0\n",
      "    ('insulin', 'level') = False          before : after  =      1.0 : 1.0\n",
      "    ('recent', 'effort') = False          before : after  =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False          before : after  =      1.0 : 1.0\n",
      "       ('vitro', 'hand') = False          before : after  =      1.0 : 1.0\n",
      "     ('exchang', 'acyl') = False          before : after  =      1.0 : 1.0\n",
      "    ('cavin', 'patient') = False          before : after  =      1.0 : 1.0\n",
      "     ('apoptosi', 'mir') = False          before : after  =      1.0 : 1.0\n",
      "         ('base', 'dna') = False          before : after  =      1.0 : 1.0\n",
      "     ('express', 'lost') = False          before : after  =      1.0 : 1.0\n",
      "     ('variou', 'human') = False          before : after  =      1.0 : 1.0\n",
      "('suppli', 'glucosephosph') = False          before : after  =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False          before : after  =      1.0 : 1.0\n",
      "      ('appear', 'play') = False          before : after  =      1.0 : 1.0\n",
      "('circul', 'liverderiv') = False          before : after  =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False          before : after  =      1.0 : 1.0\n",
      "        ('malat', 'via') = False          before : after  =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False          before : after  =      1.0 : 1.0\n",
      "  ('metastasi', 'mirna') = False          before : after  =      1.0 : 1.0\n",
      "       ('bifurc', 'tca') = False          before : after  =      1.0 : 1.0\n",
      " ('counterpart', 'hand') = False          before : after  =      1.0 : 1.0\n",
      "       ('remain', 'rel') = False          before : after  =      1.0 : 1.0\n",
      "       ('event', 'vivo') = False          before : after  =      1.0 : 1.0\n",
      "  ('resist', 'hypothes') = False          before : after  =      1.0 : 1.0\n",
      "    ('catabol', 'pyruv') = False          before : after  =      1.0 : 1.0\n",
      "   ('found', 'directli') = False          before : after  =      1.0 : 1.0\n",
      "         ('via', 'oxid') = False          before : after  =      1.0 : 1.0\n",
      "   ('public', 'retract') = False          before : after  =      1.0 : 1.0\n",
      "('inhibitor', 'decreas') = False          before : after  =      1.0 : 1.0\n",
      "     ('pdac', 'patient') = False          before : after  =      1.0 : 1.0\n",
      "('geneticsutahedu', 'acharya') = False          before : after  =      1.0 : 1.0\n",
      "    ('normal', 'glucos') = False          before : after  =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False          before : after  =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False          before : after  =      1.0 : 1.0\n",
      "       ('the', 'combin') = False          before : after  =      1.0 : 1.0\n",
      "     ('posit', 'associ') = False          before : after  =      1.0 : 1.0\n",
      "('pharmacolog', 'toxicolog') = False          before : after  =      1.0 : 1.0\n",
      "     ('human', 'cancer') = False          before : after  =      1.0 : 1.0\n",
      "   ('carolina', 'mason') = False          before : after  =      1.0 : 1.0\n",
      "     ('report', 'liver') = False          before : after  =      1.0 : 1.0\n",
      "      ('way', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "  ('synthesi', 'suppli') = False          before : after  =      1.0 : 1.0\n",
      "('metastasi', 'suppressor') = False          before : after  =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False          before : after  =      1.0 : 1.0\n",
      "     ('cancer', 'serou') = False          before : after  =      1.0 : 1.0\n",
      "       ('scienc', 'amp') = False          before : after  =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False          before : after  =      1.0 : 1.0\n",
      "      ('vitro', 'besid') = False          before : after  =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False          before : after  =      1.0 : 1.0\n",
      "  ('tripleneg', 'mdamb') = False          before : after  =      1.0 : 1.0\n",
      "          ('myc', 'dna') = False          before : after  =      1.0 : 1.0\n",
      "   ('factor', 'insulin') = False          before : after  =      1.0 : 1.0\n",
      "       ('signal', 'let') = False          before : after  =      1.0 : 1.0\n",
      "  ('metastasi', 'regul') = False          before : after  =      1.0 : 1.0\n",
      "     ('known', 'breast') = False          before : after  =      1.0 : 1.0\n",
      "      ('cancer', 'bild') = False          before : after  =      1.0 : 1.0\n",
      "    ('oncogen', 'mirna') = False          before : after  =      1.0 : 1.0\n",
      "      ('quit', 'promis') = False          before : after  =      1.0 : 1.0\n",
      "       ('mice', 'incap') = False          before : after  =      1.0 : 1.0\n",
      "   ('differ', 'express') = False          before : after  =      1.0 : 1.0\n",
      "     ('wish', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "      ('perou', 'charl') = False          before : after  =      1.0 : 1.0\n",
      "    ('stress', 'either') = False          before : after  =      1.0 : 1.0\n",
      "      ('resist', 'mous') = False          before : after  =      1.0 : 1.0\n",
      "    ('possibl', 'unusu') = False          before : after  =      1.0 : 1.0\n",
      "    ('polar', 'energet') = False          before : after  =      1.0 : 1.0\n",
      "      ('human', 'cell') = False          before : after  =      1.0 : 1.0\n",
      "     ('other', 'observ') = False          before : after  =      1.0 : 1.0\n",
      " ('person', 'treatment') = False          before : after  =      1.0 : 1.0\n",
      "      ('show', 'aggreg') = False          before : after  =      1.0 : 1.0\n",
      "     ('marcom', 'kelli') = False          before : after  =      1.0 : 1.0\n",
      "   ('brucei', 'synthes') = False          before : after  =      1.0 : 1.0\n",
      "      ('may', 'exacerb') = False          before : after  =      1.0 : 1.0\n",
      "      ('mir', 'possess') = False          before : after  =      1.0 : 1.0\n",
      "    ('induc', 'insulin') = False          before : after  =      1.0 : 1.0\n",
      "     ('safeti', 'point') = False          before : after  =      1.0 : 1.0\n",
      "  ('pathway', 'essenti') = False          before : after  =      1.0 : 1.0\n",
      "         ('mice', 'the') = False          before : after  =      1.0 : 1.0\n",
      "   ('medicin', 'albani') = False          before : after  =      1.0 : 1.0\n",
      "       ('fact', 'oppos') = False          before : after  =      1.0 : 1.0\n",
      "      ('stimul', 'mous') = False          before : after  =      1.0 : 1.0\n",
      "    ('implic', 'breast') = False          before : after  =      1.0 : 1.0\n",
      "      ('young', 'adult') = False          before : after  =      1.0 : 1.0\n",
      "  ('epicanc', 'mirletc') = False          before : after  =      1.0 : 1.0\n",
      "   ('repres', 'patient') = False          before : after  =      1.0 : 1.0\n",
      "('therapeut', 'opportun') = False          before : after  =      1.0 : 1.0\n",
      "     ('studi', 'examin') = False          before : after  =      1.0 : 1.0\n",
      "      ('novel', 'cell') = False          before : after  =      1.0 : 1.0\n",
      "      ('mice', 'differ') = False          before : after  =      1.0 : 1.0\n",
      "      ('model', 'there') = False          before : after  =      1.0 : 1.0\n",
      "   ('tight', 'junction') = False          before : after  =      1.0 : 1.0\n",
      "    ('center', 'boston') = False          before : after  =      1.0 : 1.0\n",
      "         ('hra', 'hmga') = False          before : after  =      1.0 : 1.0\n",
      "('contributor', 'progress') = False          before : after  =      1.0 : 1.0\n",
      " ('glucos', 'transport') = False          before : after  =      1.0 : 1.0\n",
      "('invasionmetastasi', 'angiogenesi') = False          before : after  =      1.0 : 1.0\n",
      "       ('cancer', 'mir') = False          before : after  =      1.0 : 1.0\n",
      "  ('counterpart', 'mir') = False          before : after  =      1.0 : 1.0\n",
      "     ('data', 'express') = False          before : after  =      1.0 : 1.0\n",
      "        ('studi', 'yet') = False          before : after  =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3f6461748>"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_50_50, list_all_bigrams_50_50, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 66.66666666666666\n",
      "Most Informative Features\n",
      "                  follow = True            after : before =      6.8 : 1.0\n",
      "                   known = True            after : before =      6.8 : 1.0\n",
      "             overexpress = True            after : before =      4.5 : 1.0\n",
      "                  effect = True            after : before =      4.2 : 1.0\n",
      "                receptor = True            after : before =      3.9 : 1.0\n",
      "                   liver = True            after : before =      3.5 : 1.0\n",
      "             betatrophin = True            after : before =      3.5 : 1.0\n",
      "                  glucos = True            after : before =      3.5 : 1.0\n",
      "                    gene = True           before : after  =      3.4 : 1.0\n",
      "                  recent = True            after : before =      3.2 : 1.0\n",
      "                     not = True            after : before =      3.2 : 1.0\n",
      "                   howev = True            after : before =      3.2 : 1.0\n",
      "                    mice = True            after : before =      3.2 : 1.0\n",
      "                 plasmid = True            after : before =      2.9 : 1.0\n",
      "                prolifer = True            after : before =      2.9 : 1.0\n",
      "              hydrodynam = True            after : before =      2.9 : 1.0\n",
      "                 lipasin = True            after : before =      2.9 : 1.0\n",
      "                   islet = True            after : before =      2.9 : 1.0\n",
      "                  replic = True            after : before =      2.9 : 1.0\n",
      "                  inject = True            after : before =      2.9 : 1.0\n",
      "                    tail = True            after : before =      2.9 : 1.0\n",
      "                   cell = True            after : before =      2.9 : 1.0\n",
      "              antagonist = True            after : before =      2.9 : 1.0\n",
      "                   encod = True            after : before =      2.9 : 1.0\n",
      "                    cell = True            after : before =      2.8 : 1.0\n",
      "                investig = True           before : after  =      2.8 : 1.0\n",
      "                   exist = True           before : after  =      2.8 : 1.0\n",
      "                   could = True           before : after  =      2.8 : 1.0\n",
      "                  observ = True           before : after  =      2.8 : 1.0\n",
      "                although = True           before : after  =      2.8 : 1.0\n",
      "                  cancer = True            after : before =      2.5 : 1.0\n",
      "                 patient = True            after : before =      2.5 : 1.0\n",
      "                   tumor = True            after : before =      2.5 : 1.0\n",
      "                    also = True            after : before =      2.5 : 1.0\n",
      "                   studi = True           before : after  =      2.4 : 1.0\n",
      "                   level = True            after : before =      2.4 : 1.0\n",
      "                   human = True            after : before =      2.3 : 1.0\n",
      "                   induc = True            after : before =      2.3 : 1.0\n",
      "                  report = True            after : before =      2.3 : 1.0\n",
      "                   point = True           before : after  =      2.2 : 1.0\n",
      "                    data = True           before : after  =      2.2 : 1.0\n",
      "                    mark = True           before : after  =      2.2 : 1.0\n",
      "                 problem = True           before : after  =      2.2 : 1.0\n",
      "                 similar = True           before : after  =      2.2 : 1.0\n",
      "                 describ = False          before : after  =      2.0 : 1.0\n",
      "                   model = False           after : before =      2.0 : 1.0\n",
      "                  effect = False          before : after  =      1.9 : 1.0\n",
      "                  enhanc = False          before : after  =      1.8 : 1.0\n",
      "                 protein = True            after : before =      1.8 : 1.0\n",
      "                 control = True            after : before =      1.8 : 1.0\n",
      "                  remain = True            after : before =      1.8 : 1.0\n",
      "                receptor = False          before : after  =      1.7 : 1.0\n",
      "                     use = True            after : before =      1.7 : 1.0\n",
      "                 increas = True            after : before =      1.7 : 1.0\n",
      "             betatrophin = False          before : after  =      1.6 : 1.0\n",
      "                  glucos = False          before : after  =      1.6 : 1.0\n",
      "                   liver = False          before : after  =      1.6 : 1.0\n",
      "                  sinduc = False           after : before =      1.6 : 1.0\n",
      "                  secret = False          before : after  =      1.6 : 1.0\n",
      "                 endogen = False          before : after  =      1.6 : 1.0\n",
      "                   young = False          before : after  =      1.6 : 1.0\n",
      "                  improv = False          before : after  =      1.6 : 1.0\n",
      "                   adult = False          before : after  =      1.6 : 1.0\n",
      "         angiopoietinlik = False          before : after  =      1.6 : 1.0\n",
      "               transient = False          before : after  =      1.6 : 1.0\n",
      "                      it = False          before : after  =      1.6 : 1.0\n",
      "                  potent = False          before : after  =      1.6 : 1.0\n",
      "                 mitogen = False          before : after  =      1.6 : 1.0\n",
      "                  analyz = False          before : after  =      1.6 : 1.0\n",
      "                  stimul = False          before : after  =      1.6 : 1.0\n",
      "                   novel = False          before : after  =      1.6 : 1.0\n",
      "                   toler = False          before : after  =      1.6 : 1.0\n",
      "             overexpress = False          before : after  =      1.6 : 1.0\n",
      "                    role = True           before : after  =      1.5 : 1.0\n",
      "                  follow = False          before : after  =      1.5 : 1.0\n",
      "                   known = False          before : after  =      1.5 : 1.0\n",
      "                    mice = False          before : after  =      1.5 : 1.0\n",
      "                  recent = False          before : after  =      1.5 : 1.0\n",
      "                   howev = False          before : after  =      1.5 : 1.0\n",
      "                     not = False          before : after  =      1.5 : 1.0\n",
      "                  report = False          before : after  =      1.5 : 1.0\n",
      "                     may = True           before : after  =      1.5 : 1.0\n",
      "                    also = False          before : after  =      1.4 : 1.0\n",
      "                  replic = False          before : after  =      1.4 : 1.0\n",
      "                  inject = False          before : after  =      1.4 : 1.0\n",
      "                   cell = False          before : after  =      1.4 : 1.0\n",
      "                    tail = False          before : after  =      1.4 : 1.0\n",
      "              antagonist = False          before : after  =      1.4 : 1.0\n",
      "                   encod = False          before : after  =      1.4 : 1.0\n",
      "                prolifer = False          before : after  =      1.4 : 1.0\n",
      "                 lipasin = False          before : after  =      1.4 : 1.0\n",
      "                 plasmid = False          before : after  =      1.4 : 1.0\n",
      "                   islet = False          before : after  =      1.4 : 1.0\n",
      "              hydrodynam = False          before : after  =      1.4 : 1.0\n",
      "                previous = True            after : before =      1.4 : 1.0\n",
      "                   human = False          before : after  =      1.3 : 1.0\n",
      "                   induc = False          before : after  =      1.3 : 1.0\n",
      "                    mous = True           before : after  =      1.3 : 1.0\n",
      "                  circul = True           before : after  =      1.3 : 1.0\n",
      "                 possibl = True           before : after  =      1.3 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e5dff748>"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 1.3 - Balanced: 50 % before - 50% after. If doi cited before and after same number of documents before are after.\n",
    "\n",
    "train_Naive_Bayes(documents_50_50_balanced, list_all_words_50_50_balanced, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 41.66666666666667\n",
      "Most Informative Features\n",
      "  ('intrigu', 'problem') = False           after : before =      1.0 : 1.0\n",
      "        ('level', 'usp') = False           after : before =      1.0 : 1.0\n",
      "       ('usp', 'appear') = False           after : before =      1.0 : 1.0\n",
      "       ('the', 'observ') = False           after : before =      1.0 : 1.0\n",
      "    ('insulin', 'level') = False           after : before =      1.0 : 1.0\n",
      "          ('neg', 'the') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "       ('confus', 'new') = False           after : before =      1.0 : 1.0\n",
      "      ('surviv', 'time') = False           after : before =      1.0 : 1.0\n",
      "     ('analysi', 'gene') = False           after : before =      1.0 : 1.0\n",
      "('antibacteri', 'antifung') = False           after : before =      1.0 : 1.0\n",
      "    ('encompass', 'sle') = False           after : before =      1.0 : 1.0\n",
      "  ('astrocyt', 'number') = False           after : before =      1.0 : 1.0\n",
      "('betatrophin', 'annot') = False           after : before =      1.0 : 1.0\n",
      "         ('base', 'dna') = False           after : before =      1.0 : 1.0\n",
      "    ('cavin', 'patient') = False           after : before =      1.0 : 1.0\n",
      "       ('cox', 'cancer') = False           after : before =      1.0 : 1.0\n",
      "     ('model', 'sinduc') = False           after : before =      1.0 : 1.0\n",
      "        ('sex', 'match') = False           after : before =      1.0 : 1.0\n",
      "        ('defec', 'may') = False           after : before =      1.0 : 1.0\n",
      "('antitubercular', 'local') = False           after : before =      1.0 : 1.0\n",
      "      ('serum', 'lipid') = False           after : before =      1.0 : 1.0\n",
      "      ('toler', 'young') = False           after : before =      1.0 : 1.0\n",
      "    ('effect', 'combat') = False           after : before =      1.0 : 1.0\n",
      "('receptor', 'antagonist') = False           after : before =      1.0 : 1.0\n",
      "       ('use', 'combin') = False           after : before =      1.0 : 1.0\n",
      "  ('level', 'olfactori') = False           after : before =      1.0 : 1.0\n",
      "   ('olfactori', 'bulb') = False           after : before =      1.0 : 1.0\n",
      "    ('read', 'abstract') = False           after : before =      1.0 : 1.0\n",
      "      ('spinal', 'cord') = False           after : before =      1.0 : 1.0\n",
      "('antiphospholipid', 'syndrom') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      "    ('find', 'interest') = False           after : before =      1.0 : 1.0\n",
      "      ('appear', 'play') = False           after : before =      1.0 : 1.0\n",
      " ('increas', 'astrocyt') = False           after : before =      1.0 : 1.0\n",
      "('circul', 'liverderiv') = False           after : before =      1.0 : 1.0\n",
      "   ('includ', 'protein') = False           after : before =      1.0 : 1.0\n",
      "       ('mlv', 'infect') = False           after : before =      1.0 : 1.0\n",
      "('spectrum', 'epigenet') = False           after : before =      1.0 : 1.0\n",
      "         ('cmet', 'may') = False           after : before =      1.0 : 1.0\n",
      "  ('combat', 'diarrhea') = False           after : before =      1.0 : 1.0\n",
      "   ('diarrheal', 'area') = False           after : before =      1.0 : 1.0\n",
      "      ('pnd', 'frontal') = False           after : before =      1.0 : 1.0\n",
      "  ('specif', 'knockout') = False           after : before =      1.0 : 1.0\n",
      "('structur', 'ubiquitinbind') = False           after : before =      1.0 : 1.0\n",
      "      ('studi', 'group') = False           after : before =      1.0 : 1.0\n",
      "('betatrophin', 'liver') = False           after : before =      1.0 : 1.0\n",
      "     ('studi', 'remark') = False           after : before =      1.0 : 1.0\n",
      "   ('greatli', 'enhanc') = False           after : before =      1.0 : 1.0\n",
      "('incongru', 'taxonomi') = False           after : before =      1.0 : 1.0\n",
      "      ('lipid', 'level') = False           after : before =      1.0 : 1.0\n",
      "('resembl', 'retroviru') = False           after : before =      1.0 : 1.0\n",
      " ('psoriasi', 'psoriat') = False           after : before =      1.0 : 1.0\n",
      "         ('key', 'gene') = False           after : before =      1.0 : 1.0\n",
      "    ('region', 'pertin') = False           after : before =      1.0 : 1.0\n",
      "('follow', 'hydrodynam') = False           after : before =      1.0 : 1.0\n",
      " ('research', 'alreadi') = False           after : before =      1.0 : 1.0\n",
      "    ('katz', 'giraudet') = False           after : before =      1.0 : 1.0\n",
      "('administr', 'insulin') = False           after : before =      1.0 : 1.0\n",
      "     ('mark', 'increas') = False           after : before =      1.0 : 1.0\n",
      "       ('remain', 'rel') = False           after : before =      1.0 : 1.0\n",
      "       ('neg', 'becaus') = False           after : before =      1.0 : 1.0\n",
      "  ('resist', 'hypothes') = False           after : before =      1.0 : 1.0\n",
      "    ('patient', 'these') = False           after : before =      1.0 : 1.0\n",
      "    ('accumul', 'studi') = False           after : before =      1.0 : 1.0\n",
      "('suggest', 'phosphoryl') = False           after : before =      1.0 : 1.0\n",
      "     ('prion', 'domain') = False           after : before =      1.0 : 1.0\n",
      "('transplant', 'kidney') = False           after : before =      1.0 : 1.0\n",
      "        ('test', 'most') = False           after : before =      1.0 : 1.0\n",
      "   ('reason', 'potenti') = False           after : before =      1.0 : 1.0\n",
      "        ('cell', 'thi') = False           after : before =      1.0 : 1.0\n",
      "   ('public', 'retract') = False           after : before =      1.0 : 1.0\n",
      "('inhibitor', 'decreas') = False           after : before =      1.0 : 1.0\n",
      "     ('pdac', 'patient') = False           after : before =      1.0 : 1.0\n",
      "       ('injuri', 'tlr') = False           after : before =      1.0 : 1.0\n",
      "    ('normal', 'glucos') = False           after : before =      1.0 : 1.0\n",
      "  ('reprogram', 'motil') = False           after : before =      1.0 : 1.0\n",
      "      ('mrna', 'profil') = False           after : before =      1.0 : 1.0\n",
      " ('supervis', 'analysi') = False           after : before =      1.0 : 1.0\n",
      "   ('induc', 'prolifer') = False           after : before =      1.0 : 1.0\n",
      "     ('elus', 'previou') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      "        ('name', 'rifl') = False           after : before =      1.0 : 1.0\n",
      "    ('domain', 'capabl') = False           after : before =      1.0 : 1.0\n",
      "     ('glucos', 'toler') = False           after : before =      1.0 : 1.0\n",
      "('hippocampu', 'individu') = False           after : before =      1.0 : 1.0\n",
      "     ('posit', 'associ') = False           after : before =      1.0 : 1.0\n",
      "('betatrophin', 'cell') = False           after : before =      1.0 : 1.0\n",
      "     ('fusion', 'qrich') = False           after : before =      1.0 : 1.0\n",
      "    ('observ', 'differ') = False           after : before =      1.0 : 1.0\n",
      "      ('state', 'induc') = False           after : before =      1.0 : 1.0\n",
      "  ('abstract', 'articl') = False           after : before =      1.0 : 1.0\n",
      "     ('report', 'liver') = False           after : before =      1.0 : 1.0\n",
      "         ('the', 'cell') = False           after : before =      1.0 : 1.0\n",
      "   ('type', 'cfsassoci') = False           after : before =      1.0 : 1.0\n",
      "   ('knockout', 'lirko') = False           after : before =      1.0 : 1.0\n",
      "('prolifer', 'independ') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      " ('demonstr', 'feasibl') = False           after : before =      1.0 : 1.0\n",
      "    ('yeast', 'protein') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e775af28>"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_50_50_balanced, list_all_bigrams_50_50_balanced, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 75.0\n",
      "Most Informative Features\n",
      "                 retract = True            after : before =      7.3 : 1.0\n",
      "                  surviv = True            after : before =      5.7 : 1.0\n",
      "                  origin = True            after : before =      5.7 : 1.0\n",
      "                   debat = True            after : before =      5.7 : 1.0\n",
      "                  consid = True            after : before =      5.7 : 1.0\n",
      "                 molecul = True            after : before =      5.7 : 1.0\n",
      "                particip = True            after : before =      5.7 : 1.0\n",
      "                   liver = True            after : before =      5.7 : 1.0\n",
      "                 mainten = True            after : before =      5.7 : 1.0\n",
      "                 disrupt = True            after : before =      5.7 : 1.0\n",
      "                   serum = True            after : before =      4.4 : 1.0\n",
      "                  glucos = True            after : before =      4.4 : 1.0\n",
      "                  improv = True            after : before =      4.4 : 1.0\n",
      "                    acid = True            after : before =      4.4 : 1.0\n",
      "                  better = True            after : before =      4.4 : 1.0\n",
      "                   water = True            after : before =      4.1 : 1.0\n",
      "                  design = True            after : before =      4.1 : 1.0\n",
      "                  residu = True            after : before =      4.1 : 1.0\n",
      "                  overal = True            after : before =      4.1 : 1.0\n",
      "               endotheli = True            after : before =      4.1 : 1.0\n",
      "                  secret = True            after : before =      4.1 : 1.0\n",
      "             chemosensit = True            after : before =      4.1 : 1.0\n",
      "                  branch = True            after : before =      4.1 : 1.0\n",
      "             biosynthesi = True            after : before =      4.1 : 1.0\n",
      "               pulmonari = True            after : before =      4.1 : 1.0\n",
      "                    rais = True            after : before =      4.1 : 1.0\n",
      "                   there = True            after : before =      4.1 : 1.0\n",
      "                    bodi = True            after : before =      4.1 : 1.0\n",
      "                  diabet = True            after : before =      4.1 : 1.0\n",
      "                synthesi = True            after : before =      4.1 : 1.0\n",
      "                   enabl = True            after : before =      4.1 : 1.0\n",
      "                  mammal = True            after : before =      4.1 : 1.0\n",
      "                   paper = True            after : before =      4.1 : 1.0\n",
      "                 context = True            after : before =      4.1 : 1.0\n",
      "                  becaus = True            after : before =      4.1 : 1.0\n",
      "                    host = True            after : before =      4.1 : 1.0\n",
      "             betatrophin = True            after : before =      4.1 : 1.0\n",
      "                    rich = True            after : before =      4.1 : 1.0\n",
      "                  articl = True            after : before =      4.1 : 1.0\n",
      "                  induct = True            after : before =      4.1 : 1.0\n",
      "                   along = True            after : before =      4.1 : 1.0\n",
      "                  outcom = True            after : before =      4.1 : 1.0\n",
      "                  divers = True            after : before =      4.1 : 1.0\n",
      "                    open = True            after : before =      4.1 : 1.0\n",
      "                    serv = True            after : before =      4.1 : 1.0\n",
      "                  reduct = True            after : before =      4.1 : 1.0\n",
      "                  medium = True            after : before =      4.1 : 1.0\n",
      "                    elev = True            after : before =      4.1 : 1.0\n",
      "                  comput = True            after : before =      4.1 : 1.0\n",
      "                  provid = True            after : before =      3.8 : 1.0\n",
      "               treatment = True            after : before =      3.8 : 1.0\n",
      "                    caus = True            after : before =      3.8 : 1.0\n",
      "                 insulin = True            after : before =      3.4 : 1.0\n",
      "                     msc = True            after : before =      3.4 : 1.0\n",
      "                   carri = True            after : before =      3.4 : 1.0\n",
      "                interest = True            after : before =      3.4 : 1.0\n",
      "                structur = True            after : before =      3.4 : 1.0\n",
      "                     via = True            after : before =      3.4 : 1.0\n",
      "                    time = True            after : before =      3.4 : 1.0\n",
      "                  common = True            after : before =      3.4 : 1.0\n",
      "                  domain = True            after : before =      3.4 : 1.0\n",
      "                  system = True            after : before =      3.4 : 1.0\n",
      "             importantli = True            after : before =      3.4 : 1.0\n",
      "                pancreat = True            after : before =      3.4 : 1.0\n",
      "                 inhibit = True           before : after  =      3.4 : 1.0\n",
      "                     mir = True           before : after  =      3.4 : 1.0\n",
      "                   blood = True           before : after  =      3.4 : 1.0\n",
      "                     dna = True           before : after  =      3.4 : 1.0\n",
      "                  differ = True           before : after  =      3.3 : 1.0\n",
      "                   valid = True            after : before =      3.1 : 1.0\n",
      "                  clinic = True            after : before =      3.1 : 1.0\n",
      "                   organ = True            after : before =      3.1 : 1.0\n",
      "                    form = True            after : before =      3.1 : 1.0\n",
      "                   mirna = True           before : after  =      3.1 : 1.0\n",
      "                   relat = True           before : after  =      3.1 : 1.0\n",
      "                 control = True           before : after  =      3.0 : 1.0\n",
      "                    mous = True           before : after  =      2.9 : 1.0\n",
      "                   genom = True           before : after  =      2.9 : 1.0\n",
      "                  sensit = True           before : after  =      2.6 : 1.0\n",
      "                  diseas = True           before : after  =      2.6 : 1.0\n",
      "                    test = True           before : after  =      2.6 : 1.0\n",
      "                  measur = True           before : after  =      2.6 : 1.0\n",
      "                  target = True           before : after  =      2.6 : 1.0\n",
      "                   indic = True           before : after  =      2.6 : 1.0\n",
      "                    gene = True           before : after  =      2.6 : 1.0\n",
      "                 process = True           before : after  =      2.6 : 1.0\n",
      "                   novel = True            after : before =      2.4 : 1.0\n",
      "                  format = True            after : before =      2.4 : 1.0\n",
      "                    fact = True            after : before =      2.4 : 1.0\n",
      "                  despit = True            after : before =      2.4 : 1.0\n",
      "                    grow = True            after : before =      2.4 : 1.0\n",
      "                approach = True            after : before =      2.4 : 1.0\n",
      "                 predict = True            after : before =      2.4 : 1.0\n",
      "                     due = True            after : before =      2.4 : 1.0\n",
      "                  altern = True            after : before =      2.4 : 1.0\n",
      "                    base = True            after : before =      2.4 : 1.0\n",
      "                  glutam = True            after : before =      2.4 : 1.0\n",
      "                   pyruv = True            after : before =      2.4 : 1.0\n",
      "            characterist = True            after : before =      2.4 : 1.0\n",
      "                 alreadi = True            after : before =      2.4 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e75615f8>"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "### 2. With one sentence citing + following 3 sentences:\n",
    "\n",
    "#### 2.1 -  All documents\n",
    "\n",
    "train_Naive_Bayes(documents_all_3sentences, list_all_words_3sentences, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 83.33333333333334\n",
      "Most Informative Features\n",
      "      ('subject', 'one') = False          before : after  =      1.0 : 1.0\n",
      "         ('find', 'the') = False          before : after  =      1.0 : 1.0\n",
      "     ('bago', 'boctopu') = False          before : after  =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False          before : after  =      1.0 : 1.0\n",
      "     ('env', 'glycogag') = False          before : after  =      1.0 : 1.0\n",
      "    ('these', 'discrep') = False          before : after  =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "        ('sex', 'match') = False          before : after  =      1.0 : 1.0\n",
      "     ('express', 'lost') = False          before : after  =      1.0 : 1.0\n",
      "       ('cox', 'cancer') = False          before : after  =      1.0 : 1.0\n",
      "     ('variou', 'human') = False          before : after  =      1.0 : 1.0\n",
      "('adipos', 'tissuederiv') = False          before : after  =      1.0 : 1.0\n",
      "('antitubercular', 'local') = False          before : after  =      1.0 : 1.0\n",
      "    ('research', 'also') = False          before : after  =      1.0 : 1.0\n",
      "      ('see', 'analysi') = False          before : after  =      1.0 : 1.0\n",
      "      ('patient', 'one') = False          before : after  =      1.0 : 1.0\n",
      "    ('patient', 'howev') = False          before : after  =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False          before : after  =      1.0 : 1.0\n",
      " ('collaps', 'individu') = False          before : after  =      1.0 : 1.0\n",
      "('contribut', 'tumorigenesi') = False          before : after  =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False          before : after  =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False          before : after  =      1.0 : 1.0\n",
      "      ('pbmc', 'cultur') = False          before : after  =      1.0 : 1.0\n",
      "      ('hour', 'revers') = False          before : after  =      1.0 : 1.0\n",
      "    ('patient', 'uniqu') = False          before : after  =      1.0 : 1.0\n",
      "    ('examin', 'neonat') = False          before : after  =      1.0 : 1.0\n",
      "     ('either', 'genet') = False          before : after  =      1.0 : 1.0\n",
      " ('statement', 'articl') = False          before : after  =      1.0 : 1.0\n",
      "    ('paprotka', 'knox') = False          before : after  =      1.0 : 1.0\n",
      "  ('dataset', 'dataset') = False          before : after  =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False          before : after  =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False          before : after  =      1.0 : 1.0\n",
      "         ('xmrv', 'mlv') = False          before : after  =      1.0 : 1.0\n",
      "      ('antenn', 'lobe') = False          before : after  =      1.0 : 1.0\n",
      "    ('katz', 'giraudet') = False          before : after  =      1.0 : 1.0\n",
      "     ('ensur', 'safeti') = False          before : after  =      1.0 : 1.0\n",
      "    ('report', 'revolv') = False          before : after  =      1.0 : 1.0\n",
      "       ('data', 'studi') = False          before : after  =      1.0 : 1.0\n",
      "    ('whether', 'modul') = False          before : after  =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False          before : after  =      1.0 : 1.0\n",
      "    ('accumul', 'studi') = False          before : after  =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False          before : after  =      1.0 : 1.0\n",
      "        ('viru', 'gain') = False          before : after  =      1.0 : 1.0\n",
      "     ('therebi', 'flag') = False          before : after  =      1.0 : 1.0\n",
      "      ('buck', 'rennak') = False          before : after  =      1.0 : 1.0\n",
      "  ('mass', 'spectromet') = False          before : after  =      1.0 : 1.0\n",
      "   ('confirm', 'observ') = False          before : after  =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False          before : after  =      1.0 : 1.0\n",
      "  ('outgrowth', 'mutat') = False          before : after  =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False          before : after  =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False          before : after  =      1.0 : 1.0\n",
      " ('hervfrdi', 'essenti') = False          before : after  =      1.0 : 1.0\n",
      "        ('taq', 'rtpcr') = False          before : after  =      1.0 : 1.0\n",
      " ('support', 'function') = False          before : after  =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False          before : after  =      1.0 : 1.0\n",
      "      ('way', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "('monocyt', 'chemoattract') = False          before : after  =      1.0 : 1.0\n",
      " ('provirus', 'amplifi') = False          before : after  =      1.0 : 1.0\n",
      "      ('level', 'viral') = False          before : after  =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False          before : after  =      1.0 : 1.0\n",
      "       ('figur', 'rhoa') = False          before : after  =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False          before : after  =      1.0 : 1.0\n",
      "      ('shown', 'figur') = False          before : after  =      1.0 : 1.0\n",
      "   ('strain', 'genbank') = False          before : after  =      1.0 : 1.0\n",
      "  ('pacif', 'immunolog') = False          before : after  =      1.0 : 1.0\n",
      "     ('order', 'combat') = False          before : after  =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False          before : after  =      1.0 : 1.0\n",
      "     ('found', 'promot') = False          before : after  =      1.0 : 1.0\n",
      "('either', 'xmrvinfect') = False          before : after  =      1.0 : 1.0\n",
      "('invitrogen', 'platinum') = False          before : after  =      1.0 : 1.0\n",
      "   ('suppress', 'dicer') = False          before : after  =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False          before : after  =      1.0 : 1.0\n",
      "         ('gene', 'set') = False          before : after  =      1.0 : 1.0\n",
      "          ('myc', 'dna') = False          before : after  =      1.0 : 1.0\n",
      "      ('miss', 'detect') = False          before : after  =      1.0 : 1.0\n",
      "        ('rna', 'andor') = False          before : after  =      1.0 : 1.0\n",
      "     ('upon', 'encount') = False          before : after  =      1.0 : 1.0\n",
      "  ('respons', 'convers') = False          before : after  =      1.0 : 1.0\n",
      "     ('target', 'cdkna') = False          before : after  =      1.0 : 1.0\n",
      "('falseposit', 'mlvxmrv') = False          before : after  =      1.0 : 1.0\n",
      "('furthermor', 'recent') = False          before : after  =      1.0 : 1.0\n",
      " ('catalysi', 'arginin') = False          before : after  =      1.0 : 1.0\n",
      "        ('via', 'three') = False          before : after  =      1.0 : 1.0\n",
      "       ('barrier', 'dy') = False          before : after  =      1.0 : 1.0\n",
      "     ('express', 'mira') = False          before : after  =      1.0 : 1.0\n",
      "  ('transmit', 'signal') = False          before : after  =      1.0 : 1.0\n",
      "   ('protein', 'includ') = False          before : after  =      1.0 : 1.0\n",
      "  ('author', 'demonstr') = False          before : after  =      1.0 : 1.0\n",
      "   ('biomark', 'measur') = False          before : after  =      1.0 : 1.0\n",
      "        ('life', 'wish') = False          before : after  =      1.0 : 1.0\n",
      "       ('msc', 'expand') = False          before : after  =      1.0 : 1.0\n",
      "       ('mpmv', 'relat') = False          before : after  =      1.0 : 1.0\n",
      "  ('laboratori', 'mous') = False          before : after  =      1.0 : 1.0\n",
      "    ('buffer', 'triton') = False          before : after  =      1.0 : 1.0\n",
      "    ('reinforc', 'need') = False          before : after  =      1.0 : 1.0\n",
      "    ('member', 'famili') = False          before : after  =      1.0 : 1.0\n",
      "      ('amplifi', 'mlv') = False          before : after  =      1.0 : 1.0\n",
      "      ('thu', 'without') = False          before : after  =      1.0 : 1.0\n",
      "      ('fact', 'differ') = False          before : after  =      1.0 : 1.0\n",
      "    ('hypothesi', 'thi') = False          before : after  =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e5bec320>"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "train_Naive_Bayes(documents_all_3sentences, list_all_bigrams_3sentences, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 53.84615384615385\n",
      "Most Informative Features\n",
      "                     mir = True           before : after  =      6.3 : 1.0\n",
      "                   mirna = True           before : after  =      6.3 : 1.0\n",
      "             overexpress = True           before : after  =      5.2 : 1.0\n",
      "                prolifer = True           before : after  =      4.7 : 1.0\n",
      "                    caus = True            after : before =      4.4 : 1.0\n",
      "                 sequenc = True            after : before =      4.4 : 1.0\n",
      "                  promot = True           before : after  =      4.1 : 1.0\n",
      "                approach = True            after : before =      3.6 : 1.0\n",
      "                    form = True            after : before =      3.6 : 1.0\n",
      "                   vitro = True           before : after  =      3.6 : 1.0\n",
      "                metastat = True           before : after  =      3.6 : 1.0\n",
      "                    role = True           before : after  =      3.2 : 1.0\n",
      "                 previou = True            after : before =      3.1 : 1.0\n",
      "                  diseas = True           before : after  =      3.0 : 1.0\n",
      "                  growth = True           before : after  =      3.0 : 1.0\n",
      "                  togeth = True           before : after  =      3.0 : 1.0\n",
      "                  factor = True           before : after  =      3.0 : 1.0\n",
      "                  normal = True           before : after  =      3.0 : 1.0\n",
      "                   known = True           before : after  =      3.0 : 1.0\n",
      "                 patient = True            after : before =      2.9 : 1.0\n",
      "                 context = True            after : before =      2.8 : 1.0\n",
      "             biosynthesi = True            after : before =      2.8 : 1.0\n",
      "                   after = True            after : before =      2.8 : 1.0\n",
      "                    base = True            after : before =      2.8 : 1.0\n",
      "                  origin = True            after : before =      2.8 : 1.0\n",
      "                   immun = True            after : before =      2.8 : 1.0\n",
      "                   major = True            after : before =      2.8 : 1.0\n",
      "                     set = True            after : before =      2.8 : 1.0\n",
      "                signatur = True            after : before =      2.8 : 1.0\n",
      "                    less = True            after : before =      2.8 : 1.0\n",
      "                pancreat = True            after : before =      2.8 : 1.0\n",
      "                research = True            after : before =      2.8 : 1.0\n",
      "                  domain = True            after : before =      2.8 : 1.0\n",
      "                 inhibit = True           before : after  =      2.8 : 1.0\n",
      "                  better = True            after : before =      2.7 : 1.0\n",
      "                 control = True           before : after  =      2.5 : 1.0\n",
      "                   these = True           before : after  =      2.5 : 1.0\n",
      "                   human = True           before : after  =      2.5 : 1.0\n",
      "                   other = True           before : after  =      2.5 : 1.0\n",
      "                    type = True           before : after  =      2.5 : 1.0\n",
      "                identifi = True           before : after  =      2.5 : 1.0\n",
      "                  target = True           before : after  =      2.5 : 1.0\n",
      "                    lead = True           before : after  =      2.5 : 1.0\n",
      "                  number = True            after : before =      2.2 : 1.0\n",
      "                     via = True            after : before =      2.2 : 1.0\n",
      "                 support = True            after : before =      2.2 : 1.0\n",
      "               treatment = True            after : before =      2.2 : 1.0\n",
      "                  exampl = True            after : before =      2.2 : 1.0\n",
      "                   tissu = True           before : after  =      2.2 : 1.0\n",
      "                demonstr = True           before : after  =      2.2 : 1.0\n",
      "               downregul = True           before : after  =      2.2 : 1.0\n",
      "                     use = True            after : before =      2.1 : 1.0\n",
      "                  branch = True            after : before =      2.0 : 1.0\n",
      "               character = True            after : before =      2.0 : 1.0\n",
      "                   local = True            after : before =      2.0 : 1.0\n",
      "                    show = True            after : before =      2.0 : 1.0\n",
      "                   littl = True            after : before =      2.0 : 1.0\n",
      "                  inform = True            after : before =      2.0 : 1.0\n",
      "                   genet = True            after : before =      2.0 : 1.0\n",
      "                  altern = True            after : before =      2.0 : 1.0\n",
      "                prognost = True            after : before =      2.0 : 1.0\n",
      "                  variou = True            after : before =      2.0 : 1.0\n",
      "                  design = True            after : before =      2.0 : 1.0\n",
      "                   exist = True            after : before =      2.0 : 1.0\n",
      "                  reveal = True            after : before =      2.0 : 1.0\n",
      "                  system = True            after : before =      2.0 : 1.0\n",
      "               therapeut = True            after : before =      2.0 : 1.0\n",
      "                  accord = True            after : before =      2.0 : 1.0\n",
      "                  induct = True            after : before =      2.0 : 1.0\n",
      "                  intern = True            after : before =      2.0 : 1.0\n",
      "                    give = True            after : before =      2.0 : 1.0\n",
      "                  overal = True            after : before =      2.0 : 1.0\n",
      "                  consid = True            after : before =      2.0 : 1.0\n",
      "                interact = True            after : before =      2.0 : 1.0\n",
      "                 molecul = True            after : before =      2.0 : 1.0\n",
      "                  diabet = True            after : before =      2.0 : 1.0\n",
      "                strategi = True            after : before =      2.0 : 1.0\n",
      "                 highest = True            after : before =      2.0 : 1.0\n",
      "                   refer = True            after : before =      2.0 : 1.0\n",
      "                synthesi = True            after : before =      2.0 : 1.0\n",
      "                    well = True            after : before =      2.0 : 1.0\n",
      "                   treat = True            after : before =      2.0 : 1.0\n",
      "                    need = True            after : before =      2.0 : 1.0\n",
      "                contrast = True            after : before =      2.0 : 1.0\n",
      "                   serum = True            after : before =      2.0 : 1.0\n",
      "                   paper = True            after : before =      2.0 : 1.0\n",
      "                 contain = True            after : before =      2.0 : 1.0\n",
      "                   appar = True            after : before =      2.0 : 1.0\n",
      "                consumpt = True            after : before =      2.0 : 1.0\n",
      "                  divers = True            after : before =      2.0 : 1.0\n",
      "                    note = True            after : before =      2.0 : 1.0\n",
      "                pathogen = True            after : before =      2.0 : 1.0\n",
      "              furthermor = True            after : before =      2.0 : 1.0\n",
      "                   phase = True            after : before =      2.0 : 1.0\n",
      "                  compar = True           before : after  =      2.0 : 1.0\n",
      "                   model = True           before : after  =      2.0 : 1.0\n",
      "                   sever = True           before : after  =      2.0 : 1.0\n",
      "                 subject = True           before : after  =      1.9 : 1.0\n",
      "             betatrophin = True           before : after  =      1.9 : 1.0\n",
      "                     rel = True           before : after  =      1.9 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e6ee12b0>"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 2.2 -  50 % before - 50% after\n",
    "\n",
    "train_Naive_Bayes(documents_50_50_3sentences, list_all_words_50_50_3sentences, 0.20)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 30.76923076923077\n",
      "Most Informative Features\n",
      "      ('subject', 'one') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'lost') = False           after : before =      1.0 : 1.0\n",
      "     ('variou', 'human') = False           after : before =      1.0 : 1.0\n",
      "    ('research', 'also') = False           after : before =      1.0 : 1.0\n",
      "    ('patient', 'howev') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      "('contribut', 'tumorigenesi') = False           after : before =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False           after : before =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False           after : before =      1.0 : 1.0\n",
      "      ('hour', 'revers') = False           after : before =      1.0 : 1.0\n",
      "    ('examin', 'neonat') = False           after : before =      1.0 : 1.0\n",
      "     ('either', 'genet') = False           after : before =      1.0 : 1.0\n",
      " ('statement', 'articl') = False           after : before =      1.0 : 1.0\n",
      "  ('dataset', 'dataset') = False           after : before =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False           after : before =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False           after : before =      1.0 : 1.0\n",
      "    ('whether', 'modul') = False           after : before =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False           after : before =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False           after : before =      1.0 : 1.0\n",
      "     ('therebi', 'flag') = False           after : before =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False           after : before =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      " ('support', 'function') = False           after : before =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False           after : before =      1.0 : 1.0\n",
      "      ('way', 'increas') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      "       ('figur', 'rhoa') = False           after : before =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False           after : before =      1.0 : 1.0\n",
      "      ('shown', 'figur') = False           after : before =      1.0 : 1.0\n",
      "     ('order', 'combat') = False           after : before =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False           after : before =      1.0 : 1.0\n",
      "   ('suppress', 'dicer') = False           after : before =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False           after : before =      1.0 : 1.0\n",
      "         ('gene', 'set') = False           after : before =      1.0 : 1.0\n",
      "          ('myc', 'dna') = False           after : before =      1.0 : 1.0\n",
      "     ('upon', 'encount') = False           after : before =      1.0 : 1.0\n",
      "     ('target', 'cdkna') = False           after : before =      1.0 : 1.0\n",
      "('furthermor', 'recent') = False           after : before =      1.0 : 1.0\n",
      " ('catalysi', 'arginin') = False           after : before =      1.0 : 1.0\n",
      "        ('via', 'three') = False           after : before =      1.0 : 1.0\n",
      "       ('barrier', 'dy') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'mira') = False           after : before =      1.0 : 1.0\n",
      "  ('transmit', 'signal') = False           after : before =      1.0 : 1.0\n",
      "   ('protein', 'includ') = False           after : before =      1.0 : 1.0\n",
      "  ('author', 'demonstr') = False           after : before =      1.0 : 1.0\n",
      "    ('buffer', 'triton') = False           after : before =      1.0 : 1.0\n",
      "    ('member', 'famili') = False           after : before =      1.0 : 1.0\n",
      "    ('hypothesi', 'thi') = False           after : before =      1.0 : 1.0\n",
      "      ('snp', 'rubella') = False           after : before =      1.0 : 1.0\n",
      "     ('longer', 'valid') = False           after : before =      1.0 : 1.0\n",
      "        ('the', 'first') = False           after : before =      1.0 : 1.0\n",
      "      ('may', 'exacerb') = False           after : before =      1.0 : 1.0\n",
      "    ('induc', 'insulin') = False           after : before =      1.0 : 1.0\n",
      "     ('safeti', 'point') = False           after : before =      1.0 : 1.0\n",
      "  ('pathway', 'essenti') = False           after : before =      1.0 : 1.0\n",
      "('miniscaffoldin', 'when') = False           after : before =      1.0 : 1.0\n",
      "       ('give', 'clear') = False           after : before =      1.0 : 1.0\n",
      "    ('implic', 'breast') = False           after : before =      1.0 : 1.0\n",
      "('factor', 'antiinflammatori') = False           after : before =      1.0 : 1.0\n",
      "  ('epicanc', 'mirletc') = False           after : before =      1.0 : 1.0\n",
      "         ('naf', 'navo') = False           after : before =      1.0 : 1.0\n",
      "        ('some', 'evid') = False           after : before =      1.0 : 1.0\n",
      "     ('level', 'variou') = False           after : before =      1.0 : 1.0\n",
      "     ('studi', 'examin') = False           after : before =      1.0 : 1.0\n",
      "('protein', 'differenti') = False           after : before =      1.0 : 1.0\n",
      "      ('model', 'there') = False           after : before =      1.0 : 1.0\n",
      "   ('tight', 'junction') = False           after : before =      1.0 : 1.0\n",
      "      ('effect', 'abil') = False           after : before =      1.0 : 1.0\n",
      " ('sequest', 'selfrepl') = False           after : before =      1.0 : 1.0\n",
      "     ('emt', 'although') = False           after : before =      1.0 : 1.0\n",
      "        ('studi', 'yet') = False           after : before =      1.0 : 1.0\n",
      "       ('relat', 'drug') = False           after : before =      1.0 : 1.0\n",
      "      ('upregul', 'crc') = False           after : before =      1.0 : 1.0\n",
      " ('signatur', 'predict') = False           after : before =      1.0 : 1.0\n",
      "    ('latrin', 'remain') = False           after : before =      1.0 : 1.0\n",
      "       ('ron', 'naaman') = False           after : before =      1.0 : 1.0\n",
      "  ('describ', 'context') = False           after : before =      1.0 : 1.0\n",
      " ('pathway', 'although') = False           after : before =      1.0 : 1.0\n",
      "        ('head', 'neck') = False           after : before =      1.0 : 1.0\n",
      "('dosedepend', 'manner') = False           after : before =      1.0 : 1.0\n",
      "  ('compar', 'noninvas') = False           after : before =      1.0 : 1.0\n",
      "('catalyz', 'dephosphoryl') = False           after : before =      1.0 : 1.0\n",
      "      ('residu', 'serv') = False           after : before =      1.0 : 1.0\n",
      "  ('highest', 'express') = False           after : before =      1.0 : 1.0\n",
      "        ('cell', 'case') = False           after : before =      1.0 : 1.0\n",
      "    ('receptor', 'high') = False           after : before =      1.0 : 1.0\n",
      "     ('remain', 'activ') = False           after : before =      1.0 : 1.0\n",
      "    ('engin', 'sequenc') = False           after : before =      1.0 : 1.0\n",
      "    ('support', 'degre') = False           after : before =      1.0 : 1.0\n",
      "      ('replic', 'rate') = False           after : before =      1.0 : 1.0\n",
      "        ('islet', 'not') = False           after : before =      1.0 : 1.0\n",
      "('involv', 'biosynthesi') = False           after : before =      1.0 : 1.0\n",
      "       ('level', 'also') = False           after : before =      1.0 : 1.0\n",
      "    ('cancer', 'target') = False           after : before =      1.0 : 1.0\n",
      "      ('dig', 'sustain') = False           after : before =      1.0 : 1.0\n",
      "       ('also', 'occur') = False           after : before =      1.0 : 1.0\n",
      "   ('compar', 'dataset') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e52dee10>"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_50_50_3sentences, list_all_bigrams_50_50_3sentences, 0.20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 91.66666666666666\n",
      "Most Informative Features\n",
      "                function = True           before : after  =      9.5 : 1.0\n",
      "                   model = True           before : after  =      9.5 : 1.0\n",
      "                  remain = True            after : before =      9.0 : 1.0\n",
      "                   evalu = True            after : before =      7.1 : 1.0\n",
      "                 decreas = True            after : before =      7.1 : 1.0\n",
      "                   alter = True            after : before =      6.1 : 1.0\n",
      "                 endogen = True            after : before =      6.1 : 1.0\n",
      "                 patient = True            after : before =      6.0 : 1.0\n",
      "                    lack = True           before : after  =      5.9 : 1.0\n",
      "                   limit = True           before : after  =      5.9 : 1.0\n",
      "               discoveri = True           before : after  =      5.9 : 1.0\n",
      "                  analyz = True            after : before =      5.6 : 1.0\n",
      "                individu = True            after : before =      5.6 : 1.0\n",
      "                  induct = True            after : before =      5.6 : 1.0\n",
      "                  measur = True            after : before =      5.6 : 1.0\n",
      "                conflict = True            after : before =      5.6 : 1.0\n",
      "                 attempt = True            after : before =      5.6 : 1.0\n",
      "                  assess = True            after : before =      5.6 : 1.0\n",
      "                    fail = True            after : before =      5.6 : 1.0\n",
      "                   these = True           before : after  =      5.0 : 1.0\n",
      "                 protein = True           before : after  =      4.6 : 1.0\n",
      "                research = True           before : after  =      4.6 : 1.0\n",
      "                  diabet = True            after : before =      4.5 : 1.0\n",
      "                  recent = True            after : before =      4.5 : 1.0\n",
      "                   toler = True            after : before =      4.3 : 1.0\n",
      "                     two = True           before : after  =      4.1 : 1.0\n",
      "                  togeth = True           before : after  =      4.1 : 1.0\n",
      "                  cultur = True           before : after  =      4.1 : 1.0\n",
      "                    find = True           before : after  =      4.1 : 1.0\n",
      "                  includ = True           before : after  =      4.1 : 1.0\n",
      "                  compar = True            after : before =      4.0 : 1.0\n",
      "                   novel = True            after : before =      3.7 : 1.0\n",
      "                  provid = True            after : before =      3.7 : 1.0\n",
      "                 display = True            after : before =      3.7 : 1.0\n",
      "                  cancer = True            after : before =      3.7 : 1.0\n",
      "                  inject = True            after : before =      3.7 : 1.0\n",
      "                  differ = True           before : after  =      3.5 : 1.0\n",
      "                 present = True            after : before =      3.5 : 1.0\n",
      "                  follow = True            after : before =      3.4 : 1.0\n",
      "                    vivo = True            after : before =      3.4 : 1.0\n",
      "                     aim = True            after : before =      3.4 : 1.0\n",
      "              hydrodynam = True            after : before =      3.4 : 1.0\n",
      "              transplant = True            after : before =      3.4 : 1.0\n",
      "                    tail = True            after : before =      3.4 : 1.0\n",
      "              homeostasi = True            after : before =      3.4 : 1.0\n",
      "                 plasmid = True            after : before =      3.4 : 1.0\n",
      "                 lipasin = True            after : before =      3.4 : 1.0\n",
      "                   islet = True            after : before =      3.4 : 1.0\n",
      "                 mellitu = True            after : before =      3.4 : 1.0\n",
      "                   hepat = True            after : before =      3.4 : 1.0\n",
      "                 subject = True           before : after  =      3.3 : 1.0\n",
      "                 develop = True           before : after  =      3.2 : 1.0\n",
      "                    larg = True           before : after  =      3.2 : 1.0\n",
      "                  elicit = True           before : after  =      3.2 : 1.0\n",
      "                antibodi = True           before : after  =      3.2 : 1.0\n",
      "                     dna = True           before : after  =      3.2 : 1.0\n",
      "                   deriv = True           before : after  =      3.2 : 1.0\n",
      "                    evid = True           before : after  =      3.2 : 1.0\n",
      "                    base = True           before : after  =      3.2 : 1.0\n",
      "                     led = True           before : after  =      3.2 : 1.0\n",
      "                  system = True           before : after  =      3.2 : 1.0\n",
      "                  condit = True           before : after  =      3.2 : 1.0\n",
      "                  strong = True           before : after  =      3.2 : 1.0\n",
      "                    area = True           before : after  =      3.2 : 1.0\n",
      "                  promot = True           before : after  =      3.2 : 1.0\n",
      "                  normal = True           before : after  =      3.2 : 1.0\n",
      "                     low = True           before : after  =      3.2 : 1.0\n",
      "                   sever = True           before : after  =      3.2 : 1.0\n",
      "                 multipl = True           before : after  =      3.2 : 1.0\n",
      "                    cell = True           before : after  =      3.0 : 1.0\n",
      "                  improv = True            after : before =      3.0 : 1.0\n",
      "                demonstr = True            after : before =      3.0 : 1.0\n",
      "                  enhanc = True            after : before =      3.0 : 1.0\n",
      "                  recent = False          before : after  =      3.0 : 1.0\n",
      "                 describ = True            after : before =      2.8 : 1.0\n",
      "                 patient = False          before : after  =      2.8 : 1.0\n",
      "                  mechan = True            after : before =      2.7 : 1.0\n",
      "                receptor = True            after : before =      2.5 : 1.0\n",
      "                   could = True           before : after  =      2.5 : 1.0\n",
      "                    data = True           before : after  =      2.5 : 1.0\n",
      "                identifi = True           before : after  =      2.5 : 1.0\n",
      "                     one = True           before : after  =      2.5 : 1.0\n",
      "                   group = True           before : after  =      2.5 : 1.0\n",
      "                 complex = True           before : after  =      2.5 : 1.0\n",
      "                  remain = False          before : after  =      2.4 : 1.0\n",
      "                   tissu = True            after : before =      2.4 : 1.0\n",
      "                  replic = True            after : before =      2.4 : 1.0\n",
      "                   vitro = True            after : before =      2.4 : 1.0\n",
      "                   cell = True            after : before =      2.4 : 1.0\n",
      "                   other = True            after : before =      2.4 : 1.0\n",
      "                  stimul = True            after : before =      2.4 : 1.0\n",
      "                  secret = True            after : before =      2.4 : 1.0\n",
      "                knockout = True            after : before =      2.4 : 1.0\n",
      "              antagonist = True            after : before =      2.4 : 1.0\n",
      "                  glucos = True            after : before =      2.4 : 1.0\n",
      "                    cell = False           after : before =      2.3 : 1.0\n",
      "                   point = True           before : after  =      2.3 : 1.0\n",
      "                 respons = True           before : after  =      2.3 : 1.0\n",
      "                   block = True           before : after  =      2.3 : 1.0\n",
      "                   brain = True           before : after  =      2.3 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e52935c0>"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 2.3 - Balanced: 50 % before - 50% after. If doi cited before and after same number of documents before are after.\n",
    "\n",
    "train_Naive_Bayes(documents_50_50_balanced_3sentences, list_all_words_50_50_balanced_3sentences, 0.20)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 16.666666666666664\n",
      "Most Informative Features\n",
      "  ('intrigu', 'problem') = False          before : after  =      1.0 : 1.0\n",
      "        ('rna', 'cerna') = False          before : after  =      1.0 : 1.0\n",
      "      ('subject', 'one') = False          before : after  =      1.0 : 1.0\n",
      "    ('manner', 'differ') = False          before : after  =      1.0 : 1.0\n",
      "    ('insulin', 'level') = False          before : after  =      1.0 : 1.0\n",
      "     ('bago', 'boctopu') = False          before : after  =      1.0 : 1.0\n",
      "    ('encod', 'process') = False          before : after  =      1.0 : 1.0\n",
      " ('analysi', 'supervis') = False          before : after  =      1.0 : 1.0\n",
      "       ('figur', 'cell') = False          before : after  =      1.0 : 1.0\n",
      "   ('jorissen', 'there') = False          before : after  =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False          before : after  =      1.0 : 1.0\n",
      "   ('induc', 'fluoresc') = False          before : after  =      1.0 : 1.0\n",
      "  ('protein', 'consist') = False          before : after  =      1.0 : 1.0\n",
      "    ('degener', 'these') = False          before : after  =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "    ('cavin', 'patient') = False          before : after  =      1.0 : 1.0\n",
      "        ('sex', 'match') = False          before : after  =      1.0 : 1.0\n",
      "         ('base', 'dna') = False          before : after  =      1.0 : 1.0\n",
      "('compound', 'treatment') = False          before : after  =      1.0 : 1.0\n",
      "      ('express', 'one') = False          before : after  =      1.0 : 1.0\n",
      "    ('patient', 'howev') = False          before : after  =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False          before : after  =      1.0 : 1.0\n",
      "('dataset', 'interestingli') = False          before : after  =      1.0 : 1.0\n",
      "      ('appear', 'play') = False          before : after  =      1.0 : 1.0\n",
      "    ('identifi', 'mous') = False          before : after  =      1.0 : 1.0\n",
      "      ('stop', 'glycin') = False          before : after  =      1.0 : 1.0\n",
      "     ('suppress', 'ade') = False          before : after  =      1.0 : 1.0\n",
      "('circul', 'liverderiv') = False          before : after  =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False          before : after  =      1.0 : 1.0\n",
      "      ('drive', 'cell') = False          before : after  =      1.0 : 1.0\n",
      "    ('synthet', 'prion') = False          before : after  =      1.0 : 1.0\n",
      "('xanthomona', 'suggest') = False          before : after  =      1.0 : 1.0\n",
      "     ('mediat', 'motil') = False          before : after  =      1.0 : 1.0\n",
      "         ('acid', 'irb') = False          before : after  =      1.0 : 1.0\n",
      "     ('either', 'genet') = False          before : after  =      1.0 : 1.0\n",
      "   ('result', 'current') = False          before : after  =      1.0 : 1.0\n",
      " ('statement', 'articl') = False          before : after  =      1.0 : 1.0\n",
      "('recombin', 'betatrophin') = False          before : after  =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False          before : after  =      1.0 : 1.0\n",
      "         ('xmrv', 'mlv') = False          before : after  =      1.0 : 1.0\n",
      "    ('region', 'pertin') = False          before : after  =      1.0 : 1.0\n",
      "       ('remain', 'rel') = False          before : after  =      1.0 : 1.0\n",
      "      ('retain', 'pten') = False          before : after  =      1.0 : 1.0\n",
      "        ('lee', 'howev') = False          before : after  =      1.0 : 1.0\n",
      "  ('resist', 'hypothes') = False          before : after  =      1.0 : 1.0\n",
      "       ('data', 'studi') = False          before : after  =      1.0 : 1.0\n",
      "    ('strain', 'togeth') = False          before : after  =      1.0 : 1.0\n",
      "      ('rel', 'control') = False          before : after  =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False          before : after  =      1.0 : 1.0\n",
      "         ('use', 'test') = False          before : after  =      1.0 : 1.0\n",
      "   ('cell', 'character') = False          before : after  =      1.0 : 1.0\n",
      "     ('dataset', 'both') = False          before : after  =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False          before : after  =      1.0 : 1.0\n",
      "      ('buck', 'rennak') = False          before : after  =      1.0 : 1.0\n",
      "  ('excess', 'internet') = False          before : after  =      1.0 : 1.0\n",
      "   ('public', 'retract') = False          before : after  =      1.0 : 1.0\n",
      "('transposon', 'consensus') = False          before : after  =      1.0 : 1.0\n",
      "('inhibitor', 'decreas') = False          before : after  =      1.0 : 1.0\n",
      "   ('exogen', 'cytokin') = False          before : after  =      1.0 : 1.0\n",
      "('nephropathi', 'togeth') = False          before : after  =      1.0 : 1.0\n",
      "     ('pdac', 'patient') = False          before : after  =      1.0 : 1.0\n",
      "    ('normal', 'glucos') = False          before : after  =      1.0 : 1.0\n",
      "       ('becom', 'less') = False          before : after  =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False          before : after  =      1.0 : 1.0\n",
      " ('understand', 'local') = False          before : after  =      1.0 : 1.0\n",
      "  ('stimul', 'adipocyt') = False          before : after  =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False          before : after  =      1.0 : 1.0\n",
      "     ('found', 'report') = False          before : after  =      1.0 : 1.0\n",
      "('hippocampu', 'individu') = False          before : after  =      1.0 : 1.0\n",
      "     ('posit', 'associ') = False          before : after  =      1.0 : 1.0\n",
      "('round', 'immunoclear') = False          before : after  =      1.0 : 1.0\n",
      "      ('valu', 'improv') = False          before : after  =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False          before : after  =      1.0 : 1.0\n",
      "      ('way', 'increas') = False          before : after  =      1.0 : 1.0\n",
      "     ('report', 'liver') = False          before : after  =      1.0 : 1.0\n",
      "  ('human', 'admscsbet') = False          before : after  =      1.0 : 1.0\n",
      "  ('patient', 'express') = False          before : after  =      1.0 : 1.0\n",
      "('monocyt', 'chemoattract') = False          before : after  =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False          before : after  =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False          before : after  =      1.0 : 1.0\n",
      "      ('base', 'report') = False          before : after  =      1.0 : 1.0\n",
      "  ('pacif', 'immunolog') = False          before : after  =      1.0 : 1.0\n",
      "   ('central', 'nervou') = False          before : after  =      1.0 : 1.0\n",
      "       ('ade', 'produc') = False          before : after  =      1.0 : 1.0\n",
      "       ('mrna', 'encod') = False          before : after  =      1.0 : 1.0\n",
      "       ('favour', 'atp') = False          before : after  =      1.0 : 1.0\n",
      "   ('glucos', 'intoler') = False          before : after  =      1.0 : 1.0\n",
      "        ('mass', 'mice') = False          before : after  =      1.0 : 1.0\n",
      "       ('format', 'mir') = False          before : after  =      1.0 : 1.0\n",
      "       ('nerv', 'regul') = False          before : after  =      1.0 : 1.0\n",
      "       ('factor', 'the') = False          before : after  =      1.0 : 1.0\n",
      "    ('method', 'enrich') = False          before : after  =      1.0 : 1.0\n",
      "       ('tissu', 'show') = False          before : after  =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False          before : after  =      1.0 : 1.0\n",
      "         ('gene', 'set') = False          before : after  =      1.0 : 1.0\n",
      "       ('novel', 'gene') = False          before : after  =      1.0 : 1.0\n",
      "         ('amp', 'ryan') = False          before : after  =      1.0 : 1.0\n",
      "        ('test', 'also') = False          before : after  =      1.0 : 1.0\n",
      "   ('factor', 'insulin') = False          before : after  =      1.0 : 1.0\n",
      "('furthermor', 'recent') = False          before : after  =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e4455320>"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "train_Naive_Bayes(documents_50_50_balanced_3sentences, list_all_bigrams_50_50_balanced_3sentences, 0.20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 66.66666666666666\n",
      "Most Informative Features\n",
      "                    grow = True            after : before =      7.7 : 1.0\n",
      "                    poor = True            after : before =      7.7 : 1.0\n",
      "                  mainli = True            after : before =      6.0 : 1.0\n",
      "                    upon = True            after : before =      6.0 : 1.0\n",
      "                concentr = True            after : before =      6.0 : 1.0\n",
      "                     per = True            after : before =      6.0 : 1.0\n",
      "                   littl = True            after : before =      6.0 : 1.0\n",
      "               pulmonari = True            after : before =      6.0 : 1.0\n",
      "                   enabl = True            after : before =      6.0 : 1.0\n",
      "                  extend = True            after : before =      6.0 : 1.0\n",
      "                   medic = True            after : before =      6.0 : 1.0\n",
      "                    serv = True            after : before =      6.0 : 1.0\n",
      "                 disrupt = True            after : before =      6.0 : 1.0\n",
      "                  better = True            after : before =      5.7 : 1.0\n",
      "                   enzym = True            after : before =      4.6 : 1.0\n",
      "                   phase = True            after : before =      4.6 : 1.0\n",
      "                   liver = True            after : before =      4.6 : 1.0\n",
      "                   besid = True            after : before =      4.6 : 1.0\n",
      "                pancreat = True            after : before =      4.6 : 1.0\n",
      "                  design = True            after : before =      4.3 : 1.0\n",
      "              oncogenesi = True            after : before =      4.3 : 1.0\n",
      "                   debat = True            after : before =      4.3 : 1.0\n",
      "                   lipin = True            after : before =      4.3 : 1.0\n",
      "                  compet = True            after : before =      4.3 : 1.0\n",
      "                  stabil = True            after : before =      4.3 : 1.0\n",
      "                    when = True            after : before =      4.3 : 1.0\n",
      "                     snp = True            after : before =      4.3 : 1.0\n",
      "                 mention = True            after : before =      4.3 : 1.0\n",
      "                    deep = True            after : before =      4.3 : 1.0\n",
      "                    acut = True            after : before =      4.3 : 1.0\n",
      "                    with = True            after : before =      4.3 : 1.0\n",
      "                 practic = True            after : before =      4.3 : 1.0\n",
      "               transient = True            after : before =      4.3 : 1.0\n",
      "                    rich = True            after : before =      4.3 : 1.0\n",
      "              experiment = True            after : before =      4.3 : 1.0\n",
      "                  materi = True            after : before =      4.3 : 1.0\n",
      "                  specul = True            after : before =      4.3 : 1.0\n",
      "                  divers = True            after : before =      4.3 : 1.0\n",
      "                  tradit = True            after : before =      4.3 : 1.0\n",
      "                  approv = True            after : before =      4.3 : 1.0\n",
      "                    life = True            after : before =      4.3 : 1.0\n",
      "                contrari = True            after : before =      4.3 : 1.0\n",
      "                    open = True            after : before =      4.3 : 1.0\n",
      "               intervent = True            after : before =      4.3 : 1.0\n",
      "                    focu = True            after : before =      4.3 : 1.0\n",
      "             triglycerid = True            after : before =      4.3 : 1.0\n",
      "                    give = True            after : before =      4.3 : 1.0\n",
      "                   shift = True            after : before =      4.3 : 1.0\n",
      "                 mainten = True            after : before =      4.3 : 1.0\n",
      "                   renal = True            after : before =      4.3 : 1.0\n",
      "                    mark = True            after : before =      4.3 : 1.0\n",
      "                  comput = True            after : before =      4.3 : 1.0\n",
      "               morpholog = True            after : before =      4.3 : 1.0\n",
      "                    mous = True           before : after  =      4.3 : 1.0\n",
      "                     via = True            after : before =      4.0 : 1.0\n",
      "                     mir = True           before : after  =      3.8 : 1.0\n",
      "                 previou = True            after : before =      3.8 : 1.0\n",
      "                 decreas = True            after : before =      3.7 : 1.0\n",
      "                 nuclear = True            after : before =      3.6 : 1.0\n",
      "                prognost = True            after : before =      3.6 : 1.0\n",
      "                  common = True            after : before =      3.6 : 1.0\n",
      "                  review = True            after : before =      3.6 : 1.0\n",
      "                    elev = True            after : before =      3.6 : 1.0\n",
      "                 complex = True            after : before =      3.5 : 1.0\n",
      "                   blood = True           before : after  =      3.5 : 1.0\n",
      "                   relat = True           before : after  =      3.5 : 1.0\n",
      "                     neg = True           before : after  =      3.5 : 1.0\n",
      "                 univers = True            after : before =      3.3 : 1.0\n",
      "                 primari = True            after : before =      3.3 : 1.0\n",
      "                  despit = True            after : before =      3.3 : 1.0\n",
      "                 prostat = True           before : after  =      3.2 : 1.0\n",
      "                  surviv = True            after : before =      3.1 : 1.0\n",
      "                  system = True            after : before =      3.0 : 1.0\n",
      "                    test = True           before : after  =      3.0 : 1.0\n",
      "                   first = True           before : after  =      2.7 : 1.0\n",
      "                 product = True           before : after  =      2.7 : 1.0\n",
      "                 process = True           before : after  =      2.7 : 1.0\n",
      "                   deriv = True           before : after  =      2.7 : 1.0\n",
      "                 similar = True           before : after  =      2.7 : 1.0\n",
      "                  biolog = True            after : before =      2.6 : 1.0\n",
      "                individu = True            after : before =      2.6 : 1.0\n",
      "                 molecul = True            after : before =      2.6 : 1.0\n",
      "                  improv = True            after : before =      2.6 : 1.0\n",
      "                histolog = True            after : before =      2.6 : 1.0\n",
      "                challeng = True            after : before =      2.6 : 1.0\n",
      "                 exchang = True            after : before =      2.6 : 1.0\n",
      "                  reptil = True            after : before =      2.6 : 1.0\n",
      "                   delay = True            after : before =      2.6 : 1.0\n",
      "                     cdk = True            after : before =      2.6 : 1.0\n",
      "                protocol = True            after : before =      2.6 : 1.0\n",
      "                     mmp = True            after : before =      2.6 : 1.0\n",
      "                antifung = True            after : before =      2.6 : 1.0\n",
      "                    bird = True            after : before =      2.6 : 1.0\n",
      "                   balbc = True            after : before =      2.6 : 1.0\n",
      "                    none = True            after : before =      2.6 : 1.0\n",
      "                     aim = True            after : before =      2.6 : 1.0\n",
      "            glycoprotein = True            after : before =      2.6 : 1.0\n",
      "                bayesian = True            after : before =      2.6 : 1.0\n",
      "            surprisingli = True            after : before =      2.6 : 1.0\n",
      "                  purpos = True            after : before =      2.6 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e3e80ba8>"
      ]
     },
     "execution_count": 70,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "### 3. With one sentence citing + following 3 sentences:\n",
    "\n",
    "#### 3.1 -  All documents\n",
    "\n",
    "train_Naive_Bayes(documents_all_5sentences, list_all_words_5sentences, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 24\n",
      "documents in training_set: \t 98\n",
      "\n",
      "Classifier accuracy percent: 79.16666666666666\n",
      "Most Informative Features\n",
      "      ('subject', 'one') = False           after : before =      1.0 : 1.0\n",
      "         ('find', 'the') = False           after : before =      1.0 : 1.0\n",
      "      ('find', 'appear') = False           after : before =      1.0 : 1.0\n",
      "     ('bago', 'boctopu') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "     ('env', 'glycogag') = False           after : before =      1.0 : 1.0\n",
      "    ('these', 'discrep') = False           after : before =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False           after : before =      1.0 : 1.0\n",
      "        ('sex', 'match') = False           after : before =      1.0 : 1.0\n",
      "   ('contrari', 'becom') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'lost') = False           after : before =      1.0 : 1.0\n",
      "       ('cox', 'cancer') = False           after : before =      1.0 : 1.0\n",
      "     ('variou', 'human') = False           after : before =      1.0 : 1.0\n",
      "('adipos', 'tissuederiv') = False           after : before =      1.0 : 1.0\n",
      "('antitubercular', 'local') = False           after : before =      1.0 : 1.0\n",
      "  ('describ', 'lengthi') = False           after : before =      1.0 : 1.0\n",
      "    ('research', 'also') = False           after : before =      1.0 : 1.0\n",
      "   ('deform', 'regular') = False           after : before =      1.0 : 1.0\n",
      "      ('patient', 'one') = False           after : before =      1.0 : 1.0\n",
      "    ('patient', 'howev') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      " ('collaps', 'individu') = False           after : before =      1.0 : 1.0\n",
      "      ('cell', 'surviv') = False           after : before =      1.0 : 1.0\n",
      "('contribut', 'tumorigenesi') = False           after : before =      1.0 : 1.0\n",
      "      ('report', 'four') = False           after : before =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False           after : before =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False           after : before =      1.0 : 1.0\n",
      "      ('pbmc', 'cultur') = False           after : before =      1.0 : 1.0\n",
      "      ('cycl', 'despit') = False           after : before =      1.0 : 1.0\n",
      "  ('follow', 'supplier') = False           after : before =      1.0 : 1.0\n",
      "      ('hour', 'revers') = False           after : before =      1.0 : 1.0\n",
      "    ('patient', 'uniqu') = False           after : before =      1.0 : 1.0\n",
      "    ('examin', 'neonat') = False           after : before =      1.0 : 1.0\n",
      "     ('either', 'genet') = False           after : before =      1.0 : 1.0\n",
      "      ('ident', 'relat') = False           after : before =      1.0 : 1.0\n",
      " ('statement', 'articl') = False           after : before =      1.0 : 1.0\n",
      "('mirna', 'interestingli') = False           after : before =      1.0 : 1.0\n",
      "    ('paprotka', 'knox') = False           after : before =      1.0 : 1.0\n",
      "      ('sle', 'patient') = False           after : before =      1.0 : 1.0\n",
      "  ('dataset', 'dataset') = False           after : before =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False           after : before =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False           after : before =      1.0 : 1.0\n",
      "         ('xmrv', 'mlv') = False           after : before =      1.0 : 1.0\n",
      "      ('antenn', 'lobe') = False           after : before =      1.0 : 1.0\n",
      "    ('katz', 'giraudet') = False           after : before =      1.0 : 1.0\n",
      "     ('ensur', 'safeti') = False           after : before =      1.0 : 1.0\n",
      "    ('report', 'revolv') = False           after : before =      1.0 : 1.0\n",
      "       ('data', 'studi') = False           after : before =      1.0 : 1.0\n",
      "        ('xfold', 'log') = False           after : before =      1.0 : 1.0\n",
      "    ('whether', 'modul') = False           after : before =      1.0 : 1.0\n",
      "        ('dna', 'abund') = False           after : before =      1.0 : 1.0\n",
      "    ('accumul', 'studi') = False           after : before =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False           after : before =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False           after : before =      1.0 : 1.0\n",
      "        ('viru', 'gain') = False           after : before =      1.0 : 1.0\n",
      "     ('therebi', 'flag') = False           after : before =      1.0 : 1.0\n",
      "      ('buck', 'rennak') = False           after : before =      1.0 : 1.0\n",
      "  ('mass', 'spectromet') = False           after : before =      1.0 : 1.0\n",
      "('toxoplasma', 'gondii') = False           after : before =      1.0 : 1.0\n",
      "   ('confirm', 'observ') = False           after : before =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False           after : before =      1.0 : 1.0\n",
      "('biosynthesi', 'these') = False           after : before =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False           after : before =      1.0 : 1.0\n",
      "       ('figur', 'they') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      " ('hervfrdi', 'essenti') = False           after : before =      1.0 : 1.0\n",
      "    ('howev', 'suffici') = False           after : before =      1.0 : 1.0\n",
      "        ('taq', 'rtpcr') = False           after : before =      1.0 : 1.0\n",
      " ('support', 'function') = False           after : before =      1.0 : 1.0\n",
      "       ('the', 'author') = False           after : before =      1.0 : 1.0\n",
      "         ('msc', 'cell') = False           after : before =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False           after : before =      1.0 : 1.0\n",
      "      ('way', 'increas') = False           after : before =      1.0 : 1.0\n",
      "      ('cell', 'expans') = False           after : before =      1.0 : 1.0\n",
      "('monocyt', 'chemoattract') = False           after : before =      1.0 : 1.0\n",
      " ('provirus', 'amplifi') = False           after : before =      1.0 : 1.0\n",
      "      ('level', 'viral') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      "       ('figur', 'rhoa') = False           after : before =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False           after : before =      1.0 : 1.0\n",
      "      ('shown', 'figur') = False           after : before =      1.0 : 1.0\n",
      "   ('strain', 'genbank') = False           after : before =      1.0 : 1.0\n",
      "      ('gdha', 'clone') = False           after : before =      1.0 : 1.0\n",
      "  ('pacif', 'immunolog') = False           after : before =      1.0 : 1.0\n",
      "     ('neuron', 'these') = False           after : before =      1.0 : 1.0\n",
      "   ('approach', 'indic') = False           after : before =      1.0 : 1.0\n",
      "     ('order', 'combat') = False           after : before =      1.0 : 1.0\n",
      "    ('bootstrap', 'one') = False           after : before =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False           after : before =      1.0 : 1.0\n",
      "('peroxisom', 'proliferatoractiv') = False           after : before =      1.0 : 1.0\n",
      "    ('compar', 'sensit') = False           after : before =      1.0 : 1.0\n",
      "     ('found', 'promot') = False           after : before =      1.0 : 1.0\n",
      "('either', 'xmrvinfect') = False           after : before =      1.0 : 1.0\n",
      "('invitrogen', 'platinum') = False           after : before =      1.0 : 1.0\n",
      "      ('site', 'length') = False           after : before =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False           after : before =      1.0 : 1.0\n",
      "         ('gene', 'set') = False           after : before =      1.0 : 1.0\n",
      "   ('suppress', 'dicer') = False           after : before =      1.0 : 1.0\n",
      "('criteria', 'highlight') = False           after : before =      1.0 : 1.0\n",
      "          ('myc', 'dna') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e1661b38>"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "train_Naive_Bayes(documents_all_5sentences, list_all_bigrams_5sentences, 0.20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 46.15384615384615\n",
      "Most Informative Features\n",
      "                   mirna = True           before : after  =      6.8 : 1.0\n",
      "                interact = True            after : before =      4.9 : 1.0\n",
      "                    base = True            after : before =      4.1 : 1.0\n",
      "                 sequenc = True            after : before =      4.1 : 1.0\n",
      "                directli = True           before : after  =      3.9 : 1.0\n",
      "                    caus = True            after : before =      3.4 : 1.0\n",
      "                   after = True            after : before =      3.4 : 1.0\n",
      "                 current = True            after : before =      3.4 : 1.0\n",
      "                 support = True            after : before =      3.4 : 1.0\n",
      "                 subsequ = True            after : before =      3.4 : 1.0\n",
      "                   major = True            after : before =      3.4 : 1.0\n",
      "                   valid = True            after : before =      3.4 : 1.0\n",
      "                    drug = True            after : before =      3.4 : 1.0\n",
      "                   colon = True           before : after  =      3.3 : 1.0\n",
      "              suppressor = True           before : after  =      3.3 : 1.0\n",
      "                 predict = True            after : before =      2.9 : 1.0\n",
      "                  provid = True            after : before =      2.9 : 1.0\n",
      "                 decreas = True            after : before =      2.9 : 1.0\n",
      "                  number = True            after : before =      2.7 : 1.0\n",
      "                  profil = True           before : after  =      2.7 : 1.0\n",
      "                  togeth = True           before : after  =      2.7 : 1.0\n",
      "                  circul = True           before : after  =      2.7 : 1.0\n",
      "                    mrna = True           before : after  =      2.7 : 1.0\n",
      "                     act = True           before : after  =      2.7 : 1.0\n",
      "                   indic = True           before : after  =      2.7 : 1.0\n",
      "                 oncogen = True           before : after  =      2.7 : 1.0\n",
      "                prolifer = True           before : after  =      2.7 : 1.0\n",
      "             overexpress = True           before : after  =      2.7 : 1.0\n",
      "             biosynthesi = True            after : before =      2.6 : 1.0\n",
      "                  format = True            after : before =      2.6 : 1.0\n",
      "                   anoth = True            after : before =      2.6 : 1.0\n",
      "               transport = True            after : before =      2.6 : 1.0\n",
      "                    form = True            after : before =      2.6 : 1.0\n",
      "                  public = True            after : before =      2.6 : 1.0\n",
      "                   small = True            after : before =      2.6 : 1.0\n",
      "                  replac = True            after : before =      2.6 : 1.0\n",
      "                  combin = True            after : before =      2.6 : 1.0\n",
      "                signatur = True            after : before =      2.6 : 1.0\n",
      "                     rna = True            after : before =      2.6 : 1.0\n",
      "                   serum = True            after : before =      2.6 : 1.0\n",
      "                 contain = True            after : before =      2.6 : 1.0\n",
      "                pancreat = True            after : before =      2.6 : 1.0\n",
      "                   appar = True            after : before =      2.6 : 1.0\n",
      "                  domain = True            after : before =      2.6 : 1.0\n",
      "                   phase = True            after : before =      2.6 : 1.0\n",
      "                  despit = True            after : before =      2.5 : 1.0\n",
      "                  biolog = True            after : before =      2.5 : 1.0\n",
      "                  system = True            after : before =      2.5 : 1.0\n",
      "                 control = True           before : after  =      2.4 : 1.0\n",
      "                   tumor = True           before : after  =      2.4 : 1.0\n",
      "                 previou = True            after : before =      2.4 : 1.0\n",
      "                     use = True            after : before =      2.3 : 1.0\n",
      "                   tissu = True           before : after  =      2.3 : 1.0\n",
      "               downregul = True           before : after  =      2.3 : 1.0\n",
      "                    lead = True           before : after  =      2.3 : 1.0\n",
      "                   human = True           before : after  =      2.2 : 1.0\n",
      "                   sever = True           before : after  =      2.2 : 1.0\n",
      "                     thi = True            after : before =      2.1 : 1.0\n",
      "                   block = True           before : after  =      2.1 : 1.0\n",
      "                  resist = True           before : after  =      2.1 : 1.0\n",
      "                     rel = True           before : after  =      2.1 : 1.0\n",
      "                  wherea = True           before : after  =      2.1 : 1.0\n",
      "                dysregul = True           before : after  =      2.1 : 1.0\n",
      "                   kinas = True           before : after  =      2.1 : 1.0\n",
      "                    head = True           before : after  =      2.1 : 1.0\n",
      "                  stimul = True           before : after  =      2.1 : 1.0\n",
      "                  compon = True           before : after  =      2.1 : 1.0\n",
      "                   relat = True           before : after  =      2.1 : 1.0\n",
      "                     yet = True           before : after  =      2.1 : 1.0\n",
      "                 prevent = True           before : after  =      2.1 : 1.0\n",
      "                    inde = True           before : after  =      2.1 : 1.0\n",
      "            tumorigenesi = True           before : after  =      2.1 : 1.0\n",
      "                prognosi = True           before : after  =      2.1 : 1.0\n",
      "                  migrat = True           before : after  =      2.1 : 1.0\n",
      "                 analysi = True           before : after  =      2.1 : 1.0\n",
      "                 unknown = True           before : after  =      2.1 : 1.0\n",
      "                  mediat = True           before : after  =      2.1 : 1.0\n",
      "                     abl = True           before : after  =      2.1 : 1.0\n",
      "               treatment = True            after : before =      2.1 : 1.0\n",
      "                  repres = True            after : before =      2.1 : 1.0\n",
      "                 complex = True            after : before =      2.1 : 1.0\n",
      "                     via = True            after : before =      2.0 : 1.0\n",
      "                    poor = True            after : before =      2.0 : 1.0\n",
      "                   immun = True            after : before =      2.0 : 1.0\n",
      "                  cultur = True            after : before =      2.0 : 1.0\n",
      "                   chang = True            after : before =      2.0 : 1.0\n",
      "                  glucos = True            after : before =      2.0 : 1.0\n",
      "                  cancer = True           before : after  =      2.0 : 1.0\n",
      "                  promot = True           before : after  =      2.0 : 1.0\n",
      "                 multipl = True           before : after  =      2.0 : 1.0\n",
      "                receptor = True           before : after  =      2.0 : 1.0\n",
      "                    show = True            after : before =      1.9 : 1.0\n",
      "                  effect = True            after : before =      1.9 : 1.0\n",
      "                   known = True           before : after  =      1.9 : 1.0\n",
      "                 context = True            after : before =      1.9 : 1.0\n",
      "                  branch = True            after : before =      1.9 : 1.0\n",
      "               character = True            after : before =      1.9 : 1.0\n",
      "                   local = True            after : before =      1.9 : 1.0\n",
      "                 process = True            after : before =      1.9 : 1.0\n",
      "                    more = True            after : before =      1.9 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e28d96d8>"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 3.2 -  50 % before - 50% after\n",
    "\n",
    "train_Naive_Bayes(documents_50_50_5sentences, list_all_words_50_50_5sentences, 0.20)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 13\n",
      "documents in training_set: \t 51\n",
      "\n",
      "Classifier accuracy percent: 38.46153846153847\n",
      "Most Informative Features\n",
      "      ('subject', 'one') = False           after : before =      1.0 : 1.0\n",
      "      ('find', 'appear') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'lost') = False           after : before =      1.0 : 1.0\n",
      "     ('variou', 'human') = False           after : before =      1.0 : 1.0\n",
      "    ('research', 'also') = False           after : before =      1.0 : 1.0\n",
      "    ('patient', 'howev') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      "      ('cell', 'surviv') = False           after : before =      1.0 : 1.0\n",
      "('contribut', 'tumorigenesi') = False           after : before =      1.0 : 1.0\n",
      "('pathway', 'mammalian') = False           after : before =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False           after : before =      1.0 : 1.0\n",
      "      ('cycl', 'despit') = False           after : before =      1.0 : 1.0\n",
      "  ('follow', 'supplier') = False           after : before =      1.0 : 1.0\n",
      "      ('hour', 'revers') = False           after : before =      1.0 : 1.0\n",
      "    ('examin', 'neonat') = False           after : before =      1.0 : 1.0\n",
      "     ('either', 'genet') = False           after : before =      1.0 : 1.0\n",
      " ('statement', 'articl') = False           after : before =      1.0 : 1.0\n",
      "      ('sle', 'patient') = False           after : before =      1.0 : 1.0\n",
      "  ('dataset', 'dataset') = False           after : before =      1.0 : 1.0\n",
      "('synthes', 'cdpcholin') = False           after : before =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False           after : before =      1.0 : 1.0\n",
      "        ('xfold', 'log') = False           after : before =      1.0 : 1.0\n",
      "    ('whether', 'modul') = False           after : before =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False           after : before =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False           after : before =      1.0 : 1.0\n",
      "     ('therebi', 'flag') = False           after : before =      1.0 : 1.0\n",
      "('toxoplasma', 'gondii') = False           after : before =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False           after : before =      1.0 : 1.0\n",
      "('biosynthesi', 'these') = False           after : before =      1.0 : 1.0\n",
      "    ('system', 'biolog') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      "    ('howev', 'suffici') = False           after : before =      1.0 : 1.0\n",
      " ('support', 'function') = False           after : before =      1.0 : 1.0\n",
      "       ('the', 'author') = False           after : before =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False           after : before =      1.0 : 1.0\n",
      "      ('way', 'increas') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      "       ('figur', 'rhoa') = False           after : before =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False           after : before =      1.0 : 1.0\n",
      "      ('shown', 'figur') = False           after : before =      1.0 : 1.0\n",
      "   ('approach', 'indic') = False           after : before =      1.0 : 1.0\n",
      "     ('order', 'combat') = False           after : before =      1.0 : 1.0\n",
      "    ('bootstrap', 'one') = False           after : before =      1.0 : 1.0\n",
      "   ('cancer', 'paradox') = False           after : before =      1.0 : 1.0\n",
      "   ('suppress', 'dicer') = False           after : before =      1.0 : 1.0\n",
      "  ('although', 'degrad') = False           after : before =      1.0 : 1.0\n",
      "         ('gene', 'set') = False           after : before =      1.0 : 1.0\n",
      "('criteria', 'highlight') = False           after : before =      1.0 : 1.0\n",
      "          ('myc', 'dna') = False           after : before =      1.0 : 1.0\n",
      "     ('upon', 'encount') = False           after : before =      1.0 : 1.0\n",
      "     ('target', 'cdkna') = False           after : before =      1.0 : 1.0\n",
      "('furthermor', 'recent') = False           after : before =      1.0 : 1.0\n",
      " ('catalysi', 'arginin') = False           after : before =      1.0 : 1.0\n",
      "        ('via', 'three') = False           after : before =      1.0 : 1.0\n",
      "       ('barrier', 'dy') = False           after : before =      1.0 : 1.0\n",
      "     ('express', 'mira') = False           after : before =      1.0 : 1.0\n",
      "  ('transmit', 'signal') = False           after : before =      1.0 : 1.0\n",
      "   ('protein', 'includ') = False           after : before =      1.0 : 1.0\n",
      "  ('author', 'demonstr') = False           after : before =      1.0 : 1.0\n",
      "    ('buffer', 'triton') = False           after : before =      1.0 : 1.0\n",
      "    ('member', 'famili') = False           after : before =      1.0 : 1.0\n",
      "    ('hypothesi', 'thi') = False           after : before =      1.0 : 1.0\n",
      "      ('snp', 'rubella') = False           after : before =      1.0 : 1.0\n",
      "     ('longer', 'valid') = False           after : before =      1.0 : 1.0\n",
      "     ('mrna', 'express') = False           after : before =      1.0 : 1.0\n",
      "        ('the', 'first') = False           after : before =      1.0 : 1.0\n",
      "      ('may', 'exacerb') = False           after : before =      1.0 : 1.0\n",
      "      ('term', 'gestat') = False           after : before =      1.0 : 1.0\n",
      "    ('induc', 'insulin') = False           after : before =      1.0 : 1.0\n",
      "     ('safeti', 'point') = False           after : before =      1.0 : 1.0\n",
      "  ('pathway', 'essenti') = False           after : before =      1.0 : 1.0\n",
      "      ('specif', 'role') = False           after : before =      1.0 : 1.0\n",
      "('miniscaffoldin', 'when') = False           after : before =      1.0 : 1.0\n",
      "         ('mice', 'the') = False           after : before =      1.0 : 1.0\n",
      "        ('four', 'time') = False           after : before =      1.0 : 1.0\n",
      "       ('give', 'clear') = False           after : before =      1.0 : 1.0\n",
      "    ('implic', 'breast') = False           after : before =      1.0 : 1.0\n",
      "('factor', 'antiinflammatori') = False           after : before =      1.0 : 1.0\n",
      "   ('warrant', 'especi') = False           after : before =      1.0 : 1.0\n",
      "  ('epicanc', 'mirletc') = False           after : before =      1.0 : 1.0\n",
      "         ('naf', 'navo') = False           after : before =      1.0 : 1.0\n",
      "        ('some', 'evid') = False           after : before =      1.0 : 1.0\n",
      "  ('antimalari', 'drug') = False           after : before =      1.0 : 1.0\n",
      "     ('level', 'variou') = False           after : before =      1.0 : 1.0\n",
      "     ('studi', 'examin') = False           after : before =      1.0 : 1.0\n",
      "     ('antigen', 'pcna') = False           after : before =      1.0 : 1.0\n",
      "('protein', 'differenti') = False           after : before =      1.0 : 1.0\n",
      "      ('model', 'there') = False           after : before =      1.0 : 1.0\n",
      "   ('tight', 'junction') = False           after : before =      1.0 : 1.0\n",
      "      ('effect', 'abil') = False           after : before =      1.0 : 1.0\n",
      " ('sequest', 'selfrepl') = False           after : before =      1.0 : 1.0\n",
      "     ('emt', 'although') = False           after : before =      1.0 : 1.0\n",
      "('contribut', 'discrep') = False           after : before =      1.0 : 1.0\n",
      "        ('studi', 'yet') = False           after : before =      1.0 : 1.0\n",
      "       ('relat', 'drug') = False           after : before =      1.0 : 1.0\n",
      "      ('upregul', 'crc') = False           after : before =      1.0 : 1.0\n",
      "     ('myeloid', 'cell') = False           after : before =      1.0 : 1.0\n",
      " ('signatur', 'predict') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e0af6b38>"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_50_50_5sentences, list_all_bigrams_50_50_5sentences, 0.20)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 66.66666666666666\n",
      "Most Informative Features\n",
      "                 patient = True            after : before =     10.0 : 1.0\n",
      "                    sinc = True            after : before =      7.7 : 1.0\n",
      "                 against = True           before : after  =      7.4 : 1.0\n",
      "                   evalu = True            after : before =      7.1 : 1.0\n",
      "                     via = True            after : before =      7.1 : 1.0\n",
      "                function = True           before : after  =      6.8 : 1.0\n",
      "                    lack = True           before : after  =      6.6 : 1.0\n",
      "                  weight = True           before : after  =      6.6 : 1.0\n",
      "                    gain = True           before : after  =      6.6 : 1.0\n",
      "               discoveri = True           before : after  =      6.6 : 1.0\n",
      "                   alter = True            after : before =      6.0 : 1.0\n",
      "                     dna = True            after : before =      6.0 : 1.0\n",
      "              differenti = True            after : before =      6.0 : 1.0\n",
      "                 endogen = True            after : before =      6.0 : 1.0\n",
      "            particularli = True            after : before =      5.4 : 1.0\n",
      "                  analyz = True            after : before =      5.4 : 1.0\n",
      "                  induct = True            after : before =      5.4 : 1.0\n",
      "                     msc = True            after : before =      5.4 : 1.0\n",
      "                conflict = True            after : before =      5.4 : 1.0\n",
      "                 attempt = True            after : before =      5.4 : 1.0\n",
      "                    fail = True            after : before =      5.4 : 1.0\n",
      "                   these = True           before : after  =      5.1 : 1.0\n",
      "                  togeth = True           before : after  =      5.1 : 1.0\n",
      "                  cultur = True           before : after  =      5.1 : 1.0\n",
      "                 present = True            after : before =      5.0 : 1.0\n",
      "                research = True           before : after  =      4.9 : 1.0\n",
      "                    need = True           before : after  =      4.4 : 1.0\n",
      "                 develop = True           before : after  =      4.3 : 1.0\n",
      "                   deriv = True           before : after  =      4.3 : 1.0\n",
      "                independ = True           before : after  =      4.3 : 1.0\n",
      "                  involv = True           before : after  =      4.3 : 1.0\n",
      "                   sever = True           before : after  =      4.3 : 1.0\n",
      "                  includ = True           before : after  =      4.3 : 1.0\n",
      "                   group = True           before : after  =      4.3 : 1.0\n",
      "                     thi = True            after : before =      4.0 : 1.0\n",
      "                   limit = True           before : after  =      4.0 : 1.0\n",
      "                 protect = True           before : after  =      4.0 : 1.0\n",
      "                therefor = True           before : after  =      3.8 : 1.0\n",
      "                  cancer = True            after : before =      3.7 : 1.0\n",
      "                 potenti = True            after : before =      3.6 : 1.0\n",
      "                    larg = True           before : after  =      3.5 : 1.0\n",
      "                  elicit = True           before : after  =      3.5 : 1.0\n",
      "                    evid = True           before : after  =      3.5 : 1.0\n",
      "                    base = True           before : after  =      3.5 : 1.0\n",
      "                     led = True           before : after  =      3.5 : 1.0\n",
      "                   exist = True           before : after  =      3.5 : 1.0\n",
      "                  system = True           before : after  =      3.5 : 1.0\n",
      "                    wang = True           before : after  =      3.5 : 1.0\n",
      "                    area = True           before : after  =      3.5 : 1.0\n",
      "                  promot = True           before : after  =      3.5 : 1.0\n",
      "                    role = True           before : after  =      3.5 : 1.0\n",
      "                  requir = True           before : after  =      3.5 : 1.0\n",
      "                  depend = True           before : after  =      3.5 : 1.0\n",
      "                  diabet = True            after : before =      3.3 : 1.0\n",
      "                pancreat = True            after : before =      3.3 : 1.0\n",
      "                  measur = True            after : before =      3.3 : 1.0\n",
      "                 subject = True           before : after  =      3.2 : 1.0\n",
      "                  variou = True            after : before =      3.1 : 1.0\n",
      "                  remain = True            after : before =      3.1 : 1.0\n",
      "                  clinic = True            after : before =      3.1 : 1.0\n",
      "                demonstr = True            after : before =      3.1 : 1.0\n",
      "                   toler = True            after : before =      3.1 : 1.0\n",
      "                 unknown = True            after : before =      3.1 : 1.0\n",
      "                  recent = True            after : before =      2.9 : 1.0\n",
      "                 protein = True           before : after  =      2.8 : 1.0\n",
      "                  provid = True            after : before =      2.8 : 1.0\n",
      "                  mechan = True            after : before =      2.8 : 1.0\n",
      "               character = True           before : after  =      2.7 : 1.0\n",
      "                   point = True           before : after  =      2.7 : 1.0\n",
      "                  diseas = True           before : after  =      2.7 : 1.0\n",
      "                 upregul = True           before : after  =      2.7 : 1.0\n",
      "                  promis = True           before : after  =      2.7 : 1.0\n",
      "                     rel = True           before : after  =      2.7 : 1.0\n",
      "                     two = True           before : after  =      2.7 : 1.0\n",
      "                   donor = True           before : after  =      2.7 : 1.0\n",
      "                  elucid = True           before : after  =      2.7 : 1.0\n",
      "                  advanc = True           before : after  =      2.7 : 1.0\n",
      "                  famili = True           before : after  =      2.7 : 1.0\n",
      "               therapeut = True           before : after  =      2.7 : 1.0\n",
      "                  origin = True           before : after  =      2.7 : 1.0\n",
      "                maintain = True           before : after  =      2.7 : 1.0\n",
      "                  intern = True           before : after  =      2.7 : 1.0\n",
      "                  strong = True           before : after  =      2.7 : 1.0\n",
      "                   lower = True           before : after  =      2.7 : 1.0\n",
      "                  achiev = True           before : after  =      2.7 : 1.0\n",
      "             importantli = True           before : after  =      2.7 : 1.0\n",
      "                 highest = True           before : after  =      2.7 : 1.0\n",
      "                 consist = True           before : after  =      2.7 : 1.0\n",
      "                  global = True           before : after  =      2.7 : 1.0\n",
      "                 problem = True           before : after  =      2.7 : 1.0\n",
      "                    idea = True           before : after  =      2.7 : 1.0\n",
      "                    miss = True           before : after  =      2.7 : 1.0\n",
      "                  replac = True           before : after  =      2.7 : 1.0\n",
      "                    obes = True           before : after  =      2.7 : 1.0\n",
      "                  discov = True           before : after  =      2.7 : 1.0\n",
      "                 primari = True           before : after  =      2.7 : 1.0\n",
      "                   paper = True           before : after  =      2.7 : 1.0\n",
      "                 publish = True           before : after  =      2.7 : 1.0\n",
      "                    drug = True           before : after  =      2.7 : 1.0\n",
      "                 suffici = True           before : after  =      2.7 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e14cf358>"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#### 3.3 - Balanced: 50 % before - 50% after. If doi cited before and after same number of documents before are after.\n",
    "\n",
    "train_Naive_Bayes(documents_50_50_balanced_5sentences, list_all_words_50_50_balanced_5sentences, 0.20)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 12\n",
      "documents in training_set: \t 50\n",
      "\n",
      "Classifier accuracy percent: 33.33333333333333\n",
      "Most Informative Features\n",
      "  ('intrigu', 'problem') = False           after : before =      1.0 : 1.0\n",
      "        ('rna', 'cerna') = False           after : before =      1.0 : 1.0\n",
      "      ('subject', 'one') = False           after : before =      1.0 : 1.0\n",
      "      ('find', 'appear') = False           after : before =      1.0 : 1.0\n",
      "    ('insulin', 'level') = False           after : before =      1.0 : 1.0\n",
      "     ('bago', 'boctopu') = False           after : before =      1.0 : 1.0\n",
      "    ('encod', 'process') = False           after : before =      1.0 : 1.0\n",
      " ('analysi', 'supervis') = False           after : before =      1.0 : 1.0\n",
      "       ('figur', 'cell') = False           after : before =      1.0 : 1.0\n",
      "   ('jorissen', 'there') = False           after : before =      1.0 : 1.0\n",
      "       ('approv', 'fda') = False           after : before =      1.0 : 1.0\n",
      "    ('manner', 'differ') = False           after : before =      1.0 : 1.0\n",
      "('streptozotocin', 'stz') = False           after : before =      1.0 : 1.0\n",
      "   ('induc', 'fluoresc') = False           after : before =      1.0 : 1.0\n",
      "  ('protein', 'consist') = False           after : before =      1.0 : 1.0\n",
      "    ('degener', 'these') = False           after : before =      1.0 : 1.0\n",
      "     ('model', 'employ') = False           after : before =      1.0 : 1.0\n",
      "('molecul', 'pharmacolog') = False           after : before =      1.0 : 1.0\n",
      "     ('mice', 'increas') = False           after : before =      1.0 : 1.0\n",
      "('betatrophin', 'angptl') = False           after : before =      1.0 : 1.0\n",
      "    ('cavin', 'patient') = False           after : before =      1.0 : 1.0\n",
      "    ('differ', 'mechan') = False           after : before =      1.0 : 1.0\n",
      "         ('base', 'dna') = False           after : before =      1.0 : 1.0\n",
      "('compound', 'treatment') = False           after : before =      1.0 : 1.0\n",
      "        ('sex', 'match') = False           after : before =      1.0 : 1.0\n",
      "      ('express', 'one') = False           after : before =      1.0 : 1.0\n",
      "     ('factor', 'induc') = False           after : before =      1.0 : 1.0\n",
      "('dataset', 'interestingli') = False           after : before =      1.0 : 1.0\n",
      "      ('appear', 'play') = False           after : before =      1.0 : 1.0\n",
      "    ('identifi', 'mous') = False           after : before =      1.0 : 1.0\n",
      "      ('stop', 'glycin') = False           after : before =      1.0 : 1.0\n",
      "  ('direct', 'interact') = False           after : before =      1.0 : 1.0\n",
      "('circul', 'liverderiv') = False           after : before =      1.0 : 1.0\n",
      "     ('suppress', 'ade') = False           after : before =      1.0 : 1.0\n",
      "  ('diabet', 'although') = False           after : before =      1.0 : 1.0\n",
      "      ('drive', 'cell') = False           after : before =      1.0 : 1.0\n",
      "    ('synthet', 'prion') = False           after : before =      1.0 : 1.0\n",
      "('xanthomona', 'suggest') = False           after : before =      1.0 : 1.0\n",
      "     ('mediat', 'motil') = False           after : before =      1.0 : 1.0\n",
      "         ('acid', 'irb') = False           after : before =      1.0 : 1.0\n",
      "     ('either', 'genet') = False           after : before =      1.0 : 1.0\n",
      "   ('result', 'current') = False           after : before =      1.0 : 1.0\n",
      " ('statement', 'articl') = False           after : before =      1.0 : 1.0\n",
      "('recombin', 'betatrophin') = False           after : before =      1.0 : 1.0\n",
      "          ('cold', 'pb') = False           after : before =      1.0 : 1.0\n",
      "         ('xmrv', 'mlv') = False           after : before =      1.0 : 1.0\n",
      "   ('effect', 'express') = False           after : before =      1.0 : 1.0\n",
      "    ('region', 'pertin') = False           after : before =      1.0 : 1.0\n",
      "       ('abl', 'stimul') = False           after : before =      1.0 : 1.0\n",
      "   ('without', 'direct') = False           after : before =      1.0 : 1.0\n",
      "       ('remain', 'rel') = False           after : before =      1.0 : 1.0\n",
      "      ('retain', 'pten') = False           after : before =      1.0 : 1.0\n",
      "     ('cell', 'attract') = False           after : before =      1.0 : 1.0\n",
      "        ('vitro', 'not') = False           after : before =      1.0 : 1.0\n",
      "        ('lee', 'howev') = False           after : before =      1.0 : 1.0\n",
      "  ('resist', 'hypothes') = False           after : before =      1.0 : 1.0\n",
      "       ('data', 'studi') = False           after : before =      1.0 : 1.0\n",
      "    ('strain', 'togeth') = False           after : before =      1.0 : 1.0\n",
      "      ('rel', 'control') = False           after : before =      1.0 : 1.0\n",
      "       ('limit', 'pool') = False           after : before =      1.0 : 1.0\n",
      "         ('use', 'test') = False           after : before =      1.0 : 1.0\n",
      "   ('cell', 'character') = False           after : before =      1.0 : 1.0\n",
      "     ('dataset', 'both') = False           after : before =      1.0 : 1.0\n",
      "('excitatoryinhibitori', 'balanc') = False           after : before =      1.0 : 1.0\n",
      "      ('buck', 'rennak') = False           after : before =      1.0 : 1.0\n",
      "  ('excess', 'internet') = False           after : before =      1.0 : 1.0\n",
      "   ('public', 'retract') = False           after : before =      1.0 : 1.0\n",
      "('transposon', 'consensus') = False           after : before =      1.0 : 1.0\n",
      "('inhibitor', 'decreas') = False           after : before =      1.0 : 1.0\n",
      "   ('exogen', 'cytokin') = False           after : before =      1.0 : 1.0\n",
      "('nephropathi', 'togeth') = False           after : before =      1.0 : 1.0\n",
      "     ('pdac', 'patient') = False           after : before =      1.0 : 1.0\n",
      " ('longterm', 'consequ') = False           after : before =      1.0 : 1.0\n",
      "    ('normal', 'glucos') = False           after : before =      1.0 : 1.0\n",
      "       ('becom', 'less') = False           after : before =      1.0 : 1.0\n",
      "     ('graft', 'experi') = False           after : before =      1.0 : 1.0\n",
      "      ('mice', 'defici') = False           after : before =      1.0 : 1.0\n",
      " ('understand', 'local') = False           after : before =      1.0 : 1.0\n",
      "  ('stimul', 'adipocyt') = False           after : before =      1.0 : 1.0\n",
      "     ('cavin', 'repres') = False           after : before =      1.0 : 1.0\n",
      "    ('howev', 'suffici') = False           after : before =      1.0 : 1.0\n",
      "     ('found', 'report') = False           after : before =      1.0 : 1.0\n",
      "('hippocampu', 'individu') = False           after : before =      1.0 : 1.0\n",
      "     ('posit', 'associ') = False           after : before =      1.0 : 1.0\n",
      " ('indirectli', 'cell') = False           after : before =      1.0 : 1.0\n",
      "('round', 'immunoclear') = False           after : before =      1.0 : 1.0\n",
      "       ('the', 'author') = False           after : before =      1.0 : 1.0\n",
      "      ('valu', 'improv') = False           after : before =      1.0 : 1.0\n",
      "         ('twice', 'pb') = False           after : before =      1.0 : 1.0\n",
      "      ('way', 'increas') = False           after : before =      1.0 : 1.0\n",
      "     ('report', 'liver') = False           after : before =      1.0 : 1.0\n",
      "  ('human', 'admscsbet') = False           after : before =      1.0 : 1.0\n",
      "  ('patient', 'express') = False           after : before =      1.0 : 1.0\n",
      "('monocyt', 'chemoattract') = False           after : before =      1.0 : 1.0\n",
      "   ('administr', 'sglt') = False           after : before =      1.0 : 1.0\n",
      " ('name', 'betatrophin') = False           after : before =      1.0 : 1.0\n",
      "      ('base', 'report') = False           after : before =      1.0 : 1.0\n",
      "  ('pacif', 'immunolog') = False           after : before =      1.0 : 1.0\n",
      "   ('angptl', 'display') = False           after : before =      1.0 : 1.0\n",
      "   ('approach', 'indic') = False           after : before =      1.0 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3e060d080>"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_Naive_Bayes(documents_50_50_balanced_5sentences, list_all_bigrams_50_50_balanced_5sentences, 0.20)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# %%%%%%%%%%%%%%%%%%%%%%%%%%%%%\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Unsupervised Classification"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'pca_vectors' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m/project/eLife_retractions/unsupervised_classification.ipynb\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mpca_vectors\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'pca_vectors' is not defined"
     ]
    }
   ],
   "source": [
    "df = df_documents_all                  #1.1\n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification.ipynb\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'pca_vectors' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m/project/eLife_retractions/unsupervised_classification.ipynb\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mpca_vectors\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'pca_vectors' is not defined"
     ]
    }
   ],
   "source": [
    "df = df_documents_50_50_balanced       #1.3\n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification.ipynb\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'pca_vectors' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m/project/eLife_retractions/unsupervised_classification.ipynb\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mpca_vectors\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'pca_vectors' is not defined"
     ]
    }
   ],
   "source": [
    "df = df_documents_all_3sentences       #2.1\n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification.ipynb\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'pca_vectors' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m/project/eLife_retractions/unsupervised_classification.ipynb\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mpca_vectors\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'pca_vectors' is not defined"
     ]
    }
   ],
   "source": [
    "df = df_documents_50_50_balanced_3sentences #3.3\n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification.ipynb\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's do a similar analysis using the citation corpus manually annotated by Awais Athar. \n",
    "* Can we distinguish between one type of sentence or another? And let's check later comparing with the sentiment annotated.\n",
    "\n",
    "http://cl.awaisathar.com/citation-sentiment-corpus/"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Source_Paper_ID</th>\n",
       "      <th>Target_Paper_ID</th>\n",
       "      <th>Sentiment</th>\n",
       "      <th>Citation_Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>A00-1043</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>We analyzed a set of articles and identified s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>H05-1033</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Table 3: Example compressions Compression AvgL...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>I05-2009</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>5.3 Related works and discussion Our two-step ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>I05-2009</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>(1999) proposed a summarization system based o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>I05-2009</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>We found that the deletion of lead parts did n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>I08-1016</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Automatic text summarization approaches have o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>I08-2101</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>p</td>\n",
       "      <td>al., 1994), compression of sentences with Auto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>J02-4002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Because of this, it is generally accepted that...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>J02-4004</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Additionally, some research has explored cutti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>J02-4005</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>p</td>\n",
       "      <td>But in fact, the issue of editing in text summ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>J02-4005</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Jing and McKeown (2000) and Jing (2000) propos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>J02-4005</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Our work in sentence reformulation is differen...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>J02-4005</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>n</td>\n",
       "      <td>Jing and McKeown (2000) have proposed a rule-b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>J05-3002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>As previously observed in the literature (Mani...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>J05-3002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>In addition to sentence fusion, compression al...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>J05-3002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>While earlier approaches for text compression ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>J05-3002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>While this approach exploits only syntactic an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>J05-3002</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>In addition to reducing the original sentences...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>W02-0404</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Previous research has addressed revision in si...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>W02-0404</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>To contrast, [Jing &amp; McKeown, 2000] concentrat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>W03-1004</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>1 Introduction Text-to-text generation is an e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>W03-1102</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>p</td>\n",
       "      <td>The recent approach for editing extracted text...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>W09-0604</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>First, splitting and merging of sentences (Jin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>W09-0604</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>1 Introduction The task of sentence compressio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>W09-0604</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>One of the applications is in automatic summar...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>W09-2807</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>In cut-and-paste summarization (Jing and McKeo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>W09-2807</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Close to the problem studied here is Jing and ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>W09-2808</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Jing and McKeown (1999; 2000) found that human...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>W09-2808</td>\n",
       "      <td>A00-2024</td>\n",
       "      <td>o</td>\n",
       "      <td>Like the work of Jing and McKeown (2000) and M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>A00-1026</td>\n",
       "      <td>A92-1018</td>\n",
       "      <td>o</td>\n",
       "      <td>The SPECIALIST minimal commitment parser relie...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8706</th>\n",
       "      <td>W06-1618</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Part-of-speech tags are assigned by the MXPOST...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8707</th>\n",
       "      <td>W06-1666</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>We used a publicly available tagger (Ratnapark...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8708</th>\n",
       "      <td>W06-1701</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Our first model (MA-ME) is based on disambigua...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8709</th>\n",
       "      <td>W06-3327</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>p</td>\n",
       "      <td>2 Method Maximum Entropy Markov Models (MEMMs)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8710</th>\n",
       "      <td>W06-3603</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>We use the same preprocessing steps as Turian ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8711</th>\n",
       "      <td>W06-3603</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Step Description mean stddev % 1.5 Sample 1.5s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8712</th>\n",
       "      <td>W06-3603</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The initial state contains terminal items, who...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8713</th>\n",
       "      <td>W07-1202</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>It uses a log-linear model to define a distrib...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8714</th>\n",
       "      <td>W07-1209</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>So, we pre-tagged the input to the Bikel parse...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8715</th>\n",
       "      <td>W07-1516</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>p</td>\n",
       "      <td>More recent work has achieved state-of-the-art...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8716</th>\n",
       "      <td>W07-2053</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>We use MXPOST tagger (Adwait, 1996) for POS ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8717</th>\n",
       "      <td>W07-2206</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The supertagger uses a log-linear model to def...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8718</th>\n",
       "      <td>W08-0206</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Hw6: Implement beam search and reduplicate the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8719</th>\n",
       "      <td>W08-0206</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>For Hw6, students compared their POS tagging r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8720</th>\n",
       "      <td>W08-0206</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>For instance, for Maximum Entropy, I picked (B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8721</th>\n",
       "      <td>W08-0409</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>We tagged all the sentences in the training an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8722</th>\n",
       "      <td>W08-0611</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>2A maximum-entropy-based part of speech tagger...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8723</th>\n",
       "      <td>W09-0416</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The features we used are as follows:  Direct a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8724</th>\n",
       "      <td>W09-0715</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Using an Maximum Entropy approach to POS taggi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8725</th>\n",
       "      <td>W96-0111</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Ratnaparkhi, 1996), a single inconsistency in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8726</th>\n",
       "      <td>W97-0301</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The maximum entropy models used here are simil...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8727</th>\n",
       "      <td>W97-0301</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The training samples are respectively used to ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8728</th>\n",
       "      <td>W97-0301</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The search also uses a Tag Dictionary construc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8729</th>\n",
       "      <td>W98-1116</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>p</td>\n",
       "      <td>Models that can handle non-independent lexical...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8730</th>\n",
       "      <td>W98-1117</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>Its applications range from sentence boundary ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8731</th>\n",
       "      <td>W98-1118</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>p</td>\n",
       "      <td>He has achieved state-of-the art results by ap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8732</th>\n",
       "      <td>W99-0606</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>B = (Brill and Wu, 1998); M = (Magerman, 1995)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8733</th>\n",
       "      <td>W99-0607</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>The model we use is similar to that of (Ratnap...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8734</th>\n",
       "      <td>W99-0607</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>p</td>\n",
       "      <td>Our model exploits the same kind of tag-n-gram...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8735</th>\n",
       "      <td>W99-0608</td>\n",
       "      <td>W96-0213</td>\n",
       "      <td>o</td>\n",
       "      <td>In that table, TBL stands for Brill's transfor...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>8736 rows  4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Source_Paper_ID Target_Paper_ID Sentiment  \\\n",
       "0           A00-1043        A00-2024         o   \n",
       "1           H05-1033        A00-2024         o   \n",
       "2           I05-2009        A00-2024         o   \n",
       "3           I05-2009        A00-2024         o   \n",
       "4           I05-2009        A00-2024         o   \n",
       "5           I08-1016        A00-2024         o   \n",
       "6           I08-2101        A00-2024         p   \n",
       "7           J02-4002        A00-2024         o   \n",
       "8           J02-4004        A00-2024         o   \n",
       "9           J02-4005        A00-2024         p   \n",
       "10          J02-4005        A00-2024         o   \n",
       "11          J02-4005        A00-2024         o   \n",
       "12          J02-4005        A00-2024         n   \n",
       "13          J05-3002        A00-2024         o   \n",
       "14          J05-3002        A00-2024         o   \n",
       "15          J05-3002        A00-2024         o   \n",
       "16          J05-3002        A00-2024         o   \n",
       "17          J05-3002        A00-2024         o   \n",
       "18          W02-0404        A00-2024         o   \n",
       "19          W02-0404        A00-2024         o   \n",
       "20          W03-1004        A00-2024         o   \n",
       "21          W03-1102        A00-2024         p   \n",
       "22          W09-0604        A00-2024         o   \n",
       "23          W09-0604        A00-2024         o   \n",
       "24          W09-0604        A00-2024         o   \n",
       "25          W09-2807        A00-2024         o   \n",
       "26          W09-2807        A00-2024         o   \n",
       "27          W09-2808        A00-2024         o   \n",
       "28          W09-2808        A00-2024         o   \n",
       "29          A00-1026        A92-1018         o   \n",
       "...              ...             ...       ...   \n",
       "8706        W06-1618        W96-0213         o   \n",
       "8707        W06-1666        W96-0213         o   \n",
       "8708        W06-1701        W96-0213         o   \n",
       "8709        W06-3327        W96-0213         p   \n",
       "8710        W06-3603        W96-0213         o   \n",
       "8711        W06-3603        W96-0213         o   \n",
       "8712        W06-3603        W96-0213         o   \n",
       "8713        W07-1202        W96-0213         o   \n",
       "8714        W07-1209        W96-0213         o   \n",
       "8715        W07-1516        W96-0213         p   \n",
       "8716        W07-2053        W96-0213         o   \n",
       "8717        W07-2206        W96-0213         o   \n",
       "8718        W08-0206        W96-0213         o   \n",
       "8719        W08-0206        W96-0213         o   \n",
       "8720        W08-0206        W96-0213         o   \n",
       "8721        W08-0409        W96-0213         o   \n",
       "8722        W08-0611        W96-0213         o   \n",
       "8723        W09-0416        W96-0213         o   \n",
       "8724        W09-0715        W96-0213         o   \n",
       "8725        W96-0111        W96-0213         o   \n",
       "8726        W97-0301        W96-0213         o   \n",
       "8727        W97-0301        W96-0213         o   \n",
       "8728        W97-0301        W96-0213         o   \n",
       "8729        W98-1116        W96-0213         p   \n",
       "8730        W98-1117        W96-0213         o   \n",
       "8731        W98-1118        W96-0213         p   \n",
       "8732        W99-0606        W96-0213         o   \n",
       "8733        W99-0607        W96-0213         o   \n",
       "8734        W99-0607        W96-0213         p   \n",
       "8735        W99-0608        W96-0213         o   \n",
       "\n",
       "                                          Citation_Text  \n",
       "0     We analyzed a set of articles and identified s...  \n",
       "1     Table 3: Example compressions Compression AvgL...  \n",
       "2     5.3 Related works and discussion Our two-step ...  \n",
       "3     (1999) proposed a summarization system based o...  \n",
       "4     We found that the deletion of lead parts did n...  \n",
       "5     Automatic text summarization approaches have o...  \n",
       "6     al., 1994), compression of sentences with Auto...  \n",
       "7     Because of this, it is generally accepted that...  \n",
       "8     Additionally, some research has explored cutti...  \n",
       "9     But in fact, the issue of editing in text summ...  \n",
       "10    Jing and McKeown (2000) and Jing (2000) propos...  \n",
       "11    Our work in sentence reformulation is differen...  \n",
       "12    Jing and McKeown (2000) have proposed a rule-b...  \n",
       "13    As previously observed in the literature (Mani...  \n",
       "14    In addition to sentence fusion, compression al...  \n",
       "15    While earlier approaches for text compression ...  \n",
       "16    While this approach exploits only syntactic an...  \n",
       "17    In addition to reducing the original sentences...  \n",
       "18    Previous research has addressed revision in si...  \n",
       "19    To contrast, [Jing & McKeown, 2000] concentrat...  \n",
       "20    1 Introduction Text-to-text generation is an e...  \n",
       "21    The recent approach for editing extracted text...  \n",
       "22    First, splitting and merging of sentences (Jin...  \n",
       "23    1 Introduction The task of sentence compressio...  \n",
       "24    One of the applications is in automatic summar...  \n",
       "25    In cut-and-paste summarization (Jing and McKeo...  \n",
       "26    Close to the problem studied here is Jing and ...  \n",
       "27    Jing and McKeown (1999; 2000) found that human...  \n",
       "28    Like the work of Jing and McKeown (2000) and M...  \n",
       "29    The SPECIALIST minimal commitment parser relie...  \n",
       "...                                                 ...  \n",
       "8706  Part-of-speech tags are assigned by the MXPOST...  \n",
       "8707  We used a publicly available tagger (Ratnapark...  \n",
       "8708  Our first model (MA-ME) is based on disambigua...  \n",
       "8709  2 Method Maximum Entropy Markov Models (MEMMs)...  \n",
       "8710  We use the same preprocessing steps as Turian ...  \n",
       "8711  Step Description mean stddev % 1.5 Sample 1.5s...  \n",
       "8712  The initial state contains terminal items, who...  \n",
       "8713  It uses a log-linear model to define a distrib...  \n",
       "8714  So, we pre-tagged the input to the Bikel parse...  \n",
       "8715  More recent work has achieved state-of-the-art...  \n",
       "8716  We use MXPOST tagger (Adwait, 1996) for POS ta...  \n",
       "8717  The supertagger uses a log-linear model to def...  \n",
       "8718  Hw6: Implement beam search and reduplicate the...  \n",
       "8719  For Hw6, students compared their POS tagging r...  \n",
       "8720  For instance, for Maximum Entropy, I picked (B...  \n",
       "8721  We tagged all the sentences in the training an...  \n",
       "8722  2A maximum-entropy-based part of speech tagger...  \n",
       "8723  The features we used are as follows:  Direct a...  \n",
       "8724  Using an Maximum Entropy approach to POS taggi...  \n",
       "8725  Ratnaparkhi, 1996), a single inconsistency in ...  \n",
       "8726  The maximum entropy models used here are simil...  \n",
       "8727  The training samples are respectively used to ...  \n",
       "8728  The search also uses a Tag Dictionary construc...  \n",
       "8729  Models that can handle non-independent lexical...  \n",
       "8730  Its applications range from sentence boundary ...  \n",
       "8731  He has achieved state-of-the art results by ap...  \n",
       "8732  B = (Brill and Wu, 1998); M = (Magerman, 1995)...  \n",
       "8733  The model we use is similar to that of (Ratnap...  \n",
       "8734  Our model exploits the same kind of tag-n-gram...  \n",
       "8735  In that table, TBL stands for Brill's transfor...  \n",
       "\n",
       "[8736 rows x 4 columns]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "df_athar = pd.read_csv('citation_sentiment_corpus.txt', \n",
    "                    sep = '\\t', \n",
    "                    names = [\"Source_Paper_ID\", \n",
    "                             \"Target_Paper_ID\", \n",
    "                             \"Sentiment\",\n",
    "                             \"Citation_Text\"],\n",
    "                    skiprows = 18)\n",
    "df_athar\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Let's look for a balanced dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Same number of positive and negative citing sentences (\"Source_Paper_ID\") for the same cited doi ('Target_Paper_ID')\n",
    "from modules.get_stemmed_sentences_and_list_words import *\n",
    "\n",
    "list_doi_added = []\n",
    "df_athar_balanced_negative_sentences = pd.DataFrame()\n",
    "df_athar_balanced_positive_sentences = pd.DataFrame()\n",
    "df_athar_balanced_neutral_sentences = pd.DataFrame()\n",
    "\n",
    "for doi in df_athar[\"Target_Paper_ID\"].unique():\n",
    "    \n",
    "    df_only_this_cited_doi = df_athar[df_athar[\"Target_Paper_ID\"] == doi]\n",
    "    \n",
    "    df_athar_balanced_all_negative_sentences = df_only_this_cited_doi[df_only_this_cited_doi[\"Sentiment\"] == \"n\"]\n",
    "    df_athar_balanced_all_positive_sentences = df_only_this_cited_doi[df_only_this_cited_doi[\"Sentiment\"] == \"p\"]\n",
    "    df_athar_balanced_all_neutral_sentences = df_only_this_cited_doi[df_only_this_cited_doi[\"Sentiment\"] == \"o\"]\n",
    "    \n",
    "    number_all_negative_sentences = df_athar_balanced_all_negative_sentences.shape[0]\n",
    "    number_all_neutral_sentences = df_athar_balanced_all_neutral_sentences.shape[0]\n",
    "    number_all_positive_sentences = df_athar_balanced_all_positive_sentences.shape[0]\n",
    "    \n",
    "    if  number_all_negative_sentences <= number_all_neutral_sentences:\n",
    "        df_athar_balanced_neutral_sentences = df_athar_balanced_neutral_sentences.append(\n",
    "                                                        df_athar_balanced_all_neutral_sentences[:number_all_negative_sentences]\n",
    "                                                        )\n",
    "        df_athar_balanced_negative_sentences = df_athar_balanced_negative_sentences.append(\n",
    "                                                        df_athar_balanced_all_negative_sentences\n",
    "                                                        )    \n",
    "    else: \n",
    "        df_athar_balanced_negative_sentences = df_athar_balanced_negative_sentences.append(\n",
    "                                                        df_athar_balanced_all_negative_sentences[:number_all_neutral_sentences]\n",
    "                                                        )\n",
    "        df_athar_balanced_neutral_sentences = df_athar_balanced_neutral_sentences.append(\n",
    "                                                        df_athar_balanced_all_neutral_sentences\n",
    "                                                        )    \n",
    "\n",
    "df_athar_documents_50_50_balanced = df_athar_balanced_neutral_sentences.append(df_athar_balanced_negative_sentences)\n",
    "\n",
    "# used for unsupervised\n",
    "athar_sentences_before = df_athar_balanced_neutral_sentences.Citation_Text\n",
    "athar_sentences_after = df_athar_balanced_negative_sentences.Citation_Text\n",
    "\n",
    "(athar_documents_50_50_balanced, athar_list_all_words_50_50_balanced, athar_list_all_bigrams_50_50_balanced) = get_tuple_articles_stemmed_classified_and_list_words(athar_sentences_before, athar_sentences_after)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(276, 4)"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_athar_balanced_negative_sentences.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(552, 4)"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_athar_documents_50_50_balanced.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Using all documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "from modules.get_stemmed_sentences_and_list_words import *\n",
    "#import imp\n",
    "#imp.reload(modules.get_stemmed_sentences_and_list_words)\n",
    "\n",
    "df_athar_negative = df_athar.loc[df_athar['Sentiment'] == \"n\", ['Sentiment','Citation_Text']]\n",
    "df_athar_neutral= df_athar.loc[df_athar['Sentiment'] == \"o\", ['Sentiment','Citation_Text']]#[:df_athar_negative.shape[0]]\n",
    "\n",
    "sentences_neutral = df_athar_neutral.Citation_Text\n",
    "sentences_negative = df_athar_negative.Citation_Text\n",
    "\n",
    "df_documents_athar = df_athar_neutral.append(df_athar_negative)\n",
    "\n",
    "(documents_athar, list_all_words_athar, list_all_bigrams_athar) = get_tuple_articles_stemmed_classified_and_list_words(sentences_neutral, \n",
    "                                                                                                                       sentences_negative,\n",
    "                                                                                                                      'neutral',\n",
    "                                                                                                                      'negative')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Sentiment', 'Citation_Text'], dtype='object')"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_athar_neutral.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(280, 2)"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_athar_negative.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "7627"
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(sentences_neutral)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 1581\n",
      "documents in training_set: \t 6326\n",
      "\n",
      "Classifier accuracy percent: 93.61163820366856\n",
      "Most Informative Features\n",
      "                 kashket = True           negati : neutra =     61.6 : 1.0\n",
      "             sentencebas = True           negati : neutra =     44.0 : 1.0\n",
      "                magnitud = True           negati : neutra =     44.0 : 1.0\n",
      "                mccarley = True           negati : neutra =     44.0 : 1.0\n",
      "                 revisit = True           negati : neutra =     44.0 : 1.0\n",
      "                 overfit = True           negati : neutra =     44.0 : 1.0\n",
      "                    ongo = True           negati : neutra =     44.0 : 1.0\n",
      "              outperform = True           negati : neutra =     39.1 : 1.0\n",
      "                  defici = True           negati : neutra =     37.0 : 1.0\n",
      "              sublanguag = True           negati : neutra =     26.4 : 1.0\n",
      "             rosenschein = True           negati : neutra =     26.4 : 1.0\n",
      "                galleyet = True           negati : neutra =     26.4 : 1.0\n",
      "                kozareva = True           negati : neutra =     26.4 : 1.0\n",
      "          governmentbind = True           negati : neutra =     26.4 : 1.0\n",
      "     nullnullnullnullnul = True           negati : neutra =     26.4 : 1.0\n",
      "                    stsg = True           negati : neutra =     26.4 : 1.0\n",
      "               bestknown = True           negati : neutra =     26.4 : 1.0\n",
      "                untransl = True           negati : neutra =     26.4 : 1.0\n",
      "              examplebas = True           negati : neutra =     26.4 : 1.0\n",
      "                     mrl = True           negati : neutra =     26.4 : 1.0\n",
      "                   usabl = True           negati : neutra =     26.4 : 1.0\n",
      "                   grain = True           negati : neutra =     26.4 : 1.0\n",
      "                    alik = True           negati : neutra =     26.4 : 1.0\n",
      "                    niwa = True           negati : neutra =     26.4 : 1.0\n",
      "         nullnullnullnul = True           negati : neutra =     26.4 : 1.0\n",
      "                  doesnt = True           negati : neutra =     26.4 : 1.0\n",
      "               unrealist = True           negati : neutra =     26.4 : 1.0\n",
      "              thoroughli = True           negati : neutra =     26.4 : 1.0\n",
      "                   avenu = True           negati : neutra =     26.4 : 1.0\n",
      "             wicentowski = True           negati : neutra =     26.4 : 1.0\n",
      "                    suet = True           negati : neutra =     26.4 : 1.0\n",
      "              wordtransl = True           negati : neutra =     26.4 : 1.0\n",
      "                    advp = True           negati : neutra =     26.4 : 1.0\n",
      "               ochandney = True           negati : neutra =     26.4 : 1.0\n",
      "                     hoc = True           negati : neutra =     26.4 : 1.0\n",
      "                  analyt = True           negati : neutra =     26.4 : 1.0\n",
      "                  edmond = True           negati : neutra =     26.4 : 1.0\n",
      "                    exce = True           negati : neutra =     26.4 : 1.0\n",
      "                   sager = True           negati : neutra =     26.4 : 1.0\n",
      "                    poon = True           negati : neutra =     26.4 : 1.0\n",
      "                    lund = True           negati : neutra =     26.4 : 1.0\n",
      "                 freedom = True           negati : neutra =     26.4 : 1.0\n",
      "                 unstabl = True           negati : neutra =     26.4 : 1.0\n",
      "               jayaraman = True           negati : neutra =     26.4 : 1.0\n",
      "                 brought = True           negati : neutra =     26.4 : 1.0\n",
      "                  unansw = True           negati : neutra =     26.4 : 1.0\n",
      "              russolassn = True           negati : neutra =     26.4 : 1.0\n",
      "               traintest = True           negati : neutra =     26.4 : 1.0\n",
      "                 contend = True           negati : neutra =     26.4 : 1.0\n",
      "                   drive = True           negati : neutra =     26.4 : 1.0\n",
      "             nullnullnul = True           negati : neutra =     26.4 : 1.0\n",
      "                     dot = True           negati : neutra =     26.4 : 1.0\n",
      "                   somer = True           negati : neutra =     26.4 : 1.0\n",
      "                   solid = True           negati : neutra =     26.4 : 1.0\n",
      "                  thread = True           negati : neutra =     26.4 : 1.0\n",
      "                    adjp = True           negati : neutra =     26.4 : 1.0\n",
      "                headhead = True           negati : neutra =     26.4 : 1.0\n",
      "                    morc = True           negati : neutra =     26.4 : 1.0\n",
      "           contextdepend = True           negati : neutra =     26.4 : 1.0\n",
      "                  histor = True           negati : neutra =     26.4 : 1.0\n",
      "                    monz = True           negati : neutra =     26.4 : 1.0\n",
      "                     ucb = True           negati : neutra =     26.4 : 1.0\n",
      "                    arti = True           negati : neutra =     26.4 : 1.0\n",
      "               allomorph = True           negati : neutra =     26.4 : 1.0\n",
      "                 finnish = True           negati : neutra =     26.4 : 1.0\n",
      "                   capac = True           negati : neutra =     26.4 : 1.0\n",
      "                   nitta = True           negati : neutra =     26.4 : 1.0\n",
      "               multitext = True           negati : neutra =     26.4 : 1.0\n",
      "               benchmark = True           negati : neutra =     26.4 : 1.0\n",
      "                 burgess = True           negati : neutra =     26.4 : 1.0\n",
      "                download = True           negati : neutra =     26.4 : 1.0\n",
      "                     int = True           negati : neutra =     26.4 : 1.0\n",
      "                  faster = True           negati : neutra =     26.4 : 1.0\n",
      "                   karov = True           negati : neutra =     26.4 : 1.0\n",
      "                   sharp = True           negati : neutra =     26.4 : 1.0\n",
      "                     fox = True           negati : neutra =     26.4 : 1.0\n",
      "                  fairli = True           negati : neutra =     20.5 : 1.0\n",
      "                  behind = True           negati : neutra =     18.9 : 1.0\n",
      "                superior = True           negati : neutra =     18.9 : 1.0\n",
      "                 fluenci = True           negati : neutra =     18.9 : 1.0\n",
      "                maintain = True           negati : neutra =     18.9 : 1.0\n",
      "               wellknown = True           negati : neutra =     18.3 : 1.0\n",
      "                  remain = True           negati : neutra =     17.3 : 1.0\n",
      "                    away = True           negati : neutra =     16.8 : 1.0\n",
      "                  notori = True           negati : neutra =     15.8 : 1.0\n",
      "                     mmr = True           negati : neutra =     15.8 : 1.0\n",
      "                     oov = True           negati : neutra =     15.8 : 1.0\n",
      "                 isozaki = True           negati : neutra =     15.8 : 1.0\n",
      "                    room = True           negati : neutra =     15.8 : 1.0\n",
      "                     ill = True           negati : neutra =     15.8 : 1.0\n",
      "                   optic = True           negati : neutra =     15.8 : 1.0\n",
      "                  jesscm = True           negati : neutra =     15.8 : 1.0\n",
      "               homograph = True           negati : neutra =     15.8 : 1.0\n",
      "                  rogati = True           negati : neutra =     15.8 : 1.0\n",
      "                unexplor = True           negati : neutra =     15.8 : 1.0\n",
      "                 shieber = True           negati : neutra =     15.8 : 1.0\n",
      "                manifest = True           negati : neutra =     15.8 : 1.0\n",
      "                   break = True           negati : neutra =     15.8 : 1.0\n",
      "               insuffici = True           negati : neutra =     15.8 : 1.0\n",
      "                submodel = True           negati : neutra =     15.8 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3d2ce8ef0>"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "train_Naive_Bayes(documents_athar, list_all_words_athar, 0.20)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3d3b46dd8>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3d3b46240>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df = df_documents_athar                \n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification_athar.ipynb"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Using same number neutral  than negative sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 112\n",
      "documents in training_set: \t 448\n",
      "\n",
      "Classifier accuracy percent: 87.5\n",
      "Most Informative Features\n",
      "                     lin = True           neutra : negati =     15.8 : 1.0\n",
      "                     cut = True           neutra : negati =     15.5 : 1.0\n",
      "                   koehn = True           negati : neutra =     14.5 : 1.0\n",
      "                 mckeown = True           neutra : negati =     14.1 : 1.0\n",
      "                   brown = True           negati : neutra =     12.9 : 1.0\n",
      "                  collin = True           negati : neutra =     11.3 : 1.0\n",
      "                 similar = True           neutra : negati =     10.4 : 1.0\n",
      "                    rapp = True           neutra : negati =      8.7 : 1.0\n",
      "                    jing = True           neutra : negati =      8.4 : 1.0\n",
      "                thesauru = True           neutra : negati =      8.1 : 1.0\n",
      "                yarowski = True           negati : neutra =      7.8 : 1.0\n",
      "                     ney = True           negati : neutra =      7.8 : 1.0\n",
      "                although = True           negati : neutra =      7.8 : 1.0\n",
      "              unsupervis = True           negati : neutra =      7.0 : 1.0\n",
      "                     och = True           negati : neutra =      6.9 : 1.0\n",
      "                    show = True           negati : neutra =      6.5 : 1.0\n",
      "                   klein = True           negati : neutra =      6.3 : 1.0\n",
      "                mihalcea = True           neutra : negati =      6.3 : 1.0\n",
      "                   optim = True           negati : neutra =      5.6 : 1.0\n",
      "                 increas = True           negati : neutra =      5.6 : 1.0\n",
      "           stateoftheart = True           negati : neutra =      5.6 : 1.0\n",
      "                  machin = True           negati : neutra =      5.6 : 1.0\n",
      "             ratnaparkhi = True           negati : neutra =      5.1 : 1.0\n",
      "                  measur = True           neutra : negati =      5.1 : 1.0\n",
      "                   reduc = True           neutra : negati =      5.1 : 1.0\n",
      "                   deros = True           neutra : negati =      5.1 : 1.0\n",
      "                 definit = True           neutra : negati =      5.1 : 1.0\n",
      "               phrasebas = True           negati : neutra =      4.9 : 1.0\n",
      "                   howev = True           negati : neutra =      4.9 : 1.0\n",
      "                    deal = True           negati : neutra =      4.8 : 1.0\n",
      "                supervis = True           negati : neutra =      4.8 : 1.0\n",
      "                 current = True           negati : neutra =      4.8 : 1.0\n",
      "                 complex = True           negati : neutra =      4.8 : 1.0\n",
      "                   level = True           negati : neutra =      4.8 : 1.0\n",
      "                treebank = True           negati : neutra =      4.8 : 1.0\n",
      "                  follow = True           neutra : negati =      4.5 : 1.0\n",
      "                   first = True           neutra : negati =      4.5 : 1.0\n",
      "                  reason = True           neutra : negati =      4.5 : 1.0\n",
      "                  vector = True           neutra : negati =      4.5 : 1.0\n",
      "                  tagger = True           neutra : negati =      4.4 : 1.0\n",
      "                   evalu = True           negati : neutra =      4.3 : 1.0\n",
      "                 describ = True           neutra : negati =      4.2 : 1.0\n",
      "                    rate = True           negati : neutra =      4.2 : 1.0\n",
      "                     not = True           negati : neutra =      4.2 : 1.0\n",
      "                 network = True           neutra : negati =      4.1 : 1.0\n",
      "                    lack = True           negati : neutra =      4.1 : 1.0\n",
      "           significantli = True           negati : neutra =      4.1 : 1.0\n",
      "                    high = True           negati : neutra =      4.1 : 1.0\n",
      "                 instead = True           negati : neutra =      4.1 : 1.0\n",
      "                  either = True           negati : neutra =      4.1 : 1.0\n",
      "                  effect = True           negati : neutra =      4.1 : 1.0\n",
      "                  higher = True           negati : neutra =      4.1 : 1.0\n",
      "                judgment = True           negati : neutra =      4.1 : 1.0\n",
      "                 problem = True           negati : neutra =      4.1 : 1.0\n",
      "                    well = True           negati : neutra =      4.0 : 1.0\n",
      "                  parser = True           negati : neutra =      4.0 : 1.0\n",
      "                 summari = True           neutra : negati =      3.9 : 1.0\n",
      "                   defin = True           neutra : negati =      3.9 : 1.0\n",
      "              weischedel = True           neutra : negati =      3.9 : 1.0\n",
      "                 unknown = True           neutra : negati =      3.9 : 1.0\n",
      "                  produc = True           negati : neutra =      3.8 : 1.0\n",
      "                  result = True           negati : neutra =      3.6 : 1.0\n",
      "            partofspeech = True           neutra : negati =      3.5 : 1.0\n",
      "                    text = True           neutra : negati =      3.5 : 1.0\n",
      "               distribut = True           neutra : negati =      3.5 : 1.0\n",
      "                  correl = True           negati : neutra =      3.3 : 1.0\n",
      "                  requir = True           negati : neutra =      3.3 : 1.0\n",
      "                    much = True           negati : neutra =      3.3 : 1.0\n",
      "                charniak = True           negati : neutra =      3.3 : 1.0\n",
      "                question = True           negati : neutra =      3.3 : 1.0\n",
      "                   while = True           negati : neutra =      3.3 : 1.0\n",
      "                  output = True           negati : neutra =      3.3 : 1.0\n",
      "                  colloc = True           negati : neutra =      3.3 : 1.0\n",
      "               bootstrap = True           negati : neutra =      3.3 : 1.0\n",
      "                   still = True           negati : neutra =      3.3 : 1.0\n",
      "               paraphras = True           negati : neutra =      3.3 : 1.0\n",
      "               difficult = True           negati : neutra =      3.3 : 1.0\n",
      "                    must = True           negati : neutra =      3.3 : 1.0\n",
      "                  precis = True           negati : neutra =      3.3 : 1.0\n",
      "               wellknown = True           negati : neutra =      3.3 : 1.0\n",
      "                  resnik = True           neutra : negati =      3.3 : 1.0\n",
      "                 sequenc = True           neutra : negati =      3.3 : 1.0\n",
      "                  integr = True           neutra : negati =      3.3 : 1.0\n",
      "              particular = True           neutra : negati =      3.3 : 1.0\n",
      "                    rule = True           neutra : negati =      3.2 : 1.0\n",
      "                    time = True           negati : neutra =      3.1 : 1.0\n",
      "                    rank = True           neutra : negati =      3.1 : 1.0\n",
      "                    part = True           neutra : negati =      3.1 : 1.0\n",
      "                   limit = True           negati : neutra =      3.0 : 1.0\n",
      "                   train = True           negati : neutra =      2.9 : 1.0\n",
      "                    pang = True           negati : neutra =      2.9 : 1.0\n",
      "                  metric = True           negati : neutra =      2.9 : 1.0\n",
      "              comparison = True           negati : neutra =      2.9 : 1.0\n",
      "                contextu = True           neutra : negati =      2.7 : 1.0\n",
      "                  markov = True           neutra : negati =      2.7 : 1.0\n",
      "                  knight = True           neutra : negati =      2.7 : 1.0\n",
      "                   creat = True           neutra : negati =      2.7 : 1.0\n",
      "                  nation = True           neutra : negati =      2.7 : 1.0\n",
      "                frequenc = True           neutra : negati =      2.7 : 1.0\n",
      "                   anoth = True           neutra : negati =      2.7 : 1.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<nltk.classify.naivebayes.NaiveBayesClassifier at 0x7fc3c62f4668>"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_athar_negative = df_athar.loc[df_athar['Sentiment'] == \"n\", ['Sentiment','Citation_Text']]\n",
    "df_athar_neutral_selection = df_athar.loc[df_athar['Sentiment'] == \"o\", ['Sentiment','Citation_Text']][:df_athar_negative.shape[0]]\n",
    "\n",
    "df_documents_athar_50_50 = df_athar_negative.append(df_athar_neutral_selection)\n",
    "\n",
    "################\n",
    "\n",
    "\"\"\"\n",
    "from modules.get_stemmed_sentences_and_list_words import *\n",
    "import imp\n",
    "imp.reload(modules.get_stemmed_sentences_and_list_words)\n",
    "\"\"\"\n",
    "\n",
    "sentences_neutral = df_athar_neutral_selection.Citation_Text\n",
    "sentences_negative = df_athar_negative.Citation_Text\n",
    "(documents_athar_50_50, list_all_words_athar_50_50, list_all_bigrams_athar_50_50) = get_tuple_articles_stemmed_classified_and_list_words(sentences_neutral, \n",
    "                                                                                                                       sentences_negative,\n",
    "                                                                                                                      'neutral',\n",
    "                                                                                                                      'negative')\n",
    "\n",
    "################\n",
    "\n",
    "\n",
    "\n",
    "train_Naive_Bayes(documents_athar_50_50, list_all_words_athar_50_50, 0.20)\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3c62f49b0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3d3b46208>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df = df_documents_athar_50_50                \n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification_athar.ipynb"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Using balanced dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "documents in test_set: \t 110\n",
      "documents in training_set: \t 442\n",
      "\n",
      "Classifier accuracy percent: 74.54545454545455\n",
      "Most Informative Features\n",
      "                   while = True            after : before =     12.4 : 1.0\n",
      "              outperform = True            after : before =     11.8 : 1.0\n",
      "                 bilingu = True           before : after  =      7.6 : 1.0\n",
      "                although = True            after : before =      7.5 : 1.0\n",
      "                    time = True            after : before =      7.1 : 1.0\n",
      "                 problem = True            after : before =      7.1 : 1.0\n",
      "                 address = True            after : before =      6.4 : 1.0\n",
      "                  correl = True            after : before =      5.7 : 1.0\n",
      "                   small = True            after : before =      5.7 : 1.0\n",
      "                    show = True            after : before =      5.4 : 1.0\n",
      "                advantag = True            after : before =      5.0 : 1.0\n",
      "                    best = True            after : before =      5.0 : 1.0\n",
      "                   match = True           before : after  =      5.0 : 1.0\n",
      "                    noun = True           before : after  =      5.0 : 1.0\n",
      "                    make = True            after : before =      4.4 : 1.0\n",
      "                judgment = True            after : before =      4.4 : 1.0\n",
      "                   motiv = True            after : before =      4.4 : 1.0\n",
      "                   posit = True           before : after  =      4.3 : 1.0\n",
      "                   limit = True            after : before =      4.2 : 1.0\n",
      "                 present = True            after : before =      4.2 : 1.0\n",
      "                   level = True            after : before =      3.8 : 1.0\n",
      "                  provid = True            after : before =      3.8 : 1.0\n",
      "                    lack = True            after : before =      3.7 : 1.0\n",
      "                  rather = True            after : before =      3.7 : 1.0\n",
      "                  origin = True            after : before =      3.7 : 1.0\n",
      "                   singl = True            after : before =      3.7 : 1.0\n",
      "                   three = True            after : before =      3.7 : 1.0\n",
      "                 possibl = True            after : before =      3.7 : 1.0\n",
      "           significantli = True            after : before =      3.7 : 1.0\n",
      "                strategi = True            after : before =      3.7 : 1.0\n",
      "                  factor = True            after : before =      3.7 : 1.0\n",
      "                    hand = True            after : before =      3.7 : 1.0\n",
      "               difficult = True            after : before =      3.7 : 1.0\n",
      "                 instead = True            after : before =      3.7 : 1.0\n",
      "                    less = True            after : before =      3.7 : 1.0\n",
      "                 complex = True            after : before =      3.7 : 1.0\n",
      "                    seem = True            after : before =      3.7 : 1.0\n",
      "                 mckeown = True           before : after  =      3.6 : 1.0\n",
      "                  length = True           before : after  =      3.6 : 1.0\n",
      "               transduct = True           before : after  =      3.6 : 1.0\n",
      "                   updat = True           before : after  =      3.6 : 1.0\n",
      "                    good = True           before : after  =      3.6 : 1.0\n",
      "                  calcul = True           before : after  =      3.6 : 1.0\n",
      "                  riloff = True           before : after  =      3.6 : 1.0\n",
      "                    giza = True           before : after  =      3.6 : 1.0\n",
      "               phrasebas = True            after : before =      3.6 : 1.0\n",
      "                     thi = True            after : before =      3.5 : 1.0\n",
      "                   point = True            after : before =      3.4 : 1.0\n",
      "                    much = True            after : before =      3.4 : 1.0\n",
      "                   exist = True            after : before =      3.4 : 1.0\n",
      "                   natur = True            after : before =      3.4 : 1.0\n",
      "                   refer = True           before : after  =      3.4 : 1.0\n",
      "                   given = True           before : after  =      3.4 : 1.0\n",
      "                     not = True            after : before =      3.4 : 1.0\n",
      "                  better = True            after : before =      3.3 : 1.0\n",
      "                   howev = True            after : before =      3.3 : 1.0\n",
      "                  report = True            after : before =      3.3 : 1.0\n",
      "                    tree = True           before : after  =      3.2 : 1.0\n",
      "                    must = True            after : before =      3.0 : 1.0\n",
      "                   relev = True            after : before =      3.0 : 1.0\n",
      "                 increas = True            after : before =      3.0 : 1.0\n",
      "                    help = True            after : before =      3.0 : 1.0\n",
      "                consider = True            after : before =      3.0 : 1.0\n",
      "                     edg = True            after : before =      3.0 : 1.0\n",
      "                   basic = True            after : before =      3.0 : 1.0\n",
      "                    type = True            after : before =      3.0 : 1.0\n",
      "                    lavi = True            after : before =      3.0 : 1.0\n",
      "                    fact = True            after : before =      3.0 : 1.0\n",
      "                    well = True            after : before =      3.0 : 1.0\n",
      "                 without = True            after : before =      3.0 : 1.0\n",
      "                   typic = True            after : before =      3.0 : 1.0\n",
      "                contrast = True            after : before =      3.0 : 1.0\n",
      "                 potenti = True            after : before =      3.0 : 1.0\n",
      "                 current = True            after : before =      3.0 : 1.0\n",
      "                linguist = True            after : before =      3.0 : 1.0\n",
      "                constitu = True           before : after  =      3.0 : 1.0\n",
      "                 subject = True           before : after  =      3.0 : 1.0\n",
      "                  string = True           before : after  =      3.0 : 1.0\n",
      "                krishnan = True           before : after  =      3.0 : 1.0\n",
      "               framework = True           before : after  =      3.0 : 1.0\n",
      "                   quirk = True           before : after  =      3.0 : 1.0\n",
      "                    news = True           before : after  =      3.0 : 1.0\n",
      "                  averag = True           before : after  =      3.0 : 1.0\n",
      "                    when = True           before : after  =      3.0 : 1.0\n",
      "                stochast = True           before : after  =      3.0 : 1.0\n",
      "                  eisner = True           before : after  =      3.0 : 1.0\n",
      "                investig = True           before : after  =      3.0 : 1.0\n",
      "                   focus = True           before : after  =      3.0 : 1.0\n",
      "                 product = True           before : after  =      3.0 : 1.0\n",
      "                    full = True           before : after  =      3.0 : 1.0\n",
      "                 sequenc = True           before : after  =      3.0 : 1.0\n",
      "                  result = True            after : before =      2.9 : 1.0\n",
      "                   sever = True            after : before =      2.8 : 1.0\n",
      "                   human = True            after : before =      2.7 : 1.0\n",
      "                   studi = True            after : before =      2.7 : 1.0\n",
      "                 classif = True           before : after  =      2.7 : 1.0\n",
      "                 perform = True            after : before =      2.7 : 1.0\n",
      "                question = True            after : before =      2.6 : 1.0\n",
      "                restrict = True            after : before =      2.6 : 1.0\n",
      "                  precis = True           before : after  =      2.6 : 1.0\n"
     ]
    }
   ],
   "source": [
    "model_Naive_Bayes = train_Naive_Bayes(athar_documents_50_50_balanced, athar_list_all_words_50_50_balanced, 0.20)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Stored 'df' (DataFrame)\n"
     ]
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3c6116c18>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fc3c62f4860>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df = df_athar_documents_50_50_balanced                \n",
    "\n",
    "%store df\n",
    "%run unsupervised_classification_athar.ipynb\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's use the model to classify other sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['before', 'before', 'after']\n"
     ]
    }
   ],
   "source": [
    "import imp\n",
    "import sys\n",
    "sys.path.insert(0, \"./modules\")\n",
    "\n",
    "from modules.get_stemmed_sentences_and_list_words import *\n",
    "\n",
    "\n",
    "\n",
    "list_sentences = [\"hidden framework \", \"predict update\",  \"make present\"] #athar_sentences_after[12]\n",
    "list_sentences_tokenized_stemmed = get_stemmed_sentence(list_sentences)\n",
    "\n",
    "all_words_freq = nltk.FreqDist(athar_list_all_words_50_50_balanced)\n",
    "word_features = list(all_words_freq.keys()) # Those are all teh words in the document. Each word is a feature\n",
    "\n",
    "list_features_for_all_sentences = []\n",
    "for sentence in list_sentences_tokenized_stemmed:\n",
    "    features = find_features(sentence, word_features)\n",
    "    list_features_for_all_sentences.append(features)\n",
    "    \n",
    "predicted = model_Naive_Bayes.classify_many(list_features_for_all_sentences)\n",
    "print(predicted)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Let's use the model with the sentences from retraction watch:\n",
    "\n",
    "* Note that we are creating here the features using athar_list_all_words_50_50_balanced. However, to train another agorithm you must use all words from the docuements"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 1.1 -  All documents\n",
    "\n",
    "#YOU CAN USE df_Articles_before_after_retraction instead of sentences = sentences_before + sentences_after\n",
    "sentences_before = df_sentences_before.sentences_citing\n",
    "sentences_after = df_sentences_after.sentences_citing\n",
    "\n",
    "\n",
    "#YOU CAN USE df_Articles_before_after_retraction instead of sentences = sentences_before + sentences_after\n",
    "sentences_before_after = sentences_before.append(sentences_after)\n",
    "\n",
    "#(documents_all, list_all_words, list_all_bigrams) = get_tuple_articles_stemmed_classified_and_list_words(sentences_before, sentences_after)\n",
    "#df_documents_all = df_sentences_before.append(df_sentences_after) # I will used this in unsupervised models\n",
    "\n",
    "list_sentences = sentences_before_after #sentences_after #athar_sentences_after[12]\n",
    "list_sentences_tokenized_stemmed = get_stemmed_sentence(list_sentences)\n",
    "\n",
    "all_words_freq = nltk.FreqDist(athar_list_all_words_50_50_balanced)\n",
    "word_features = list(all_words_freq.keys()) # Those are all teh words in the document. Each word is a feature\n",
    "\n",
    "list_features_for_all_sentences = []\n",
    "for sentence in list_sentences_tokenized_stemmed:\n",
    "    features = find_features(sentence, word_features)\n",
    "    list_features_for_all_sentences.append(features)\n",
    "    \n",
    "predicted = model_Naive_Bayes.classify_many(list_features_for_all_sentences)\n",
    "print(predicted)\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 90 sentences_before(len(sentences_before)): 33 classified as non-criticising (predicted.count('before')); 57 critizising\n",
    "### 32 sentences_after: 8 classified as non-criticising, 24 as critizising\n",
    "\n",
    "### 122 sentences: 41 non-critizising; 81 critizising"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DOI_cited</th>\n",
       "      <th>doi_article_citing</th>\n",
       "      <th>before_retraction</th>\n",
       "      <th>after_retraction</th>\n",
       "      <th>sentences_citing</th>\n",
       "      <th>Naive_Bayes_prediction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1186/s13033-017-0143-5</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1)  Although there has been meaningful debate...</td>\n",
       "      <td>after</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1002/cbin.10291</td>\n",
       "      <td>10.1042/BSR20160174</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>To verify the activation of FOXO1in our model...</td>\n",
       "      <td>after</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   DOI_cited   doi_article_citing  before_retraction  \\\n",
       "0  10.1186/s13033-017-0143-5                  NaN                  0   \n",
       "1         10.1002/cbin.10291  10.1042/BSR20160174                  1   \n",
       "\n",
       "   after_retraction                                   sentences_citing  \\\n",
       "0                 1   1)  Although there has been meaningful debate...   \n",
       "1                 0  To verify the activation of FOXO1in our model...   \n",
       "\n",
       "  Naive_Bayes_prediction  \n",
       "0                  after  \n",
       "1                  after  "
      ]
     },
     "execution_count": 182,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# df_1sentence has the sentences citing for each section\n",
    "# df1sentence_sentences_classification has the sentences citing together. I will use this.\n",
    "\n",
    "df1sentence_sentences_classification_NBayes = df1sentence_sentences_classification\n",
    "\n",
    "list_prediction_NBayes = []\n",
    "for index, row, in df1sentence_sentences_classification_NBayes.iterrows():\n",
    "    #print(row.sentences_citing)\n",
    "    \n",
    "    list_sentences = [row.sentences_citing] #sentences_after #athar_sentences_after[12]\n",
    "    list_sentences_tokenized_stemmed = get_stemmed_sentence(list_sentences)\n",
    "\n",
    "    all_words_freq = nltk.FreqDist(athar_list_all_words_50_50_balanced)\n",
    "    word_features = list(all_words_freq.keys()) # Those are all teh words in the document. Each word is a feature\n",
    "\n",
    "    list_features_for_all_sentences = []\n",
    "    for sentence in list_sentences_tokenized_stemmed:\n",
    "        features = find_features(sentence, word_features)\n",
    "        list_features_for_all_sentences.append(features)\n",
    "\n",
    "    predicted = model_Naive_Bayes.classify_many(list_features_for_all_sentences)\n",
    "    list_prediction_NBayes = list_prediction_NBayes + predicted\n",
    "    #print(index, '\\t', predicted)\n",
    "\n",
    "df1sentence_sentences_classification_NBayes['Naive_Bayes_prediction'] = list_prediction_NBayes\n",
    "\n",
    "df1sentence_sentences_classification_NBayes.head(2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of documents: \n",
      " before_classified_as_non_critizising: \t 33 \n",
      " before_classified_as_critizising: \t 57 \n",
      " after_classified_as_non_critizising: \t 8 \n",
      " after_classified_as_critizising: \t 24\n"
     ]
    }
   ],
   "source": [
    "before_classified_as_non_critizising = list(df1sentence_sentences_classification_NBayes.loc[df1sentence_sentences_classification_NBayes.before_retraction == 1, 'Naive_Bayes_prediction']).count('before')\n",
    "before_classified_as_critizising = list(df1sentence_sentences_classification_NBayes.loc[df1sentence_sentences_classification_NBayes.before_retraction == 1, 'Naive_Bayes_prediction']).count('after')\n",
    "\n",
    "after_classified_as_non_critizising = list(df1sentence_sentences_classification_NBayes.loc[df1sentence_sentences_classification_NBayes.before_retraction == 0, 'Naive_Bayes_prediction']).count('before')\n",
    "after_classified_as_critizising = list(df1sentence_sentences_classification_NBayes.loc[df1sentence_sentences_classification_NBayes.before_retraction == 0, 'Naive_Bayes_prediction']).count('after')\n",
    "\n",
    "print('Number of documents:', \n",
    "      '\\n before_classified_as_non_critizising: \\t', before_classified_as_non_critizising,\n",
    "      '\\n before_classified_as_critizising: \\t', before_classified_as_critizising,\n",
    "      '\\n after_classified_as_non_critizising: \\t', after_classified_as_non_critizising,\n",
    "      '\\n after_classified_as_critizising: \\t', after_classified_as_critizising\n",
    "      )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {},
   "outputs": [],
   "source": [
    "sentences_NBayes_predicts_critizising = (\n",
    "    df1sentence_sentences_classification_NBayes.loc[\n",
    "    df1sentence_sentences_classification_NBayes['Naive_Bayes_prediction'] == 'after',\n",
    "        ['sentences_citing', 'before_retraction']])\n",
    "\n",
    "sentences_NBayes_predicts_non_critizising = (\n",
    "    df1sentence_sentences_classification_NBayes.loc[\n",
    "    df1sentence_sentences_classification_NBayes['Naive_Bayes_prediction'] == 'before',\n",
    "        ['sentences_citing', 'before_retraction']])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>sentences_citing</th>\n",
       "      <th>before_retraction</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>in a S961-induced insulin resistance mouse mod...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>One quite promising study was published recent...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Other recent efforts have described the creati...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Others have shown that incongruence with taxon...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>In cancers, the dysregulation of miRNAs has be...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhi...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Also, several miRNAs have been found to be dir...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Some miRNAs are involved in tumorigenesis by a...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>We also added a  baseline  condition in which ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>Together, these experiments indicate that Ax21...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>There is no direct evidence of a physiological...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>GAMT was identified as a p53 target gene that ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>Together with  let-7c  , both  miR-125  and  m...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>These results are in agreement with those prev...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>Plasmodium falciparum  [  33  ,  34  ]. \\n   ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>It is shown that ketamine can function on opi...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>It is shown that ketamine can function on opi...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>APOC3 could also activate insulin-resistance p...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>Most recently, to add to the confusion, a new ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>A recent report found an association between a...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>This report by Lombardi, et al was followed b...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>detected MLV-related viruses which are distinc...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>that described the existence of sequences clos...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>Curiously, one study described PCR detection o...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>Table 7  Comparison of MLV sequences amplifie...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>More recently, matters were further complicate...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>Lo  , (FDA/CBER, Bethesda, Maryland) reviewed ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>2010  ).    2010  ).</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>As the clinical risks of MSCs due to the use o...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>He et al [  10  ] recently further investigate...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>Besides, according to some studies, S1P is cap...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>Indeed, the range of autoimmune/autoinflammato...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>The essential role of Cited2, a negative regu...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>Similarly, other groups have previously report...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>In a similar approach, Nevins and colleagues ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>Breast Cancer Res  Breast Cancer Research : B...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>The combination of  in vitro  signatures assoc...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>To determine the sensitivity of ovarian cance...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>Preparation of tumor cell lysates (TCLs)  B16...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>In vertebrates, odor mixture interactions were...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>Some vector integrases, such as those for phag...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                      sentences_citing  before_retraction\n",
       "3    in a S961-induced insulin resistance mouse mod...                  1\n",
       "14   One quite promising study was published recent...                  0\n",
       "17   Other recent efforts have described the creati...                  1\n",
       "19   Others have shown that incongruence with taxon...                  1\n",
       "30   In cancers, the dysregulation of miRNAs has be...                  0\n",
       "31    Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhi...                  1\n",
       "32   Also, several miRNAs have been found to be dir...                  1\n",
       "44   Some miRNAs are involved in tumorigenesis by a...                  1\n",
       "55   We also added a  baseline  condition in which ...                  1\n",
       "58   Together, these experiments indicate that Ax21...                  1\n",
       "59   There is no direct evidence of a physiological...                  0\n",
       "60   GAMT was identified as a p53 target gene that ...                  1\n",
       "61   Together with  let-7c  , both  miR-125  and  m...                  1\n",
       "67   These results are in agreement with those prev...                  1\n",
       "68    Plasmodium falciparum  [  33  ,  34  ]. \\n   ...                  1\n",
       "75    It is shown that ketamine can function on opi...                  1\n",
       "80    It is shown that ketamine can function on opi...                  1\n",
       "86   APOC3 could also activate insulin-resistance p...                  1\n",
       "87   Most recently, to add to the confusion, a new ...                  1\n",
       "88   A recent report found an association between a...                  1\n",
       "90    This report by Lombardi, et al was followed b...                  1\n",
       "91   detected MLV-related viruses which are distinc...                  1\n",
       "92   that described the existence of sequences clos...                  1\n",
       "95   Curiously, one study described PCR detection o...                  1\n",
       "97    Table 7  Comparison of MLV sequences amplifie...                  1\n",
       "99   More recently, matters were further complicate...                  1\n",
       "100  Lo  , (FDA/CBER, Bethesda, Maryland) reviewed ...                  1\n",
       "103                               2010  ).    2010  ).                  1\n",
       "106  As the clinical risks of MSCs due to the use o...                  0\n",
       "107  He et al [  10  ] recently further investigate...                  1\n",
       "108  Besides, according to some studies, S1P is cap...                  0\n",
       "110  Indeed, the range of autoimmune/autoinflammato...                  1\n",
       "117   The essential role of Cited2, a negative regu...                  1\n",
       "122  Similarly, other groups have previously report...                  1\n",
       "127   In a similar approach, Nevins and colleagues ...                  1\n",
       "128   Breast Cancer Res  Breast Cancer Research : B...                  0\n",
       "129  The combination of  in vitro  signatures assoc...                  0\n",
       "130   To determine the sensitivity of ovarian cance...                  1\n",
       "132   Preparation of tumor cell lysates (TCLs)  B16...                  0\n",
       "134  In vertebrates, odor mixture interactions were...                  1\n",
       "137  Some vector integrases, such as those for phag...                  1"
      ]
     },
     "execution_count": 194,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences_NBayes_predicts_non_critizising"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " %%%%%%%%%%%%    0    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  \n",
      "      1)\n",
      "     \n",
      "     Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,\n",
      "     \n",
      "      4)\n",
      "     \n",
      "     research has already begun to investigate treatments for the disorder. \n",
      "      1\n",
      "     \n",
      "     \n",
      "     \n",
      "      3)\n",
      "     \n",
      "     In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.  1)  Although there has been meaningful debate as to whether IGD is a formal psychiatric disorder with solid diagnostic criteria,  4)  research has already begun to investigate treatments for the disorder.  1    3)  In a survey of 1,397 Korean people, problematic game use was associated with nicotine use, depressive disorder, and anxiety disorder.\n",
      "\n",
      " %%%%%%%%%%%%    1    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " To verify the activation of FOXO1in our model, we measured mRNA levels of  PIK3C3  and  Sod2  , gene targets of FOXO1 that also encode for autophagy-associated proteins [  47    49  ].   To verify the activation of FOXO1in our model, we measured mRNA levels of  PIK3C3  and  Sod2  , gene targets of FOXO1 that also encode for autophagy-associated proteins [  47    49  ].\n",
      "\n",
      " %%%%%%%%%%%%    2    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ]. Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [\n",
      "     \n",
      "      32\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      33\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ].  Boiling or chlorinating water at the point of use, combined with increased sanitation and hygiene coverage effectively combat diarrhea morbidity and mortality [  32  ,  33  ,  34  ]. The persistent practice of open defecation may have exacerbated the occurrence of diarrheal in the area [  34  ].\n",
      "\n",
      " %%%%%%%%%%%%    5    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ). However, the effects of betatrophin on human islets were not analyzed (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). Betatrophin is a novel -cell mitogen reported by Yi\n",
      "                           \n",
      "                            et al\n",
      "                           \n",
      "                           (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ) that enhances endogenous -cell replication and improves glucose tolerance and insulin secretion following hydrodynamic tail injections of plasmids encoding mouse and human betatrophin into mice with insulin resistance induced by the insulin receptor antagonist, S961. Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ). \n",
      "\n",
      "                           Betatrophin, also known as lipasin (\n",
      "                           \n",
      "                            19\n",
      "                           \n",
      "                           ) or angiopoietin-like 8 (\n",
      "                           \n",
      "                            20\n",
      "                           \n",
      "                           ), was recently described as a potent stimulator of mouse -cell proliferation (\n",
      "                           \n",
      "                            21\n",
      "                           \n",
      "                           ).  Betatrophin, also known as lipasin (  19  ) or angiopoietin-like 8 (  20  ), was recently described as a potent stimulator of mouse -cell proliferation (  21  ). Its transient overexpression in the liver induces -cell proliferation and improves glucose tolerance in young adult mice (  21  ).\n",
      "\n",
      " %%%%%%%%%%%%    6    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  16  However, although these findings are interesting, the receptor for HGF is the protooncogene C-Met, which may pose a problem from a drugability safety point of view.  1  The official name of the gene encoding mouse betatrophin is Gm6484, but it has been annotated a number of times under different names: EG624219  2  ,  3  , RIFL  4  , Lipasin  5  and ANGPTL8.  14  ,  15  These data suggest the existence of a circulating factor induced in glucagon resistant states which can induce -cell proliferation independent of a vagus nerve signal to the pancreas.  Interestingly, it was recently reported that a liver specific glucagon receptor knockout displays increased -cell proliferation and hyperplasia similar to what has been previously reported for the global glucagon receptor knockout,  14  and that wild-type islets transplanted under the kidney capsule of glucagon receptor deficient mice or the liver specific knockout likewise increase their -cell proliferation.  1  ,  19  They confirm, albeit in a NOD-Scid immunodeficient background, that S961 induced insulin resistance results in a marked increase in hepatic betatrophin expression and an increase in the proliferation of the pancreatic -cells. This observationcombined with studies from the same group demonstrating that a liver specific INSR knockout displays a large increase in the pancreatic -cell mass  10  whereas muscle specific INSR knockout has normal glucose metabolism  11  led the authors to suggest the liver as a possible source of the circulating factor.  13  Together, these data provide compelling evidence for a circulating liver-derived factor in insulin resistant mice that is able to induce proliferation of mouse and human -cells.  1  They developed an elegant pharmacological model of insulin resistance utilizing a peptide insulin receptor antagonist, S961, invented by Lauge Schffer at Novo Nordisk A/S  17  which induces severe insulin resistance when infused in mice.  12  The observation that a liver-specific INSR knockout (the LIRKO mouse) results in increased -cell mass was further studied by the group of Rohit N. Kulkarni: they used a parabiotic model where the circulation of mice is coupled by surgery thus allowing the study of the effect of circulating factors between mice of different genotypes.  18  To investigate the effect of betatrophin in vivo  ,  expression in the liver was achieved by hydrodynamic tail injection of expression plasmids encoding mouse and human betatrophin.  1  did not investigate the effect of betatrophin on triglycerides, the consequence of loss-of-function of betatrophin on -cell mass and glucose homeostasis, or the dependence of the effect on ANGPTL3.  13  Importantly, it was also shown that serum from LIRKO mice was able to induce specific -cell replication in wild-type mice by interperitoneal serum injection and that LIRKO serum could increase mouse and human -cell replication rates in vitro.  13  It was further shown that wild-type islets transplanted into the kidney capsule of LIRKO mice also increased their proliferation rate demonstrating that the effect on proliferation is uncoupled from the vagus innervation of the pancreas in this model.    16  However, although these findings are interesting, the receptor for HGF is the protooncogene C-Met, which may pose a problem from a drugability safety point of view.  1  The official name of the gene encoding mouse betatrophin is Gm6484, but it has been annotated a number of times under different names: EG624219  2  ,  3  , RIFL  4  , Lipasin  5  and ANGPTL8.  14  ,  15  These data suggest the existence of a circulating factor induced in glucagon resistant states which can induce -cell proliferation independent of a vagus nerve signal to the pancreas.  Interestingly, it was recently reported that a liver specific glucagon receptor knockout displays increased -cell proliferation and hyperplasia similar to what has been previously reported for the global glucagon receptor knockout,  14  and that wild-type islets transplanted under the kidney capsule of glucagon receptor deficient mice or the liver specific knockout likewise increase their -cell proliferation.  1  ,  19  They confirm, albeit in a NOD-Scid immunodeficient background, that S961 induced insulin resistance results in a marked increase in hepatic betatrophin expression and an increase in the proliferation of the pancreatic -cells. This observationcombined with studies from the same group demonstrating that a liver specific INSR knockout displays a large increase in the pancreatic -cell mass  10  whereas muscle specific INSR knockout has normal glucose metabolism  11  led the authors to suggest the liver as a possible source of the circulating factor.  13  Together, these data provide compelling evidence for a circulating liver-derived factor in insulin resistant mice that is able to induce proliferation of mouse and human -cells.  1  They developed an elegant pharmacological model of insulin resistance utilizing a peptide insulin receptor antagonist, S961, invented by Lauge Schffer at Novo Nordisk A/S  17  which induces severe insulin resistance when infused in mice.  12  The observation that a liver-specific INSR knockout (the LIRKO mouse) results in increased -cell mass was further studied by the group of Rohit N. Kulkarni: they used a parabiotic model where the circulation of mice is coupled by surgery thus allowing the study of the effect of circulating factors between mice of different genotypes.  18  To investigate the effect of betatrophin in vivo  ,  expression in the liver was achieved by hydrodynamic tail injection of expression plasmids encoding mouse and human betatrophin.  1  did not investigate the effect of betatrophin on triglycerides, the consequence of loss-of-function of betatrophin on -cell mass and glucose homeostasis, or the dependence of the effect on ANGPTL3.  13  Importantly, it was also shown that serum from LIRKO mice was able to induce specific -cell replication in wild-type mice by interperitoneal serum injection and that LIRKO serum could increase mouse and human -cell replication rates in vitro.  13  It was further shown that wild-type islets transplanted into the kidney capsule of LIRKO mice also increased their proliferation rate demonstrating that the effect on proliferation is uncoupled from the vagus innervation of the pancreas in this model.\n",
      "\n",
      " %%%%%%%%%%%%    7    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ]. Because SGLT2 inhibitors decrease insulin levels [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], and because circulating betatrophin levels were remarkably elevated by administration of an insulin receptor blocker resulting in liver insulin resistance [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], we hypothesized that administration of SGLT2 inhibitors, such as canagliflozin, may increase circulating betatrophin levels and therefore may influence serum lipid concentrations. The reason for the potentially positive association between betatrophin and glycemic control as evaluated by HbA1c or FPG remains unclear since the effect of betatrophin on regeneration of pancreatic  cells which was previously reported [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ] is currently considered to be negative [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [\n",
      "     \n",
      "      4\n",
      "     \n",
      "     ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [\n",
      "     \n",
      "      14\n",
      "     \n",
      "     ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. The production of betatrophin in the liver is greatly enhanced under insulin resistance caused by the administration of an insulin receptor blocker [  4  ], and therefore it may be theologically possible that the agents which can decrease circulating insulin levels, such as sodium glucose transporter 2 (SGLT2) inhibitors [  14  ], increase circulating betatrophin levels, resulting in the change of serum lipids levels. A previously reported effect of betatrophin on regeneration of pancreatic  cells is currently considered to be negative [  4  -  8  ].\n",
      "\n",
      " %%%%%%%%%%%%    8    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  OTHER FACTORS  Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,  2013  ).  \n",
      "\n",
      "\n",
      "\n",
      "         OTHER FACTORS\n",
      "        \n",
      "\n",
      "         Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,\n",
      "         \n",
      "          2013\n",
      "         \n",
      "         ).  OTHER FACTORS  Betatrophin has been shown to induce -cell proliferation in a mouse model of insulin resistance on the basis of gain-of-function evidence derived from over-expression of betatrophin in the mouse liver (Yi et al.,  2013  ).\n",
      "\n",
      " %%%%%%%%%%%%    9    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Another example is the Akt signaling cascade (\n",
      "        \n",
      "         32\n",
      "        \n",
      "        ) or the overexpression of human epidermal growth factor receptor-2/neu tyrosine kinase.  \n",
      "\n",
      " %%%%%%%%%%%%    11    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Although the exact mechanism, by which PTEN4A could block TGF-induced -catenin translocation from the cell membrane into the cytoplasm, remains elusive, a previous study has suggested that phosphorylation of -catenin might induce its translocation via dissociation from E-cadherin complexes [\n",
      "      \n",
      "       50\n",
      "      \n",
      "      ].  \n",
      "\n",
      " %%%%%%%%%%%%    13    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  \n",
      "     34)\n",
      "    \n",
      "    Results from our previous study\n",
      "    \n",
      "     19)\n",
      "    \n",
      "    showed that marked increases in astrocyte number and level of GFAP expression in the PND 21 frontal cortex after postnatal VPA treatment.  \n",
      "\n",
      " %%%%%%%%%%%%    15    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].   Additionally, studies conducted by Xiang et al., showed that PDAC patients with mutant  TP  53  R172H  and upregulated CAVIN1 represented the patient group with the shortest survival time after resection [  115  ].\n",
      "\n",
      " %%%%%%%%%%%%    16    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [  31  ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [  31  ] created a strain of  B. subtilis  able to grow on untreated natural feedstocks through expression of  C. cellulolyticum  Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin. Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ] created a strain of\n",
      "      \n",
      "       B. subtilis\n",
      "      \n",
      "      able to grow on untreated natural feedstocks through expression of\n",
      "      \n",
      "       C. cellulolyticum\n",
      "      \n",
      "      Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin.  Although degradation of lignocellulose has been shown to be possible with minicellulosomes containing only three enzymes [  31  ], should we wish to increase the complexity of our minicellulosomes in the future, we may have to examine ways of increasing the stability, for example, by examining the effects of different 5 mRNA leader sequences, or by engineering the sequence to reduce homology. [  31  ] created a strain of  B. subtilis  able to grow on untreated natural feedstocks through expression of  C. cellulolyticum  Cel5A, Cel9E, and Cel48F, an endoglucanase/xylanase, endoglucanase/exoglucanase, and a processive endoglucanase respectively, in combination with a cell wall-associated mini-scaffoldin.\n",
      "\n",
      " %%%%%%%%%%%%    18    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].   One of the intriguing problems discussed included magnetic effects such as the giant, low field magnetoresistance observed at room temperature in organic nanowires presented by Wilfred van der Wiel [  1  ].\n",
      "\n",
      " %%%%%%%%%%%%    22    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " RhoA has been reported to be one of the targets of miR-31 in breast cancer [  10  ], and plays an important role as a molecular switch in transducing extracellular signals to actin and microtubule cytoskeleton [  11  ].   RhoA has been reported to be one of the targets of miR-31 in breast cancer [  10  ], and plays an important role as a molecular switch in transducing extracellular signals to actin and microtubule cytoskeleton [  11  ].\n",
      "\n",
      " %%%%%%%%%%%%    23    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [  3  ,  4  ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [  5  -  9  ]. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [  32  ] and pro-metastatic [  5  ,  6  ] or anti-metastatic functions [  9  ] have been identified. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [\n",
      "      \n",
      "       32\n",
      "      \n",
      "      ] and pro-metastatic [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ] or anti-metastatic functions [\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ] have been identified. The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      -\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ]. The abnormal expression profiles of miRNAs have been examined in many different cancers including breast cancer [  3  ,  4  ] and their roles in the proliferation, apoptosis, invasion/metastasis and angiogenesis of normal and cancer cells are being investigated aggressively [  5  -  9  ]. Many miRNAs that regulate epithelial to mesenchymal transition (EMT) [  32  ] and pro-metastatic [  5  ,  6  ] or anti-metastatic functions [  9  ] have been identified.\n",
      "\n",
      " %%%%%%%%%%%%    24    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Recently, miRNAs have been shown to play a role in invasion and metastasis [  11  -  15  ].  \n",
      "\n",
      "      Recently, miRNAs have been shown to play a role in invasion and metastasis [\n",
      "      \n",
      "       11\n",
      "      \n",
      "      -\n",
      "      \n",
      "       15\n",
      "      \n",
      "      ].  Recently, miRNAs have been shown to play a role in invasion and metastasis [  11  -  15  ].\n",
      "\n",
      " %%%%%%%%%%%%    25    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [  17  ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [  18  ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [  6  -  10  ], head and neck squamous cell carcinoma (HNSCC) [  11  ], hepatocellular carcinoma [  12  ], squamous cell carcinoma of tongue [  13  ], and lung cancer [  14  ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [  2  ], prostate cancer [  15  ], gastric cancer [  16  ], breast cancer [  17  ], and serous ovarian cancer [  18  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation  in vitro  [  17  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [\n",
      "      \n",
      "       18\n",
      "      \n",
      "      ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ], head and neck squamous cell carcinoma (HNSCC) [\n",
      "      \n",
      "       11\n",
      "      \n",
      "      ], hepatocellular carcinoma [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ], squamous cell carcinoma of tongue [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ], and lung cancer [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ], prostate cancer [\n",
      "      \n",
      "       15\n",
      "      \n",
      "      ], gastric cancer [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ], breast cancer [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ], and serous ovarian cancer [\n",
      "      \n",
      "       18\n",
      "      \n",
      "      ]. Recent studies have shown that miR-31 expression is specifically attenuated in metastatic breast cancer cell lines and miR-31 inhibits breast cancer metastasis by targeting multiple genes [  17  ]; miR-31 is underexpressed in serous ovarian carcinomas, and in a number of serous cancer cell lines with a dysfunctional p53 pathway (OVCAR8, OVCA433, and SKOV3), miR-31 overexpression inhibits proliferation and induces apoptosis; however, in other lines with functional p53 (HEY and OVSAYO), miR-31 has no effect [  18  ]. More and more evidence shows that miR-31 has different expression pattern in different cancers: it is up-regulated in colorectal cancer (CRC) [  6  -  10  ], head and neck squamous cell carcinoma (HNSCC) [  11  ], hepatocellular carcinoma [  12  ], squamous cell carcinoma of tongue [  13  ], and lung cancer [  14  ]; but it is down-regulated in invasive urothelial carcinoma of the bladder [  2  ], prostate cancer [  15  ], gastric cancer [  16  ], breast cancer [  17  ], and serous ovarian cancer [  18  ]. On the other hand, overexpression of miR-31 suppresses metastasis in breast cancer cell lines, and does not affect proliferation  in vitro  [  17  ].\n",
      "\n",
      " %%%%%%%%%%%%    26    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  H3K9Ac ChIP  L v P  p  L v 5Aza  p  P v 5Aza  p  Epi./Cancer  MIRLET7c  21  +  34.26  -0.14  3.07  54.948  *  0.986  1.505  -/[  33  ]  MIR141  12  +  7.2  -0.46  4.31  2.928  *  2.235  *  1.110  [  34  ]  MIR15b  3  +  11.41  -4.65  -4.02  2.071  *  0.616  0.986  -/[  35  ]  MIR16-2  3  +  10.52  -3.6  -2.54  2.713  *  1.424  *  0.742  -/[  36  ]  MIR423  17  +  8.91  -0.81  2.39  4.857  *  0.774  2.445  *  -/[  37  ]  MIR491  9  +  9.03  -2.08  0.83  5.352  *  1.117  1.301  -/[  38  ]  MIR615  12  +  4.03  -3.45  5.5  1.9E+03  *  1.231  32.672  *  -/-  MIR618  12  -  4.18  2.44  5.73  4.1E+02  *  1.945  *  1.385  -/[  39  ]  MIR99a  21  +  26.52  -2.9  3.72  2.329  *  1.035  0.908  -/[  40  ]  MIR130a  11  +  -7.19  -1.92  -3.85  0.004  *  2.532  *  1.102  -/[  41  ]  MIR135b  1  -  -3.93  2.8  -7.82  0.003  *  0.337  1.828  -/[  42  ]  MIR137  1  -  -3.81  1.19  -3.41  0.016  *  2.173  5.897  [  43  ]  MIR196b  7  -  -11.26  2.07  -5.05  0.356  *  1.591  *  0.829  [  21  ]/[  44  ]  MIR205  1  +  -26.47  2.37  -12.09  1.2E-05  *  1.1E+02  *  1.659  [  13  ]/[  15  ]  MIR21  17  +  -21.68  13.78  -12.98  0.637  *  2.362  *  3.272  *  [  19  ]/[  18  ]  MIR24-1  9  +  -5.64  3.73  -0.27  0.057  *  1.569  *  1.231  -/[  45  ]  MIR31  9  -  -2.79  -9.75  -3.04  1.7E-06  *  1.357  0.959  -/[  46  ]  MIR376a-2  14  +  -5.98  2.96  2.59  0.020  *  4.857  2.888  -/[  47  ]  MIR424  X  -  -3.94  1.95  -2.56  0.259  *  0.883  4.287  *  -/[  39  ]  MIR654  14  +  -5.42  2.57  4.14  0.136  *  1.357  0.295  *  -/-  Table listing significantly changed miRNA genes identified in this study. \n",
      "\n",
      "\n",
      "           H3K9Ac ChIP\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           L v P\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           L v 5Aza\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           P v 5Aza\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           p\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "           Epi./Cancer\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIRLET7c\n",
      "          \n",
      "\n",
      "\n",
      "          21\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          34.26\n",
      "         \n",
      "\n",
      "          -0.14\n",
      "         \n",
      "\n",
      "          3.07\n",
      "         \n",
      "\n",
      "          54.948\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.986\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.505\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           33\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR141\n",
      "          \n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          7.2\n",
      "         \n",
      "\n",
      "          -0.46\n",
      "         \n",
      "\n",
      "          4.31\n",
      "         \n",
      "\n",
      "          2.928\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.235\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.110\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           34\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR15b\n",
      "          \n",
      "\n",
      "\n",
      "          3\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          11.41\n",
      "         \n",
      "\n",
      "          -4.65\n",
      "         \n",
      "\n",
      "          -4.02\n",
      "         \n",
      "\n",
      "          2.071\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.616\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.986\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           35\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR16-2\n",
      "          \n",
      "\n",
      "\n",
      "          3\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          10.52\n",
      "         \n",
      "\n",
      "          -3.6\n",
      "         \n",
      "\n",
      "          -2.54\n",
      "         \n",
      "\n",
      "          2.713\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.424\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.742\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR423\n",
      "          \n",
      "\n",
      "\n",
      "          17\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          8.91\n",
      "         \n",
      "\n",
      "          -0.81\n",
      "         \n",
      "\n",
      "          2.39\n",
      "         \n",
      "\n",
      "          4.857\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.774\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          2.445\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/[\n",
      "          \n",
      "           37\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR491\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          9.03\n",
      "         \n",
      "\n",
      "          -2.08\n",
      "         \n",
      "\n",
      "          0.83\n",
      "         \n",
      "\n",
      "          5.352\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.117\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.301\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           38\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR615\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          4.03\n",
      "         \n",
      "\n",
      "          -3.45\n",
      "         \n",
      "\n",
      "          5.5\n",
      "         \n",
      "\n",
      "          1.9E+03\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.231\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          32.672\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/-\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR618\n",
      "          \n",
      "\n",
      "\n",
      "          12\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          4.18\n",
      "         \n",
      "\n",
      "          2.44\n",
      "         \n",
      "\n",
      "          5.73\n",
      "         \n",
      "\n",
      "          4.1E+02\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.945\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.385\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           39\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR99a\n",
      "          \n",
      "\n",
      "\n",
      "          21\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          26.52\n",
      "         \n",
      "\n",
      "          -2.9\n",
      "         \n",
      "\n",
      "          3.72\n",
      "         \n",
      "\n",
      "          2.329\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.035\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.908\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           40\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR130a\n",
      "          \n",
      "\n",
      "\n",
      "          11\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -7.19\n",
      "         \n",
      "\n",
      "          -1.92\n",
      "         \n",
      "\n",
      "          -3.85\n",
      "         \n",
      "\n",
      "          0.004\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.532\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.102\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           41\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR135b\n",
      "          \n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.93\n",
      "         \n",
      "\n",
      "          2.8\n",
      "         \n",
      "\n",
      "          -7.82\n",
      "         \n",
      "\n",
      "          0.003\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.337\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          1.828\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           42\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR137\n",
      "          \n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.81\n",
      "         \n",
      "\n",
      "          1.19\n",
      "         \n",
      "\n",
      "          -3.41\n",
      "         \n",
      "\n",
      "          0.016\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.173\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          5.897\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           43\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR196b\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          7\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -11.26\n",
      "         \n",
      "\n",
      "          2.07\n",
      "         \n",
      "\n",
      "          -5.05\n",
      "         \n",
      "\n",
      "          0.356\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.591\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.829\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           21\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           44\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR205\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          1\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -26.47\n",
      "         \n",
      "\n",
      "          2.37\n",
      "         \n",
      "\n",
      "          -12.09\n",
      "         \n",
      "\n",
      "          1.2E-05\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.1E+02\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.659\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          [\n",
      "          \n",
      "           13\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           15\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "            MIR21\n",
      "           \n",
      "\n",
      "\n",
      "\n",
      "          17\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -21.68\n",
      "         \n",
      "\n",
      "          13.78\n",
      "         \n",
      "\n",
      "          -12.98\n",
      "         \n",
      "\n",
      "          0.637\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          2.362\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          3.272\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          [\n",
      "          \n",
      "           19\n",
      "          \n",
      "          ]/[\n",
      "          \n",
      "           18\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR24-1\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.64\n",
      "         \n",
      "\n",
      "          3.73\n",
      "         \n",
      "\n",
      "          -0.27\n",
      "         \n",
      "\n",
      "          0.057\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.569\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.231\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           45\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR31\n",
      "          \n",
      "\n",
      "\n",
      "          9\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -2.79\n",
      "         \n",
      "\n",
      "          -9.75\n",
      "         \n",
      "\n",
      "          -3.04\n",
      "         \n",
      "\n",
      "          1.7E-06\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.357\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.959\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           46\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR376a-2\n",
      "          \n",
      "\n",
      "\n",
      "          14\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.98\n",
      "         \n",
      "\n",
      "          2.96\n",
      "         \n",
      "\n",
      "          2.59\n",
      "         \n",
      "\n",
      "          0.020\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          4.857\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          2.888\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          -/[\n",
      "          \n",
      "           47\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR424\n",
      "          \n",
      "\n",
      "\n",
      "          X\n",
      "         \n",
      "\n",
      "          -\n",
      "         \n",
      "\n",
      "          -3.94\n",
      "         \n",
      "\n",
      "          1.95\n",
      "         \n",
      "\n",
      "          -2.56\n",
      "         \n",
      "\n",
      "          0.259\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          0.883\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          4.287\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/[\n",
      "          \n",
      "           39\n",
      "          \n",
      "          ]\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "           MIR654\n",
      "          \n",
      "\n",
      "\n",
      "          14\n",
      "         \n",
      "\n",
      "          +\n",
      "         \n",
      "\n",
      "          -5.42\n",
      "         \n",
      "\n",
      "          2.57\n",
      "         \n",
      "\n",
      "          4.14\n",
      "         \n",
      "\n",
      "          0.136\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          1.357\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "          0.295\n",
      "         \n",
      "\n",
      "          *\n",
      "         \n",
      "\n",
      "          -/-\n",
      "         \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "        Table listing significantly changed miRNA genes identified in this study.   H3K9Ac ChIP  L v P  p  L v 5Aza  p  P v 5Aza  p  Epi./Cancer  MIRLET7c  21  +  34.26  -0.14  3.07  54.948  *  0.986  1.505  -/[  33  ]  MIR141  12  +  7.2  -0.46  4.31  2.928  *  2.235  *  1.110  [  34  ]  MIR15b  3  +  11.41  -4.65  -4.02  2.071  *  0.616  0.986  -/[  35  ]  MIR16-2  3  +  10.52  -3.6  -2.54  2.713  *  1.424  *  0.742  -/[  36  ]  MIR423  17  +  8.91  -0.81  2.39  4.857  *  0.774  2.445  *  -/[  37  ]  MIR491  9  +  9.03  -2.08  0.83  5.352  *  1.117  1.301  -/[  38  ]  MIR615  12  +  4.03  -3.45  5.5  1.9E+03  *  1.231  32.672  *  -/-  MIR618  12  -  4.18  2.44  5.73  4.1E+02  *  1.945  *  1.385  -/[  39  ]  MIR99a  21  +  26.52  -2.9  3.72  2.329  *  1.035  0.908  -/[  40  ]  MIR130a  11  +  -7.19  -1.92  -3.85  0.004  *  2.532  *  1.102  -/[  41  ]  MIR135b  1  -  -3.93  2.8  -7.82  0.003  *  0.337  1.828  -/[  42  ]  MIR137  1  -  -3.81  1.19  -3.41  0.016  *  2.173  5.897  [  43  ]  MIR196b  7  -  -11.26  2.07  -5.05  0.356  *  1.591  *  0.829  [  21  ]/[  44  ]  MIR205  1  +  -26.47  2.37  -12.09  1.2E-05  *  1.1E+02  *  1.659  [  13  ]/[  15  ]  MIR21  17  +  -21.68  13.78  -12.98  0.637  *  2.362  *  3.272  *  [  19  ]/[  18  ]  MIR24-1  9  +  -5.64  3.73  -0.27  0.057  *  1.569  *  1.231  -/[  45  ]  MIR31  9  -  -2.79  -9.75  -3.04  1.7E-06  *  1.357  0.959  -/[  46  ]  MIR376a-2  14  +  -5.98  2.96  2.59  0.020  *  4.857  2.888  -/[  47  ]  MIR424  X  -  -3.94  1.95  -2.56  0.259  *  0.883  4.287  *  -/[  39  ]  MIR654  14  +  -5.42  2.57  4.14  0.136  *  1.357  0.295  *  -/-  Table listing significantly changed miRNA genes identified in this study.\n",
      "\n",
      " %%%%%%%%%%%%    27    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [  37  -  40  ]. This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [\n",
      "       \n",
      "        37\n",
      "       \n",
      "       -\n",
      "       \n",
      "        40\n",
      "       \n",
      "       ].  This miRNA has been best studied in humans, where its dysregulation is implicated in breast, lung, colorectal and head and neck cancers [  37  -  40  ].\n",
      "\n",
      " %%%%%%%%%%%%    28    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " The tumor suppressor miRNA of miR-31 were downregulated in BC datasets comparing to the BO datasets [  27  ].  Analysis of known breast cancer related miRNAs  We also analyzed miRNAs previously reported to be differentially expressed in BC, including oncogenic miRNAs, miR-155[  17  ], miR-21[  18  ,  19  ], miR-25[  30  ], and miR-27a[  24  ], and tumor suppressor miRNAs, miR-125a/b[  17  ], miR-17[  26  ], miR-205[  25  ], miR-27b[  24  ], miR-31[  27  ], and miR-34a[  28  ,  29  ]. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  27  ], was observed to be downregulated in BC datasets. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [\n",
      "      \n",
      "       27\n",
      "      \n",
      "      ], was observed to be downregulated in BC datasets.  The tumor suppressor miRNA of miR-31 were downregulated in BC datasets comparing to the BO datasets [  27  ].  Analysis of known breast cancer related miRNAs  We also analyzed miRNAs previously reported to be differentially expressed in BC, including oncogenic miRNAs, miR-155[  17  ], miR-21[  18  ,  19  ], miR-25[  30  ], and miR-27a[  24  ], and tumor suppressor miRNAs, miR-125a/b[  17  ], miR-17[  26  ], miR-205[  25  ], miR-27b[  24  ], miR-31[  27  ], and miR-34a[  28  ,  29  ]. MiR-31, which is expressed in normal breast cells and was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  27  ], was observed to be downregulated in BC datasets.\n",
      "\n",
      " %%%%%%%%%%%%    29    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " miR-31 also inhibits breast cancer metastasis [  66  ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [  67  ]. miR-31 also inhibits breast cancer metastasis [\n",
      "       \n",
      "        66\n",
      "       \n",
      "       ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [\n",
      "       \n",
      "        67\n",
      "       \n",
      "       ].  miR-31 also inhibits breast cancer metastasis [  66  ] and over-expression of miR-31 significantly enhanced proliferation and tumorigenicity of lung cancer cells [  67  ].\n",
      "\n",
      " %%%%%%%%%%%%    33    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [  50  -  52  ]. This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [\n",
      "       \n",
      "        50\n",
      "       \n",
      "       -\n",
      "       \n",
      "        52\n",
      "       \n",
      "       ].  This miRNA regulates metastasis by opposing local invasion and metastatic colonization in this cancer [  50  -  52  ].\n",
      "\n",
      " %%%%%%%%%%%%    34    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  MiR-31 expression was elevated in endometrial cancer [\n",
      "         \n",
      "          15\n",
      "         \n",
      "         ] but paradoxically down-regulated in breast [\n",
      "         \n",
      "          16\n",
      "         \n",
      "         ] and prostate cancer [\n",
      "         \n",
      "          18\n",
      "         \n",
      "         ].  \n",
      "\n",
      " %%%%%%%%%%%%    35    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [  24  ,  36  ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([  36  ] and Sossey-Alaoui, unpublished data). Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [  24  ,  36  ]. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [  24  ,  36  ]. Expression levels of miR-31diminish as the tumors progress to more invasive stages [  24  ] and become undetectable in metastatic BC tumors [  36  ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [  24  ], RhoA, Radexin [  36  ] and several integrin subunits [  47  ] that regulate key steps in the invasion-metastasis cascade. In fact, several miRs, miR-15a, miR-16-1, and let-7 [  23  ,  26  -  30  ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [  23  ,  31  ,  32  ], possess oncogenic properties  Several recent reports have identified a major role of miR31 in cancer metastasis [  33  -  36  ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] and Sossey-Alaoui, unpublished data). Expression levels of miR-31diminish as the tumors progress to more invasive stages [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ] and become undetectable in metastatic BC tumors [\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ], RhoA, Radexin [\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] and several integrin subunits [\n",
      "          \n",
      "           47\n",
      "          \n",
      "          ] that regulate key steps in the invasion-metastasis cascade. miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [\n",
      "          \n",
      "           24\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ]. In fact, several miRs, miR-15a, miR-16-1, and let-7 [\n",
      "          \n",
      "           23\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           26\n",
      "          \n",
      "          -\n",
      "          \n",
      "           30\n",
      "          \n",
      "          ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [\n",
      "          \n",
      "           23\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           31\n",
      "          \n",
      "          ,\n",
      "          \n",
      "           32\n",
      "          \n",
      "          ], possess oncogenic properties\n",
      "         \n",
      "\n",
      "          Several recent reports have identified a major role of miR31 in cancer metastasis [\n",
      "          \n",
      "           33\n",
      "          \n",
      "          -\n",
      "          \n",
      "           36\n",
      "          \n",
      "          ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts. miR-31 expression levels are high in early stage BC tumors, allowing for its pro-invasive, pro-metastatic target genes to remain under tight control [  24  ,  36  ]. In BC mouse models, re-expression of miR-31 in the triple-negative MDA-MB-231 BC cells, which do not express endogenous miR-31, almost completely inhibits the metastatic potential of these cells without affecting the growth of the primary tumors while specifically inhibiting its pro-metastatic target genes ([  36  ] and Sossey-Alaoui, unpublished data). Loss of miR-31 expression is accompanied by concomitant increase in expression of its pro-invasive and pro-metastatic target genes, therefore, allowing for the tumor to become more invasive and ultimately metastasizes [  24  ,  36  ]. On the other hand, knockdown of miR-31 in the non invasive luminal MCF7 BC cells results in lifting the inhibitory effect imposed by miR-31 on its target genes and imparts aggressive and metastatic phenotype to these cells comparable to observed in MDA-MB-231 cells [  24  ,  36  ]. Expression levels of miR-31diminish as the tumors progress to more invasive stages [  24  ] and become undetectable in metastatic BC tumors [  36  ]. We and others have previously shown that miR-31, a BC metastasis suppressor gene, is a major contributor to BC progression and metastasis by regulating a cohort of a pro-metastatic target genes, including WAVE3 [  24  ], RhoA, Radexin [  36  ] and several integrin subunits [  47  ] that regulate key steps in the invasion-metastasis cascade. In fact, several miRs, miR-15a, miR-16-1, and let-7 [  23  ,  26  -  30  ] function as tumor suppressors, and others, miR-155, miR-17-5p, and miR-21 [  23  ,  31  ,  32  ], possess oncogenic properties  Several recent reports have identified a major role of miR31 in cancer metastasis [  33  -  36  ] With regard to BC, we reported that miR-31 expression is lost in aggressive basal-type breast cancer cell lines compared to the non-invasive luminal counterparts.\n",
      "\n",
      " %%%%%%%%%%%%    36    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [  22  ], esophageal [  23  ], lung [  24  ], oral [  25  ] and head and neck [  26  ] cancer, and a tumor suppressor gene in breast [  27  ] and gastric [  28  ] cancers and malignant mesothelioma [  29  ].  Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ], esophageal [\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ], lung [\n",
      "     \n",
      "      24\n",
      "     \n",
      "     ], oral [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ] and head and neck [\n",
      "     \n",
      "      26\n",
      "     \n",
      "     ] cancer, and a tumor suppressor gene in breast [\n",
      "     \n",
      "      27\n",
      "     \n",
      "     ] and gastric [\n",
      "     \n",
      "      28\n",
      "     \n",
      "     ] cancers and malignant mesothelioma [\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ]. Furthermore, MIR31 has been reported to be an oncomir in various human cancers, including colorectal [  22  ], esophageal [  23  ], lung [  24  ], oral [  25  ] and head and neck [  26  ] cancer, and a tumor suppressor gene in breast [  27  ] and gastric [  28  ] cancers and malignant mesothelioma [  29  ].\n",
      "\n",
      " %%%%%%%%%%%%    37    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  miR-31  miR-31 was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  61  ].  Table 1  miRNAs and their targets in breast cancer cells  miRNA  Target  Functional pathway  Reference  Tumor suppressor miRNAs  miR-206  ESR1  ER signaling  [  28  ,  33  ]  miR-17-5p  AIB1  ,  CCND1  ,  E2F1  Proliferation  [  37  ,  38  ]  miR-125a, b  HER2  ,  HER3  Anchorage-dependent growth  [  40  ,  41  ]  miR-200  BMI1  ,  ZEB1  ,  ZEB2  TGF- signaling  [  47  ,  52  ,  54  ]  let-7  H-RAS  ,  HMGA2  ,  LIN28  ,  PEBP1  Proliferation, differentiation  [  73  -  75  ]  miR-34a  CCND1  ,  CDK6  ,  E2F3  ,  MYC  DNA damage, proliferation  [  76  -  78  ]  miR-31  FZD3  ,  ITGA5  ,  M-RIP  ,  MMP16  ,  RDX  ,  RHOA  Metastasis  [  61  ]  Oncogenic miRNAs  miR-21  BCL-2  ,  TPM1  ,  PDCD4  ,  PTEN  ,  MASPIN  Apoptosis  [  64  -  67  ]  miR-155  RHOA  TGF- signaling  [  68  ]  miR-10b  HOXD10  Metastasis  [  69  ]  miR-373/520c  CD44  Metastasis  [  79  ]  miRNAs and their targets in breast cancer.    miR-31  miR-31 was recently shown to prevent metastasis at multiple steps by inhibiting the expression of prometastatic genes [  61  ].  Table 1  miRNAs and their targets in breast cancer cells  miRNA  Target  Functional pathway  Reference  Tumor suppressor miRNAs  miR-206  ESR1  ER signaling  [  28  ,  33  ]  miR-17-5p  AIB1  ,  CCND1  ,  E2F1  Proliferation  [  37  ,  38  ]  miR-125a, b  HER2  ,  HER3  Anchorage-dependent growth  [  40  ,  41  ]  miR-200  BMI1  ,  ZEB1  ,  ZEB2  TGF- signaling  [  47  ,  52  ,  54  ]  let-7  H-RAS  ,  HMGA2  ,  LIN28  ,  PEBP1  Proliferation, differentiation  [  73  -  75  ]  miR-34a  CCND1  ,  CDK6  ,  E2F3  ,  MYC  DNA damage, proliferation  [  76  -  78  ]  miR-31  FZD3  ,  ITGA5  ,  M-RIP  ,  MMP16  ,  RDX  ,  RHOA  Metastasis  [  61  ]  Oncogenic miRNAs  miR-21  BCL-2  ,  TPM1  ,  PDCD4  ,  PTEN  ,  MASPIN  Apoptosis  [  64  -  67  ]  miR-155  RHOA  TGF- signaling  [  68  ]  miR-10b  HOXD10  Metastasis  [  69  ]  miR-373/520c  CD44  Metastasis  [  79  ]  miRNAs and their targets in breast cancer.\n",
      "\n",
      " %%%%%%%%%%%%    40    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " While the suppressive effects of miR-31, miR-126, miR-206, and miR-335 on metastasis have been directly documented  in vivo  [  8  ,  9  ], the roles of miR-130 and miR-200 in metastasis are implied by  in vitro  studies [  3  ,  7  ], but have yet to be analyzed directly  in vivo  . However, the authors [  4  ] did not address the relevance of these miR-200-dependent signaling events for  in vivo  metastatic abilities, nor did they determine the contributions of other known anti-metastatic miRNAs - such as miR-31, miR-126, miR-206 and miR-335 [  8  ,  9  ] - for mediating the observed anti-malignant responses.   While the suppressive effects of miR-31, miR-126, miR-206, and miR-335 on metastasis have been directly documented  in vivo  [  8  ,  9  ], the roles of miR-130 and miR-200 in metastasis are implied by  in vitro  studies [  3  ,  7  ], but have yet to be analyzed directly  in vivo  . However, the authors [  4  ] did not address the relevance of these miR-200-dependent signaling events for  in vivo  metastatic abilities, nor did they determine the contributions of other known anti-metastatic miRNAs - such as miR-31, miR-126, miR-206 and miR-335 [  8  ,  9  ] - for mediating the observed anti-malignant responses.\n",
      "\n",
      " %%%%%%%%%%%%    42    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Previous studies have attempted to delineate their role in the regulation of metastasis and disease progression (\n",
      "         \n",
      "          34\n",
      "         \n",
      "         \n",
      "         \n",
      "          36\n",
      "         \n",
      "         ).  \n",
      "\n",
      " %%%%%%%%%%%%    45    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ]. A recent study reported that IL-17 alone or in combination with BAFF promoted the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ]. Such factors may contribute to the lupus phenotype, because IL-17 acts in conjunction with B-cell activating factor (BAFF) in promoting the survival and proliferation of human B cells and their differentiation into antibody-producing cells [  25  ].\n",
      "\n",
      " %%%%%%%%%%%%    46    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " As BAFF is capable of inducing T  H  17 cell differentiation in addition to regulating B cell activation [  41  ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis. As BAFF is capable of inducing T\n",
      "      \n",
      "       H\n",
      "      \n",
      "      17 cell differentiation in addition to regulating B cell activation [\n",
      "      \n",
      "       41\n",
      "      \n",
      "      ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis.  As BAFF is capable of inducing T  H  17 cell differentiation in addition to regulating B cell activation [  41  ], the possible role of BAFF and IL17A in this phenomenon needs to be better defined in SS pathogenesis.\n",
      "\n",
      " %%%%%%%%%%%%    47    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].  Besides patients with lupus having abnormally high levels of IL-17A along with IFN-\n",
      "       \n",
      "        \n",
      "       \n",
      "       are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [\n",
      "       \n",
      "        12\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ]. Besides patients with lupus having abnormally high levels of IL-17A along with IFN-    are reported in previous studies which have shown that the increased levels of serum IL-17A act as potent inflammatory responses [  12  ,  13  ].\n",
      "\n",
      " %%%%%%%%%%%%    48    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Among these genes, it is interesting to note that TRAF3IP2 (alias ACT1) is a negative regulator of B cell function, its absence leading to lymphoproliferation and autoantibody production  [20]  , but ACT1 is also essential in IL-17 dependent signaling during autoimmune diseases  [21]  , IL-17 being implicated during lupus physiopathology  [22]  . On the other hand, the down expression of ACT1 (TRAF3IP2), could be linked to SLE because of the importance of this negative regulator on the B cell function\n",
      "              \n",
      "               [20]\n",
      "              \n",
      "              \n",
      "              \n",
      "               [22]\n",
      "              \n",
      "              .  Among these genes, it is interesting to note that TRAF3IP2 (alias ACT1) is a negative regulator of B cell function, its absence leading to lymphoproliferation and autoantibody production  [20]  , but ACT1 is also essential in IL-17 dependent signaling during autoimmune diseases  [21]  , IL-17 being implicated during lupus physiopathology  [22]  .\n",
      "\n",
      " %%%%%%%%%%%%    49    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " The sample was then diluted 40 times in dilution buffer and immunoprecipitations, washes and elution were performed as before ([  18  ]).   The sample was then diluted 40 times in dilution buffer and immunoprecipitations, washes and elution were performed as before ([  18  ]).\n",
      "\n",
      " %%%%%%%%%%%%    50    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Chromatin Immunoprecipitation (ChIP) assays  BT474 cells treated or not with RAD001 (20 nM) were washed and cross-linked with formaldehyde at room temperature for 8 min essentially as previously described [  22  ].    Chromatin Immunoprecipitation (ChIP) assays  BT474 cells treated or not with RAD001 (20 nM) were washed and cross-linked with formaldehyde at room temperature for 8 min essentially as previously described [  22  ].\n",
      "\n",
      " %%%%%%%%%%%%    51    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " For direction, reprogramming motility and toxin degradation in bacteria [  102  ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption.  For direction, reprogramming motility and toxin degradation in bacteria [\n",
      "      \n",
      "       102\n",
      "      \n",
      "      ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption. For direction, reprogramming motility and toxin degradation in bacteria [  102  ] demonstrates the feasibility of regulatory reprogramming, which may permit more efficient hexose and pentose consumption.\n",
      "\n",
      " %%%%%%%%%%%%    53    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].   Despite their article withdrawal, they emphasized that the USP4 crystal structure and the ubiquitin-binding data in [  2  ] are not in question. We regret that cited reference 26 [  2  ] in the paper has been retracted [  3  ]. Luna-Vargas et al., retracted the paper because they could not reproduce the results of lower  K  m  for the USP4 catalytic domain under their described conditions [  2  ].\n",
      "\n",
      " %%%%%%%%%%%%    54    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  \n",
      "\n",
      "      USP4 is overexpressed in various types of cancer and the increased levels of USP4 appear to play a functional role in malignant cells (\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       20\n",
      "      \n",
      "      \n",
      "      \n",
      "       22\n",
      "      \n",
      "      ).  \n",
      "\n",
      " %%%%%%%%%%%%    56    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).   These observations are consistent with others observation that the LKB1/AMPK stress polarity pathway is not evolutionarily conserved; it is not required for the maintenance of polarity during energetic stress in either flies [  44  ,  45  ] or fish [  46  ,  47  ] [no evidence exists in amphibians, reptiles, or birds], instead, the pathway is evolutionarily young, raising the possibility that it may have co-evolved with GIV to meet the metabolic demands of endotherms (birds and mammals).\n",
      "\n",
      " %%%%%%%%%%%%    57    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [  5  ,  6  ]. Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ].  Interestingly, the expression of a phospho-mimetic mutant of MLC was capable of rescuing the polarity defects seen in AMPK-null flies implicating actin:myosin filament assembly as a major player downstream of LKB [  5  ,  6  ].\n",
      "\n",
      " %%%%%%%%%%%%    64    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " These findings were further confirmed by immunohistochemical studies with a CPOX-specific antibody, as well [  33  ]. By quantitative real-time PCR (qRT-PCR), we measured the mRNA levels of key genes in a total of 20 tumor samples that had been surgically resected from brain tumor patients [  33  ].   These findings were further confirmed by immunohistochemical studies with a CPOX-specific antibody, as well [  33  ]. By quantitative real-time PCR (qRT-PCR), we measured the mRNA levels of key genes in a total of 20 tumor samples that had been surgically resected from brain tumor patients [  33  ].\n",
      "\n",
      " %%%%%%%%%%%%    65    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. The possibility that an unusual branched TCA cycle may operate in the asexual stages of\n",
      "     \n",
      "      P. falciparum\n",
      "     \n",
      "     , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ], but subsequently retracted [\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. Importantly, and in contrast to a previous report [  13  ], citrate isotopomers containing +5 labeled carbons were not detected, indicating minimal catabolism of -ketoglutarate via the reductive arm of the TCA cycle (Figure  1  B). The possibility that an unusual branched TCA cycle may operate in the asexual stages of  P. falciparum  , fuelled by the catabolism of glutamine via both the oxidative and reductive arms of the TCA cycle, was recently proposed [  13  ], but subsequently retracted [  17  ]. Significantly, we found no evidence for operation of a bifurcated or branched TCA cycle in which glutamine is converted to malate via both oxidative and reductive arms of the TCA cycle, as previously proposed [  13  ,  17  ]. Collectively, these analyzes show that the  P. falciparum  asexual stages catabolize both pyruvate and glutamate in a conventional TCA cycle, and argue against the operation of a bifurcated TCA cycle, as previously proposed [  13  ,  17  ].\n",
      "\n",
      " %%%%%%%%%%%%    66    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [  13  ].  Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ]. Recently, it has been discovered that, at least during their asexual blood stages, malarial parasites have atypical, branched TCA metabolism, which is largely disconnected from glycolysis and therefore plays a minor role in energy metabolism [  13  ].\n",
      "\n",
      " %%%%%%%%%%%%    70    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[  25  ]. demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[\n",
      "     \n",
      "      25\n",
      "     \n",
      "     ].  demonstrated the compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P(3)-25), which is known to possess anti-bacterial, anti-fungal, anti-tubercular, and local anesthetic activities, reduced phosphorylation of p65 by inhibiting upstream kinases including protein kinase A, CK2 etc resulting in down-regulation of nuclear factor (NF) kappaB-dependent reporter gene, COX2 in cancer cells with constitutive expression of NF kappaB[  25  ].\n",
      "\n",
      " %%%%%%%%%%%%    71    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [  2  ].  Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [\n",
      "             \n",
      "              2\n",
      "             \n",
      "             ]. Members of this family of receptors are tetrameric proteins consisting of two extracellular -subunits and two transmembrane -subunits linked by disulfide bonds [  2  ].\n",
      "\n",
      " %%%%%%%%%%%%    72    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance. There is no evidence to suggest a significant displacement of government funding by international support [\n",
      "     \n",
      "      45\n",
      "     \n",
      "     ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.  There is no evidence to suggest a significant displacement of government funding by international support [  45  ]; indeed the global level of government funding remained relatively consistent between 2006 and 2010 despite large increases in donor assistance.\n",
      "\n",
      " %%%%%%%%%%%%    73    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ]. \n",
      "\n",
      "       In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       -\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ].   In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ].\n",
      "\n",
      " %%%%%%%%%%%%    76    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      TLR2-4 have been implicated in pathological pain [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       37\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       40\n",
      "      \n",
      "      ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ].\n",
      "\n",
      " %%%%%%%%%%%%    77    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ].\n",
      "\n",
      " %%%%%%%%%%%%    78    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ]. \n",
      "\n",
      "       In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       -\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [\n",
      "       \n",
      "        44\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        46\n",
      "       \n",
      "       ].   In addition, accumulating studies have indicated that TLRs, expressed widely on spinal glia, are involved in the development of neuropathic pain after nerve injury [  44  -  46  ]. TLRs in spinal cord may have a role in the early establishment of neuropathic pain after peripheral nerve injury [  44  ,  46  ].\n",
      "\n",
      " %%%%%%%%%%%%    81    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      TLR2-4 have been implicated in pathological pain [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       37\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       40\n",
      "      \n",
      "      ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. Previous study has also confirmed the role of TLR3 in spinal nerve injury induced pathological pain, with a kind of TLR3 ASO [  16  ]. TLR2-4 have been clarified to be major mediators in neuropathic pain [  14  ,  16  ,  17  ]. However, other studies reported that TLR3 stimulation could induce TNF-, IL-6 and even COX-2  in vitro  [  16  ,  37  ,  40  ].  TLR2-4 have been implicated in pathological pain [  13  ,  14  ,  16  ,  17  ].\n",
      "\n",
      " %%%%%%%%%%%%    82    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ]. It has been suggested that TLR2, TLR3, and TLR4 play a role in the initiation of neuropathic pain through the recognition of host-derived endogenous ligands [  19  -  21  ]. In line with these reports, it is notable that all of these TLR members are implicated in nerve injury-induced pain hypersensitivity [  19  -  21  ].\n",
      "\n",
      " %%%%%%%%%%%%    83    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [  13  ].  Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     ]. Mutations in either of these genes result in embryonic lethality and Ten-a mutants enhance the segmentation phenotype of weak alleles of Ten-m/Odz [  13  ].\n",
      "\n",
      " %%%%%%%%%%%%    84    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " The  Drosophila  homologs,  Ten-m  and  Ten-a  , are the only pair-rule genes that do not encode traditional transcription factors [  3  -  5  ].  The\n",
      "      \n",
      "       Drosophila\n",
      "      \n",
      "      homologs,\n",
      "      \n",
      "       Ten-m\n",
      "      \n",
      "      and\n",
      "      \n",
      "       Ten-a\n",
      "      \n",
      "      , are the only pair-rule genes that do not encode traditional transcription factors [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      -\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. The  Drosophila  homologs,  Ten-m  and  Ten-a  , are the only pair-rule genes that do not encode traditional transcription factors [  3  -  5  ].\n",
      "\n",
      " %%%%%%%%%%%%    89    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Novel retroviruses may also be involved [  31  ,  32  ] but that possibility has been challenged [  33  ].  Novel retroviruses may also be involved [\n",
      "      \n",
      "       31\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       32\n",
      "      \n",
      "      ] but that possibility has been challenged [\n",
      "      \n",
      "       33\n",
      "      \n",
      "      ]. Novel retroviruses may also be involved [  31  ,  32  ] but that possibility has been challenged [  33  ].\n",
      "\n",
      " %%%%%%%%%%%%    93    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [  1  ,  30  ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [  30  ] and healthy donors. Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [\n",
      "       \n",
      "        1\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        30\n",
      "       \n",
      "       ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [\n",
      "       \n",
      "        30\n",
      "       \n",
      "       ] and healthy donors.  Importantly, assay contamination cannot be assessed by detection of murine DNA alone since MLVs contaminate a significant proportion of non-murine cell lines common in laboratories [  1  ,  30  ]. A recent study amplified polytropic MLV sequences rather than XMRV from chronic fatigue patient samples [  30  ] and healthy donors.\n",
      "\n",
      " %%%%%%%%%%%%    94    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [  2  ,  7  ], because all studies employed highly sensitive PCR methods. [  7  ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors. It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ], because all studies employed highly sensitive PCR methods. [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors. It is unlikely that our detection procedures caused such a big difference from those studies that reported a prevalence of 67% or 86.5% [  2  ,  7  ], because all studies employed highly sensitive PCR methods. [  7  ] found murine leukemia virus (MLV)-related sequences in genomic DNA of peripheral blood mononuclear cells (PBMCs) in 32 of 37 (86.5%) CFS patients and three of 44 (6.8%) healthy blood donors.\n",
      "\n",
      " %%%%%%%%%%%%    96    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [  16  ]. In contrast to the published VP [  1  ] and WPI [  3  ] XMRV sequences, which are tightly clustered, the  gag  sequences found in this study were dispersed, similar to the sequences reported in [  16  ];  i.e  ., the 15 unique XMRV-related partial  gag  sequences found among from the 37 single PCR products were distributed over a minimum of 3 clusters, each of which contains endogenous MLV sequences of a different subtype (XMV, PMV, and MPMV (xenotropic, polytropic, modified polytropic MLV)). Several reports have appeared in the literature since then contesting these findings [  4  -  6  ,  8  ,  9  ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [  16  ]. Several reports have appeared in the literature since then contesting these findings [\n",
      "      \n",
      "       4\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       8\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       9\n",
      "      \n",
      "      ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ]. \n",
      "\n",
      "      Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ].  Recently, sequences related to other murine leukemia viruses (MLVs) were reported in 80% of CFS patients versus only a small percentage of healthy controls [  16  ]. In contrast to the published VP [  1  ] and WPI [  3  ] XMRV sequences, which are tightly clustered, the  gag  sequences found in this study were dispersed, similar to the sequences reported in [  16  ];  i.e  ., the 15 unique XMRV-related partial  gag  sequences found among from the 37 single PCR products were distributed over a minimum of 3 clusters, each of which contains endogenous MLV sequences of a different subtype (XMV, PMV, and MPMV (xenotropic, polytropic, modified polytropic MLV)). Several reports have appeared in the literature since then contesting these findings [  4  -  6  ,  8  ,  9  ], while a recent publication claimed that 80% of CFS patients, but not healthy controls, contained endogenous MLV-like sequences, but were negative for mouse mitochondrial DNA [  16  ].\n",
      "\n",
      " %%%%%%%%%%%%    98    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " It is therefore not surprising that MLV-related ERVs are found in the genomes of amphibians, reptiles, birds and mammals [  113  ], and that X/P-MLV-related viruses and viral sequences have now been reported in humans [  114  -  119  ]. This, coupled with the recent finding of  M/Pmv  related  env  and  glycogag  sequences in human blood donors and chronic fatigue patients [  119  ] points out the need for further work to clarify the evolutionary path linking the human and mouse viruses and to describe the epidemiology of this virus family in wild mice [  121  ].   It is therefore not surprising that MLV-related ERVs are found in the genomes of amphibians, reptiles, birds and mammals [  113  ], and that X/P-MLV-related viruses and viral sequences have now been reported in humans [  114  -  119  ]. This, coupled with the recent finding of  M/Pmv  related  env  and  glycogag  sequences in human blood donors and chronic fatigue patients [  119  ] points out the need for further work to clarify the evolutionary path linking the human and mouse viruses and to describe the epidemiology of this virus family in wild mice [  121  ].\n",
      "\n",
      " %%%%%%%%%%%%    101    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  in people with CFS using tests with less sensitive PCR tests [  5  ,  12  ]. study since like previous studies, this study also failed to identify XMRV in any of the CFS samples or controls [  6  -  12  ].  can at best detect 1 copy of XMRV/MuLV in a background of 30 to 50 ng and 100 to 250 ng of DNA respectively [  5  ,  12  ]. Unlike other reports [  5  ,  12  ], we also found no evidence of active XMRV/MuLV viremia using highly sensitive RT-PCR tests excluding possibilities of peripheral infection seeding the blood compartment from other body locations. A more recent study failed to detect XMRV, but found a polytropic MuLV most similar to mouse endogenous retroviruses in 87% of CFS cases [  12  ].    in people with CFS using tests with less sensitive PCR tests [  5  ,  12  ]. study since like previous studies, this study also failed to identify XMRV in any of the CFS samples or controls [  6  -  12  ].  can at best detect 1 copy of XMRV/MuLV in a background of 30 to 50 ng and 100 to 250 ng of DNA respectively [  5  ,  12  ]. Unlike other reports [  5  ,  12  ], we also found no evidence of active XMRV/MuLV viremia using highly sensitive RT-PCR tests excluding possibilities of peripheral infection seeding the blood compartment from other body locations. A more recent study failed to detect XMRV, but found a polytropic MuLV most similar to mouse endogenous retroviruses in 87% of CFS cases [  12  ].\n",
      "\n",
      " %%%%%%%%%%%%    102    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  PBMCs from patients with CFS are not more likely to have a signal for MLV-related viruses than controls  Recently MLV-related virus DNA was detected in patients with CFS using nested PCR [  2  ]. [  2  ], but the no template controls also amplified a DNA product. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  22  ], or due to very low levels of MLV related sequences in human DNA. [  25  ], Satterfield et al. [  2  ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls. [  24  ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [  8  -  11  ], two states [  7  ], or other countries [  3  -  6  ,  23  ,  25  ]. A positive control, in which an XMRV gp70-reactive rat monoclonal antibody 83A25 [  21  ] was used to immunoprecipitate gp70, readily detected gp70 from XMRV-infected ferret cells (Figure  1A, B  last lanes). [  24  ] did not detect MLV in CFS patients from 17 states in the United States. [  1  ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [  3  ,  4  ], the Netherlands [  5  ], China [  6  ], Japan [  12  ,  23  ], and the United States [  7  -  10  ,  19  ,  24  ] that did not detect XMRV DNA in patients with CFS. [  2  ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [  22  ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. Most of these PCR products were also highly related to MLV-related sequences that were previously identified in samples from patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  24  ], Knox et al. [\n",
      "      \n",
      "       22\n",
      "      \n",
      "      ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. [\n",
      "      \n",
      "       1\n",
      "      \n",
      "      ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ], the Netherlands [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ], China [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ], Japan [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       23\n",
      "      \n",
      "      ], and the United States [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] that did not detect XMRV DNA in patients with CFS. [\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ], Satterfield et al. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       20\n",
      "      \n",
      "      ]. [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [\n",
      "      \n",
      "       22\n",
      "      \n",
      "      ], or due to very low levels of MLV related sequences in human DNA. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ], Knox et al. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] did not detect MLV in CFS patients from 17 states in the United States. [\n",
      "      \n",
      "       24\n",
      "      \n",
      "      ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [\n",
      "      \n",
      "       8\n",
      "      \n",
      "      -\n",
      "      \n",
      "       11\n",
      "      \n",
      "      ], two states [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ], or other countries [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       23\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ]. [\n",
      "      \n",
      "       2\n",
      "      \n",
      "      ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls.  PBMCs from patients with CFS are not more likely to have a signal for MLV-related viruses than controls  Recently MLV-related virus DNA was detected in patients with CFS using nested PCR [  2  ]. [  2  ], but the no template controls also amplified a DNA product. Sequence analysis showed that sequences in both CFS and healthy controls aligned with MLV sequences found in mice and reported in patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  22  ], or due to very low levels of MLV related sequences in human DNA. [  25  ], Satterfield et al. [  2  ] reported the presence of murine leukemia virus (MLV)-related virus gene sequences in 86.5% of CFS patients and 6.8% of controls. [  24  ] who studied patients from multiple states of the continental United States, whereas other studies have reported patients from a single geographic area of the United States [  8  -  11  ], two states [  7  ], or other countries [  3  -  6  ,  23  ,  25  ]. A positive control, in which an XMRV gp70-reactive rat monoclonal antibody 83A25 [  21  ] was used to immunoprecipitate gp70, readily detected gp70 from XMRV-infected ferret cells (Figure  1A, B  last lanes). [  24  ] did not detect MLV in CFS patients from 17 states in the United States. [  1  ] in which XMRV DNA was detected in 67% of CFS patients and 3.7% of controls, there are numerous reports from the United Kingdom [  3  ,  4  ], the Netherlands [  5  ], China [  6  ], Japan [  12  ,  23  ], and the United States [  7  -  10  ,  19  ,  24  ] that did not detect XMRV DNA in patients with CFS. [  2  ], we detected MLV-related viral DNA in all human samples tested, regardless of whether they were from patients with CFS, inflammatory diseases, or normal controls. [  22  ] reported that Invitrogen Platinum Taq PCR Master Mix was contaminated with mouse DNA sequences; however, they did not detect murine sequences in Applied Biosystems Taq PCR Master Mix. Most of these PCR products were also highly related to MLV-related sequences that were previously identified in samples from patients with CFS or prostate cancer [  2  ,  19  ,  20  ]. [  24  ], Knox et al.\n",
      "\n",
      " %%%%%%%%%%%%    104    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  \n",
      "\n",
      "      A very recent publication reports finding MLV-like\n",
      "      \n",
      "       gag\n",
      "      \n",
      "      sequences in 32 out of 37 (86.5%) CFS patients and in 3 out of 44 (6.8%) healthy blood donors\n",
      "      \n",
      "       [29]\n",
      "      \n",
      "      . Nevertheless, we can presently not formally exclude that a proportion of the non-XMRV proviruses that have been amplified in the report by Lo and co-workers\n",
      "      \n",
      "       [29]\n",
      "      \n",
      "      could have been missed using our primer set.  \n",
      "\n",
      " %%%%%%%%%%%%    105    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Nested PCR was performed under the same conditions for 45 amplification cycles with 5 l of the first round PCR product and two different primer pairs, Gag-I-F (  5-TCTCGAGATCATGGGACAGA-3  ) and Gag-I-R (  5-AGAGGGTAAGGGCAGGGTAA-3  ) or NP116 (  5-CATGGGACAGACCGTAACTACC-3  ) and NP117 (  5-GCAGATCGGGACGGAGGTTG-3  ), both of which have been shown to detect both XMRV and MLV sequences  [6]  . While one study reported the presence of other MLV-like sequences in CFS patients  [6]  , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination  [7]  . \n",
      "\n",
      "       [6]\n",
      "      \n",
      "      . While one study reported the presence of other MLV-like sequences in CFS patients\n",
      "      \n",
      "       [6]\n",
      "      \n",
      "      , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination\n",
      "      \n",
      "       [7]\n",
      "      \n",
      "      . Nested PCR was performed under the same conditions for 45 amplification cycles with 5 l of the first round PCR product and two different primer pairs, Gag-I-F (  5-TCTCGAGATCATGGGACAGA-3  ) and Gag-I-R (  5-AGAGGGTAAGGGCAGGGTAA-3  ) or NP116 (  5-CATGGGACAGACCGTAACTACC-3  ) and NP117 (  5-GCAGATCGGGACGGAGGTTG-3  ), both of which have been shown to detect both XMRV and MLV sequences  [6]  . While one study reported the presence of other MLV-like sequences in CFS patients  [6]  , others identified mouse DNA, human cell lines or commercial laboratory reagents to be a possible source of MLV contamination  [7]  .\n",
      "\n",
      " %%%%%%%%%%%%    109    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  As FoxP3 is not exclusively expressed in Tregs [\n",
      "     \n",
      "      46\n",
      "     \n",
      "     ], we measured the intracellular expression of IL-10, a cytokine constitutively produced at low levels by Tregs [\n",
      "     \n",
      "      47\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      48\n",
      "     \n",
      "     ].  \n",
      "\n",
      " %%%%%%%%%%%%    111    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " [  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].  Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [\n",
      "     \n",
      "      2\n",
      "     \n",
      "     -\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ]. [  8  ] Wang et al. Supervised analysis of gene expression has been used to discover gene signatures to identify patients at risk of recurrence in colon cancer [  2  -  8  ].\n",
      "\n",
      " %%%%%%%%%%%%    112    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " [  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].  This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [\n",
      "      \n",
      "       1\n",
      "      \n",
      "      -\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ]. [  59  -  61  ] Vorinostat is a member of a histone deacetylases (HADC) with a broad spectrum of epigenetic activities; it has been approved by the FDA to treat cutaneous T-cell lymphoma in 2006. This growing need for personalized treatment has pushed the development of high-through technologies such as microarray and high throughput sequencing to the research forefront, where compound selection methods based on DNA or mRNA profiling have been developed to achieve highest benefit from therapeutic intervention but at the same time lowest risk of side effects [  1  -  6  ]. Since it has been also shown to have effect on treating breast cancer [  62  -  68  ], it has undergone multiple Phase I and II clinical trials as an anti breast cancer drug [  69  -  73  ].\n",
      "\n",
      " %%%%%%%%%%%%    114    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " A recent study investigated the genetic profiles of centenarians and claimed evidence for Methuselah genes which enable certain people to live to 100 and beyond (Sebastiani et al.,  2010  ).   A recent study investigated the genetic profiles of centenarians and claimed evidence for Methuselah genes which enable certain people to live to 100 and beyond (Sebastiani et al.,  2010  ).\n",
      "\n",
      " %%%%%%%%%%%%    115    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  \n",
      "         [25]\n",
      "        \n",
      "        computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.  [25]  computed the posterior probabilities of individual SNPs using a likelihood like the one presented here.\n",
      "\n",
      " %%%%%%%%%%%%    116    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [\n",
      "     \n",
      "      61\n",
      "     \n",
      "     -\n",
      "     \n",
      "      63\n",
      "     \n",
      "     ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     cell growth [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. In\n",
      "     \n",
      "      T. brucei\n",
      "     \n",
      "     , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      71\n",
      "     \n",
      "     ]. \n",
      "      In T. brucei\n",
      "     \n",
      "     , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      70\n",
      "     \n",
      "     ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. In addition, a small fraction of PC is generated by sequential methylation of PE [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [\n",
      "     \n",
      "      11\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      21\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      59\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      60\n",
      "     \n",
      "     ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [\n",
      "     \n",
      "      64\n",
      "     \n",
      "     ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids\n",
      "     \n",
      "      de novo\n",
      "     \n",
      "     [\n",
      "     \n",
      "      68\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [\n",
      "     \n",
      "      65\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      66\n",
      "     \n",
      "     ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [\n",
      "     \n",
      "      67\n",
      "     \n",
      "     ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [\n",
      "     \n",
      "      5\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      6\n",
      "     \n",
      "     ], RNA transport [\n",
      "     \n",
      "      7\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      8\n",
      "     \n",
      "     ] and processing [\n",
      "     \n",
      "      9\n",
      "     \n",
      "     -\n",
      "     \n",
      "      12\n",
      "     \n",
      "     ], protein localization [\n",
      "     \n",
      "      13\n",
      "     \n",
      "     -\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ], and transcription [\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ]. In eukaryotes, PE can be synthesized by decarboxylation of phosphatidylserine (PS), by head group exchange with PS, by acylation of lyso-PE, or by the CDP-ethanolamine branch of the Kennedy pathway [  65  ,  66  ]. In yeast and mammals, arginine methylation has been associated with a diversity of cellular processes including signal transduction [  5  ,  6  ], RNA transport [  7  ,  8  ] and processing [  9  -  12  ], protein localization [  13  -  15  ], and transcription [  16  ].  In T. brucei  , PC is synthesized solely by the CDP-choline branch of the Kennedy pathway, while PE is produced exclusively via the CDP-ethanolamine branch of the Kennedy pathway [  67  ,  69  ,  70  ]. In mammalian and yeast cells, the bulk of the PC pool is synthesized by the CDP-choline branch of the Kennedy pathway [  64  ]. In  T. brucei  , the pool of PI used for GPI synthesis is supplied from glucose-6-phosphate by the action of PI synthase, an enzyme shown to be essential in both bloodstream and procyclic form trypanosomes [  68  ,  70  ,  71  ]. Arginine methylation has been shown to generally alter protein function by modulating protein-protein interactions, protein-nucleic acid interactions, and protein trafficking [  11  ,  21  ,  59  ,  60  ]. In addition to serving as a precursor for triacylglycerol (TAG), DAG is also used to synthesize phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [  64  ]. Arginine residues that serve as substrates for PRMTs are usually found within glycine/arginine rich (GAR) domains [  61  -  63  ]. As for other eukaryotes, PC and PE constitute the majority of phospholipids in trypanosomes [  67  ]. Of great importance is the fact that, as opposed to other parasitic organisms, trypanosomes synthesize phospholipids  de novo  [  68  ]. In addition, a small fraction of PC is generated by sequential methylation of PE [  64  ]. Disruption of the enzymes of the CDP-ethanolamine pathway by RNA interference have shown that this branch of the Kennedy pathway is essential for both procyclic and bloodstream form  T. brucei  cell growth [  69  ,  71  ].\n",
      "\n",
      " %%%%%%%%%%%%    118    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ]. SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      31\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ]. As described for previously characterized prion determining regions of yeast proteins [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      28\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     -\n",
      "     \n",
      "      43\n",
      "     \n",
      "     ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure\n",
      "     \n",
      "      5\n",
      "     \n",
      "     A-C and Additional file\n",
      "     \n",
      "      2\n",
      "     \n",
      "     : Figure S2B). However, only a limited number of Q/N rich sequences are\n",
      "     \n",
      "      bone fide\n",
      "     \n",
      "     prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [\n",
      "     \n",
      "      22\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      23\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      27\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      29\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      34\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      40\n",
      "     \n",
      "     ].  SupC needed for translation termination has been used with fusions of Q-rich yeast protein regions to detect prion-like behavior [  29  ,  31  ,  34  ]. As described for previously characterized prion determining regions of yeast proteins [  22  ,  23  ,  28  ,  29  ,  34  ,  40  -  43  ], both the 519Q and 582Q also conferred upon GFP a capacity to exist in distinct states and showed aggregation pattern similar to NM-GFP (Figure  5  A-C and Additional file  2  : Figure S2B). However, only a limited number of Q/N rich sequences are  bone fide  prion domains capable of propagating these aggregates over multiple cell generations even when expressed at low levels [  22  ,  23  ,  27  ,  29  ,  34  ,  40  ].\n",
      "\n",
      " %%%%%%%%%%%%    119    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].  As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [\n",
      "      \n",
      "       46\n",
      "      \n",
      "      ]. As an example, phosphorylation of nuclear caspase-2 at Ser122 by a DNA-dependent protein kinase induces non-apoptotic activation of the caspase and results in cell cycle arrest at a G2/M DNA damage checkpoint to allow DNA repair [  46  ].\n",
      "\n",
      " %%%%%%%%%%%%    120    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  30  In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,  31  DNA repair,  32  lipid sensing,  33  tumor suppressor,  34  metabolic regulation,  35  and regulation of oxidant levels in cells.  \n",
      "\n",
      "         30\n",
      "        \n",
      "\n",
      "       In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,\n",
      "       \n",
      "\n",
      "         31\n",
      "        \n",
      "\n",
      "       DNA repair,\n",
      "       \n",
      "\n",
      "         32\n",
      "        \n",
      "\n",
      "       lipid sensing,\n",
      "       \n",
      "\n",
      "         33\n",
      "        \n",
      "\n",
      "       tumor suppressor,\n",
      "       \n",
      "\n",
      "         34\n",
      "        \n",
      "\n",
      "       metabolic regulation,\n",
      "       \n",
      "\n",
      "         35\n",
      "        \n",
      "\n",
      "       and regulation of oxidant levels in cells.  30  In addition to its role in apoptosis, evidence suggests a potential role for CASP2 in nonapoptotic processes, including cell cycle regulation,  31  DNA repair,  32  lipid sensing,  33  tumor suppressor,  34  metabolic regulation,  35  and regulation of oxidant levels in cells.\n",
      "\n",
      " %%%%%%%%%%%%    124    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].    Despite the increasing use of such approaches in oncology [  73  -  75  ], autoimmunity and infection [  76  ,  77  ] for the identification of prognostic or predictive biomarkers, systems biology has been only recently applied to vaccinology though the number of information are steadily increasing [  78  -  80  ].\n",
      "\n",
      " %%%%%%%%%%%%    125    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [  3  ].  One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [\n",
      "     \n",
      "      3\n",
      "     \n",
      "     ]. One of these methods relies on gene expression profiling based predictors, which can be used to further inform the decision making process and increase a clinician's ability to successfully treat cancer patients [  3  ].\n",
      "\n",
      " %%%%%%%%%%%%    126    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Taking these concepts further, Potti and colleagues [  34  ] combined microarray data from the NCI-60 cell lines with historical pharmacologic data generated from the NCI-60 panel at the National Cancer Institute to define expression signatures capable of discriminating between cell lines that are sensitive to various drugs and those that are resistant.    Taking these concepts further, Potti and colleagues [  34  ] combined microarray data from the NCI-60 cell lines with historical pharmacologic data generated from the NCI-60 panel at the National Cancer Institute to define expression signatures capable of discriminating between cell lines that are sensitive to various drugs and those that are resistant.\n",
      "\n",
      " %%%%%%%%%%%%    131    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].  The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ]. The 4T1 cells were derived from the mammary tumors of BALB/c mice lacking protein expression of the estrogen receptor  [  12  ,  13  ].\n",
      "\n",
      " %%%%%%%%%%%%    133    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Nevertheless, empirical research in the field of how we perceive odours is still fairly new, although we know more today about our brain's strategy in computing odour perception [  25  -  28  ] than we did only a few years ago.   Nevertheless, empirical research in the field of how we perceive odours is still fairly new, although we know more today about our brain's strategy in computing odour perception [  25  -  28  ] than we did only a few years ago.\n",
      "\n",
      " %%%%%%%%%%%%    135    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Olfactory cortical neurons have been shown to receive multiglomerular inputs (Illig and Haberly,\n",
      "      \n",
      "       2003\n",
      "      \n",
      "      ; Murakami et al.,\n",
      "      \n",
      "       2005\n",
      "      \n",
      "      ; Zou et al.,\n",
      "      \n",
      "       2005\n",
      "      \n",
      "      ; Lei et al.,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Zou and Buck,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Rennaker et al.,\n",
      "      \n",
      "       2007\n",
      "      \n",
      "      ; Poo and Isaacson,\n",
      "      \n",
      "       2009\n",
      "      \n",
      "      ; Stettler and Axel,\n",
      "      \n",
      "       2009\n",
      "      \n",
      "      ), and individual OC neurons may reasonably collect such multiglomerular inputs in a different manner in different OC areas (Kadohisa and Wilson,\n",
      "      \n",
      "       2006\n",
      "      \n",
      "      ; Yoshida and Mori,\n",
      "      \n",
      "       2007\n",
      "      \n",
      "      ; Kikuta et al.,\n",
      "      \n",
      "       2008\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       2010\n",
      "      \n",
      "      ; Wesson and Wilson,\n",
      "      \n",
      "       2010\n",
      "      \n",
      "      ).  \n",
      "\n",
      " %%%%%%%%%%%%    136    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Indeed, there were two reports presenting spontaneous transformation and/or aneuploidy of ASCs, following long-term in vitro culture [  42  ,  43  ].   Indeed, there were two reports presenting spontaneous transformation and/or aneuploidy of ASCs, following long-term in vitro culture [  42  ,  43  ].\n",
      "\n",
      " %%%%%%%%%%%%    139    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " For example, flavonoids showed antimicrobial activity [  69  ]. For example, flavonoids showed antimicrobial activity [\n",
      "     \n",
      "      69\n",
      "     \n",
      "     ].  For example, flavonoids showed antimicrobial activity [  69  ].\n",
      "\n",
      " %%%%%%%%%%%%    140    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P  3  agonism [  8  ,  9  ,  10  ], these effects were also observed with selective modulation of S1P  1  R [  11  ,  12  ,  13  ,  14  ,  15  ].  Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P\n",
      "       \n",
      "        3\n",
      "       \n",
      "       agonism [\n",
      "       \n",
      "        8\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        9\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        10\n",
      "       \n",
      "       ], these effects were also observed with selective modulation of S1P\n",
      "       \n",
      "        1\n",
      "       \n",
      "       R [\n",
      "       \n",
      "        11\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        12\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        13\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        14\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        15\n",
      "       \n",
      "       ]. Whereas cardiodynamic (heart rate [HR] reduction, delay in atrio ventricular (AV) conduction) and pulmonary effects had initially been related to S1P  3  agonism [  8  ,  9  ,  10  ], these effects were also observed with selective modulation of S1P  1  R [  11  ,  12  ,  13  ,  14  ,  15  ].\n",
      "\n",
      " %%%%%%%%%%%%    141    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.  Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [\n",
      "              \n",
      "               24\n",
      "              \n",
      "              ,\n",
      "              \n",
      "               26\n",
      "              \n",
      "              -\n",
      "              \n",
      "               28\n",
      "              \n",
      "              ]. Others have reported that changes in occludin and ZO-1 expression in response to environmental stimuli may account for changes in barrier properties in the pulmonary epithelia [  24  ,  26  -  28  ].  Since maintenance of normal pulmonary barrier function depends on intact epithelial tight junctions [  24  ,  26  ], transmission electron microscopy was used in this study to examine their morphological alterations.\n"
     ]
    }
   ],
   "source": [
    "for index, row in sentences_NBayes_predicts_critizising.iterrows():\n",
    "    print(\"\\n %%%%%%%%%%%%   \",index, \"   - before retraction: \", row.before_retraction, \"-   %%%%%%%%%%%%% \\n\\n\", row.sentences_citing)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      " %%%%%%%%%%%%    3    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " in a S961-induced insulin resistance mouse model [  5  ].  in a S961-induced insulin resistance mouse model [\n",
      "                 \n",
      "                  5\n",
      "                 \n",
      "                 ]. in a S961-induced insulin resistance mouse model [  5  ].\n",
      "\n",
      " %%%%%%%%%%%%    14    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].   One quite promising study was published recently, stating that mutated TP53 caused poor prognosis to pancreatectomy through upregulation of PTRF (cavin-1) in patients with preoperative serum [  26  ], but the publication was retracted due to the use of wrong antibodies in the study [  27  ].\n",
      "\n",
      " %%%%%%%%%%%%    17    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [  16  ,  18  -  21  ,  25  ,  26  ].  Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       18\n",
      "      \n",
      "      -\n",
      "      \n",
      "       21\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       25\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       26\n",
      "      \n",
      "      ]. Other recent efforts have described the creation of organisms that employ designed minicellulosomes, and as a result are capable of utilizing various cellulosic materials and growing and even producing ethanol from them [  16  ,  18  -  21  ,  25  ,  26  ].\n",
      "\n",
      " %%%%%%%%%%%%    19    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [  43  ]. Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [\n",
      "       \n",
      "        43\n",
      "       \n",
      "       ].  Others have shown that incongruence with taxonomy is not unusual in fluorescent proteins [  43  ].\n",
      "\n",
      " %%%%%%%%%%%%    30    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].  In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [\n",
      "      \n",
      "       3\n",
      "      \n",
      "      ]), tumor progression [\n",
      "      \n",
      "       4\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ], and clinical outcomes, such as patient survival [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       7\n",
      "      \n",
      "      ]. In cancers, the dysregulation of miRNAs has been proven to be involved in oncogenesis (reviewed in [  3  ]), tumor progression [  4  ,  5  ], and clinical outcomes, such as patient survival [  6  ,  7  ].\n",
      "\n",
      " %%%%%%%%%%%%    31    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells  Cell Biology International  2012  36  3  311  319  10.1042/cbi20110069  2-s2.0-84859243460  22070397  36  Miyaki  S.  Sato  T.  Inoue  A. Tumor invasiveness was assessed by determining the extent of infiltration of cancer cells to the surrounding tissue (stroma, fat pad, skin and muscle tissue), as previously described [  36  ].    Nagel  M.-D.  Vayssade  M.  Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells  Cell Biology International  2012  36  3  311  319  10.1042/cbi20110069  2-s2.0-84859243460  22070397  36  Miyaki  S.  Sato  T.  Inoue  A. Tumor invasiveness was assessed by determining the extent of infiltration of cancer cells to the surrounding tissue (stroma, fat pad, skin and muscle tissue), as previously described [  36  ].\n",
      "\n",
      " %%%%%%%%%%%%    32    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [  7  -  10  ].  Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [\n",
      "      \n",
      "       7\n",
      "      \n",
      "      -\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ]. Also, several miRNAs have been found to be directly associated with tumor progression and metastasis [  7  -  10  ].\n",
      "\n",
      " %%%%%%%%%%%%    44    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[  11    19  ].  Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[\n",
      "     \n",
      "      11\n",
      "     \n",
      "     \n",
      "     \n",
      "      19\n",
      "     \n",
      "     ]. Some miRNAs are involved in tumorigenesis by acting as either oncogenes or tumour supressor genes[  11    19  ].\n",
      "\n",
      " %%%%%%%%%%%%    55    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " We also added a  baseline  condition in which participants read the abstract of an article from the same issue of  JPSP  by Mahajan and colleagues  [49]  .   We also added a  baseline  condition in which participants read the abstract of an article from the same issue of  JPSP  by Mahajan and colleagues  [49]  .\n",
      "\n",
      " %%%%%%%%%%%%    58    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (  Lee et al., 2009  ;  Lee et al., 2013  ;  Han et al., 2011  ;  Han et al., 2013  ). We previously showed that Ax21 was found in the supernatant of  Xoo  cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (  Lee et al., 2009  ;  Han et al., 2011  ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (  Han et al., 2011  ), and probed with an anti-Ax21 antibody (  Fig.  Subsequent research from our lab, focused on the biological function of Ax21 in  Xanthomonas  , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (  Han et al., 2011  ). The generation of this antibody was first described in  Han et al. Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (\n",
      "        \n",
      "         Lee et al., 2009\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Lee et al., 2013\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2013\n",
      "        \n",
      "        ). We previously showed that Ax21 was found in the supernatant of\n",
      "        \n",
      "         Xoo\n",
      "        \n",
      "        cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (\n",
      "        \n",
      "         Lee et al., 2009\n",
      "        \n",
      "        ;\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (\n",
      "        \n",
      "         Han et al., 2011\n",
      "        \n",
      "        ), and probed with an anti-Ax21 antibody (\n",
      "        \n",
      "         Fig. \n",
      "\n",
      "       Subsequent research from our lab, focused on the biological function of Ax21 in\n",
      "       \n",
      "        Xanthomonas\n",
      "       \n",
      "       , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (\n",
      "       \n",
      "        Han et al., 2011\n",
      "       \n",
      "       ). Together, these experiments indicate that Ax21 is not processed by RaxB and does not require the predicted type I secretion components (RaxA, RaxB and RaxC) for secretion as previously suggested (  Lee et al., 2009  ;  Lee et al., 2013  ;  Han et al., 2011  ;  Han et al., 2013  ). We previously showed that Ax21 was found in the supernatant of  Xoo  cultures, and culturing methods were developed for Ax21 enrichment in the supernatant (  Lee et al., 2009  ;  Han et al., 2011  ). PXO99 cultures were grown similarly to the previously described methods for enriching for Ax21 in the supernatant (  Han et al., 2011  ), and probed with an anti-Ax21 antibody (  Fig.  Subsequent research from our lab, focused on the biological function of Ax21 in  Xanthomonas  , suggested that Ax21 serves as a cellcell signaling molecule mediating motility, biofilm formation and virulence (  Han et al., 2011  ). The generation of this antibody was first described in  Han et al.\n",
      "\n",
      " %%%%%%%%%%%%    59    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis. Although functional proof of this mechanism is necessary, several reports support our model [\n",
      "      \n",
      "       52\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       58\n",
      "      \n",
      "      -\n",
      "      \n",
      "       60\n",
      "      \n",
      "      ]. There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       55\n",
      "      \n",
      "      ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [\n",
      "      \n",
      "       54\n",
      "      \n",
      "      ] underlines this hypothesis.  There is no direct evidence of a physiological importance of p53 signaling in fasting, but some studies report an activation of p53, and an induction of its target genes, upon glucose deprivation in cultured cells [  54  ,  55  ]. Although functional proof of this mechanism is necessary, several reports support our model [  52  ,  54  ,  55  ,  58  -  60  ]. The observation that p53 knock-out mice are incapable of inducing liver fatty acid oxidation upon fasting [  54  ] underlines this hypothesis.\n",
      "\n",
      " %%%%%%%%%%%%    60    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [  74  ].  GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [\n",
      "       \n",
      "        74\n",
      "       \n",
      "       ]. GAMT was identified as a p53 target gene that plays as a key downstream effector of adaptive response to nutritional stress [  74  ].\n",
      "\n",
      " %%%%%%%%%%%%    61    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Together with  let-7c  , both  miR-125  and  miR-99  are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [  51  ]. Together with\n",
      "      \n",
      "       let-7c\n",
      "      \n",
      "      , both\n",
      "      \n",
      "       miR-125\n",
      "      \n",
      "      and\n",
      "      \n",
      "       miR-99\n",
      "      \n",
      "      are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [\n",
      "      \n",
      "       51\n",
      "      \n",
      "      ].  Together with  let-7c  , both  miR-125  and  miR-99  are over-expressed by at least 50% in the foetal hippocampus of individuals with Down syndrome compared to age and sex matched controls suggesting that miRNAs are playing an important role in this brain region, which is pertinent for learning and long-term memory formation [  51  ].\n",
      "\n",
      " %%%%%%%%%%%%    67    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " These results are in agreement with those previously reported by Olszewski  et al  [  42  ]. At this stage the parasites are early rings and after 32 hours (within 1 cycle) the metabolites from the medium and red blood cells were extracted with 80% methanol on dry ice, as described by Olszewski  et al  [  42  ]. Metabolites were extracted and incorporation of heavy isotopes was analysed by liquid chromatography followed by mass spectrometry as previously described [  42  ,  47  ]. The metabolites were analysed by LC-MS using a Synergy Hydro-RP column (Phenomenex, UK) and an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific, UK) and RAW files were converted and loaded into MAVEN, as detailed by Olszewski  et al  [  42  ]. \n",
      "\n",
      "      The second reaction product of the oxidative deamination of glutamate by GDHa is -ketoglutarate, an intermediate of the\n",
      "      \n",
      "       P. falciparum\n",
      "      \n",
      "      TCA pathway [\n",
      "      \n",
      "       42\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       46\n",
      "      \n",
      "      ].  These results are in agreement with those previously reported by Olszewski  et al  [  42  ]. At this stage the parasites are early rings and after 32 hours (within 1 cycle) the metabolites from the medium and red blood cells were extracted with 80% methanol on dry ice, as described by Olszewski  et al  [  42  ]. Metabolites were extracted and incorporation of heavy isotopes was analysed by liquid chromatography followed by mass spectrometry as previously described [  42  ,  47  ]. The metabolites were analysed by LC-MS using a Synergy Hydro-RP column (Phenomenex, UK) and an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific, UK) and RAW files were converted and loaded into MAVEN, as detailed by Olszewski  et al  [  42  ].\n",
      "\n",
      " %%%%%%%%%%%%    68    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Plasmodium falciparum  [  33  ,  34  ]. \n",
      "       Plasmodium falciparum\n",
      "      \n",
      "      [\n",
      "      \n",
      "       33\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       34\n",
      "      \n",
      "      ].   Plasmodium falciparum  [  33  ,  34  ].\n",
      "\n",
      " %%%%%%%%%%%%    75    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  It is shown that ketamine can function on opioid receptors [\n",
      "       \n",
      "        38\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        39\n",
      "       \n",
      "       ] and TLRs [\n",
      "       \n",
      "        40\n",
      "       \n",
      "       -\n",
      "       \n",
      "        42\n",
      "       \n",
      "       ] and thus inhibiting astrocytic activation.  \n",
      "\n",
      " %%%%%%%%%%%%    80    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  It is shown that ketamine can function on opioid receptors [\n",
      "       \n",
      "        38\n",
      "       \n",
      "       ,\n",
      "       \n",
      "        39\n",
      "       \n",
      "       ] and TLRs [\n",
      "       \n",
      "        40\n",
      "       \n",
      "       -\n",
      "       \n",
      "        42\n",
      "       \n",
      "       ] and thus inhibiting astrocytic activation.  \n",
      "\n",
      " %%%%%%%%%%%%    86    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [  19  ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [  20  ]. APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [\n",
      "      \n",
      "       19\n",
      "      \n",
      "      ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [\n",
      "      \n",
      "       20\n",
      "      \n",
      "      ].  APOC3 could also activate insulin-resistance pathways in endothelial cells causing endothelial dysfunction [  19  ] and stimulate adipocytes to produce cytokines such as monocyte chemoattractant protein (MCP) 1 and interleukin (IL)6 and suppresses their production of adiponectin [  20  ].\n",
      "\n",
      " %%%%%%%%%%%%    87    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Most recently, to add to the confusion, a new paper [  6  ] reports an association between CFS and a different retrovirus - a report erroneously described in some of the press coverage as confirmation of the original report of Lombardi  et al  . In that paper, human T-lymphotropic virus type II (HTLV-II) was detected in a study remarkably similar to those reported in the new papers [  1  ,  6  ] (which do not cite it). [  6  ]. The recently reported [  6  ] murine retrovirus distinct from XMRV, more closely related to polytropic MLV (should it be called PMRV? There is also a polytropic MLV that can infect the cells of both species, and it is this virus that most closely resembles the retrovirus identified in the latest claim for a retroviral association with CFS [  6  ]. were collected over several years from persons with no contact with each other and widely dispersed across states in New England [  6  ], it does not make epidemiological sense that the two types of CFS-associated MLV segregate according to the laboratory performing the tests.   Most recently, to add to the confusion, a new paper [  6  ] reports an association between CFS and a different retrovirus - a report erroneously described in some of the press coverage as confirmation of the original report of Lombardi  et al  . In that paper, human T-lymphotropic virus type II (HTLV-II) was detected in a study remarkably similar to those reported in the new papers [  1  ,  6  ] (which do not cite it). [  6  ]. The recently reported [  6  ] murine retrovirus distinct from XMRV, more closely related to polytropic MLV (should it be called PMRV? There is also a polytropic MLV that can infect the cells of both species, and it is this virus that most closely resembles the retrovirus identified in the latest claim for a retroviral association with CFS [  6  ]. were collected over several years from persons with no contact with each other and widely dispersed across states in New England [  6  ], it does not make epidemiological sense that the two types of CFS-associated MLV segregate according to the laboratory performing the tests.\n",
      "\n",
      " %%%%%%%%%%%%    88    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [  10  ].  A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ]. A recent report found an association between a different retrovirus (murine leukemia virus) and CFS (87% of cases, 7% of controls) [  10  ].\n",
      "\n",
      " %%%%%%%%%%%%    90    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  This report by Lombardi, et al was followed by 4 subsequent reports of failure to detect any murine leukemia virus (MLV)-related virus gene sequences in blood from CFS patients [\n",
      "      \n",
      "       12\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       66\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       67\n",
      "      \n",
      "      ] and one report of MLV-like virus gag gene sequences, but not XMRV, in 86.5% CFS cases compared with only 6.8% of healthy volunteer blood donors [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ].  \n",
      "\n",
      " %%%%%%%%%%%%    91    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " detected MLV-related viruses which are distinct from XMRV but resemble polytropic endogenous MLVs in CFS patients and healthy blood donors [  13  ]. [  13  ] were derived from contaminating MLV RNA and/or DNA. mentioned in the report that Platinum Taq from Invitrogen gave them the best results among  Taq  polymerases from several suppliers and was used to test the patient samples [  13  ]. [  13  ], assurance that control samples were assayed simultaneously with the positively identified ones in a blinded, randomized way was missing in their study, unfortunately.  In studies investigating XMRV infection, a PCR approach to detect proviral DNA and/or a RT-PCR approach to detect viral RNA have been commonly employed [  1  ,  3  -  6  ,  8  ,  13  -  15  ]. They also used Invitrogen's Superscript II RT and Platinum Taq for RT-PCR, albeit in a two-step cDNA synthesis and PCR amplification procedure [  13  ]. The nucleotide sequences of the representative clone [GenBank:  AB597300  ] were aligned with sequences deposited in GenBank as follows: MLV-like virus from CFS patients types 1, 2 and 3 [GenBank:  HM630562  ,  HM630558  , and  HM630559  ] [  13  ], XMRV strain VP62 [GenBank:  NC_007815  ] [  2  ] and one representative PmERV on chr 7 [GenBank:  AC167978  ; nt 65,391-64,647] (Figure  3  ).   detected MLV-related viruses which are distinct from XMRV but resemble polytropic endogenous MLVs in CFS patients and healthy blood donors [  13  ]. [  13  ] were derived from contaminating MLV RNA and/or DNA. mentioned in the report that Platinum Taq from Invitrogen gave them the best results among  Taq  polymerases from several suppliers and was used to test the patient samples [  13  ]. [  13  ], assurance that control samples were assayed simultaneously with the positively identified ones in a blinded, randomized way was missing in their study, unfortunately.  In studies investigating XMRV infection, a PCR approach to detect proviral DNA and/or a RT-PCR approach to detect viral RNA have been commonly employed [  1  ,  3  -  6  ,  8  ,  13  -  15  ]. They also used Invitrogen's Superscript II RT and Platinum Taq for RT-PCR, albeit in a two-step cDNA synthesis and PCR amplification procedure [  13  ]. The nucleotide sequences of the representative clone [GenBank:  AB597300  ] were aligned with sequences deposited in GenBank as follows: MLV-like virus from CFS patients types 1, 2 and 3 [GenBank:  HM630562  ,  HM630558  , and  HM630559  ] [  13  ], XMRV strain VP62 [GenBank:  NC_007815  ] [  2  ] and one representative PmERV on chr 7 [GenBank:  AC167978  ; nt 65,391-64,647] (Figure  3  ).\n",
      "\n",
      " %%%%%%%%%%%%    92    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [  6  ]. in their analysis of CFS patient samples [  6  ].  that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [\n",
      "      \n",
      "       6\n",
      "      \n",
      "      ]. that described the existence of sequences closely related to polytropic and modified-polytropic murine leukemia viruses (MLVs)--but not XMRV--in blood samples from CFS patients [  6  ]. in their analysis of CFS patient samples [  6  ].\n",
      "\n",
      " %%%%%%%%%%%%    95    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [  5  ]. It is striking that there have been no independent reports of patient-derived XMRV integration sites nor have there been any descriptions of polytropic or modified polytropic MLV integration sites in human samples despite the apparent detection of these viruses in CFS patients [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [\n",
      "      \n",
      "       5\n",
      "      \n",
      "      ]. Curiously, one study described PCR detection of a second MLV (modified polytropic MLV), but not XMRV itself, in the blood of some CFS patients [  5  ].\n",
      "\n",
      " %%%%%%%%%%%%    97    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Table 7  Comparison of MLV sequences amplified from patient samples [  16  ] with mouse genomic sequences  Sequence  Length (nt)  Closest relative  GenBank no  . Sequences from [  16  ] are colored blue.  Similarity  Nucleotide difference  51_PCR_LF2_GagR (  JF288878  )  608  Mus musculus BAC clone RP23-457E5  AC121813  100%  0/608  51_PCR_LF3_GagR (  JF288879  )  250  Mus musculus chrom 7, clone RP24-220N8  AC167466  99%  1/250  15_PCR_LF2_GagR (  JF288880  )  608  Mus musculus BAC clone RP23-152O2  AC163634  100%  0/608  15_PCR_LF3_GagR (  JF288881  )  271  Mus musculus BAC clone RP23-152O2  AC163634  &gt;99%  1/271  52_PCR_GagF_GagR (  JF288882  )  525  Mouse DNA sequence, clone CH29-187G15  CU407131  100%  0/525  52_PCR_LF2_GagR (  JF288883  )  540  Mus musculus chrom 5, clone RP23-280N22  AC123679  &gt;99%  1/540  112_PCR_LF2_GagR (  JF288884  )  691  Mouse DNA sequence, CH29-187G15  CU407131  &gt;99%  6/691  NB: Gaps are treated as mismatches  Because the sequences we amplified were similar to the MLV sequences detected in CFS patients [  16  ], we also analyzed the sequences reported in that study. Furthermore, a recent study reported a high frequency of MLV that was distinct from XMRV by PCR in patients with chronic fatigue syndrome [  16  ]. [  16  ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure  1  ). Positive samples yielded PCR products at 153 bp [  16  ]. [\n",
      "      \n",
      "       16\n",
      "      \n",
      "      ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure\n",
      "      \n",
      "       1\n",
      "      \n",
      "      ).   Table 7  Comparison of MLV sequences amplified from patient samples [  16  ] with mouse genomic sequences  Sequence  Length (nt)  Closest relative  GenBank no  . Sequences from [  16  ] are colored blue.  Similarity  Nucleotide difference  51_PCR_LF2_GagR (  JF288878  )  608  Mus musculus BAC clone RP23-457E5  AC121813  100%  0/608  51_PCR_LF3_GagR (  JF288879  )  250  Mus musculus chrom 7, clone RP24-220N8  AC167466  99%  1/250  15_PCR_LF2_GagR (  JF288880  )  608  Mus musculus BAC clone RP23-152O2  AC163634  100%  0/608  15_PCR_LF3_GagR (  JF288881  )  271  Mus musculus BAC clone RP23-152O2  AC163634  &gt;99%  1/271  52_PCR_GagF_GagR (  JF288882  )  525  Mouse DNA sequence, clone CH29-187G15  CU407131  100%  0/525  52_PCR_LF2_GagR (  JF288883  )  540  Mus musculus chrom 5, clone RP23-280N22  AC123679  &gt;99%  1/540  112_PCR_LF2_GagR (  JF288884  )  691  Mouse DNA sequence, CH29-187G15  CU407131  &gt;99%  6/691  NB: Gaps are treated as mismatches  Because the sequences we amplified were similar to the MLV sequences detected in CFS patients [  16  ], we also analyzed the sequences reported in that study. Furthermore, a recent study reported a high frequency of MLV that was distinct from XMRV by PCR in patients with chronic fatigue syndrome [  16  ]. [  16  ] detected polytropic and modified polytropic MLV sequences, but not XMRV, in blood samples from chronic fatigue patients (Figure  1  ). Positive samples yielded PCR products at 153 bp [  16  ].\n",
      "\n",
      " %%%%%%%%%%%%    99    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " More recently, matters were further complicated by the publication of a study finding  gag  sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [  17  ]. Sequences were aligned against VP62 [Genbank:  EF185282  ], MLV-releated virus CFS isolate CSF-type1 ([Genbank:  HM630562  ], as described in Lo [  17  ]) and mouse strain 129X1/SvJ [Genbank  AAHY01591888.1  ].  More recently, matters were further complicated by the publication of a study finding\n",
      "      \n",
      "       gag\n",
      "      \n",
      "      sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [\n",
      "      \n",
      "       17\n",
      "      \n",
      "      ]. More recently, matters were further complicated by the publication of a study finding  gag  sequences similar to those of four different polytropic endogenous MLVs in an unrelated US CFS cohort, but no evidence of XMRV [  17  ]. Sequences were aligned against VP62 [Genbank:  EF185282  ], MLV-releated virus CFS isolate CSF-type1 ([Genbank:  HM630562  ], as described in Lo [  17  ]) and mouse strain 129X1/SvJ [Genbank  AAHY01591888.1  ].\n",
      "\n",
      " %%%%%%%%%%%%    100    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Lo  , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [  31  ].  Lo\n",
      "       \n",
      "       , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [\n",
      "       \n",
      "        31\n",
      "       \n",
      "       ]. Lo  , (FDA/CBER, Bethesda, Maryland) reviewed his previously published findings on the presence of MLV-related virus gene sequences in both CFS patients and healthy controls [  31  ].\n",
      "\n",
      " %%%%%%%%%%%%    103    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  2010  ).    2010  ).\n",
      "\n",
      " %%%%%%%%%%%%    106    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].  As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [\n",
      "     \n",
      "      15\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      16\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ]. As the clinical risks of MSCs due to the use of FBS have become more recognized, culture media containing a variety of growth factors that could replace animal serum, such as human-serum, platelet lysate derivatives, and sphingosine-1-phosphate have been developed [  15  ,  16  ,  17  ].\n",
      "\n",
      " %%%%%%%%%%%%    107    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " He et al [  10  ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs. He et al [\n",
      "      \n",
      "       10\n",
      "      \n",
      "      ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs.  He et al [  10  ] recently further investigated the role of S1P in the growth and multipotency maintenance of human bone marrow and adipose tissue-derived MSCs.\n",
      "\n",
      " %%%%%%%%%%%%    108    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).  Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs\n",
      "      \n",
      "       in vitro\n",
      "      \n",
      "      (\n",
      "      \n",
      "       He et al., 2010\n",
      "      \n",
      "      ). Besides, according to some studies, S1P is capable of promoting the differentiation of MSCs  in vitro  (  He et al., 2010  ).\n",
      "\n",
      " %%%%%%%%%%%%    110    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Indeed, the range of autoimmune/autoinflammatory diseases that have been investigated encompasses SLE [  20  ,  21  ,  48  ,  49  ], juvenile idiopathic arthritis [  16  ,  50  -  53  ], multiple sclerosis [  54  ,  55  ], rheumatoid arthritis [  56  -  59  ], Sjogren's syndrome [  60  ], diabetes [  61  ,  62  ], inflammatory bowel disease [  63  ], psoriasis and psoriatic arthritis [  45  ,  47  ], inflammatory myopathies [  64  ,  65  ], scleroderma [  66  ,  67  ], vasculitis [  68  ] and anti-phospholipid syndrome [  69  ].   Indeed, the range of autoimmune/autoinflammatory diseases that have been investigated encompasses SLE [  20  ,  21  ,  48  ,  49  ], juvenile idiopathic arthritis [  16  ,  50  -  53  ], multiple sclerosis [  54  ,  55  ], rheumatoid arthritis [  56  -  59  ], Sjogren's syndrome [  60  ], diabetes [  61  ,  62  ], inflammatory bowel disease [  63  ], psoriasis and psoriatic arthritis [  45  ,  47  ], inflammatory myopathies [  64  ,  65  ], scleroderma [  66  ,  67  ], vasculitis [  68  ] and anti-phospholipid syndrome [  69  ].\n",
      "\n",
      " %%%%%%%%%%%%    117    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  The essential role of Cited2, a negative regulator for HIF-1    , in heart development and neurulation  Proceedings of the National Academy of Sciences of the United States of America  2002  99  16  10488  10493  10.1073/pnas.162371799  2-s2.0-0036679122  12149478  75  Kranc  K. R.  Schepers  H.  Rodrigues  N. P.  Cited2 is an essential regulator of adult hematopoietic stem cells  Cell Stem Cell  2009  5  6  659  665  10.1016/j.stem.2009.11.001  2-s2.0-70450253358  19951693  76  Lou  X. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [  50  ,  51  ]. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [\n",
      "            \n",
      "             50\n",
      "            \n",
      "            ,\n",
      "            \n",
      "             51\n",
      "            \n",
      "            ].   The essential role of Cited2, a negative regulator for HIF-1    , in heart development and neurulation  Proceedings of the National Academy of Sciences of the United States of America  2002  99  16  10488  10493  10.1073/pnas.162371799  2-s2.0-0036679122  12149478  75  Kranc  K. R.  Schepers  H.  Rodrigues  N. P.  Cited2 is an essential regulator of adult hematopoietic stem cells  Cell Stem Cell  2009  5  6  659  665  10.1016/j.stem.2009.11.001  2-s2.0-70450253358  19951693  76  Lou  X. These functions may also be modulated by specific post-translational modifications such as phosphorylation and methylation [  50  ,  51  ].\n",
      "\n",
      " %%%%%%%%%%%%    122    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Similarly, other groups have previously reported portability of gene expression signatures [  13  ,  14  ].  Similarly, other groups have previously reported portability of gene expression signatures [\n",
      "      \n",
      "       13\n",
      "      \n",
      "      ,\n",
      "      \n",
      "       14\n",
      "      \n",
      "      ]. Similarly, other groups have previously reported portability of gene expression signatures [  13  ,  14  ].\n",
      "\n",
      " %%%%%%%%%%%%    127    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  In a similar approach, Nevins and colleagues [  25  ] demonstrated that gene expression signatures deriving from the NCI-60 cell line set matched with cytotoxic sensitivity data could be used to predict response to chemotherapy in tumours from patients treated with the same drugs.    In a similar approach, Nevins and colleagues [  25  ] demonstrated that gene expression signatures deriving from the NCI-60 cell line set matched with cytotoxic sensitivity data could be used to predict response to chemotherapy in tumours from patients treated with the same drugs.\n",
      "\n",
      " %%%%%%%%%%%%    128    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].    Breast Cancer Res  Breast Cancer Research : BCR  1465-5411  1465-542X  BioMed Central  3236331  bcr2909  10.1186/bcr2909  Correction  Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer  Bild  Andrea H  1  2  andreab@genetics.utah.edu  Parker  Joel S  3  4  andreab@genetics.utah.edu  Gustafson  Adam M  5  andreab@genetics.utah.edu  Acharya  Chaitanya R  2  andreab@genetics.utah.edu  Hoadley  Katherine A  3  4  andreab@genetics.utah.edu  Anders  Carey  2  andreab@genetics.utah.edu  Marcom  P Kelly  2  andreab@genetics.utah.edu  Carey  Lisa A  3  7  andreab@genetics.utah.edu  Potti  Anil  2  andreab@genetics.utah.edu  Nevins  Joseph R  2  andreab@genetics.utah.edu  Perou  Charles M  3  4  6  8  andreab@genetics.utah.edu  1  Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA  2  Duke Institute for Genome Sciences &amp; Policy, Duke University Medical Center, 2121 CIEMAS, Durham, NC 27701, USA  3  Lineberger Comprehensive Cancer Center, University of North Carolina, 102 Mason Farm Road, Chapel Hill, NC 27599, USA  4  Department of Genetics, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, USA  5  The Pulmonary Center, Boston University School of Medicine, 715 Albany St, Boston, MA 02118, USA  6  Department of Pathology &amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  7  Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA  8  Carolina Center for Genome Sciences, 5016 Genetic Medicine Building, University of North Carolina, Chapel Hill, NC 27599, USA  2011  12  7  2011  12  1  2012  13  4  406  406  Copyright 2011 BioMed Central Ltd  2011  BioMed Central Ltd  In our previous publication [  1  ], Figure 4 involved the analysis of chemotherapy-response signatures (as carried out independently by author AP and described in a 2006 Nature Medicine article [  2  ,  3  ]). It has recently been determined that the chemotherapy-response signatures in [  2  ] are not reproducible, causing retraction of that article [  3  ].\n",
      "\n",
      " %%%%%%%%%%%%    129    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      " The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].   The combination of  in vitro  signatures associated with drug sensitivity in cell lines was thought to provide composite signatures that could predict response to multidrug regimens and be translated to patients receiving multidrug chemotherapy [  96  ].  An alternative attempt to predict chemosensitivity to specific chemotherapy regimens was developed with the use of  in vitro  models [  96  ].\n",
      "\n",
      " %%%%%%%%%%%%    130    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      "  To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [  8  -  12  ,  17  ,  18  ], of predictive marker genes [  19  ], relevant genomics [  19  ,  20  ], or proteomics [  21  ]. \n",
      "\n",
      "     To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [\n",
      "     \n",
      "      8\n",
      "     \n",
      "     -\n",
      "     \n",
      "      12\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      17\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      18\n",
      "     \n",
      "     ], of predictive marker genes [\n",
      "     \n",
      "      19\n",
      "     \n",
      "     ], relevant genomics [\n",
      "     \n",
      "      19\n",
      "     \n",
      "     ,\n",
      "     \n",
      "      20\n",
      "     \n",
      "     ], or proteomics [\n",
      "     \n",
      "      21\n",
      "     \n",
      "     ].   To determine the sensitivity of ovarian cancer cells toward platinum compounds several methods were described like measurement of cell viability [  8  -  12  ,  17  ,  18  ], of predictive marker genes [  19  ], relevant genomics [  19  ,  20  ], or proteomics [  21  ].\n",
      "\n",
      " %%%%%%%%%%%%    132    - before retraction:  0 -   %%%%%%%%%%%%% \n",
      "\n",
      "  Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].    Preparation of tumor cell lysates (TCLs)  B16 cell lysates were prepared as described previously with slight modification [  33  ].\n",
      "\n",
      " %%%%%%%%%%%%    134    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,  2003  ), in the olfactory bulb (Davison and Katz,  2007  ; Giraudet et al.,  2002  ; Lin et al.,  2006  ; Tabor et al.,  2004  ) and in the olfactory cortex (Lei et al.,  2006  ; Zou and Buck,  2006  ).  In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,\n",
      "           \n",
      "            2003\n",
      "           \n",
      "           ), in the olfactory bulb (Davison and Katz,\n",
      "           \n",
      "            2007\n",
      "           \n",
      "           ; Giraudet et al.,\n",
      "           \n",
      "            2002\n",
      "           \n",
      "           ; Lin et al.,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ; Tabor et al.,\n",
      "           \n",
      "            2004\n",
      "           \n",
      "           ) and in the olfactory cortex (Lei et al.,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ; Zou and Buck,\n",
      "           \n",
      "            2006\n",
      "           \n",
      "           ). In vertebrates, odor mixture interactions were observed at different levels of the olfactory system, in the periphery (Duchamp-Viret et al.,  2003  ), in the olfactory bulb (Davison and Katz,  2007  ; Giraudet et al.,  2002  ; Lin et al.,  2006  ; Tabor et al.,  2004  ) and in the olfactory cortex (Lei et al.,  2006  ; Zou and Buck,  2006  ).\n",
      "\n",
      " %%%%%%%%%%%%    137    - before retraction:  1 -   %%%%%%%%%%%%% \n",
      "\n",
      " Some vector integrases, such as those for phages C31 [  119  -  121  ], BT1 [  122  ], as well as the  Escherichia coli Tn7  transposon [  123  ], recognize specific DNA sequences or degenerate sequences that exist in mammalian genomes.   Some vector integrases, such as those for phages C31 [  119  -  121  ], BT1 [  122  ], as well as the  Escherichia coli Tn7  transposon [  123  ], recognize specific DNA sequences or degenerate sequences that exist in mammalian genomes.\n"
     ]
    }
   ],
   "source": [
    "for index, row in sentences_NBayes_predicts_non_critizising.iterrows():\n",
    "    print(\"\\n %%%%%%%%%%%%   \",index, \"   - before retraction: \", row.before_retraction, \"-   %%%%%%%%%%%%% \\n\\n\", row.sentences_citing)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Let's filter the sentences analyse:\n",
    "\n",
    "Critizising: After retraction and classified as critizising by the Naive Bayes model\n",
    "\n",
    "    \n",
    "Non-critizising: Before retraction and classified as neutral by the Naive Bayes model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "metadata": {},
   "outputs": [],
   "source": [
    "mask_before = (df1sentence_sentences_classification_NBayes.before_retraction == 1) & (\n",
    "        df1sentence_sentences_classification_NBayes.Naive_Bayes_prediction == 'before')\n",
    "\n",
    "mask_after = (df1sentence_sentences_classification_NBayes.before_retraction == 0) & (\n",
    "        df1sentence_sentences_classification_NBayes.Naive_Bayes_prediction == 'after')\n",
    "        \n",
    "sentences_before_non_critizising_filtered = df1sentence_sentences_classification_NBayes[mask_before].sentences_citing\n",
    "sentences_after_critizising_filtered = df1sentence_sentences_classification_NBayes[mask_after].sentences_citing\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(33,)"
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences_before_non_critizising_filtered.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(24,)"
      ]
     },
     "execution_count": 208,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences_after_critizising_filtered.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for sentence in sentences_before_non_critizising_filtered:\n",
    "    print(sentence)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:Python3]",
   "language": "python",
   "name": "conda-env-Python3-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
